1:00 pm – 5:30 pm   Pre-Meeting Symposia

Page 6   HLA Antibody Diagnostics and Management
Room E353AB

Page 6   The State of the Art in Kidney Transplantation – An Update for the Busy Clinician
Room E450B

Page 7   Exciting Updates in Transplant ID 2017: Case-based learning with Audience Response
Room E353C

Page 8   Preserving Native Renal Function in Liver Transplantation: Case Focused Session
Room E450A

Page 9   Challenges in Transplant Listing and Organ Allocation
Room E350

Page 10  Basic Immunology and Transplant Immunology for the Clinician
Room E451B

Page 11  Advanced Immunology Updates for Basic and Clinical Scientists
Room E451A

5:30 pm – 6:00 pm   Thomas Starzl, MD, PhD Tribute Program

Page 11   Arie Crown Theater
Open to all ATC registered attendees and exhibitors

6:00 pm – 7:30 pm   Opening Reception, Exhibits and Poster Session A

Presenters in Attendance
Hall D1
Pre-Meeting Symposia
1:00 pm – 5:30 pm

**HLA Antibody Diagnostics and Management**
Room E353AB

Allorecognition and Transplant Immunodiagnostics
Moderators: Frans Claas, PhD, Leiden University Medical Center, Leiden, Netherlands and Anat Tambur, DMD, PhD, Northwestern University, Chicago, IL, USA

1:00 pm  HLA Genetics, Immunogenicity and Epitopes
Frans Claas, PhD
Leiden University Medical Center
Leiden, Netherlands

1:20 pm  HLA Antibody Effector Pathways
William Baldwin, MD, PhD
Cleveland Clinic Main Campus, Lerner Research Institute
Cleveland, OH, USA

1:40 pm  Cell and Solid Phase based Assays – The Basics
Howard Gebel, PhD
Emory University Hospital
Atlanta, GA, USA

2:00 pm  Myths/Limitations of Immunodiagnostics
Kathryn Tinckam, MD
University Health Network
Toronto, ON, Canada

2:20 pm  Histopathology and Molecular Diagnostics
Robert Colvin, MD
Massachusetts General Hospital/Harvard Medical School
Boston, MA, USA

2:40 pm  Panel / Case Discussion

3:15 pm  Coffee Break

Immunologic Memory and Naive HLA Responses – We will overcome some day?
Moderators: Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB, USA and Chris Wiebe, MD, University of Manitoba, Winnipeg, MB, USA

3:45 pm  Approach to the Highly Sensitized Patient
Mark Stegall, MD
Mayo Clinic
Rochester, MN, USA

4:05 pm  Treatment of Early ABMR – What’s the Evidence?
John Friedewald, MD
Northwestern University
Chicago, IL, USA

4:25 pm  De novo DSA – Prevention/Risk Assessment
Chris Wiebe, MD
University of Manitoba
Winnipeg, Canada

4:45 pm  De novo DSA – ABMR – Treatment – Where are we?
Stanley Jordan, MD
Cedars-Sinai
West Hollywood, CA, USA

5:05 pm  Panel/Case Discussion

The State of the Art in Kidney Transplantation – An Update for the Busy Clinician
Room E450B

The Immunology of Kidney Transplantation
Moderators: Reza Abdi, Brigham & Women’s Hospital, Boston, MA, USA and Emilio Poggio, MD, Cleveland Clinic, Cleveland, OH, USA

1:00 pm  Immunobiology of Rejection for the Nephrologist
Philip F. Halloran, MD, PhD
University of Alberta
Edmonton, AB, Canada

1:20 pm  Immunosuppression Current Approaches and Future Strategies
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA
1:40 pm  Immunological Assessment of the Transplant Recipient  
Robert Bray, PhD  
Emory University  
Atlanta, GA, USA

2:00 pm  Non-tissue Diagnosis of Rejection  
Paolo Cravedi, MD, PhD  
Mount Sinai Hospital NY  
New York, USA

2:20 pm  Discussion

Issues in Candidate Evaluation  
Moderators:  Lorenzo Gallon, MD, Northwestern University, Chicago, IL, USA and Jennifer Lai, MD, University of California San Francisco, San Francisco, CA, USA

2:40 pm  Evaluation of the Combined Organ Transplant Candidate  
Richard Formica, MD  
Yale University School of Medicine  
New Haven, CT, USA

James Trotter, MD  
Baylor  
Dallas, TX, USA

2:55 pm  Evaluation of the Living Kidney Donor  
David Landsberg, MD  
St. Paul’s Hospital  
Vancouver, BC, Canada

3:10 pm  Panel Discussion

3:20 pm  Break

Expect the Unexpected:  Complications  
Moderators:  Randy Sung, MD, University of Michigan, Ann Arbor, MI, USA and Milagros Samaniego, MD, University of Michigan Med School, Ann Arbor, MI, USA

3:45 pm  Management of Malignancy in the Post-Transplant Setting  
Christopher Blosser, MD  
University of Washington  
Seattle, WA, USA

4:00 pm  Management of Recurrent Complement Mediated Glomerular Diseases  
Jean Francis, MD  
Boston University Medical Center  
Boston, MA, USA

4:15 pm  Surgical Complications after Kidney Transplantation for the Non-Surgeon  
Kenneth Newell, MD, PhD  
Emory University School of Medicine  
Atlanta, GA, USA

4:30 pm  Discussion

Transplant Infections  
Moderators:  Deepali Kumar, MD, University of Toronto, Toronto, ON, Canada and Marian Michaels, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

4:45 pm  Challenging Cases in CMV  
Michael Ison, MD, MS  
Northwestern University Feinberg School of Medicine  
Chicago, IL, USA

5:00 pm  BK Virus – Prevention and Treatment  
Daniel Brennan, MD, FACP  
Washington University in St. Louis  
St. Louis, MO, USA

5:15 pm  Discussion

Exciting Updates in Transplant ID 2017:  Case-based learning with Audience Response  
Room E353C

Antibiotics:  The Good the Bad and The Ugly  
Moderators:  Shirish Huprikar, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA and Emily Blumberg, MD, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

1:00 pm  MDR GNR Bacteria  
Stephanie Pouch, MD, MS  
The Ohio State University Wexner Medical Center  
Columbus, OH, USA

1:20 pm  VRE:  Best Practice and Insights  
Anoma Nellore, MD  
University of Alabama  
Birmingham, AL, USA

1:40 pm  From the PharmD desk:  “Top 10” Things TID Docs Should Know  
Shellee Grim, PharmD, MS-CTS, BCPS  
Loyola University Medical Center  
Chicago, IL, USA
Antifungal Testing, Prevention and Treatment Stewardship in SOT
Moderators: Nicole Theodoropoulos, MD, MS, University of Massachusetts Memorial Medical Center, Worcester, MA, USA and Shahid Husain, MD, MS, University of Toronto, Toronto, ON, Canada

2:00 pm Fungus among Us: State of the Art Diagnostics
John Baddley, MD, MSPH
University of Alabama at Birmingham
Birmingham, AL, USA

2:20 pm An Ounce or a Pound of Fungal Prevention?
Shirish Huprikar, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

2:40 pm Antifungal Treatment
Rachel Miller, MD
Duke University
Durham, NC, USA

3:00 pm Coffee Break

Difficult Pathogens & Situations in Transplant
Moderators: Lara Danziger-Isakov, MD, MPH, University of Cincinnati, Cincinnati, OH, USA and Michele I. Morris, MD, FACP, FIDSA, University of Miami Miller School of Medicine, Miami, FL, USA

3:30 pm NTM: Help!
Ricardo La Hoz, MD, FACP
University of Texas Southwestern Medical Center
Dallas, TX, USA

3:50 pm Respiratory Viruses
Sherif Mossad, MD, FACP, FIDSA, FAST
Cleveland Clinic Foundation
Cleveland, OH, USA

4:10 pm Recurrent UTI/bacteriuria/MDRO
Aldiana Soljic, MD
Massachusetts General Hospital
Boston, MA, USA

4:30 pm On Your Toes: Rapid Fire Cases with The ID COP Executive Committee Members
Lara Danziger-Isakov, MD, MPH
University of Cincinnati
Cincinnati, OH, USA

Shirish Huprikar, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Camille Kotton, MD
Massachusetts General Hospital
Boston, MA, USA

Deepali Kumar, MD
University of Toronto
Toronto, ON, Canada

Sherif Mossad, MD, FACP, FIDSA, FAST
Cleveland Clinic Foundation
Cleveland, OH, USA

Nicole Theodoropoulos, MD, MS
University of Massachusetts Memorial Medical Center
Worcester, MA, USA

Ricardo La Hoz, MD, FACP
University of Texas Southwestern Medical Center
Dallas, TX, USA

Susanna Tan, MD
Stanford University
Stanford, CA, USA

Preserving Native Renal Function in Liver Transplantation: Case Focused Session
Room E450A

Evaluation and Management of Renal Dysfunction in Patients with Cirrhosis (Case Based) – Audience Response
Moderators: Catherine Frenette, MD, Scripps Clinic Department of Organ Transplant, La Jolla, CA, USA and Mitra Nadim, MD, University of Southern California / Keck Hospital of USC, Los Angeles, CA, USA

1:00 pm The ABC’s Of Assessing Renal Function
Sumeet Asrani, MD
Baylor University Medical Center
Dallas, TX, USA

1:25 pm Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 1:30 pm | Hyponatremia: Why we Care and What to Do about it                                              | Scott Biggins, MD  
University of Washington  
Seattle, WA, USA                                                                 |
| 1:55 pm | Discussion                                                                                       |                                                                                                                                             |
| 2:00 pm | Etiology and Management of Renal Dysfunction on the Liver Wait-List                             | Patrick Kamath, MD  
Mayo Clinic  
Rochester, MN, USA                                                                 |
| 2:25 pm | Discussion                                                                                       |                                                                                                                                             |
| 2:30 pm | PRO: Can We Predict Irreversible Renal Failure and Need For SLK?                                | Larry Melton, MD, PhD  
Hackensack UMC  
Hackensack, NJ, USA                                                                 |
| 2:45 pm | CON: Can We Predict Irreversible Renal Failure and Need For SLK?                                | Mitra Nadim, MD  
University of Southern California / Keck Hospital of USC  
Los Angeles, CA, USA  
| 3:00 pm | Discussion                                                                                       |                                                                                                                                             |
| 3:15 pm | Coffee Break                                                                                     |                                                                                                                                             |
| 3:30 pm | Preserving Renal Function after Liver Transplantation (Case Based)                               | Pratima Sharma, MD, University of Michigan  
Ann Arbor, MI, USA  
Alexander Wiseman, MD, University of Colorado Denver  
Aurora, CO, USA                                                                 |
| 3:45 pm | Preserving Renal Function during the Liver Transplant Procedure                                 | Claus Niemann, MD  
UCSF  
San Francisco, CA, USA                                                                 |
| 4:05 pm | Discussion                                                                                       |                                                                                                                                             |
| 4:10 pm | Early Post-Transplant Nephroprotective Strategies                                                | Pratima Sharma, MD  
University of Michigan  
Ann Arbor, MI, USA                                                                 |
| 4:30 pm | Discussion                                                                                       |                                                                                                                                             |
| 4:35 pm | Late Renal Protection: Immunosuppression and CKD Management                                     | Alexander Wiseman, MD  
University of Colorado Denver  
Aurora, CO, USA                                                                 |
| 4:55 pm | Discussion                                                                                       |                                                                                                                                             |
| 5:00 pm | The SLK Allocation Policy is Appropriate                                                         | Richard Formica, MD  
Yale University School of Medicine  
New Haven, CT, USA                                                                 |
| 5:10 pm | The SLK Allocation Policy needs to be Modified                                                   | Stuart Flechner, MD, FACS  
Cleveland Clinic Foundation  
Cleveland, OH, USA                                                                 |
| 5:20 pm | Discussion                                                                                       |                                                                                                                                             |

**Challenges in Transplant Listing and Organ Allocation**

**Room E350**

Optimizing the Transplant Listing Process; Unique Approaches from Various Centers  
Moderators: Micah Davis, University Hospitals  
Cleveland Medical Center, Cleveland, OH, USA and Melissa Roberts, MSN, RN, CPTC, Tampa General Hospital, Tampa, FL, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 1:00 pm | Rush                                                                                             | Edward Hollinger, MD, PhD  
Rush University Medical Center  
Chicago, IL, USA                                                                 |
| 1:15 pm | Northwestern                                                                                     | Aneesha Shetty, MBBD, MPH  
Northwestern University, Feinberg School of Medicine  
Chicago, IL, USA                                                                 |
| 1:30 pm | Cleveland Clinic                                                                                 | Tracy Evans-Walker, RN, MSN, CNP, CCTC  
Cleveland Clinic  
Cleveland, OH, USA                                                                 |
| 1:45 pm | Discussion                                                                                       |                                                                                                                                             |

Not Everyone Can be a Transplant Candidate  
Moderators: Micah Davis, University Hospitals  
Cleveland Medical Center, Cleveland, OH, USA and Melissa Roberts, MSN, RN, CPTC, Tampa General Hospital, Tampa, FL, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 2:00 pm | Optimizing Resources to Make it Happen                                                           | Teri Browne, PhD  
University of South Carolina  
Columbia, SC, USA                                                                 |
| 2:10 pm | Assessing and Improving Medication Adherence Prior to Transplant                                 | Katelyn Richards, PharmD  
Beth Israel Deaconess Medical Center  
Boston, MA, USA                                                                 |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:25 pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
2:20 pm  Having the Difficult Conversation  
Prince Mohan, MD  
Geisinger Medical Center  
Danville, PA, USA

2:30 pm  Discussion

Impact of the New Kidney Allocation System on Transplant Program Workflow  
Moderators: Micah Davis, University Hospitals  
Cleveland Medical Center, Cleveland, OH, USA and  
Melissa Roberts, MSN, RN, CPTC, Tampa General Hospital, Tampa, FL, USA

2:45 pm  Impact of the New Kidney Allocation System on Transplant Program Workflow  
Nicole McCormick, MS, MBA, NP-C, CCTC  
University of Colorado, Division of Renal Diseases & Hypertension  
Denver, CO, USA

3:05 pm  Discussion

3:15 pm  Coffee Break

Stewarding a Scarce Resource-Everybody Plays a Role  
Moderators: Jeff Orlowski, MS, CPTC, LifeShare  
Transplant Donor Services of Oklahoma, Oklahoma City, OK, USA and Suzanne McGuire, RN, BSN, CCTC, UCLA, Lancaster, CA, USA

David Goldberg, MD  
University of Pennsylvania  
Philadelphia, PA, USA

4:05 pm  Discussion

Options for those without Options  
Moderators: Jeff Orlowski, MS, CPTC, LifeShare  
Transplant Donor Services of Oklahoma, Oklahoma City, OK, USA and Suzanne McGuire, RN, BSN, CCTC, UCLA, Lancaster, CA, USA

4:15 pm  List Exchange/National Kidney Registry  
Marian Charlton, SRN, RN  
Cornell  
New York, NY, USA

4:25 pm  Alturistic Donors  
Bekir Tanriover, MD, MPH, FAST  
UT Southwestern  
Dallas, TX, USA

4:35 pm  Desensitization Protocols  
Russell J. Crew, MD  
NY-Presbyterian/Columbia University Medical Center  
New York, NY, USA

4:45 pm  Discussion

Accepting High KDPI Kidneys – The Who, What, When and How  
Moderators: Jeff Orlowski, MS, CPTC, LifeShare  
Transplant Donor Services of Oklahoma, Oklahoma City, OK, USA and Suzanne McGuire, RN, BSN, CCTC, UCLA, Lancaster, CA, USA

5:00 pm  Accepting High KDPI Kidneys – The Who, What, When and How  
Lloyd Ratner, MD, MPH  
Columbia University  
New York, NY, USA

5:20 pm  Discussion

Basic Immunology and Transplant Immunology for the Clinician  
Room E451B  
Moderators: Robert Gaston, MD, University of Alabama at Birmingham, Birmingham, AL, USA and Ginny Bumgardner, MD, PhD, Ohio State University, Columbus, OH, USA

1:00 pm  Overview of the Immune Response  
Robert Fairchild, PhD  
Cleveland Clinic  
Cleveland, OH, USA

1:25 pm  Inflammation and Innate Immunity and their Impact on Allograft Rejection  
Peter Heeger, MD  
Icahn School of Medicine at Mount Sinai  
New York, NY, USA

1:50 pm  Development and Detection of Donor Reactive T Cell Responses  
Melissa Yeung, MD  
Brigham & Women’s Hospital  
Boston, MA, USA

2:15 pm  T Cell Mediated Rejection: Effector Mechanisms  
Ronald Gill, PhD  
University of Colorado – Denver  
Aurora, CO, USA

2:40 pm  B Cell/Antibody Mediated Rejection  
Peter Nickerson MD, FRCP  
University of Manitoba  
Winnipeg, MB, USA

3:05 pm  Coffee Break
3:30 pm  T Cell and B Cell Targeted Immunosuppression in Transplantation
Roslyn Mannon, MD
University of Alabama, Birmingham, Birmingham, AL, USA

3:55 pm  Impact of Immunologic Memory
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

4:20 pm  Understanding and Interpreting Genomic Studies in Transplantation
Barbara Murphy, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

4:45 pm  Tolerance
Kenneth Newell, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

Advanced Immunology Updates for Basic and Clinical Scientists

Room E451A
Moderators:  Marisa Alegre, MD, PhD, The University of Chicago, Chicago, IL, USA and Jonathan Maltzman, MD, PhD, Stanford University, Palo Alto, CA, USA

1:00 pm  Update on Innate Immunity
Fadi Lakkis, MD
University Pittsburgh
Pittsburgh, PA, USA

1:30 pm  Update on NK Cells and Rejection
Sheri Krams, PhD
Stanford Univ School of Med
Stanford, CA, USA

2:00 pm  Update on T Cells Subsets and Alloimmunity
Leonardo Riella, MD, PhD
Brigham and Women’s Hospital
Boston, MA, USA

2:30 pm  Update on B Cell Subsets and Alloimmunity
Anita Chong, PhD
The University of Chicago
Chicago, IL, USA

3:00 pm  Coffee Break

3:30 pm  Update on Regulatory T Cells
Jamil Azzi, MD
Harvard Medical School, Brigham and Women’s Hospital
Boston, MA, USA

4:00 pm  Update on Memory T Cells
Mandy Ford, PhD
Emory University
Atlanta, GA, USA

4:30 pm  Top 10 Immunology Papers of the Year
Jonathan Bromberg, MD, PhD
University of Maryland
Baltimore, MD, USA

Thomas Starzl, MD, PhD Tribute Program (Open to all ATC registered attendees and exhibitors)
5:30 pm – 6:00 pm
Arie Crown Theater

Opening Reception with Exhibits
6:00 pm – 7:30 pm
Hall D1

Poster Session A
6:00 pm – 7:30 pm
Hall D1

Poster Viewing: 6:00 pm – 7:30 pm
Presenters in Attendance: 6:00 pm – 7:30 pm
Poster Session A can be found on pages 104-129.
### AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Sunday, April 30, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:15 am</td>
<td>Sunrise Symposia</td>
</tr>
<tr>
<td>Page 15</td>
<td>The CKDPC Web-Based Life ESRA Risk Calculator Should Not be Used to Counsel and Select young Living Kidney Donor Candidates Room E450B</td>
</tr>
<tr>
<td>Page 15</td>
<td>Transplantation in the Elderly: Is 80 the New 60? Room E354B</td>
</tr>
<tr>
<td>Page 15</td>
<td>Pushing Boundaries for Recipient Selection in Lung Transplant Room E353C</td>
</tr>
<tr>
<td>Page 16</td>
<td>Practical Challenges in Intestinal Transplant – A Discussion of Cases with Major Centers Room E350</td>
</tr>
<tr>
<td>Page 16</td>
<td>Machine Perfusion Goes Prime Time in Liver Transplantation Room E451B</td>
</tr>
<tr>
<td>Page 16</td>
<td>Alcohol and Liver Transplantation: Is it Time for a Reality Check? Room E353AB</td>
</tr>
<tr>
<td>Page 16</td>
<td>Amyloid: Cardiac Transplantation for a Multi-System Illness Room E351</td>
</tr>
<tr>
<td>Page 17</td>
<td>Top Papers in Transplant Infectious Diseases Room E354A</td>
</tr>
<tr>
<td>Page 17</td>
<td>VCA: Psychosocial Care of VCA Patients: Emerging Aspects Room E352</td>
</tr>
<tr>
<td>Page 17</td>
<td>Optimizing Pharmacologic Risk Assessment of Transplant Recipients and Living Donors Room E450A</td>
</tr>
<tr>
<td>8:30 am – 9:30 am</td>
<td>Plenary</td>
</tr>
<tr>
<td>Page 17</td>
<td>Joint Plenary Session I Arie Crown Theater</td>
</tr>
<tr>
<td>9:30 am – 9:45 am</td>
<td>Joint Award Session</td>
</tr>
<tr>
<td>Page 18</td>
<td>Arie Crown Theater</td>
</tr>
<tr>
<td>9:45 am – 10:00 am</td>
<td>ASTS Pioneer Award</td>
</tr>
<tr>
<td>Page 18</td>
<td>Arie Crown Theater</td>
</tr>
<tr>
<td>10:00 am – 10:15 am</td>
<td>AST Lifetime Achievement Award</td>
</tr>
<tr>
<td>Page 18</td>
<td>Arie Crown Theater</td>
</tr>
<tr>
<td>10:15 am – 10:45 am</td>
<td>Coffee Break with Exhibits Hall D1</td>
</tr>
<tr>
<td>10:45 am – 11:15 am</td>
<td>State-of-the-Art Address</td>
</tr>
<tr>
<td>Page 18</td>
<td>The Tortuous Path to Allograft-specific Therapies Arie Crown Theater</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Midday Symposia</td>
</tr>
<tr>
<td>Page 18</td>
<td>Advances of Laparoscopic Technique in Living Donor Hepatectomy Room E350</td>
</tr>
<tr>
<td>Page 18</td>
<td>Re-transplantation of a VCA – Debate Room E352</td>
</tr>
<tr>
<td>Page 19</td>
<td>Allo-induced Autoimmunity: The Perfect and Underappreciated Storm in Transplantation Room E451B</td>
</tr>
<tr>
<td>Page 19</td>
<td>Chronic Antibody Mediated Rejection – When Should We Intervene and Does It Matter? Arie Crown Theater</td>
</tr>
<tr>
<td>Page 19</td>
<td>Why are Kidneys Discarded and What Can Be Done about It? Room E354A</td>
</tr>
<tr>
<td>Page 19</td>
<td>Management of Viral Hepatitis Before and After Solid Organ Transplantation Room E450B</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>1:00 pm – 2:15 pm</td>
<td>Luncheon Workshops*</td>
</tr>
<tr>
<td>1:30 pm – 4:30 pm</td>
<td>Transplantation in Depth</td>
</tr>
<tr>
<td>2:30 pm – 4:00 pm</td>
<td>Concurrent Oral Abstract Sessions</td>
</tr>
<tr>
<td>2:30 pm – 5:30 pm</td>
<td>Student Program</td>
</tr>
</tbody>
</table>

**Page 20**

- **Strategies for Extending the Cardiac Donor Pool**
  Room E351

- **Strategies for Expanding the Donor Pool in Lung Transplantation**
  Room E451A

- **Advances in Beta Cell Replacement**
  Room E350

- **CMV in 2017: What's Hot, What's New?**
  Room E354B

- **Bench to Bedside – B cells**
  Room E353C

- **Resident Immune Cells in Immunity and Transplant**
  Room E353AB

**Page 21**

- **1:00 pm – 2:15 pm Luncheon Workshops***

- **Ticketed Events**

- **1:30 pm – 4:30 pm Transplantation in Depth**

  - **The Endothelium as a Target of Alloimmune Attack in Transplantation**
    Room E353AB

- **2:30 pm – 4:00 pm Concurrent Oral Abstract Sessions**

  - **Assessing Risk for Antibody-Mediated Rejection in Kidney Transplant Recipients**
    Room E354A

  - **B Cells in Alloimmunity**
    Room E350

  - **Clinical Science: Liver – Hepatocellular Carcinoma**
    Room E451B

  - **Cutting Edge – Cytomegalovirus**
    Room E353C

  - **Heart Waitlist and Allocation: Working to Get It Right**
    Room E267

**Page 22**

**Page 23**

**Page 24**

**Page 25**

**Page 26**

- **Kidney HLA Antibodies**
  Room E354B

- **Kidney: Pediatric Immune Injury and Recurrent Disease**
  Room E451A

- **Novel Immunosuppression Regimens – Tacrolimus Combinations**
  Room E450B

- **Psychosocial and Mediation Adherence Concerns**
  Room E271B

**Page 27**

- **Pediatric Liver**
  Room E271A

- **Predicting Tolerance and Rejection**
  Room E351

- **VCA**
  Room E270

**Page 28**

**Page 29**

**Page 30**

**Page 31**

**Page 32**

- **The Science, The Art and the Allure of Transplantation**
  Room E253ABCD

- **Case-Based Approach to the Multidisciplinary Management of Complex Chronic Disease States Post-Transplantation**
  Room E258

- **Coffee Break with Exhibits**
  Hall D1
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>Concurrent Oral Abstract Sessions</td>
</tr>
<tr>
<td>Page 34</td>
<td><strong>Clinical Science: Kidney</strong>&lt;br&gt;Immunosuppression: Desensitization&lt;br&gt;Room E354B</td>
</tr>
<tr>
<td>Page 34</td>
<td><strong>Innate Immunity</strong>&lt;br&gt;Room E350</td>
</tr>
<tr>
<td>Page 35</td>
<td><strong>Kidney Allocation: Changes and Consequences</strong>&lt;br&gt;Room E450A</td>
</tr>
<tr>
<td>Page 36</td>
<td><strong>Kidney Clinical Complications – 1</strong>&lt;br&gt;Room E354A</td>
</tr>
<tr>
<td>Page 36</td>
<td><strong>Kidney: Acute Cellular Rejection</strong>&lt;br&gt;Room E451B</td>
</tr>
<tr>
<td>Page 37</td>
<td><strong>Liver Allocation, Utilization and Machine Perfusion</strong>&lt;br&gt;Room E451A</td>
</tr>
<tr>
<td>Page 38</td>
<td><strong>Liver: Viral Hepatitis</strong>&lt;br&gt;Room E271A</td>
</tr>
<tr>
<td>Page 38</td>
<td><strong>Lung Transplantation from Donation to Retransplantation</strong>&lt;br&gt;Room E270</td>
</tr>
<tr>
<td>Page 39</td>
<td><strong>New Insights – HCV/HIV</strong>&lt;br&gt;Room E271B</td>
</tr>
<tr>
<td>Page 40</td>
<td><strong>Novel Immunosuppression – DSA Monitoring</strong>&lt;br&gt;Room E450B</td>
</tr>
<tr>
<td>Page 40</td>
<td><strong>Pancreas Transplantation</strong>&lt;br&gt;Room E267</td>
</tr>
<tr>
<td>Page 41</td>
<td><strong>Pathways of Clinical Rejection</strong>&lt;br&gt;Room E351</td>
</tr>
<tr>
<td>Page 41</td>
<td><strong>T Cell Biology and Alloimmunity</strong>&lt;br&gt;Room E352</td>
</tr>
<tr>
<td>Page 42</td>
<td><strong>Tolerance: Clinical Studies</strong>&lt;br&gt;Room E353C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6:00 pm – 7:00 pm</th>
<th>Poster Session B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Presenters in Attendance&lt;br&gt;Hall D1</td>
</tr>
</tbody>
</table>
Sunrise Symposia
7:00 am – 8:15 am

The CKDPC Web-Based “Lifetime ESRD Risk Calculator” Should Not Be Used to Counsel and Select Young Living Kidney Donor Candidates
Room E450B
Moderators: Stuart Flechner, MD, FACS, Cleveland Clinic Foundation, Cleveland, OH, USA and Lisa Florence, MD, Swedish Organ Transplant Program, Seattle, WA, USA

7:00 am PRO – The CKDPC Web-Based “Lifetime ESRD Risk Calculator” Should Not Be Used to Counsel and Select Young Living Kidney Donor Candidates
Robert Steiner, MD
UCSD Center for Transplantation, University of California at San Diego La Jolla, CA, USA

7:25 am CON – The CKDPC Web-Based “Lifetime ESRD Risk Calculator” Should Not Be Used to Counsel and Select Young Living Kidney Donor Candidates
Krista Lentine, MD
Saint Louis Univ Sch of Med
St Louis, MO, USA

7:50 am Discussion

Transplantation in the Elderly: Is 80 the New 60?
Room E354B
Moderators: Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington DC, USA and Joanna Schaenman, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

7:00 am Epidemiology and Outcomes in the Elderly Transplant Recipient
Greg Knoll, MD
The Ottawa Hospital
Ottawa, Canada

7:20 am Evaluation of Frailty and Association with Post Transplant Outcomes
Mara McAdams DeMarco
Johns Hopkins University
Baltimore, MD, USA

7:40 am Rehabilitation of the Elderly Transplant Candidate Prior to Transplantation
Michael Englesbe, MD
University of Michigan
Ann Arbor, MI, USA

8:00 am Discussion

Pushing Boundaries for Recipient Selection in Lung Transplant
Room E353C
Moderators: Joshua Mooney, MD, Stanford University Medical Center, Stanford, CA, USA and Sangeeta Bhorade, MD, Northwestern University, Chicago, IL, USA

7:00 am Expanding Recipient Access: Advanced Age
Wayne Tsuang, MD, MHS
Cleveland Clinic
Cleveland, OH, USA

7:20 am Expanding Recipient Access: The Role of Extracorporeal Membranous Oxygenation (ECMO)
Carli Lehr, MD
Cleveland Clinic
Cleveland, OH, USA

7:40 am Expanding Recipient Access: The Impact of Esophageal Dysmotility
Joseph Pilewski, MD
University of Pittsburgh

8:00 am Discussion
Practical Challenges in Intestinal Transplant – A Discussion of Cases with Major Centers
Room E350
Moderator: Thiago Beduschi, MD, University of Miami, Miami, FL, USA
7:00 am Panelists:
Kishore Iyer, MD
Mount Sinai Medical Center
New York, NY, USA
David Mercer, MD
University of Nebraska Medical Center
Omaha, NE, USA
Richard Mangus, MD, FACS, MS
Indiana University School of Medicine
Indianapolis, IN, USA
Cal Matsumoto, MD
Georgetown University Hospital
Washington, DC, USA

Machine Perfusion Goes Prime Time in Liver Transplantation
Room E451B
Moderators: James Markmann, MD, PhD, Massachusetts General Hospital, Boston, MA, USA and Henri Leuvenink, PhD, University of Groningen, Netherlands
7:00 am Machine Perfusion to Enhance Standard Livers and Recover Otherwise Discarded Organs
Darius Mirza
University of Birmingham
Birmingham, United Kingdom
7:25 am Establishing Machine Perfusion as the Standard of Care in the UK
Peter Friend
University of Oxford
Oxford, United Kingdom
7:50 am Can We implement Machine Perfusion Nationally in the US?
James Guerrera, MD
Columbia University Medical Center
New York, NY, USA

Alcohol and Liver Transplantation: Is it Time for a Reality Check?
Room E353AB
Moderators: Michael Lucey, MD, FRCPI, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA and TBD
7:00 am Alcoholic Liver Disease and Liver Transplantation: What Are the Challenges Involved?
Thomas Schiano, MD, FACS
Ichan School of Medicine, Mt. Sinai
New York, NY, USA
7:25 am The Ethics of Liver Transplantation in the Management of Alcoholic Liver Disease
Zeeshan Butt, PhD
Northwestern University Feinberg School of Medicine
Chicago, IL, USA
7:50 am Can We Predict Recidivism After Liver Transplantation and Does it Really Matter?
Andrea DiMartini, MD
University of Pittsburgh
Pittsburgh, PA, USA

Amyloid: Cardiac Transplantation for a Multi-System Illness
Room E351
Moderators: David Nelson, MD, INTEGRIS Baptist Med Ctr of Oklahoma, Oklahoma City, OK, USA and Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA
7:00 am Amyloid: What A Tangled Web We Weave. Considerations When Assessing Patients for Transplant Who Have Amyloid.
TBD
7:15 am Cardiac Amyloid: Clinical Trials Past, Present and Future
TBD
7:30 am Combined Organ Transplantation for Amyloidosis: Kidney and Liver
TBD
7:45 am A Journey from Diagnosis to Post-Transplant Life: Amyloid (Lifecycle Presentation: Case and Discussion by All Panelists)
Hari Mallidi, MD
Brigham and Women’s Hospital
Boston, MA, USA
8:00 am Discussion
Top Papers in Transplant Infectious Diseases

Room E354A
Moderators: Emily Blumberg, MD, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA and Atul Humar, MD, Toronto General Hospital, Toronto, ON, USA

7:00 am  Top 5 Papers: Viruses
Lara Danziger-Isakov, MD, MPH
University of Cincinnati
Cincinnati, OH, USA

7:25 am  Top 5 Papers: Bacteria
Shirish Huprikar, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

7:50 am  Top 5 Papers: Fungi et al.
Robin Avery, MD
Johns Hopkins
Baltimore, MD, USA

VCA: Psychosocial Care of VCA Patients: Emerging Aspects

Room E352
Moderators: Gerry S. Lipshutz, MD, MS, UCLA, Los Angeles, CA, USA and Linda Cendales, MD, Duke University, Durham, NC, USA

7:00 am  Key Domains of the Psychosocial Assessment in VCA
Sheila Jowsey-Gregoire, MD
Mayo Clinic
Rochester, MN, USA

7:25 am  Psychosocial Complications in VCA: Worldwide Experience and Considerations
Palmina Petruzzo, MD
University of Cagliari
Cagliari, Italy

7:50 am – 8:15 am  Psychosocial Aspects of Genitourinary Transplantation and Review of the Current Experience
Curtis Cetrulo, MD
Massachusetts General Hospital
Boston, MA, USA

Optimizing Pharmacologic Risk Assessment of Transplant Recipients and Living Donors

Room E450A
Moderators: Maya Campara, PharmD, BCPS, University of Illinois at Chicago, Chicago, IL, USA and Bharath Ravichandran, PharmD, University of Maryland Medical Center, Baltimore, MD, USA

7:00 am  Identification and Management of High Pharmacologic Risk Candidates
Jennifer Trofe-Clark, PharmD, BCPS
Univ of Pennsylvania
Philadelphia, PA, USA

7:25 am  Structuring and Sustaining Transplant Pharmacy Services in the Pre-Transplant Setting
Angela Maldonado, PharmD, BCPS
Vidant Medical Center – Transplant Services
Greenville, NC, USA

7:50 am  Pharmacologic Risk Assessment in Living Donors
Laura Myhre, PharmD, BCPS
Mayo Clinic Rochester
Rochester, MN, USA

Joint Plenary Session I

8:30 am – 9:30 am

Arie Crown Theater

Chairs: Anil Chandraker, MD, FASN, FRCP, Brigham and Women's Hospital, Boston, MA, USA and Timothy L. Pruett, MD, University of Minnesota, Minneapolis, MN, USA

8:30 am  Transplanting Hepatitis C Kidneys into Negative Kidney Recipients [THINKER] Trial (Abstract #1)

8:45 am  EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients (Abstract #2)
Christine M. Durand, Diane Brown, Russell Wesson, Nicole Bha, Fizza Naqvi, Darin Ostrander, Mary G. Bowring, Allan B. Massie, Sarah Rasmussen, Jeremy Sugarman, Dorry L. Segev, Mark Sulkowski, Niraj Desai. Baltimore, MD.
Emerging Application of Active Immune Targeted Delivery in Transplantation (Abstract #3)
Mayuko Uehara, Jamil Azzi, Baharak Bahmani, Jianjun Cheng, Qian Yin, Li Tang, Kaimin Cai, Qidi Sun, Mincheol Kwon, Qiaobing Xu, Gerald Brandacher, Reza Abdi. Boston; IL; Baltimore.

Uptake of Extracellular Mitochondria Activates Human Endothelial Cells That Stimulate Alloreactive Effector T Cell Responses (Abstract #4)
Todd V. Brennan, Feifei Feng, Liwen Lin, Mingqing Song, Qi-Jing Li, Allan D. Kirk, He Xu. Durham, NC.

Joint Award Session
9:30 am – 9:45 am
Arie Crown Theater

ASTS Pioneer Award
9:45 am – 10:00 am
Arie Crown Theater

AST Lifetime Achievement Award
10:00 am – 10:15 am
Arie Crown Theater

Coffee Break with Exhibits
10:15 am – 10:45 am
Hall D1

State-of-the-Art Address
10:45 am – 11:15 am
Arie Crown Theater

The Tortuous Path to Allograft-specific Therapies
Marc Jenkins, PhD
University of Minnesota Medical School
Minneapolis, MN, USA

Midday Symposia
11:30 am – 1:00 pm

Advances of Laparoscopic Technique in Living Donor Hepatectomy
Room E450A
Moderators: Kyung-Suk Suh, MD, Seoul National University Hospital, Seoul, Republic of Korea and Kim Olthoff, MD, University of Pennsylvania, Philadelphia, PA, USA

11:30 am Pure Laparoscopic Donor Right Hepatectomy Using ICG Technique
Kyung-Suk Suh, MD
Seoul National University Hospital
Seoul, Republic of Korea

11:50 am Hybrid and Other Modified Laparoscopic Donor Hepatectomy
Susumu Eguchi
Nagasaki University Graduate School of Biomedical Sciences
Nagasaki, Japan

12:10 pm Robot-assisted Donor Hepatectomy
Pier Cristoforo Giulianotti, MD, FACS
University of Illinois
Chicago, IL, USA

12:30 pm Discussion

Re-transplantation of a VCA – Debate
Room E352
Moderators: Kenneth Brayman, MD, PhD, University of Virginia Health System, Charlottesville, VA, USA and Darla Granger, MD, St. John Hospital and Medical Center, Detroit, MI, USA

11:30 am Re-transplantation of a VCA – PRO
Warren Breidenbach, MD
University of Arizona
Tucson, AZ, USA

12:00 pm Re-transplantation of a VCA – CON
Simon Talbot, MD
Brigham and Women’s Hospital
Boston, MA, USA

12:30 pm Discussion
**Allo-induced Autoimmunity: The Perfect and Underappreciated Storm in Transplantation**

**Room E451B**  
Moderators: Robert Fairchild, PhD, Cleveland Clinic, Cleveland, OH, USA and Lori West, MD, D.Phil, University of Alberta/CNTRP, Edmonton, AB, Canada

**11:30 am** Autoimmunity in Lung Transplantation  
Thalachallour Mohanakumar, PhD  
St. Joseph’s Hospital and Medical Center  
Phoenix, AZ, USA

**12:00 pm** Apoptotic Exosomes: The Missing Link between Tissue Injury, Autoantibodies and Rejection  
Marie-Josee Hebert  
CHUM  
Montreal, QC, Canada

**12:30 pm** Natural Antibodies from Allosensitization to Rejection  
Emmanuel Zorn, PhD  
Columbia Univ.  
New York, NY, USA

**Chronic Antibody Mediated Rejection – When Should We Intervene and Does It Matter?**

**Arie Crown Theater**  
Moderators: E. Steve Woodle, MD, Univ of Cincinnati Clg of Med, Cincinnati, OH, USA and Michael Davis, MD, University of New Mexico, Albuquerque, NM, USA

**11:30 am** The Impact of Alloantibody/Subclinical AMR on Chronic Allograft Injury  
Alexandre Loupy, MD, PhD  
Paris Transplant Group  
Paris, France

**12:00 pm** What is the Impact of Clinical AMR on Long-Term Outcomes?  
Dorry Segev, MD, PhD  
Johns Hopkins University  
Baltimore, MD, USA

**12:30 pm** Therapies for AMR: What Works and is there Anything New?  
Stanley Jordan, MD  
Cedar Sinai Los Angeles  
West Hollywood, CA, USA

**Why are Kidneys Discarded and What Can Be Done about It?**

**Room E354A**  
Moderators: Amit Mathur, MD, MS, FACS, Mayo Clinic Arizona, Phoenix, AZ, USA and Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington DC, USA

**11:30 am** Epidemiology of Deceased Donor Kidney Discards in the United States  
Jesse Schold, PhD, M. Stat, M.Ed.  
Cleveland Clinic Foundation  
Cleveland, OH, USA

**12:00 pm** PRO: Biopsy of Deceased Donor Kidneys Provides Valuable Information  
Michael Mengel, MD  
University of Alberta  
Edmonton, Canada

**12:15 pm** CON: Biopsy of Deceased Donor Kidneys Provides Valuable Information  
Arthur Matas  
University of Minnesota  
Minneapolis, MN, USA

**12:30 pm** Strategies to Decrease Organ Discard – From Pumps to Policy  
Lloyd Ratner, MD, MPH  
Columbia University  
New York, NY, USA

**Management of Viral Hepatitis Before and After Solid Organ Transplantation**

**Room E450B**  
Moderators: Walid Ayoub, MD, Cedars Sinai Medical Center, Los Angeles, CA, USA and Nancy Reau, MD, Rush University Medical Center, Chicago, IL, USA

**11:30 am** Treatment of Hepatitis C Before and After Liver Transplantation  
Robert Brown, MD  
Weill Cornell Medical College  
New York, NY, USA

**12:00 pm** Treatment of Hepatitis C Before and After Non-Liver Transplantation  
Norah Terrault, MD, MPH  
UCSF  
San Francisco, CA, USA

**12:30 pm** Management of Hepatitis B in Organ Transplant Candidates and Recipients  
Paul Martin, MD  
University of Miami School of Medicine  
Miami, FL, USA
Strategies for Extending the Cardiac Donor Pool
Room E351
Moderators: Geetha Bhat, PhD, MD, FACC, FAST, Advocate Christ Medical Center, Oak Lawn, IL, USA and Jeffrey Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA

11:30 am Are We Currently Taking Too Many Risks or Not Enough?
Allen Anderson, MD, FACC
Northwestern University
Chicago, IL, USA

11:45 am High Risk Donors: What the Department of Health Says or Doesn’t Say
Robin Avery, MD
Johns Hopkins
Baltimore, MD, USA

12:00 pm Hepatitis C Donors: Do New Therapies Mean New Options?
Jignesh Patel, MD, PhD
Cedars-Sinai Heart Institute
Beverly Hills, CA, USA

12:15 pm OCS: Is It Ready for Prime Time?
Abbas Ardehali, MD
UCLA
Los Angeles, CA, USA

12:30 pm DCD Hearts: Small Step or Great Leap in Expanding the Donor Pool?
Kumud Dhital, MD, PhD, FRACS
St Vincent’s Hospital
Sydney, Australia

12:45 pm Discussion

Strategies for Expanding the Donor Pool in Lung Transplantation
Room E451A
Moderators: Cassie Kennedy, MD, Mayo Clinic, Rochester, MN, USA and Cynthia Gries, MD, MSc, Florida Hospital, Orlando, FL, USA

11:30 am Expanding the Lung Donor Pool: Ex Vivo Lung Perfusion
Andrew Fisher, PhD, FRCP
Newcastle University
Newcastle Upon Tyne, United Kingdom

12:00 pm Expanding the Lung Donor Pool: Use of Increased Risk Donors
Michael Ison, MD, MS
Northwestern University Feinberg School of Medicine
Chicago, IL, USA

12:30 pm Expanding the Current Donor Pool: Donation After Circulatory Determination of Death (DCD)
Joshua Mooney, MD
Stanford University Medical Center
Stanford, CA, USA

Advances in Beta Cell Replacement
Room E350
Moderators: Jon Odorico, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA and James Markmann, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

11:30 am From Licensure to Application, What’s Next for Allogeneic Islet Transplantation
Jose Oberholzer, MD
Univ of Illinois at Chicago
Chicago, IL, USA

12:00 pm Advances in Islet Xenotransplantation
Bernhard Hering, MD
Univ of Minnesota
Minneapolis, MN, USA

12:30 pm Stem Cell Derived Beta Cells
Peter Stock, MD, PhD
UCSF
San Francisco, CA, USA

CMV in 2017: What’s Hot, What’s New?
Room E354B
Moderators: Deepali Kumar, MD, University of Toronto, Toronto, ON, Canada and Nassim Kamar, MD, PhD, Toulouse University Hospital, Toulouse, France

11:30 am Negative Impacts of CMV on the Transplant Allograft & Optimal Prevention
Raymund Razonable, MD
Mayo Clinic
Rochester, MN, USA

12:00 pm The T Cell Response to CMV Infection: Bench to Bedside
Laurie Snyder, MD, MHS
Duke University
Durham, NC, USA

12:30 pm Anti-CMV Armamentarium of the Future
Camille Kotton, MD
Massachusetts General Hospital
Boston, MA, USA
Bench to Bedside – B cells

Room E353C
Moderators: Xian Li, MD, PhD, Houston Methodist, Houston, TX, USA and Anita Chong, PhD, The University of Chicago, Chicago, IL, USA

11:30 am Basic- How B Cells Influence the Immune Response
Peter Nickerson, MD, FRCPC
University of Manitoba
Winnipeg, MB, Canada

12:00 pm Translational- Regulatory B Cells in Kidney Transplant Recipients
David Rothstein, MD
Univ of Pittsburgh
Pittsburgh, PA, USA

12:30 pm Clinical- B Cell Modulation in Transplantation
Menna Clatworthy
University of Cambridge
Cambridge, United Kingdom

Resident Immune Cells in Immunity and Transplant

Room E353AB
Moderators: Mandy Ford, PhD, Emory University, Atlanta, GA, USA and Jordan Pober, MD, PhD, Yale University School of Med, New Haven, CT, USA

11:30 am Differentiation of Tissue Resident Memory T cells
Alexander Kroemer
Georgetown University
Washington, DC, USA

12:00 pm Tissue Resident Memory T Cells in Lung Inflammation and Asthma
Daniel Kreisel, MD, PhD
Washington University St. Louis
St. Louis, MO, USA

12:30 pm Impact of Donor-Derived Tissue-Resident Cells on Alloimmunity Following Transplantation
Gavin Pettigrew, MD
University of Cambridge
Cambridge, United Kingdom

Luncheon Workshops – Ticketed Events

1:00 pm – 2:15 pm

1. Liver Transplant Histopathology and Clinical Correlation: A Review of Both the Basic and Complex
   Moderators: Thomas D. Schiano, MD, FACS, Icahn School of Medicine, Mt. Sinai, New York, NY, USA and M. Isabel Fiel, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA

2. How to Maximize Islet Yield from Chronic Pancreatitis Pancreases Intended for Islet Auto-Transplantation
   Moderators: Michael Hughes, Jr., MD, University of Louisville, Louisville, KY, USA, Rainer Gruebner, MD, SUNY Upstate Medical University, Syracuse, NY, USA and Balamurugan N. Appakalai, PhD, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY, USA

3. The Role of Professional Coaching in Developing Emotional Intelligence and Promoting Cultural Competency
   Moderators: Jorge Ortiz, MD, University of Toledo, Toledo, OH, USA and Jayme Locke, MD, MPH, University of Alabama at Birmingham, Birmingham, AL, USA

4. Transplant Dermatology: New Evidence, New Approaches and a Fresh Mandate for Interdisciplinary Collaboration
   Moderators: Christina Lee Chung, MD, Drexel University, Philadelphia, PA, USA and Simon Yoo, Northwestern University

5. TransQIP: A View from the Trenches – Results of the Pilot Phase for Kidney and Liver Transplantation
   Moderators: Stuart Greenstein, MD, Montefiore Medical Center, Bronx, NY, USA, Ryutaro Hirose, MD, UCSF, San Francisco, CA, USA and Justin Parekh, MD, UT Southwestern, Dallas, TX, USA

Transplantation in Depth

1:30 pm – 4:30 pm

The Endothelium as a Target of Alloimmune Attack in Transplantation

Room E353AB
Moderators: David Briscoe, MD, MB, BCH, Boston Children’s Hospital, Boston, MA, USA and Bryna Burrell, PhD, Immune Tolerance Network, Bethesda, MD, USA

1:30 pm Mechanisms of Transendothelial Migration
William Muller, MD, PhD
Northwestern University Feinberg School of Medicine
Chicago, IL, USA

2:05 pm The Role of Lymphatic Endothelium in Regulating Adaptive Immunity
Melody Swartz, PhD
University of Chicago
Chicago, IL, USA
2:40 pm  Tregs and Transendothelial Migration  
Jonathan Bromberg, MD, PhD  
University of Maryland  
Baltimore, MD, USA

3:15 pm  The Endothelium and Its Role in Allograft Rejection  
Jordan Pober, MD, PhD  
Yale University School of Med  
New Haven, CT, USA

3:50 pm  Anti-Donor Antibody and Endothelial Injury  
Elaine Reed, PhD  
Univ of California LA  
Los Angeles, CA, USA

4:25 pm  Discussion

Concurrent Oral Abstract Sessions  
2:30 pm – 4:00 pm

Assessing Risk for Antibody-Mediated Rejection in Kidney Transplant Recipients

Room E354A
Chairs: David Landsberg, MD, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada and E. Steve Woodle, University of Cincinnati, Cincinnati, OH, United States

2:30 pm  Lower Mean Tacrolimus Troughs Increase Risk of De Novo Donor-Specific Antibodies in the First Year of Kidney Transplant (Abstract #5)  
Scott Davis, Jane Gralla, Patrick Klem, Alexander Wiseman, James Cooper. Aurora, CO.

2:42 pm  Kidney Transplant Rejection Associated with DQ Eplet Mismatches (Abstract #6)  
Samuel Chakola, Paul Warner, Nicole Andeen, Behzad Najafian, Nicolae Lea, Christopher Blosser. Seattle, WA.

2:54 pm  Association with Tacrolimus Intraindividual Variability, Acute Microinflammation Based on 1 Year-Transplanted Kidney Biopsy After Transplantation and Biopsy-Proven Acute Rejection (Abstract #7)  

3:06 pm  Long-Term Liver and Kidney Survival Following Combined Liver-Kidney Transplantation, with or without Preformed Donor-Specific Antibodies (Abstract #8)  
Arnaud Del Bello, Oriol Bestard, Jonathan Visentin, Nicolas Congy-Jolivet, Lionel Couzi, Martine Neau-Cransac, Frederic Jambon, Nassim Kamar. Toulouse, France; Barcelona, Spain; Bordeaux, France.

3:18 pm  Biological Interplay Between Circulating HLA-sp Alloreactive Memory B-Cells and Long-Lived Plasma Cells in Kidney Transplant Patients Undergoing Chronic ABMR (Abstract #9)  
Sergi Luque, Marc Lúcia, Marta Jarque, Elena Crespo, Edoardo Melilli, Jaume Martorell, Josep M. Cruzado, Joan Torras, Josep M. Grinyó, Oriol Bestard. Barcelona, Spain; Stanford.

3:30 pm  Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients (Abstract #10)  
Marie Marron-Wojewodzki, Ilan Szwarc, Céline Rene, Georges Mourad, Moglie Le Quintrec. Montpellier, France.

3:42 pm  Long-Term Outcome of Antibody-Mediated Rejection Due to Pre-Existing vs. De Novo DSA in Kidney Allograft Recipients (Abstract #11)  

B Cells in Alloimmunity

Room E350
Chairs: David Rothstein, Univ of Pittsburgh, Pittsburgh, PA, United States and Melissa Yeung, Brigham & Women’s Hospital / Harvard Medical School, Boston, MA, United States

2:30 pm  Characterization of a B Lymphocyte Signature Predictive of Chronic Lung Allograft Dysfunction (Abstract #12)  
2:42 pm B Cell-Derived Cytokines Rather Than T/B Cognate Interactions Mediate CD8 T Cell Reconstitution Following Lymphoablation (Abstract #13)
Daniel B. Zwick, Katayoun Ayasoufi, Ran Fan, Victoria Gorbacheva, Karen S. Keslar, Robert L. Fairchild, Anna Valujskikh. Cleveland, OH.

2:54 pm Dual Targeting with Carfilzomib and Tocilizumab Abrogates Antibody-Mediated Rejection and Prolongs Survival in a Highly Sensitized Rhesus Model of Kidney Transplantation (Abstract #14)

3:06 pm Effective Targeting Plasma Cells with Daratumumab (Anti-CD38) and Mozobil (Anti-CXCR4) in a Sensitized Non-Human Primate Model (Abstract #15)

3:18 pm Dual Targeting of Costimulation and Proteasome to Desensitize and Prolong Graft Survival of Sensitized Nonhuman Primates (Abstract #16)
Jean Kwun, Christopher Burghuber, Miriam Manook, Brian Ezekian, Jaeberm Park, Kyle Freishlag, Janghoon Yoon, Neal Iwakoshi, Alton Farris, Stuart Knechtle. Durham, NC; Seoul, Korea; Atlanta, GA.

3:30 pm Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation (Abstract #17)
Miriam Manook, Jean Kwun, Janghoon Yoon, Kannan Samy, Andrea MacDonlad, He Xu, Richard Smith, Stephen Sacks, Anthony Dorling, Nizam Mamode, Stuart Knechtle. Durham, NC; Sondon, United Kingdom; London, United Kingdom.

3:42 pm TACI Polymorphisms Associated with De Novo Alloantibodies in Humans and Allograft Rejection in Mice (Abstract #18)
Jeffrey L. Platt, Evan A. Farkash, Adam R. Lefferts, Milagros Samaniego, Marilia Cascalho. Ann Arbor, MI.

Clinical Science: Liver – Hepatocellular Carcinoma
Room E451B
Chairs: John Lake, University of Minnesota, Minneapolis, MN, United States and Gregory McKenna, Baylor University Medical Center, Dallas, TX, United States

2:30 pm Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation (Abstract #19)

2:42 pm Current Treatments for Small Hepatocellular Carcinoma: A Network Meta-Analysis of Randomized Controlled Trials (Abstract #20)
Zhiyong Guo, Zhouying Zheng, Xiaoshun He, Guodong Chen. Guangzhou, China.

2:54 pm Multicenter Validation of a Clinicopathologic Risk Score to Predict Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4984 Patients from the US Multicenter HCC Transplant Consortium (Abstract #21)
Vatche G. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium. LA.

3:06 pm A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium (Abstract #22)
Vatche G. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium. LA.
Long Wait Time Regions for Liver Transplantation for HCC Have a Higher Cumulative Incidence of Death (Abstract #23)
Rachel Hogen, Joseph Dinorcia, Mary Lo, Brian Nguyen, Yuri Genyk, Linda Sher, Kiran Dhanireddy. Los Angeles, CA.

Hispanic Paradox in Patients with Liver Cirrhosis (Abstract #24)

Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beyond Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750) (Abstract #25)
Kwang-Woong Lee, Seoung-Hoon Kim, Nam-Joon Yi, Suk-Kyun Hong, Gyunghul Yoon, Hyeyeon Kim, Donggyu Oh, Sung-Sik Han, Sang-Jae Park, Kyung-Suk Suh. Seoul, Republic of Korea; Goyangsi, Republic of Korea.

Prospective Randomized Trial for Predicting CMV Infection According to Baseline CMV-Specific T-Cell Immunity in Kidney Transplant Patients (Abstract #27)
Marta Jarque, Edoardo Melilli, Alex Gutierrez, Francesco Moreso, Luís Guirado, Anna Manonelles, Josep M. Cruzado, Sergi Luque, Elena Crespo, Nuria Montero, Fritz Diekman, Josep M. Grinyó, Oriol Bestard. Barcelona, Spain; Zaragoza, Spain.

Pre-Transplant CMV-Specific T-Cell Immunity Is an Additional Independent Variable Predicting CMV Infection After Kidney Transplantation (Abstract #28)
Elena Crespo, Marta Jarque, Sergio Luque, Edoardo Melilli, Anna Manonelles, Salvador Gil-Vernet, Josep M. Cruzado, Josep M. Grinyó, Oriol Bestard. Barcelona, Spain.

Efficacy and Safety of ASP0113 versus Placebo in CMV-Seronegative Kidney Transplant Patients Receiving an Organ from a CMV-Seropositive Donor (Abstract #29)
Flavio L. Vincenti, Klemens Budde, Pierre Merville, Fuad Shihab, V. Ram Peddi, Malay Shah, Elisabeth Cassuto-Viguier, Alexander Weidemann, Misun Lee, Teresa Flegel, Jay Erdman, Xuegong Wang, Christopher Lademacher. San Francisco; Berlin, Germany; Bordeaux, France; Salt Lake City; Lexington; Nice, France; Erlangen, Germany; Cologne, Germany; Chicago.

Impact of T-Cell Depletion on CMV-Specific Memory T and B Cell Homeostatic Proliferation After Kidney Transplantation (Abstract #30)
Marta Jarque, Sergi Luque, Elena Crespo, Edoardo Melilli, Joan Torras, Josep M. Grinyó, Oriol Bestard. Barcelona, Spain.

Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis (Abstract #31)
Yoichiro Natori, Ali Alghamdi, Deepali Kumar, Veronica Miller, Per Ljungman, Shahid Husain, Atul Humar. Toronto, Canada; Berkeley; Solna, Sweden.
3:42 pm  BK Virus, Cytomegalovirus and Epstein-Barr Virus Reactivation in Renal Transplant Patients: Results from a Large Multicenter Study (Abstract #32)

Heart Waitlist and Allocation: Working to Get It Right

Room E267
Chairs: Allen Anderson, MD, Northwestern, Chicago, IL, United States and Sean Pinney, MD, Mount Sinai Hospital, New York, NY, United States

2:30 pm  To Accept or Not Accept, That Is the Question: Donor Heart Selection Process and Outcome of Discarded Organs Transplanted in Another Center (Abstract #33)
Arezu Z. Alibadi-Zuckermann, Johannes Goekler, Alexandra Kaider, Julia Riebandt, Roxana Moayedifar, Emilio Osorio, Thomas Haberl, Guenter Laufer, Jacqueline Smits, Andreas Oliver Zuckermann. Vienna, Austria; Leiden, Netherlands.

2:42 pm  Minimal Effect of Broader Heart Sharing on Regional Outcomes (Abstract #34)
Abbas Bitar, M. Skeans, R. Davies, M. Farr, A. Kao, L. Robbins-Callahan, J. Rogers, S. Silvestry, Monica Colvin. Ann Arbor, MI; Mpls, MN; Wilmington, DE; NY, NY; KC, MO; Richmond, VA; Durham, NC; Orlando, FL.

2:54 pm  Trends in the Number and Medical Urgency of Adult Heart Transplant Candidates Listed as Status 1A from 2006-2015 (Abstract #35)
William F. Parker, Matthew Churpek, Savitri Fedson, Edward Garrity. Chicago, IL; Houston, TX.

3:06 pm  Precise Antibody Characterization Using Multiple Solid Phase Assay Platforms Is Critical for Accurate Virtual Crossmatching (Abstract #36)
Dong Li, Olga Timofeeva, Mariam Awwad, Chelsea Cody, Samer S. Najjar, Sandra Rosen-Bronson. Washington, DC.

3:18 pm  Redefining Pediatric Heart Status 1A and 1B Criteria: Results of Early Policy Evaluation (Abstract #37)
Wida Cherikh, Ryan Davies, Yulin Cheng, William Mahle. Richmond, VA; Wilmington, DE; Atlanta, GA.

3:30 pm  The Ultimate Calculated Panel Reactive Antibody Value Predicts Mortality After Heart Transplantation (Abstract #38)
Evan Kransdorf, Michelle Kittleson, Jignesh Patel, Marcelo Pando, Lawrence Czer, Jon Kobashigawa. Los Angeles; Phoenix.

3:42 pm  Simultaneous or Sequential Heart-Liver Transplantation Confer Superior Survival in Patients with Listed for Heart-Liver Transplantation: A National Analysis (Abstract #39)
Kevin Anderson, Michael Mulvihill, Babatudne Yerokun, Andrew Barbas, Matthew Hartwig. Durham, NC.

Innate Pathways of Clinical Alloreactivity

Room E352
Chairs: Camila Macedo, MD, Starzl Transplantation Institute- University of Pittsburgh, Pittsburgh, PA, United States and Angus Thomson, PhD, DSc, University of Pittsburgh, Pittsburgh, PA, United States

2:30 pm  Innate Lymphoid Cells Play a Critical Role in Regulating Allograft Homeostasis in Human Intestinal Transplantation (Abstract #40)
Priscilla Cha, Brenna Houlihan, Jason Kaiser, Christopher Cosentino, Brian Monahan, Anshi Shukla, Jason Hawksworth, Cal Matsumoto, Thomas Fishbein, Alexander Kroemer. Washington, DC.

2:42 pm  Autophagy Regulates LG3 Maturation and Export in Apoptotic Exosome-Like Vesicles (Abstract #41)
Déborah Beilleiva, Migneault Francis, Gingras Diane, Boillard Éric, Dieudé Mélanie, Hébert Marie-Josée. Montréal, Canada; Québec, Canada; Edmonton, Canada.
2:54 pm  mTOR Inhibition Diminishes Peripheral Blood CD8+CD28-CD38hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection (Abstract #42)

Kidney HLA Antibodies
Room E354B
Chairs: Amgad El-Agroudy, MBChB, PhD, FASN, FACP, Mansoura University, Mansoura, DK, Egypt and Richard Fatica, MD, Cleveland Clinic, Cleveland, OH, United States

2:30 pm  De Novo Donor-Specific Antibodies After Allograft Nephrectomy (Abstract #47)

3:06 pm  A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells (Abstract #43)
J. J. Driscoll, S. Tremblay, S. J. Knechtle, E. S. Woodle. Cincinnati, OH; Durham, NC.

2:42 pm  De Novo, Non-Donor Specific HLA Antibodies Are Associated with Inferior Allograft Outcomes After Kidney and Simultaneous Kidney-Pancreas Transplantation (Abstract #48)

3:18 pm  Significant Allosensitisation Despite Early, within 24 Hour, Graft Nephrectomy (Abstract #51)
3:30 pm  Graft Survival in De Novo Donor-Specific Antibodies and Positive Flow Crossmatch Kidney Transplants Is influenced by Class I and Class II (Abstract #52)

3:42 pm  Incidence of De Novo Donor-Specific Antibodies Following Kidney Transplantation (Abstract #53)

3:06 pm  Post-Donation Remaining Donor Kidney Function as Measured by CKD-EPI Formula at 2 Years Correlates and Is Predicted by Remaining Donor Kidney Volume (Abstract #57)

3:18 pm  Advanced Donation within a Paired Exchange Program (Abstract #58)
Marian Charlton, Farrah Desrosiers, Gretchen Bretzlafl, David Serur. New York, NY.

3:30 pm  Shared Epitopes Contribute to Accumulation of Highly Sensitized Patients in Kidney Paired Donation Program (Abstract #54)
Stanislaw Stepkowski, Beata Mierzewiska, Caitlin Baum, Dulat Bekbolsynov, Robert Brunner, Jonathan Kopke, Susan Rees, Michael Rees. Toledo, OH.

3:42 pm  More Rapid Decline in Male VS Female Living Kidney Donations (LKD) Varies by Income (Abstract #60)

2:30 pm  Current Practice and Ethical Dimensions of Implementing APOL1 Testing into Living Donor Evaluation: A National Survey (Abstract #59)
Elisa Gordon, Catherine Wicklund, Richard R. Sharp, Julia Lee, Crystal Johnson, John Friedewald. Chicago; Rochester.

2:42 pm  Assessment of the Risk Index for Living Donor Kidney Transplantation (LKDPI) in a European Cohort (Abstract #55)
Oliver Staack, Gregor Rehse, Dmytro Khadzhyinov, Anna Kleinsteuber, Lukas Lehner, Michael Duerr, Klemens Budde, Fabian Halleck. Berlin, Germany.

2:54 pm  Zero HLA Mismatch Matters in ABO Incompatible Kidney Transplant (Abstract #56)

2:30 pm  Inflammatory Cytokines Are Associated with Angiotensin II Type 1 Receptor Antibodies and Vascular Inflammation in Pediatric Renal Transplantation (Abstract #61)
Meghan H. Pearl, Jonathan Grotts, Maura Rossetti, Qiuheng Zhang, Miguel F. Palma Diaz, David W. Gjertson, Patricia Weng, Elaine Reed, Eileen W. Tsai. Los Angeles, CA; Durham, NC.

2:54 pm  Longitudinal Study of Donor Specific Antibodies in a Pediatric Kidney Transplant Population; Response to Optimization of Anti-Proliferative Therapy (Abstract #63) Amanda Rounds, Mary Moss, Margret Bock, Jens Goebel. Aurora, CO.


3:18 pm  HLA Eplet Mismatches Predict DSA Formation, Graft Survival and Re-Transplantation Rate in Pediatric Renal Transplantation (Abstract #65) Matthew P. Sypek, Steve Hiho, Linda Cantwell, Peter Hughes, Amelia Le Page, Joshua Y. Kausman. Melbourne, Australia.

3:30 pm  HLA-C Mismatching and Humoral Alloimmune Responses in Pediatric Kidney Recipients with Subclinical Vascular Injury (Abstract #66) Michael Seifert, Megan Yanik, Vera Hauptfeld-Dolejsek, Roslyn Mannon. Birmingham, AL.

3:18 pm De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients (Abstract #72)
Jae Geun Lee, Kye Ha Huh, Jongwon Ha, Chang-Kwon Oh, Man Ki Ju, Chan-Duck Kim, Hong Rae Cho, Cheol Woong Jung, Beom Jin Lim, Yu Seun Kim. Seoul, Republic of Korea; Suwon, Republic of Korea; Daegu, Republic of Korea; Ulsan, Republic of Korea.

3:30 pm De Novo Use of Everolimus Reduces Late-Onset Cytomegalovirus Primary Disease Occurring After Antiviral Prophylaxis Discontinuation in Kidney Transplant Recipients (Abstract #73)
Arnaud Devresse, Véronique Avettand-Fenoel, Anne Scemla, Lise Morin, Xavier Lebreton, Claire Tinel, Lucile Amrouche, Lionel Lammart, Marc-Olivier Timsit, Julien Zuber, Christophe Legendre, Dany Anglicheau. Brussels, Belgium; Paris, France.

3:42 pm Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant (Abstract #74)
Scott Davis, Jane Gralla, Patrick Klem, Alexander Wiseman, James Cooper. Aurora, CO.

Pediatric Liver

Room E271A
Chairs: Udeme Ekong, MD MPH, Yale University School of Medicine, New Haven, CT, United States and Saeed Mohammad, Northwestern University, Chicago, Illinois, United States

2:30 pm Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma (Abstract #75)
Michael Kueht, Sarah Jane Commander, Tu-Anh Ha, Abbas Rana, Yan Shi, Sanjeev Vasudevan, John Goss. Houston.

2:42 pm Personalizing Immunosuppression with Molecular Phenotyping in Pediatric Liver Transplantation (Abstract #76)
Mylarappa Ningappa, Chethan Ashokkumar, Qing Sun, Brandon W. Higgs, Kyle Solty, Geoff Bond, George Mazariegis, Rakesh Sindhi. Pittsburgh.

2:54 pm Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation (Abstract #77)
Swati Antala, Laurine Bow, Raffaella Moroti, Geliang Gan, Deng Yanhong, Udeme Ekong, Sukru Emre. New Haven, CT.

3:06 pm Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study (Abstract #78)

3:18 pm 20 and 25-Year Outcomes Following Pediatric Liver Transplantation (Abstract #79)
Walter S. Andrews, Nitika A. Gupta, Udeme D. Ekong. Kansas City, MO; Atlanta, GA; New Haven, CT.

3:30 pm Impact of Peri-Transplant Viral Upper Respiratory Infection on Pediatric Liver Transplant Outcomes (Abstract #80)
Jordan A. Kohler, Tamir A. Miloh, Kathleen E. Hosek, John A. Goss, Flor M. Munoz. Houston, TX.

3:42 pm Assessing Self-Efficacy During the Transition from Pediatric to Adult Liver Transplant Care (Abstract #81)
Jacob L. Bilhartz, M. James Lopez, Sally J. Eder, Emily M. Fredericks. Ann Arbor, MI.

Predicting Tolerance and Rejection

Room E351
Chairs: Paolo Cravedi, Icahn School of Medicine at Mount Sinai, New York, United States and Minnie Sarwal, MD, FRCP, PhD, UCSF, San Francisco, CA, United States

2:30 pm High Regulatory T Cells Rate Early After Lung Transplantation Is Associated with Bronchiolitis Obliterans Syndrome Development (Abstract #82)
2:42 pm Compartmental Infiltration of Kidney Allograft with Monocyte-Macrophage Subtypes Defines the Type of Rejection (Abstract #83)
Thierry van den Bosch, Marian Clahsen-van Groningen, Farhad Rezaee, Dennis Hesselink, Daan Nieboer, Ewout Steyerberg, Carla Baan, Ajda Rowshani. Rotterdam, Netherlands.

3:06 pm A Universal Strategy to Characterize Allograft Infiltrating Cells by Bioinformatics Deconvolution of Next Generation Sequencing Data (Abstract #88)

2:54 pm Pre-Transplant Circulating TNFR2+ Regulatory T Cells Predict Acute Rejection within the First 6 Months After Kidney Transplantation (Abstract #84)
Minh-Tri J. P. Nguyen, Sossy K. Sahakian, Shuqing Liu, Yifan Wang, Jean I. Tchervenkov, Steven Paraskevas. New York, NY; Montreal, QC, Canada.

2:30 pm The Impact of Social Support on Kidney Transplant Listing Decisions: Results from a Discrete Choice Experiment (Abstract #89)
Keren Ladin, Joanna Emerson, Zeeshan Butt, Elisa Gordon, Douglas Hanto, Tara Lavelle. Medford, MA; Boston, MA.

3:18 pm Novel Personalized Immune-Monitoring Assay for Predicting Operational Tolerance by Using Humanized Mouse Model (Abstract #86)

2:42 pm A Possible Unintended Consequence of the Kidney Allocation System: The Effect of Duration of Dialysis on Mental Health Outcomes (Abstract #90)
Shannon Radomski, Irene Feurer, Rachel Forbes, Beatrice Concepcion, Heidi Schaefer. Washington, DC; Nashville, TN.

3:06 pm Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients (Abstract #92)

3:30 pm Pre-Transplant Evaluation of KSORTSM to Assess Risk for Rejection in Highly Sensitized Patients (Abstract #87)

Psychosocial and Medication Adherence Concerns
Room E271B

2:30 pm The Impact of Social Support on Kidney Transplant Listing Decisions: Results from a Discrete Choice Experiment (Abstract #89)
Keren Ladin, Joanna Emerson, Zeeshan Butt, Elisa Gordon, Douglas Hanto, Tara Lavelle. Medford, MA; Boston, MA.

2:42 pm A Possible Unintended Consequence of the Kidney Allocation System: The Effect of Duration of Dialysis on Mental Health Outcomes (Abstract #90)
Shannon Radomski, Irene Feurer, Rachel Forbes, Beatrice Concepcion, Heidi Schaefer. Washington, DC; Nashville, TN.

2:54 pm Antidepressant Medication Use Before and After Kidney Transplant: Implications for Post-Transplant Outcomes (Abstract #91)
Krista Lentine, Abhijit Naik, Rosemary Ouseph, Zidong Zhang, David Axelrod, Dorry Segev, Vikas Dharaindharma, Daniel Brennan, Henry Randall, Raj Gadi, Ngan Lam, Gregory Hess, Mark Schnitzler, Bertram Kasiske. St. Louis; Ann Arbor; Greenville; Baltimore; Edmonton, Canada; Philadelphia; Minneapolis.

3:06 pm Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients (Abstract #92)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:18 pm</td>
<td>Educational Strategies for Increased Wait-Listing Rates: Opportunities for Dialysis Center Intervention (Abstract #93)</td>
<td>Amy Waterman, John Peipert, Huiling Xiao, Christina Goalby, Krista Lentine. Los Angeles, CA; St. Louis, MO.</td>
<td>Los Angeles, CA; St. Louis, MO.</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Predictors of Web-Based Patient Portal Usage Among Kidney and Liver Transplant Recipients (Abstract #94)</td>
<td>Aldrick P. Ruiz, Kayla D. Smith, Joel Wedd, Kendra Little, Stephen Pastan, Rachel E. Patzer. Atlanta, GA.</td>
<td>Atlanta, GA.</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Preventing of Rejection of Vascularized Composite Allografts by Targeting T Cell Metabolism (Abstract #102)</td>
<td>Byoung Chol Oh, Chih Hsien Cheng, Georg J. Furtmüller, W. P. Andrew Lee, Jonathan D. Powell, Gerald Brandacher. Baltimore, MD.</td>
<td>Baltimore, MD.</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Clinical Significance of Alloantibodies in Hand Transplantation: Impact on Rejection and Functional Outcome (Abstract #96)</td>
<td>Erik Berglund, Mette Andersen Ljungdahl, Darko Bogdanovic, David Berglund, Jonas Wadström, Annemarie Weissbencher, Palmina Petruzzo, Stefan Schneeberger. Stockholm, Sweden; Innsbruck, Austria; Uppsala, Sweden; Lyon, France.</td>
<td>Stockholm, Sweden; Innsbruck, Austria; Uppsala, Sweden; Lyon, France.</td>
</tr>
<tr>
<td>2:54 pm</td>
<td>Living and Deceased Donor Uterus Transplant Trial – The 2-Arm Czech Uterus Transplant Trial: The First Year Report with Four Cases Done so Far (Abstract #98)</td>
<td>Jiri Fronek, Roman Chmel, Libor Janousek, Marta Novackova, Jan Matecha, Michael Olausson. Prague, Czech Republic; Goteborg, Sweden.</td>
<td>Prague, Czech Republic; Goteborg, Sweden.</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Preventing of Rejection of Vascularized Composite Allografts by Targeting T Cell Metabolism (Abstract #102)</td>
<td>Byoung Chol Oh, Chih Hsien Cheng, Georg J. Furtmüller, W. P. Andrew Lee, Jonathan D. Powell, Gerald Brandacher. Baltimore, MD.</td>
<td>Baltimore, MD.</td>
</tr>
</tbody>
</table>

**VCA**

*Room E270*

**Chairs:** Linda Cendales, Select One, Durham, North Carolina, United States and Kadiyala Ravindra, Duke University, Durham, NC, United States
Student Program – The Science, The Art and the Allured of Transplantation
2:30 pm – 5:30 pm

**Fundamental Concepts of Transplantation**

**Room E253ABCD**
Moderators: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD, USA and David Mercer, MD, University of Nebraska Medical Center, Omaha, NE, USA

2:30 pm **Why Transplant Surgery is Exciting (Thoughts from the ASTS President)**
Timothy Pruett, MD
University of Minnesota
Minneapolis, MN, USA

2:45 pm **Why Transplant Medicine is Exciting (Thoughts from the AST President)**
Anil Chandraker, MD
Brigham & Women’s Hospital
Boston, MA, USA

3:00 pm **Why Bile is Exciting: Liver Transplantation**
Wendy Grant, MD
University of Nebraska Medical Center
Omaha, NE, USA

3:15 pm **Why Urine is Exciting: Kidney Transplantation**
John Gill, MD, MS
University of British Columbia
Vancouver, BC, Canada

3:30 pm **Why Big Data is Exciting: Outcomes Research in Transplantation**
Dorry Segev, MD, PhD
Johns Hopkins University
Baltimore, MD, USA

3:45 pm **Why Mice are Exciting: Basic Science Research in Transplantation**
Robert Fairchild, PhD
Cleveland Clinic
Cleveland, OH, USA

4:00 pm **Coffee Break**

4:30 pm **Why Bugs are Exciting: Transplant ID**
Deepali Kumar, MD
University of Toronto
Toronto, ON, Canada

4:45 pm **Why Drugs are Exciting: Transplant Pharmacology**
Christin Rogers, PharmD
Beth Israel Deaconess Medical Center
Boston, MA, USA

5:00 pm **Why Things are Exciting above the Diaphragm: Thoracic Transplantation**
Maryl Johnson
University of Wisconsin-Madison
Madison, WI, USA

5:15 pm **Discussion**

**Pediatric Symposium 1**
2:30 pm – 6:00 pm

**Room E265**

Antibodies and Pediatric Transplantation – What, When, Why, (and How)?
Moderators: Minnie Sarwal, MD, PhD, MRCP, UCSF, San Francisco, CA, USA and Asha Moudgil, MD, Children’s National Med. Ctr., Washington DC, USA

2:30 pm **Surveillance Biopsies to Diagnose AMR: Risk vs. Benefit in Children**
Jens Goebel, MD
University of Colorado Denver
Aurora, CO, USA

2:50 pm **Is There Evidence for DSA and Biopsy Surveillance in Children After a Solid Organ Transplant?**
Katherine Twombley, MD
Medical University of South Carolina
Charleston, SC, USA

3:10 pm **Bortezomib and Newer Therapies for the Treatment of AMR in Children**
Priya Verghese, MD, MPH
University of Minnesota
Minneapolis, MN, USA

3:30 pm **Use of Translational Science Technology (Gene Expression Profiling Testing) in Pediatric Solid Organ Transplant Patients to Monitor for Rejection**
Brendan Keating, PhD
University of Pennsylvania
Philadelphia, PA, USA

3:50 pm **Discussion**

4:00 pm **Coffee Break**
Ethics in Pediatric Transplantation – Should This Kid Get a Transplant
Moderators: Minnie Sarwal, MD, PhD, MRCP, UCSF, San Francisco, CA, USA and Asha Moudgil, MD, Children’s National Med. Ctr., Washington DC, USA

4:30 pm Panelists:
Sarah Kizilbash, MD
Minnesota
Minneapolis, MN, USA

Vikas Dharnidharka, MD, MPH
Washington University School of Medicine
St Louis, MO, USA

George Mazariagos, MD
Pittsburgh
Pittsburgh, PA, USA

Elizabeth Rand, MD
Children’s Hospital of Philadelphia
Philadelphia, PA, USA

Lainie Ross, MD, PhD
University of Chicago
Chicago, IL, USA

Aaron Wightman, MD, MA
University of Washington School of Medicine
Seattle, WA, USA

Allied Health Symposium 1
2:30 pm – 6:00 pm

Case-Based Approach to the Multidisciplinary Management of Complex Chronic Disease States Post-Transplantation
Room E258

Management of Metabolic Complications Post-Transplantation
Moderators: Nicole Alvey, PharmD, Rush University Medical Center, Chicago, IL, USA and Joelle Nelson, PharmD, BCPS, University of Florida Shands Hospital, Gainesville, FL, USA

2:30 pm Management of Post-Transplant Diabetes Mellitus
Jeong Park, PharmD
University of Michigan College of Pharmacy
Ann Arbor, MI, USA

2:45 pm New Treatment Guidelines and the Management of Post-Transplant Dyslipidemias
Steven Gabardi, PharmD
Brigham and Woman’s Hospital
Boston, MA, USA

3:00 pm Bariatric Surgery in the Transplant Patient: Effects on Immunosuppression
Rita Alloway, PharmD
University of Cincinnati
Cincinnati, OH, USA

Management of Mineral and Bone Disorders and Dermatologic Complications Post-Transplantation
Moderators: Nicole McCormick, MS, MBA, NP-C, CCTC, University of Colorado, Division of Renal Diseases & Hypertension, Denver, CO, USA and Jillian Fose, PharmD, UW Health, Madison, WI, USA

3:15 pm Making Sense of Hyperparathyroidism after Kidney Transplantation
Michelle Josephson, MD
University of Chicago
Chicago, IL, USA

3:30 pm Tough Break: Managing Osteoporosis after Transplantation
Harold Rosen, MD
BIDMC
Boston, MA, USA

4:00 pm Coffee Break

Management of Special Populations Post-Transplantation
Moderators: Gregory Malat, PharmD, Hahnemann University Hospital, Philadelphia, PA, USA and Carissa Garza, PharmD, Vanderbilt University Medical Center, Nashville, TN, USA

4:30 pm Use of Novel Oral Anticoagulants in the Transplant Population
Christopher Ensor, PharmD
University of Pittsburgh
Pittsburgh, PA, USA

4:50 pm Biologics in Management of Inflammatory Bowel Diseases Post-Transplantation
Ryan Stidham, MD, MSc
University of Michigan
Ann Arbor, MI, USA

5:10 pm HIV Management Post-Transplantation
Andrew Santeusanio, PharmD
Mt. Sinai
New York, NY, USA

5:30 pm – 6:00 pm Discussion
Coffee Break with Exhibits  
4:00 pm – 4:30 pm  

Hall D1

Concurrent Oral Abstract Sessions  
4:30 pm – 6:00 pm  

Clinical Science: Kidney Immunosuppression: Desensitization  
Room E354B  
Chairs: Martha Pavlakis, MD, Beth Israel Deaconess Med Ctr, Boston, MA, United States and Brian Stephany, The Cleveland Clinic Foundation, Cleveland, OH, United States

4:30 pm Desensitization versus Deceased Donor Kidney Transplantation: What to Choose When Both Become Available? (Abstract #103)  

4:42 pm Even with National Sharing, the Prospects of a 100% Sensitized Patient Receiving a Transplant Vary Dramatically Depending on the Precise CPRA Value (Abstract #104)  
Darren Stewart, Anna Kucheryavaya, Dolly Tyan, Howard Gebel, Robert Bray, Nicole Turgeon. Richmond, VA; Palo Alto, CA; Atlanta, GA.

4:54 pm A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations (Abstract #105)  

5:06 pm Induction of Proliferative Responses in B Cell and Plasma Cell Populations Following Proteasome Inhibitor Desensitization Treatment in Rhesus Macaques and Humans (Abstract #106)  

5:18 pm In Vivo Administration of Plerixafor in Humans Mobilizes Bone Marrow Resident Plasma Cells That Demonstrate Apoptosis in Both Bone Marrow and Peripheral Blood (Abstract #107)  

5:30 pm Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant (Abstract #108)  

5:42 pm Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization (Abstract #109)  

Innate Immunity  
Room E350  
Chairs: Abdallah Elkhal, Ph.D, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States and Dianne McKay, ucsd, la jolla, United States

4:30 pm Nucleic Acid Scavenging Microfiber Mesh Inhibits Trauma Induced Inflammation and Thrombosis After Organ Transplantation (Abstract #110)  
Jean Kwun, Jaewoo Lee, Jennifer Jackman, Miriam Manook, Eric Elster, Allan Kirk, Bruce Sullenger. Durham, NC; Bethesda, MD.

4:42 pm Host-Derived, Intragraft Dendritic Cells Are Extensively Cross-Dressed by Donor MHC (Abstract #111)  
Andrew D. Hughes, Hethua Dai, Amanda L. Williams, Martin H. Oberbarnscheidt, Adrian E. Morelli, Fadi G. Lakkis. Pittsburgh, PA.
35

4:54 pm Circulating Inflammatory Factors in Deceased Organ Donors Result in Innate Immune Activation (Abstract #112)
Todd V. Brennan, Liwen Lin, Justin Pollara. Durham, NC.

5:06 pm Accelerated Rejection of Secondary Third Party Allografts in Older Recipients Is Facilitated by an Augmented Innate Immune Response (Abstract #113)
Timm Heinbokel, Koichiro Minami, Abdallah Elkhal, Stefan G. Tullius. Boston, MA.

5:18 pm Reduction of Recipient Cell Cross-Dressing with Donor MHC Molecules Prolongs Allograft Survival in Mice (Abstract #114)
Jose Marino, Haley E. Tector, Bruno Gonzalez-Nolasco, Alexandre Lellouch, Alycen Harney, Curtis L. Cetrulo, Jr, James F. Markmann, Gilles Benichou. Boston, MA.

Kidney Allocation: Changes and Consequences

Room E450A
Chairs: Jeffrey Halldorson, MD, University of California at San Diego, La Jolla, CA, United States and Raymond Lynch, MD, MS, Emory University, Atlanta, GA, United States

4:30 pm Increase in Post-Transplant Mortality Under KAS (Abstract #117)

4:42 pm Unintended Consequence of the New Kidney Allocation System – Disproportionate Allocation of High Quality Kidneys to Highly Sensitized Recipients (Abstract #118)
Bhamidipati Murthy, Nhu Thao Galvan, Jennifer Moffett, Christine O’Mahony, John Goss, Abbas Rana. Houston, TX.

4:54 pm Is Deceased Donor Kidney Transplantation (DDTX) Justified in Patients with More Than 10 Years of Pre-TX Dialysis Exposure? (Abstract #119)
Caren Rose, Jagbir Gill, Julie Lesage, Yayuk Joffres, John Gill. Vancouver, Canada.

5:06 pm Geographic Disparity in Kidney Transplantation After KAS (Abstract #120)
Sheng Zhou, Allan Massie, Xun Luo, Eric Chow, Sunjae Bae, Sommer Gentry, Sally Gustafson, Andrew Wey, Bryn Thompson, Nicholas Salkowski, Jon Snyder, Dorry Segev. Baltimore; Annapolis; Minneapolis.

5:18 pm Waitlist Desensitization and the Rate of Deceased Donor Kidney Transplantation After Implementation of the Kidney Allocation System (Abstract #121)
Edmund Huang, Stanley Jordan, Reiad Najjar, Jua Choi, Alice Peng, Ashley Vo. Los Angeles, CA.

5:30 pm Reduction in Kidney Offer Acceptance at Centers Undergoing Systems Improvement Agreements (Abstract #122)
Mary Bowring, Lauren Nicholas, Allan Massie, Dorry Segev. Baltimore.

5:42 pm Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies (Abstract #123)
Christian Jacquelin, Benoit Audry, Corrine Antoine, Caroline Suberbielle, Denis Glotz, Anat R. Tambur. Saint Denis, France; Paris, France; Chicago.
Kidney Clinical Complications 1

Room E354A
Chairs: Antonio di Carlo, Temple University Hospital, Philadelphia, PA, United States and Eliyahu Khankin, MD, FASN, Beth Israel Deaconess Medical Center, Boston, MA, United States

4:30 pm Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study (Abstract #124)

5:30 pm Ambulatory Antibiotic Utilization and Outcomes in an Adult Kidney Transplant Population: A Pharmacovigilance Analysis (Abstract #129)
L. Avery, C. Fominaya, R. Crawford, David Taber. Charleston, SC.

4:42 pm Venous Thromboembolism and the Risk of Death and Graft Loss in Kidney Transplant Recipients (Abstract #125)

5:42 pm Maternal Risks and Pregnancy Outcomes After Kidney Transplantation: A Single Center Experience (Abstract #130)

Kidney: Acute Cellular Rejection

Room E451B
Chairs: Rajendra Baliga, MD, FACP, FASN, FAST, Tampa General Hospital, Tampa, FL, United States and Michael Mengel, MD, University of Alberta, Edmonton, AB, Canada

4:30 pm Preceeding the Rejection: Clinical Results of a Saliva Test After Renal Transplantation (Abstract #131)
Dietmar K. Abendroth, Michael Marzinzig, Manfred J. Stangl. Ulm, Germany; Munich, Germany.

4:42 pm A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection (Abstract #132)

5:06 pm Outcomes Following Hysterectomy in Kidney Transplant Recipients (Abstract #127)

4:54 pm Organs with Extended Cold Ischemia Time May Offer Aged Kidney Transplant Recipients New Options in an Expanded Donor Pool (Abstract #133)
Merve Postalcioglu, Benjamin C. Byun, Arnaud D. Kaze, Andrew Siedlecki, Edgar L. Milford, Reza Abd. Boston, MA.

4:54 pm A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection (Abstract #132)
5:06 pm  Short-Term Adverse Effects of Early Borderline Changes in Renal Allograft Biopsies (Abstract #134)

4:42 pm  Preliminary Results of Clinical Normothermic Ex Vivo Liver Perfusion in a North American Setting (Abstract #139)

5:18 pm  Immunosuppression and Graft Rejection in Living-Related HLA-Identical Renal Transplantation (Abstract #135)
Rime Ossman, Mathieu Jamme, Pierre Galichon, Alexandre Hertig, Bruno Moulin, Christophe Legendre, Emmanuel Morelon, Jean-Luc Taupin, Lionel Rostaing, Eric Rondeau. Paris, France; Strasbourg, France; Lyon, France; Toulouse, France.

4:54 pm  Normothermic Regional Perfusion of Donors Following Circulatory Death Improves Outcomes in Liver Transplantation (Abstract #140)
Elizabeth V. Mowlem, Lucy V. Randle, Corrina Fear, Keziah Crick, Simon Messer, Stephen Large, Andrew J. Butler, Christopher J. E. Watson. Cambridge, United Kingdom; Oxford, United Kingdom.

5:30 pm  The Innate Immune-System May Play an Enhanced Role in Acute Cellular Rejection in Patients on Belatacept-Based Immunosuppression (Abstract #136)
Dejan Dobi, Qizhi Tang, Sindhu Chandran, Flavio Vincenti, Zoltan Laszik. San Francisco, CA.

5:06 pm  Improving Liver Allocation Using Optimized Neighborhoods (Abstract #141)
Sanjay Mehrotra, Vikram Kilambi. Evanston, IL.

5:18 pm  MELD-Based Allocation Leads to Inferior Survival After Liver Transplantation (Abstract #142)

5:42 pm  Kidney Quality Dramatically Influences Patient and Death Censored Graft Survival in SLK Recipients (Abstract #143)
Tiffany Zens, Juan Danobeitia, Paul Stahler, Glen Levenson, Robert Redfield, Anthony D’Alessandro, Luis Fernandez. Madison, WI.

5:06 pm  Improved Liver Allocation Using Optimized Neighborhoods (Abstract #141)
Sanjay Mehrotra, Vikram Kilambi. Evanston, IL.

5:18 pm  MELD-Based Allocation Leads to Inferior Survival After Liver Transplantation (Abstract #142)

5:42 pm  Increased Use of Donation After Cardiac Death Donors Increases Access to Transplantation without Adverse Effect on Outcomes (Abstract #144)
Liver: Viral Hepatitis

Room E271A
Chairs: Surakit Pungpapong, MD, FAST, Mayo Clinic College of Medicine, Jacksonville, FL, United States and Elizabeth Verna, MD, MS, Columbia University, New York, NY, United States

4:30 pm Use of Ledipasvir/Sofosbuvir with or without Ribavirin in Patients Post-Liver Transplant: Evaluation of Real-World Datasets (Abstract #145)
S. Flamm, M. Charlton, M. Manns, M. Prieto, I. Fernandez, M. C. Londono, R. M. Kwok, C. Smith, S. Lee, H. Ngo, A. Osinusi, A. Copans, L. Rossaro, M. Shoreibah, O. Massoud, M. Curry, M. Bourliere. Chicago; Murray; Hannover, Germany; Valencia, Spain; Madrid, Spain; Barcelona, Spain; DC; Georgetown; Foster City; Birmingham; Boston; Marsielle, France.

4:42 pm The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis (Abstract #146)
Zhiyong Guo, Jincui Gu, Xiaoshun He, Guodong Chen. Guangzhou, China.

4:54 pm Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD) (Abstract #147)
Jacob Korula, Tariq Shah, Elizabeth Ranger, Elsa Barba, Don Vu, Robert Naraghi. Los Angeles, CA.

5:06 pm Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers (Abstract #148)
Saikiran M. Kilaru, Elliot B. Tapper, Michael P. Curry. New York, NY; Ann Arbor, MI; Boston, MA.

5:18 pm A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers (Abstract #149)
Nikhil Kapila, Bobby Zervos, Bahaaeldeen Ismail, Christina C. Lindenmeyer, Vedha Sanghi, K. V. Narayanan Menon, Gabriel Schnickel, John Rivas, Diego Reino, Andreas Tzakis. Weston, FL; Cleveland, OH.

5:30 pm Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents? (Abstract #150)

5:42 pm A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence (Abstract #151)
Wei-Chen Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan. Taoyuan, Taiwan.

Lung Transplantation from Donation to Retransplantation

Room E270
Chairs: Sangeeta Bhorade, Northwestern University, Chicago, United States and Deborah Levine, MD, University of Texas, San Antonio, TX, United States

4:30 pm Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction (Abstract #152)
Deepak Nayak, K. Garcia, P. Pirrotte, R. Hachem, R. Bremner, M. Smith, T. Mohanakumar. Phoenix, AZ; St. Louis, MO.

4:42 pm Circulating Exosomes Isolated from Human Lung Transplant Recipients with Rejection Are Immunogenic and Induce Antibodies to Lung Associated Self-Antigens, Ka1 Tubulin and Collagen-V (Abstract #153)

4:54 pm Addition of FEV1 Drop to LAS May Improve Access of CF Patients to Transplant: Analysis of the SRTR and US CF Foundation Patient Registries (Abstract #154)
Elliott Dasenbrook, M. Skeans, A. Fink, B. Marshall, Maryam Valapour. Cleveland; Minneapolis; Bethesda.
Sunday, April 30

5:06 pm  Truth in Pathology: Autopsy Findings in Lungs Declined for Transplantation (Abstract #155)
Amy L. Friedman, Jeffrey Lewis, Helen Irving, Kristin W. Delli Carpini. New York, NY.

5:18 pm  Respiratory Viral Infections Following Human Lung Transplant Can Induce Exosomes with Lung Self-Antigens, KAT1Tubulin and Collagen V (Abstract #156)

5:30 pm  Poor Outcomes on the Waiting List for Pediatric Lung Retransplant Patients Listed in Low Volume Centers (Abstract #157)
Brandi B. Scully, Jeffrey S. Heinle, Michael L. Kueht, E. Dean McKenzie, George B. Mallory, Ernestina Melicoff, Abbas Rana. Houston, TX.

5:42 pm  Risk Factors for Post-Transplant Lymphoproliferative Disorders in Epstein-Barr Virus Mismatch Lung Transplant Recipients (Abstract #158)

New Insights – HCV / HIV

Room E271B
Chairs: Rachel Miller, MD, Duke University, Durham, NC, United States and Nicole Theodoropoulos, MD MS, UMass Memorial Medical Center, Worcester, MA, United States

4:30 pm  Protease Inhibitor-Based Regimens Are Associated with Inferior Outcomes in HIV-Infected Kidney Transplant Recipients (Abstract #159)
Brittany A. Shelton, Deirdre Sawinski, Rhiannon D. Reed, Paul A. MacLennan, Shikha Mehta, Jayme E. Locke. Birmingham; Philadelphia.

4:42 pm  Deceased Donors with a History of IV Drug Use and Donor Derived Hepatitis C Virus (Abstract #160)
Daniel Kaul, Marissa Clark, Marian Michaels, Susan Trusty, Cameron Wolfe. Richmond, VA; Richmond.

4:54 pm  Transplantation of Organs from Donors with Hepatitis C: The Potential to Substantially Increase Transplant Activity (Abstract #161)
Patrick B. Trotter, Matthew Robb, Ines Ushiro-Lumb, James Powell, Christopher Watson, J. A. Bradley, James Neuberger. Cambridge, United Kingdom; Bristol, United Kingdom; Edinburgh, United Kingdom; Birmingham, United Kingdom.

5:06 pm  HCV+ Waitlist Candidates More Likely to Die Waiting for Kidney Transplant from HCV- Donor (Abstract #162)
Brittany A. Shelton, Deirdre Sawinski, Shikha Mehta, Rhiannon D. Reed, Paul A. MacLennan, Jayme E. Locke. Birmingham; Philadelphia.

5:18 pm  Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis (Abstract #163)
Bryce Kiberd, Karthik K. Tennankore, Karen Doucette. Halifax, NS, Canada; Edmonton, AB, Canada.

5:30 pm  Knowledge and Attitudes Associated with Willingness to Accept HIV+ Organs Among Persons Living with HIV (Abstract #164)
Saad Anjum, Samantha Halpern, Komal Kumar, Anh Nyugen, Sarah Rasmussen, Allan Massie, Aaron Tobian, Dorry Segev, Jeremy Sugarman, Christine Durand. Baltimore.

5:42 pm  Impact of Ritonavir on Graft Function in Human Immunodeficiency Virus Infected Kidney Transplant Recipients (Abstract #165)
Kerri Roach, Erika Meredith, Marshall Lyon. Atlanta, GA.
Novel Immunosuppression – DSA Monitoring

Room E450B

Chairs: Yihung Huang, MD, University of California, Davis, Sacramento, CA, United States and Fuad Shihab, M.D., University of Utah, Salt Lake, UT, United States

4:30 pm  Experience with the Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients (Abstract #166)

4:42 pm  Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials (Abstract #167)
Matthew J. Everly, Robert Townsend, Howard M. Gebel, Robert A. Bray. Los Angeles, CA; Lawrenceville, NJ; Atlanta, GA.

4:54 pm  Multiple Dosing of Anti-C1s Antibody TNT009 – Effect on HLA Antibody-Triggered Complement Activation in Healthy Volunteers and Kidney Transplant Recipients with Antibody-Mediated Rejection (Abstract #168)
Jakob Muhlbacher, Bernd Jilma, Markus Wahrmann, Farsad Eskandary, James C. Gilbert, Sandip Panicker, Georg A. Böhming. Vienna, Austria; San Francisco, CA.

5:06 pm  Post-Transplant Reduction in Pre-Existing Donor-Specific Antibody Levels After Belatacept-vs Cyclosporine-Based Immunosuppression (Abstract #169)
R. Bray, H. Gebel, R. Townsend, M. Polinsky, L. Yang, U. Meier-Kriesche, C. P. Larsen. Atlanta, GA; Lawrenceville, NJ.

5:18 pm  Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA (Abstract #170)
Marc-Antoine Béland, Réal Noël, Isabelle Côté, Isabelle Lapointe, Eric Wagner, Julie Riopel, Eva Latulippe, Olivier Désy, Stéphanie Béland, Isabelle Houde, Sacha A. De Serres. Quebec City, QC, Canada.

5:30 pm  Changes in Peripheral Blood Gene Expression Profile After Calcineurin Inhibitor (CNI) Withdrawal in Kidney Transplant Recipients (Abstract #167)

5:42 pm  Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study (Abstract #172)

Pancreas Transplantation

Room E267

Chairs: Ty Dunn, MD MS, University of Minnesota, Minneapolis, MN, United States and Nicole Turgeon, Emory University, Atlanta, GA, United States

4:30 pm  Endoscopic Ultrasound Guided Biopsy Sampling of the Pancreas Transplant – The Future of Graft Surveillance? (Abstract #173)

4:42 pm  Lessons Learned from Simultaneous Biopsies of Both Kidney and Pancreas Grafts in Recipients of Simultaneous Kidney-Pancreas Transplants (Abstract #174)

4:54 pm  Baseline Immune Assessment to Individualize Immunosuppression in SPK Recipients with Type 1 Diabetes (Abstract #175)
Yogish Kudva, Vikash Dadlani, Adam Miller, Mohamed Abdallah, Walter K. Kremers, Mark Stegall, Roshini Abraham. Rochester, MN.
Anti-Angiotensin Type 1 Receptor Antibodies Associate with Rejection in Simultaneous Pancreas and Kidney Transplant and Pancreas Transplant Alone Recipients (Abstract #176)
Alice Peng, Donald Dafoe, Jua Choi, Ashley Vo, Xiaohai Zhang, Reiad Najjar, Edmund Huang, Stanley C. Jordan. Los Angeles, CA.

Assessment of the Association Between Measures of Metabolic Function and Pancreas Graft Survival (Abstract #177)

Access to Simultaneous Pancreas and Kidney Transplant (SPK) Should Not Be Restricted to BMI > 28 (Abstract #178)
Mark R. Laftavi, Angelika C. Gruessner, Vaughn Whittaker, Zeki Acun, Oleh Pankowycz, Rainer Gruessner. Syracuse, NY.

The Benefits of Pancreas After Kidney (PAK) Transplantation (Abstract #179)
Michael Curry, Jon Odorico, Jonathan Fridell. Richmond, VA; Madison, WI; Indianapolis, IN.

Ectopic Lymphoid Structures Are Present in Type I T-Cell Mediated Kidney Transplant Rejection (Abstract #180)

De Novo DSA with T Cell Mediated Rejection (TCMR) Leads to Early Allograft Scarring and Dysfunction (Abstract #181)

Tracking the In Vitro Phenotype and Proliferative Capacity of CD57+ CD4 T Cells (Abstract #182)

High CTLA-4 Expression and Diminished FOXP3 Expression Underlie Differential CD28 Signaling on Human Memory Th17 Cells (Abstract #183)
Scott M. Krummey, Suzanne J. Suchard, Steven G. Nadler, Christian P. Larsen, Mandy L. Ford. Atlanta, GA; Princeton, NJ.

2B4-Mediated Inhibition of Proliferation and Glycolytic Function Attenuates T Cell Alloreactivity (Abstract #184)
Sonia J. Laurie, Danya Liu, Miriam C. Cortes, Maylene Wagener, Mandy L. Ford. Atlanta, GA.

Rapamycin Directly Alters Human Endothelial Cell Alloimmunogenicity (Abstract #185)
Victoria A. Bendersky, He Xu, Allan D. Kirk. Durham, NC.

Genomic Analysis of Gene Expression in Human Kidney Transplants Identifies Moxd1 as a Key Driver for Renal Fibrosis (Abstract #186)
Chengguo Wei, Madhav C. Menon, Weijia Zhang, Christopher Woytovich, Nimrod Philippe, John Cijiang He, Barbara Murphy, Chengguo Wei. New York, NY.

The Gut Microbiota Regulates Murine Cardiac Transplant Outcome (Abstract #187)
4:42 pm  **A Single Skin Commensal Strain Is Sufficient to Accelerate Skin Transplant Rejection** (Abstract #188)  
Yuk Man (Kevin) Lei, Luqiu Chen, Ying Wang, Anita Chong, Yasmine Belkaid, Maria-Luisa Alegre. Chicago, IL; Bethesda.

4:54 pm  **Non-Invasive Detection of Rejection with ImmunoPET Imaging** (Abstract #189)  
David V. Mathews, Kevin Lindsay, Phillip Santangelo, Ying Dong, J. Yun Tso, Andrew B. Adams. Atlanta, GA; Mountain View, CA.

5:06 pm  **Regulation of T Cell Migration by Specifically Targeting Lymphotoxin β Receptor (LTbR)-Mediated Non-Canonical NFkB Signaling** (Abstract #190)  

5:18 pm  **Role of Donor-Derived Tissue Resident Memory T cells in Modulating Alloimmunity** (Abstract #191)  
Rebecca L. Crepeau, Danya Liu, Mandy L. Ford. Atlanta, GA.

5:30 pm  **T_{Fr}:T_{FH} Cell Ratio Correlates with Anti-Donor Germinal Center Reactivity and Donor-Specific Antibody Formation Following Transplantation** (Abstract #192)  
Glenn M. La Muraglia II, Mandy L. Ford, Idelberto R. Badell. Atlanta, GA.

5:42 pm  **TIM-3 – CEACAM1 Checkpoint Regulation of T-Cell Activation and Hepatocellular Function in Liver Transplantation** (Abstract #193)  
Kojiro Nakamura, Shoichi Kageyama, Maciej Kujawski, Rebecca A. Sosa, Elaine F. Reed, Ali Zarrinpar, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski. Los Angeles, CA; Duarte, CA.

### Tolerance: Clinical Studies

**Room E353C**

**Chairs:** Sandy Feng, MDPhd, University of California San Francisco, San Francisco, CA, United States and Tatsuo Kawai, M.D., Ph.D., Massachusetts General Hospital, Boston, MA, United States

4:30 pm  **Tolerant Pediatric Liver Transplant (LT) Recipients (TOL) from WISP-R (NCT00320606) Split into Two Phenotypically Distinct Groups by PD1 Expression on CD4+ T Cells at Baseline, Prior to Immunosuppression Withdrawal (ISW)** (Abstract #194)  

4:42 pm  **Eight Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients** (Abstract #195)  

4:54 pm  **Relationship Between Mixed Chimerism and Tolerance in HLA-Matched and -Mismatched Recipients of Kidney and Hematopoietic Cell Transplants** (Abstract #196)  

5:06 pm  **A Molecular Signature Characterized by Dominance of Negative Regulation over Cytotoxic Effectors in Tolerant Kidney Allograft Recipients** (Abstract #197)  
J. Lee, J. Leventhal, C. Li, A. Katapodis, S. Ildstad, M. Suthanthiran. NY, NY; Chicago, IL; Basel, Switzerland; Louisville, KY.

5:18 pm  **Dominant Role of Clonal Deletion in Achieving Immune Tolerance After Unrelated Cord Blood Transplantation** (Abstract #198)  
Paul Szabolcs, Xiaohua Chen, Memphis Hill. Pittsburgh, PA.
5:30 pm  Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation (Abstract #199)
Maja-Theresa Dieterlen, Kristin Klaeske, Julia Fischer, Jochen Hahn, Khalil Jawad, Jens Garbade, Friedrich W. Mohr, Sven Lehmann. Leipzig, Germany.

5:42 pm  Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial (Abstract #200)

Poster Session B
6:00 pm – 7:00 pm
Hall D1
Poster Viewing: 9:30 am – 12:00 pm
2:30 pm – 7:00 pm

Presenters in Attendance: 6:00 pm – 7:00 pm
Poster Session B can be found on pages 130-154.
### Sunrise Symposia (7:00 am – 8:15 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>Tolerance – Why Aren't We There Yet?</td>
<td>E354A</td>
</tr>
<tr>
<td>47</td>
<td>Simultaneous Liver Kidney Transplantation – Where Are We and Where Are We Going?</td>
<td>E353C</td>
</tr>
<tr>
<td>47</td>
<td>Maintaining Minimal-Volume Solid Organ Pancreas Transplant Programs – Pro/Con</td>
<td>E350</td>
</tr>
<tr>
<td>47</td>
<td>Combined Liver-Kidney Transplantation: Ways to Continue Improve Outcomes</td>
<td>E353AB</td>
</tr>
<tr>
<td>48</td>
<td>DCD Liver Transplantation: Current Controversies and Future Directions</td>
<td>E450A</td>
</tr>
<tr>
<td>48</td>
<td>New Concepts in Immune Monitoring</td>
<td>E354B</td>
</tr>
<tr>
<td>48</td>
<td>Updates on Women's Health in Solid Organ Transplant</td>
<td>E451A</td>
</tr>
<tr>
<td>48</td>
<td>Emerging Infections in the Age of Global Warning – Implications for Transplantation</td>
<td>E451B</td>
</tr>
<tr>
<td>49</td>
<td>Getting the Most Bang for Your Buck: Creative Ways to Expand Pharmacy Services to Meet Regulatory Requirements</td>
<td>E351</td>
</tr>
<tr>
<td>49</td>
<td>Cytoprotection by Hematopoietically Derived Cells</td>
<td>E354B</td>
</tr>
</tbody>
</table>

### Plenary (8:30 am – 9:30 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Joint Plenary Session II</td>
<td>Arie Crown Theater</td>
</tr>
</tbody>
</table>

### ASTS Awards (9:30 am – 9:45 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>ASTS Awards</td>
<td>Arie Crown Theater</td>
</tr>
</tbody>
</table>

### ASTS Presidential Address (9:45 am – 10:15 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>ASTS Presidential Address</td>
<td>Arie Crown Theater</td>
</tr>
</tbody>
</table>

### Coffee Break with Exhibits (10:15 am – 10:45 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Coffee Break with Exhibits</td>
<td>Hall D1</td>
</tr>
</tbody>
</table>

### State-of-the-Art Presentation (10:45 am – 11:15 am)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Immune Checkpoint Inhibitors: Emerging Targets for Induction of Anti-Tumor Immunity and Transplantation Tolerance</td>
<td>Arie Crown Theater</td>
</tr>
</tbody>
</table>

### Midday Symposia (11:30 am – 1:00 pm)

<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Debates in Mechanical Circulatory Support and Cardiac Transplantation</td>
<td>E351</td>
</tr>
<tr>
<td>51</td>
<td>Cardiac Function in Liver Transplantation: Assessing and Mitigating Risk Across the Continuum of Care</td>
<td>E350</td>
</tr>
<tr>
<td>51</td>
<td>Understanding ESRD after Live Kidney Donation</td>
<td>E354B</td>
</tr>
</tbody>
</table>
Delayed Allograft Function – What is the Impact and What Therapeutics are the Most Promising?
Arie Crown Theater

Integration of APOL-1 into Kidney Transplantation: Summary of the AST Expert Workshop
Room E451B

What’s Hot in Deceased Organ Donation – Normothermic Perfusion
Room E451A

Liver Transplant for HCC in the Next Decade
Room E450A

Keeping the High MELD/PELD Patient Alive on the List
Room E352

HIV Positive Transplantation
Room E354A

Bench to Bedside – T Cell Memory
Room E353AB

Exosomes and Donor Antigen Cross Dressing in Alloimmunity
Room E353C

Immune Tolerance – Lessons from Non-Transplant Models
Room E450B

1:00 pm – 2:15 pm Luncheon Workshop*

Ticketed Events

2:30 pm – 4:00 pm Concurrent Oral Abstract Sessions

Basic Transplant Tolerance I
Room E350

Emerging Interventions in Ischemia Reperfusion Injury
Room E351

Heart Transplantation: Antibodies and Outcomes
Room E271B

2:30 pm – 6:00 pm Pediatric/Allied Health Symposium

Room E253ABCD

2:30 pm – 6:00 pm Allied Health Symposium 2

Balancing Quality & Risk
Room E258

4:00 pm – 4:30 pm Coffee Break with Exhibits
Hall D1
4:30 pm – 6:00 pm  Concurrent Oral Abstract Sessions

Page 64  Antibody Mediated Rejection in Kidney Transplant Recipients: Pathophysiology and Epidemiology
Room E354A

Page 65  B Cells and Antibody in Rejection
Room E350

Page 65  Basic Chronic Rejection
Room E351

Page 66  Disparities in Organ Transplantation
Room E353C

Page 67  Donors with Acute Kidney Injury
Room E450A

Page 67  Health Services and Policy in Organ Transplantation
Room E271A

Page 68  Infectious Pot-Pourri
Room E265

Page 69  Kidney Clinical Complications 2
Room E354B

Page 69  Kidney: Cardiovascular and Metabolic
Room E451B

Page 70  Kidney: Pediatric Adherence and Allocation
Room E353AB

Page 70  Liver Living Donors and Partial Grafts
Room E451A

Page 71  Logistic and Programmatic Challenges in Kidney Living Donation
Room E450B

Page 72  Regulatory Cells in Alloimmunity
Room E352

6:00 pm – 7:00 pm  Poster Session C
Presenters in Attendance
Hall D1
Sunrise Symposia
7:00 am – 8:15 am

Tolerance – Why aren’t we there yet?
Room E354A
Moderators: James Allan, MD, MBA, Massachusetts General Hospital, Boston, MA and Kenneth Newell, MD, PhD, Emory University School of Medicine, Atlanta, GA, USA

7:00 am Does Tolerance Outperform Optimized Immunosuppression?
John Scandling, MD
Stanford
Palo Alto, CA, USA

7:20 am Regulatory Cells and Tolerance
Sandy Feng, MD, PhD
UCSF
San Francisco, CA, USA

7:40 am Chimerism and Tolerance – It Works So What Are the Barriers?
Joseph Leventhal, MD, PhD
Northwestern University
Chicago, IL, USA

8:00 am Discussion

Simultaneous Liver Kidney Transplantation – Where are we and where are we going?
Room E353C
Moderators: Susan Orloff, MD, FACS, FAASLD, Oregon Health & Science University, Portland, OR, USA and John Friedewald, MD, Northwestern University, Chicago, IL, USA

7:00 am Summary of the Current Practice of SLK Transplantation
Darren Stewart
UNOS
Richmond, VA, USA

7:20 am The New SLK Transplant Policy – What it Does and Why
Nicole Turgeon, MD
Emory University
Atlanta, GA, USA

7:40 am Crippling Limitations of the New SLK Policy
Alexander Wiseman, MD
University of Colorado Denver
Aurora, CO, USA

8:00 am Discussion

Maintaining Minimal-Volume Solid Organ Pancreas Transplant Programs – PRO/CON
Room E350
Moderators: Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington DC, USA and Raja Kandaswamy, MD, University of Minnesota, Minneapolis, MN, USA

7:00 am PRO: Maintaining Minimal-Volume Solid Organ Pancreas Transplant Programs
Stefan Tullius, MD, PhD
Brigham and Women’s Hospital
Boston, MA, USA

7:30 am CON: Maintaining Minimal-Volume Solid Organ Pancreas Transplant Programs
Todd Pesavento, MD
Ohio State
Columbus, OH, USA

8:00 am Discussion

Combined Liver-Kidney Transplantation: Ways to Continue Improve Outcomes
Room E353AB
Moderators: Seth Karp, MD, Vanderbilt University, Nashville, TN, USA and David Mulligan, MD, Yale University/Yale New Haven Health, New Haven, CT, USA

7:00 am Overview of the New SLK Policy
Richard Formica, MD
Yale University School of Medicine
New Haven, CT, USA

7:25 am Delayed Implantation of the Kidney Allograft
Burcin Ekser, MD
Indiana University
Indianapolis, IN, USA

7:50 am Appropriate Monitoring of the Kidney Graft in SLK
Clifford Miles, MD
University of Nebraska Medical Center
Omaha, NE, USA
DCD Liver Transplantation: Current Controversies and Future Directions
Room E450A
Moderators: Linda Sher, MD, University of Southern California, Los Angeles, CA, USA and Amit Mathur, MD, MS, FACS, Mayo Clinic Arizona, Phoenix, AZ, USA

7:00 am Best Practices in the Use of Deceased After Cardiac Death Hepatic Allografts
George Loss, MD, PhD
Ochsner Medical Center
New Orleans, LA, USA

7:25 am Future Directions in DCD Liver Transplantation: Is the Pump the Solution?
Peter Friend
University of Oxford
Oxford, United Kingdom

7:50 am New Basic and Translational Science in Protecting DCD Allografts
David Foley, MD
University of Wisconsin School of Medicine and Public Health
Madison, WI, USA

New Concepts in Immune Monitoring
Room E354B
Moderators: David Taylor, MD, Cleveland Clinic, Cleveland, OH, USA and Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

7:00 am Immune Monitoring for Cardiac Transplantation, Where Are We in 2017?
Michael Shullo, PharmD
University of Pittsburgh
Pittsburgh, PA, USA

7:15 am Cell-Free DNA
Kevin Daly, MD
Boston Children’s Hospital
Boston, MA, USA

7:30 am MicroRNA
Howard Eisen, MD
Drexel University College of Medicine
Philadelphia, PA, USA

7:45 am Molecular Microscope
Sunil Kurian, PhD
The Scripps Research Institute
La Jolla, CA, USA

8:00 am Discussion

Updates on Women’s Health in Solid Organ Transplant
Room E451A
Moderators: Silvi Shah, MD, University of Cincinnati, Cincinnati, OH, USA and Kymberly Watt, MD, Mayo Clinic, Rochester, MN, USA

7:00 am Disparities in Opportunities for Transplantation
Kimberly Forde, MD, MHS
University of Pennsylvania
Philadelphia, PA, USA

7:25 am Sex Differences in Kidney Transplant Outcomes and Allocation
Matthew Levine, MD, PhD
University of Pennsylvania
Philadelphia, PA, USA

7:50 am Reproductive Health Following Solid Organ Transplant
Monika Sarkar, MD, MAS
UCSF
San Francisco, CA, USA

Emerging Infections in the Age of Global Warning – Implications for Transplantation
Room E451B
Moderators: Alejandro Restrepo, MD, Baylor College of Medicine, Houston, TX, USA and Raymund Razonnable, MD, Mayo Clinic, Rochester, MN, USA

7:00 am Zika Virus Infections – Screening Recommendations and Outcome Data
Clarisse Machado, MD
University of Sao Paolo
Sao Paolo, Brazil

7:25 am Nontuberculous Mycobacteria Infections – Management of Transplant Candidates and Recipients
Michele I. Morris, MD, FACP, FIDSA
University of Miami Miller School of Medicine
Miami, FL

7:50 am Strongyloides Infection Post-Transplant – Screening & Management of Donors & Recipients
Ricardo La Hoz, MD, FACP
University of Texas Southwestern Medical Center
Dallas, TX, USA
**Getting the Most Bang for Your Buck:**
**Creative Ways to Expand Pharmacy Services to Meet Regulatory Requirements**

**Room E351**
Moderators: Nicole Alvey, PharmD, Rush University Medical Center, Chicago, IL, USA and Annelise Nolan, PharmD, Medstar Georgetown University Hospital, Washington DC, USA

7:00 am  **Making Sense of It All: Understanding the Regulatory Requirements for Pharmacists**
Lisa Potter, PharmD
University of Chicago Medical Center
Chicago, IL, USA

7:25 am  **You’ve Been Cited: A Review of Common Pharmacy-Related Regulatory Citations and Potential Corrective Actions**
Nicole Pilch, PharmD
MUSC
Charleston, SC, USA

7:50 am  **Getting More with Less: Innovative Approaches to Expanding Pharmacy Services**
Eric Tichy, PharmD, FAST
Yale New Haven
New Haven, CT, USA

---

**Cytoprotection by Hematopoietically Derived Cells**

**Room E450B**
Moderators: James Burdick, MD, Johns Hopkins School of Medicine, St. Michaels, MD, USA and Leo Otterbein, PhD, Beth Israel Deaconess Medical Center, Boston, MA, USA

7:00 am  **Bone Marrow-Derived Hematopoietic Stem and Progenitor Cells Infiltrate Allogeneic and Syngeneic Transplants**
Paolo Fiorina, MD, PhD
Boston Children’s Hospital-Harvard Medical School
Boston, MA, USA

7:25 am  **Direct Contribution of Bone Marrow Cells to Tissue Regeneration**
Mari Dezawa, MD, PhD
Tohoku University Graduate School of Medicine
Sendai, Japan

---

**Interdisciplinary Plenary Session I**

**8:30 am – 9:30 am**

**Arie Crown Theater**

Chairs: Jean Emond, MD, Columbia University, New York, NY, USA and Charles M. Miller, MD, Cleveland Clinic, Cleveland, OH, USA

8:30 am  **Improving Communication of SRTR Transplant Program Outcomes Evaluations Using a 5-Tier System** (Abstract #201)
Jon Snyder, Andrew Wey, Nicholas Salkowski, Ajay Israni, Bertram Kasiske.
Minneapolis.
8:45 am  Is the Current Heart Allocation System Just and Fair for Blood Type O Recipients? – A Propensity-Matched Analysis of 34353 Patients in the UNOS Registry (Abstract #202)

9:00 am  MHC Class II-Peptide Complexes Displayed on Activated T Cells Guide Treg Suppression (Abstract #203)

9:15 am  HCC and Liver Transplantation Following the Recent Allocation Policy Change (Abstract #204)
Tanveen Ishaque, Allan Massie, Mary Bowring, Jessica Ruck, Andrew MacGregor Cameron, Benjamin Philosophe, Dorry Segev. Baltimore.

ASTS Awards
9:30 am – 9:45 am
Arie Crown Theater

ASTS Presidential Address
9:45 am – 10:15 am
Arie Crown Theater

Coffee Break with Exhibits
10:15 am – 10:45 am
Hall D1

State-of-the-Art Presentation
10:45 am – 11:15 am
Arie Crown Theater

Immune Checkpoint Inhibitors: Emerging Targets for Induction of Antitumor Immunity and Transplantation Tolerance
Vassiliki Boussiotis, MD, PhD
Harvard Medical School/Beth Israel Deaconess Medical Center
Boston, MA, USA

Midday Symposia
11:30 am – 1:00 pm

Debates in Mechanical Circulatory Support and Cardiac Transplantation
Room E351
Moderators: Andreas Zuckermann, MD, University of Vienna, Vienna, Austria and David Baran, MD, Newark Beth Israel Medical Center, Livingston, NJ, USA

11:30 am  Case Presentation
Brent Lampert, DO
Ohio State Wexner Medical Center
Columbus, OH, USA

11:35 am  PRO: Mechanical Circulatory Support Rather Should Be Used in Patients Who Are Not Thought Candidates for Transplantation Due to Concerns Over Compliance
Valluvan Jeevanandam, MD
University of Chicago
Chicago, IL, USA

11:48 am  CON: Mechanical Circulatory Support Rather Should Be Used in Patients Who Are Not Thought Candidates for Transplantation Due to Concerns Over Compliance
Francisco Arabia, MD
Cedars-Sinai Medical Center
Los Angeles, CA, USA

12:00 pm  Case Presentation
Jared Herr, MD
Sutter Health – California Pacific Medical Center
San Francisco, CA, USA

12:05 pm  PRO: Destination Therapy Patients Who Are INTERMACS Profile 4-5 Should Be Implanted as Destination Therapy
Scott Silvestry, MD
Florida Transplant Institute
Orlando, FL, USA

12:18 pm  CON: Destination Therapy Patients Who Are INTERMACS Profile 4-5 Should Be Implanted as Destination Therapy
Josef Stehlik, MD, MPH
University of Utah
Salt Lake City, UT, USA

12:30 pm  Case Presentation
Nicholas Furiasse, MD, MSc
Cedars Sinai Health System
Los Angeles, CA, USA
12:35 pm PRO: Older Patients with Comorbidities Should be Referred for Destination Therapy Rather Than Transplantation
Nir Uriel, MD
University of Chicago
Chicago, IL, USA

12:48 pm CON: Older Patients with Comorbidities Should Be Referred for Destination Therapy Rather Than Transplantation
TBD

Cardiac Function in Liver Transplantation: Assessing and Mitigating Risk across the Continuum of Care

Room E350
Moderators: Laura Hammel, MD, University of Wisconsin Hospitals and Clinics, Madison, WI, USA and Lisa VanWagner, MD, MSc, Northwestern University, Chicago, IL, USA

11:30 am When Is Chronic Atrial Fibrillation a Contraindication to Liver Transplantation?
Geraldine Diaz, DO
Univ of Chicago
Chicago, IL, USA

11:50 am Significant Coronary Artery Disease – When is it Critical, When to Revascularize
Sean Pinney, MD
Mount Sinai Hospital
New York, NY, USA

12:10 pm Mitigating Pulmonary Hypertension to Allow for Successful Liver Transplantation
Sanjiv Shah, MD
Northwestern University
Chicago, IL, USA

12:30 pm Optimal Management of Cardiac Dysfunction after Liver Transplantation
Laura Hammel, MD
University of Wisconsin Hospitals and Clinics
Madison, WI, USA

12:50 pm Discussion

Understanding ESRD after Live Kidney Donation

Room E354B
Moderators: Arthur Matas, MD, University of Minnesota, Minneapolis, MN, USA and Robert Gaston, MD, University of Alabama at Birmingham, Birmingham, AL, USA

11:30 am Lesions Learned from ESRD in the General Population
Bryce Kiberd, MD
Dalhousie University
Halifax, NS, Canada

12:00 pm What Can the SRTR Database Teach Us?
Jon Snyder, PhD
Scientific Registry of Transplant Recipients
Minneapolis, MN, USA

12:30 pm Donor Selection to Minimize Long-Term Risk
Arthur Matas, MD
University of Minnesota
Minneapolis, MN, USA

Delayed Allograft Function – What is the Impact and What Therapeutics are the Most Promising?

Arie Crown Theater
Moderators: Stuart Flechner, MD FACS, Cleveland Clinic Foundation, Cleveland, OH, USA and Daniel Brennan, MD, FACP, Washington University in St. Louis, St. Louis, MO, USA

11:30 am The Impact of DGF on the Patient – Trivial or Serious?
Joseph Kim, MD, PhD, MHS
Toronto General Hospital, University of Toronto
Toronto, ON, Canada

12:00 pm The Health Economic Consequences of Delayed Graft Function
Jon Friedman, MD
Optum
Cypress, CA, USA

12:30 pm Therapeutic Strategies to Reduce IRI and DGF – Does Anything Work?
Donald Hricik, MD
University Hospitals Case Medical Center Cleveland, OH, USA
Integration of APOL-1 into Kidney Transplantation: Summary of the AST Expert Workshop

Room E451B
Moderators: Anil Chandraker, MD, Brigham and Women’s Hospital, Boston, MA, USA and John S. Gill, MD, MS, University of British Columbia, Vancouver, BC, Canada

11:30 am Testing for APOL-1 Gene Variants in the Setting of Deceased Donor Kidney Transplantation: Opportunities and Barriers
Alexander Wiseman, MD
University of Colorado
Aurora, CO, USA

12:00 pm APOL-1 and Living Kidney Donation: Balancing Autonomy and Safety
Kenneth Newell, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

12:30 pm Impact of APOL-1 The Impact of Screening on Access to Kidney Transplantation Among African Americans Transplantation of Kidneys from Living and Deceased Organ Donors
Jesse Schold, PhD, M. Stat, M.Ed.
Cleveland Clinic, Lerner Research Institute
Cleveland, OH, USA

Liver Transplant for HCC in the Next Decade

Room E450A
Moderators: Christopher Sonnenday, MD, MHS, University of Michigan, Ann Arbor, MI, USA and Goran Klintmalm, MD, PhD, Baylor University Medical Center, Dallas, TX

11:30 am Evolution of Liver Transplant for HCC: 20 Years Post-Milan
Vincenzo Mazzaferro, PhD, MD
Istituto Nazionale dei tumori
Milan, Italy

12:00 pm Evolution of UNOS Policies for HCC: What Does the Future Hold?
Ryutaro Hirose, MD
UCSF
San Francisco, CA, USA

12:30 pm HCC And NASH: The Sleeping Giant and the Potential Future
Kymberly Watt, MD
Mayo Clinic
Rochester, MN, USA

Keeping the High MELD/PELD Patient Alive
On the List

Room E352
Moderators: Adnan Said, MD, MS, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA and Janice Jou, MD, MHS, Oregon Health Sciences University, Portland, OR, USA

11:30 am New Strategies for the Management of Acute on Chronic Liver Failure
Jasmohan Bajaj, MD, MS
Virginia Commonwealth University and McGuire VAMC
Richmond, VA, USA

12:00 pm Infection in the Wait-Listed Liver Transplant Candidate
Andre Kalil, MD
University of Nebraska Medical Center
Omaha, NE, USA

12:30 pm Too Sick for Transplant: Frailty, Nutrition and Predictive Score Assessments
Jennifer Lai, MD, MBA
University of California San Francisco
San Francisco, CA, USA

What’s Hot in Deceased Organ Donation – Normothermic Perfusion

Room E451A
Moderators: Joseph Magliocca, MD, Emory University, Atlanta, GA, USA and William Chapman, MD, Washington University, St. Louis, MO, USA

11:30 am Warm Perfusion of the Kidney
Sarah Hosgood, BSc, PhD
University of Cambridge
Cambridge, United Kingdom

12:00 pm Warm Perfusion in Liver Transplantation
Markus Selzner, MD
Toronto General Hospital
Toronto, ON, Canada

12:30 pm Warm Perfusion of the Heart
Jon Kobashigawa, MD
Cedars-Sinai Heart Institute
Los Angeles, CA, USA
**HIV Positive Transplantation**

**Room E354A**
Moderators: Michele I. Morris, MD, FACP, FIDSA, University of Miami Miller School of Medicine, Miami, FL, USA and Jayme Locke, MD, MPH, University of Alabama at Birmingham, Birmingham, AL, USA

11:30 am HIV Positive to Positive Transplantation – First Year Results and Outcomes in the USA
Christine Durand, MD
Johns Hopkins University
Baltimore, MD, USA

12:00 pm HIV Positive to Positive Transplantation in South Africa – The Unexpected Outcomes and Lessons Learned
Elmi Muller, MD
University of Cape Town
Cape Town, South Africa

12:30 pm HIV Positive Transplantations: Results with Maraviroc and MTOR Inhibitors
Peter Stock, MD, PhD
University of California San Francisco
San Francisco, CA, USA

---

**Exosomes and Donor Antigen Cross Dressing in Alloimmunity**

**Room E353C**
Moderators: William Burlingham, PhD, University of Wisconsin, Madison, WI, USA and Thalachallour Mohanakumar, PhD St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

11:30 am Role of Donor Dendritic Cell-Derived Exosomes in the Allo-Immune Response
Adrian Morelli, MD, PhD
University of Pittsburgh
Pittsburgh, PA, USA

12:00 pm The Critical Role of Donor Exosomes in the Initiation of Alloreactive T Cell Responses
Gilles Benichou, MD, PhD
Massachusetts General Hospital Boston
Boston, MA, USA

12:30 pm Exosomes as a Marker of Graft Injury
Prashanth Vallabhajosyula, MD
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

---

**Bench to Bedside – T Cell Memory**

**Room E353AB**
Moderators: Ronald Gill, PhD, University of Colorado – Denver, Aurora, CO, USA and Marisa Alegre, MD, PhD, The University of Chicago, Chicago, IL, USA

11:30 am Basic – T Cell Memory
Anna Valujskikh, PhD
Cleveland Clinic
Cleveland, OH, USA

12:00 pm Translational – T Cell Memory
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

12:30 pm Clinical – T Cell Memory
Carla Baan, MD
Erasmus Medical Center / University Hospital
Rotterdam, Netherlands

---

**Immune Tolerance – Lessons from Non-Transplant Models**

**Room E450B**
Moderators: Alessandro Alessandrini, PhD, Massachusetts General Hospital, Boston, MA, USA and Paige Porrett, MD, PhD, Univ of Penn, Philadelphia, PA, USA

11:30 am Immune Tolerance in Pregnancy
Indira Guleria, PhD
Brigham and Women’s Hospital
Southborough, MA, USA

12:00 pm Immunosuppressive Tumor Microenvironment
Shu-hsia Chen
Mount Sinai Hospital in New York
New York, NY, USA

12:30 pm T Cell Exhaustion in Chronic Viral Infection
TBD
Luncheon Workshops – Ticketed Events
1:00 pm – 2:15 pm

6. Looking Under the Hood of High Impact Papers Published in AJT
Moderators: Allan Kirk, MD, PhD, FACS, Duke University School of Medicine, Durham, NC, USA, Kevin Daly, MD, Boston Children's Hospital, Boston, MA, USA and David Wojciechowski, DO, Massachusetts General Hospital, Boston, MA, USA

1:00 pm TBD
TBD

1:15 pm Discussion

1:25 pm CD57+ CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection
Jaclyn Espinosa
Duke University
Durham, NC, USA

1:40 pm Discussion

1:50 pm Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial
Reena Ravikumar
Royal Free London/University of Oxford London, United Kingdom

2:05 pm Discussion

Concurrent Oral Abstract Sessions
2:30 pm – 4:00 pm

Basic Transplant Tolerance I
Room E350
Chairs: William Kitchens, MD/PhD, Emory Transplant Center, Atlanta, GA, United States and Anna Valujskikh, PhD, Cleveland Clinic, Cleveland, United States

2:30 pm Induction of Sensitization and Resistance to Transplant Tolerance by Allogeneic Pregnancy (Abstract #205)
Ashley N. Suah, James S. Young, Stella Hsu-Wei Khiew, Qiang Wang, Denping Yin, Maria-Luisa Alegre, Anita S. Chong.
Chicago, IL.

2:42 pm Induction of Delayed Renal Allograft Tolerance Using Only Clinically Available Reagents in Non-Human Primates (Abstract #206)
Kiyohiko Hotta, Tetsu Oura, Abbas Dehnadi, Svjetlan Boskovic, Masatoshi Matsunami, Ivy Rosales, Neal R. Smith, Robert C. Colvin, A. Benedict Cosimi, Tatsuo Kawai. Boston, MA.

2:54 pm Induction of Mixed Chimerism to Prolong Liver Allograft Survival in Cynomolgus Monkeys (Abstract #207)

3:06 pm Mouse FCs May Contain Lymphoid Progenitor Cells That Have the Capacity to Generate B and T Cells In Vivo (Abstract #208)
Anita Y. Chhabra, Yujie Wen, Yimimg Huang, Hong Xu, Andrea Merchak, Suzanne T. Ildstad. Louisville, KY.

3:18 pm Successful Induction of Tolerance of Fully Allogeneic Lung Graft with Adenosine A2A Receptor (A2AR) Agonist in MHC-Defined CLAWN Miniature Swine (Abstract #209)

3:30 pm Acute Mouse CMV Infection Abrogates Transplant Tolerance by Modulating Myeloid Cell Differentiation and Function: A Possible Role for Transcription Factor RORgt (Abstract #210)
Anil Dangi, Lei Zhang, Xiaomin Zhang, Zheng Jenny Zhang, Xunrong Luo. Chicago, IL.
3:06 pm  **Normothermic Donor Lung Preservation with Portable EVLP Significantly Reduces Ischemia/Reperfusion Injury in Lung Recipients by Promoting Cytokine Antagonists (Abstract #215)**

3:18 pm  **Kidney Injury Molecule-1 Mitigates Tissue Damage from Transplant Renal Ischemia Reperfusion Injury (Abstract #216)**

3:30 pm  **Extra-Renal Cardiac Injury Is Associated with Upregulation of NOD2 and Nlrp3 in the Heart After Renal IRI (Abstract #217)**
Andrew Scheinok, Sashi Kasimsetty, Elizabeth Soo, Cade Nelson, Alana Shigeoka, Dianne McKay. La Jolla, CA.

3:42 pm  **Dendritic Cell Expression of Rictor (mTORC2), but Not Raptor (mTORC1), Protects Against Renal Ischemia-Reperfusion Injury (Abstract #218)**
Helong Dai, Natasha M. Rogers, Alicia R. Watson, Daniel Fantus, Angus W. Thomson. Pittsburgh, PA; Sydney, Australia; Changhai, China.

**Heart Transplantation: Antibodies and Outcomes**

Room E271B

**Chairs: Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, United States and Jignesh Patel, MD PhD, Cedars-Sinai Heart Institute, Beverly Hills, CA, United States**

2:30 pm  **Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection (Abstract #219)**

---

**Emerging Interventions in Ischemia Reperfusion Injury**

Room E351

**Chairs: Anthony Jevnikar, MD, University Hospital - LHSC, London, Ontario, Canada and Jerzy Kupiec-Weglinski, UCLA, Los Angeles, CA, United States**

2:30 pm  **A Proof of Concept for Liver Graft Modification Using Warm Ex Vivo Perfusion – “It Is Not Just About Rescuing Marginal Grafts” (Abstract #212)**
Nicolas Goldaracena, Juan Echeverri, Nazia Selzner, David Grant, Jordan Feld, Markus Selzner. Toronto, Canada.

2:42 pm  **Treating Ischemically Damaged Porcine Kidneys with Mesenchymal Stromal Cells During Normothermic Machine Perfusion (Abstract #213)**
M. Pool, J. Sierra Parraga, M. Roemeling-van Rhijn, M. Reinders, M. Hoogduijn, R. Ploeg, H. Leuvenink, Cyril Moers. Groningen, Netherlands; Rotterdam, Netherlands; Leiden, Netherlands; Oxford, United Kingdom.

2:54 pm  **Expression of Injury and Repair Genes in Ex Vivo Perfused Swing Lung Transplants (Abstract #214)**
Peter Dromparis, Seigfried Wagner, Nader Aboelnaz, Jessica Luc, Darren Freed, Jayan Nagendran, Michael Mengel, Benjamin Adam. Edmonton, Canada.
2:42 pm Young African American Heart Transplant Recipients Have an Elevated Risk of Post-Transplant Mortality (Abstract #220)

2:54 pm Clinical Correlation of Endomyocardial Biopsies Molecular Profiling: Taking Rejection Diagnosis Beyond Histology (Abstract #221)
L. Potena, L. Borgese, A. Gaudenzi, V. Agostini, J. Reeve, M. Masetti, F. Grigioni, O. Leone, Philip Halloran. Bologna, Italy; Edmonton, Canada.

3:06 pm Validation of a Prediction Model for Cardiac Allograft Vasculopathy (Abstract #222)

3:18 pm High Titer De Novo Donor-Specific HLA Alloantibodies and Cardiac Allograft Vasculopathy After Pediatric Heart Transplantation (Abstract #223)
Bibhuti B. Das, Song Zhang, Ang Gao, Chantale Lacelle. Dallas, TX.

3:30 pm Primary Graft Dysfunction After Pediatric Heart Transplant (Abstract #224)
Katie Mowers, Kathleen Simpson, Pirooz Eghtesady, Orlando Petrucci, Charles Canter, Chesney Castleberry. St. Louis, MO.

3:42 pm Antibodies to Angiotensin Type II Receptor I Are Associated with Primary Graft Dysfunction After Orthotopic Heart Transplant in Patients with Ventricular Assist Device as Bridge to Transplant (Abstract #225)
Michelle J. Hickey, Eugene DePasquale, Sajan Shah, Darko Vucicevic, Jennifer Qiuheng Zhang, Nicole Valenzuela, Mario Deng, Elaine F. Reed. Los Angeles, CA.

Infectious Complications of Transplant

Room E265

2:30 pm BK Virus Infection and Risk of Urinary Tract Cancers Among Kidney Transplant Patients in the Transplant Cancer Match Study (Abstract #226)
Gaurav Gupta, Sarat Kuppachi, Roberto Kalil, Christopher Buck, Charles Lynch, Eric Engels. Richmond; Iowa City; Bethesda.

2:42 pm Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection (Abstract #227)
Victor H. Ferreira, A. Humar, E. Cordero, E. Blumberg, A. Limaye, F. Silveira, L. Danziger-Isakov, M. Levi, J. Kalpoe, J. Englund, Multicenter Influenza Group, Deepali Kumar. Toronto, Canada; Seville, Spain; Philadelphia; Leiden, Netherlands; Pittsburgh; Cincinnati; Denver; Seattle.

2:54 pm Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients (Abstract #228)
Victor H. Ferreira, A. Humar, E. Cordero, E. Blumberg, S. Husain, J. Kalpoe, Multicenter Influenza Group, Deepali Kumar. Toronto, Canada; Seville, Spain; Philadelphia; Leiden, Netherlands.

3:06 pm Hepatitis B Virus Infection Is Associated with Recurrent Nephropathy After Kidney Transplantation (Abstract #229)

3:18 pm Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study (Abstract #230)
Olivier Marion, Florence Abravanel, Laure Esposito, Sebastien Lhomme, Arnaud Del Bello, Jacques Izopet, Nassim Kamar. Toulouse, France.
3:30 pm Clinical Risk Factors for Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTRs): Results of an International Cohort Study (Abstract #231)
Nancy Law, Bassem Hamandi, Christine Fegbeutel, Fernanda P. Silveira, Erik A. Verschuuren, Piedad Ussetti, Peter V. Chin-Hong, Amparo Solé, Chien-Li Holmes-Liew, Eliane M. Billaud, Paolo A. Grossi, Oriol Manuel, Deborah J. Levine, Richard G. Barbers, Denis Hadjiliadis, Lianne G. Singer, Shahid Husain. Toronto, ON, Canada; Hannover, Germany; Pittsburgh, PA; Groningen, Netherlands; Madrid, Spain; San Francisco, CA; Valencia, Spain; Adelaide, Australia; Paris, France; Varese, Italy; Lausanne, Switzerland; San Antonio, TX; Los Angeles, CA; Philadelphia, PA.

2:54 pm Impact of Donor BK-Virus Replication on Posttransplant BKV Replication After Living-Donor Transplantation (Abstract #235)
Jimmy Grellier, Arnaud Del Bello, Laure Esposito, Anne Laure Hebral, Catherine Mengelle, Nassim Kamar. Toulouse, France.

3:06 pm Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence (Abstract #236)
Kawther F. Alquadan, Alfonso H. Santos, Michael J. Casey, Tezcan Ozrazgat-Baslant, Shahab Bozorgmehri, Jon A. Gregg, Karl L. Womer. Gainesville, FL.

3:18 pm Calibration of BK Virus Nucleic Acid Amplification Testing to the 1st WHO International Standard for BK Virus (Abstract #237)

3:30 pm Repeat Biopsies After the Diagnosis of BK Virus Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings (Abstract #238)

3:42 pm Urinary Retention Associated with Polyomavirus (BK) Viruria and Higher Peak Blood BK Following Kidney Transplant (KTx) (Abstract #239)
Wisit Cheungpasitporn, Hatem Amer, Fernando G. Cosio, Carrie A. Schinstock. Rochester, MN.

Kidney Clinical Psychosocial
Room E354B
Chairs: Raquel Garcia-Roca, MD, loyola university medical center, Chicago, IL, United States and Kristin Raven, MD, Beth Israel Deaconess Medical Center, Boston, MA, United States

2:30 pm Emergency Department Utilization Among Kidney Transplant Recipients in the United States (Abstract #240)
Brendan Lovasik, Rebecca Zhang, Justin Schrager, Stephen Pastan, Andrew Adams, Rachel Patzer. Atlanta, GA.
2:42 pm  Dementia and Alzheimer’s Disease Among Older Kidney Transplant Recipients (Abstract #241)

2:54 pm  Employment Patterns After Kidney Transplantation: Rates, Contributing Factors and Outcomes (Abstract #242)
Joseph Kim, Jayoti Rana, Monika Ashwin, Yanhong Li, Olusegun Famure. Toronto, ON, Canada.

3:06 pm  Impact of Cognitive Impairment on Kidney Transplantation Listing Between Sexes (Abstract #243)

3:18 pm  Prescription Opioid Use Before and After Kidney Transplant: Implications for Post-Transplant Outcomes (Abstract #244)
Krista Lentine, Ngan N. Lam, Dorry L. Segev, David A. Axelrod, Zidong Zhang, Huiling Xiao, Greory P. Hess, Bertram L. Kasiske, Raj Gadi, Radhika Devraj, Daniel C. Brennan, Henry Randall, Mark Schnitzler. St. Louis, MO; Edmonton, AB, Canada; Baltimore, MD; Greenville, NC; Philadelphia, PA; Minneapolis, MN; Edwardsville, IL.

3:30 pm  Post-Donation Experiences of Non-Directed (Altruistic) Living Kidney Donors in the United States (Abstract #245)
Ariella Maghen, Grecia B. Vargas, Sarah E. Connor, Sima Nassiri, Elisabeth M. Hicks, Lorna Kwan, Sally L. Maliski, Jeffrey Veale. Los Angeles, CA; Portland, OR; Kansas City, KS.

3:42 pm  Factors Predicting 30-Day Hospital Readmission After Kidney Transplant (Abstract #246)
Jamie Ostrem, Marissa Brokhof, Nicole Kenyon, Edward Hollinger, Stephen Jensik, Oyedolamu Olaitan, Martin Hertl, Nicole Alvey. Chicago, IL.

Liver Retransplantation and Other Complications
Room E353AB

2:30 pm  Liver Retransplantation: The Largest Post MELD Single Center Experience (Abstract #247)

2:42 pm  Contemporary Outcomes and Risk Factors of Acute Graft-versus-Host Disease After Liver Transplant (Abstract #248)
Johnathon Markus, Aymen Bukannan, Brittany Kashat, Reena Salgia. Detroit, MI.

2:54 pm  Effects of Liver Transplantation on Cardiac Function in Patients Transplanted for NASH Cirrhosis (Abstract #249)
Haripriya Maddur, Lisa VanWagner, Dyanna Li Gregory, Bernadette Wodzinski, Kameshvari Maganti, Mary Rinella. Chicago, IL.

3:06 pm  Risk of Ischemic Biliary Injury Is Not Associated with Prolonged Hepatic Artery Ischemic Times During Liver Transplantation (Abstract #250)
Erin M. Armenia, Nathan Schomaker, Avash Kalra, Jane Gralla, Aimee Truesdale, Scott W. Biggins, Trevor Nydam, James Burton. Aurora, CO; Seattle, WA.

3:18 pm  Cardiovascular Events Are a Substantial and Increasing Cause of Graft Loss in Liver Transplant Recipients (Abstract #251)
3:30 pm Clinical Evaluation of the Safety and Preliminary Efficacy of Continuous Infusion of Treprostinil to Prevent Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients (Abstract #252)

3:42 pm Early Acute Cellular Rejection (eACR) as a Marker of Immunologic Competency Following Liver Transplantation (LT) (Abstract #253)
V. Kirchner, A. Bandgdiwala, D. Vock, M. Hassan, R. Kandaswamy, J. Lake, N. Lim, A. Mahgoub, E. Minja, A. Pugalenthi, B. Sengupta, O. Serrano, J. Thompson, W. Payne, T. Pruett, S. Chinnakotla. Minneapolis, MN.

Living Kidney Donation: Post Donation Issues
Room E450B
Chairs: Joseph Buell, MD, MBA, Tulane University, New Orleans, LA, United States and Alexander Gilbert, MD, MedStar Georgetown Transplant Institute, Washington DC, DC, United States

2:30 pm Apolipoprotein L1 & Chronic Kidney Disease Risk in Young Potential Living Kidney Donors (Abstract #254)
Jayme E. Locke, Deirdre Sawinski, Rhiannon D. Reed, Brittany Shelton, Paul A. MacLennan, Vineeta Kumar, Shikha Mehta, Roslyn B. Mannan, Robert Gaston, Bruce A. Julian, J. Jeffrey Carr, James G. Terry, Meredith Kilgore, Allan B. Massie, Dorry L. Segev, Corinna M. Lewis. Birmingham; Philadelphia; Nashville; Baltimore.

2:42 pm Impact of Cold Ischemia Time on Outcomes in Kidney Paired Donation (KPD) (Abstract #255)

2:54 pm APOL1 Genotype Does Not Affect Donor Renal Function Post Live Kidney Donation (Abstract #256)

3:06 pm Post-Donation GFR Changes in Living Kidney Donors (Abstract #257)
Emilio D. Poggio, Susana Arrigain, Joshua J. Augustine, Stuart Flechner, Jesse Schold. Cleveland, OH.

3:18 pm Increased Long-Term Mortality 20 years After Living Kidney Donation (Abstract #258)
Geir Mjoen, Stein Hallan, Hallvard Holdaas. Oslo, Norway; Trondheim, Norway.

3:30 pm Long-Term Consequences of Post-Donation Preeclampsia (Abstract #259)

3:42 pm Analysis of Differences in Living Donor and Recipient Pairs Estimated GFR at Six Months Over Time (Abstract #260)
Douglas S. Keith. Pensacola, FL.

Long Term Kidney Graft Survival I
Room E450A
Chairs: Simin Goral, MD, University of Pennsylvania, Philadelphia, PA, United States and Michael Hanaway, MD, Univ of Alabama At Birmingham, Birmingham, AL, United States

2:30 pm Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts (Abstract #261)

2:42 pm The Use of Very High KDPI Kidneys in Elderly Kidney Transplant Recipients – Discarded in the U.S. but Successfully Transplanted in Europe (Abstract #262)
Fabian Halleck, Dmytro Khadzhynov, Gregor Rehse, Lukas Lehner, Eva Schrezenmeier, Michael Dürr, Klemens Budde, Oliver Staeck. Berlin, Germany.
A Non-Invasive Urinary Common Rejection Module (uCRM) Gene Expression Score Quantifies and Differentiates Kidney Transplant Injury (Abstract #263)

Epigenetic Modifications in the Progression to Chronic Renal Allograft Injury (Abstract #264)
Vineela Bontha, Daniel Maluf, Mikhail Dozmorov, Kellie Archer, Lorenzo Gallon, Valeria Mas. Charlottesville; Richmond; Columbus; Chicago.

Expression of T-Cell Mediated Rejection (TCMR) Associated Genes in Native and Renal Allograft Renal Biopsies with Inflamed Scars (i-IFTA) (Abstract #265)
Zili Lyu, Ling Pang, Gang Zeng, Yuchen Huang, Parmjeet Randhawa. Nanning, Guangxi, China; Pittsburgh, PA.

Survival Outcomes from DCD Transplant Are Comparable to DBD Transplant from Kidneys Procured from Donors > 50 Years of Age. A UNOS/OPTN Propensity Score Matched Pair Analysis (Abstract #266)

Is “Death with a Functioning Graft (DWF)’” Really Death with Function? Data from the Long-Term Deterioration of Kidney Allograft Function (DeKAF) Study (Abstract #267)

Mechanisms of Allograft Rejection
Room E352
Chairs: Scott Krummey, MD, PhD, Emory University School of Medicine, Atlanta, Georgia, United States and Leonardo Riella, MD PhD, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States

CTLA4-Ig Inhibits Effector CD8+ T Cell Function In Vivo and Rescues Ongoing Acute Allograft Rejection (Abstract #268)
James Young, Stella Khiew, Jinghui Yang, Maria-Luisa Alegre, Anita Chong. Chicago, IL.

CD4 T Cell Migration Across Lymphatic Endothelium Is Enhanced by Sphingosine 1-Phosphate (S1P) and Differentially Regulated by S1P Receptors (S1PR) (Abstract #269)

Binding of Antigens by Its Specific Antibodies Results in Exosome Formation Leading to Rejection of Syngeneic Murine Cardiac Grafts (Abstract #270)

Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORkinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival (Abstract #271)

Differential Expression of Long Noncoding RNAs During Cardiac Allograft Rejection (Abstract #272)
Guangxiang Gu, Huihui Hang, Tianfei Lu, Qiang Xia. Shanghai, China.

TIE'ing Statins to Microvascular Stability and Endothelial Cell Immunogenicity (Abstract #273)
Chandra C. Ghosh, AnneLinde Mak, Megan McGourty, Samir M. Parikh, Xiuying Chen, Sarah Goldberg, Johannes Wedel, David M. Briscoe. Boston, MA.
3:42 pm  Increased Ischemic Inflammation Induces Recipient Endogenous Memory CD4 Cell-Graft Dendritic Cell Interactions to Provide Help for Activation of Endogenous Memory CD8 T Cells (Abstract #274)
Hidetoshi Tsuda, Toshiaki Tanaka, Charles A. Su, Anna Valujskikh, Robert Fairchild. Cleveland, OH.

Organ Perfusion Strategies

Room E353C
Chairs: Cristiano Quintini, MD, Cleveland Clinic, Cleveland, oh, United States and Markus Selzner, MD, University of Toronto, Toronto, ON, Canada

2:30 pm  Ischemia-Reperfusion Injury-Induced Innate Immune Signaling in Human Orthotopic Liver Transplantation (Abstract #275)

2:42 pm  First Report of Human Liver Transplantation After Normothermic Machine Perfusion (NMP) in the United States (Abstract #276)
Qiang Liu, Basem Soliman, Giuseppe Iuppa, Ahmed Nassar, Ahmed Hassan, Teresa Diaco Uso, Koji Hashimoto, Federico Aucejo, Masato Fujiki, Bijan Egthesad, Jacek Cywinski, Samuel Irefin, John Fung, Kareem Abu-Elmagd, Charles Miller, Cristiano Quintini. Cleveland.

2:54 pm  36 Hours of Ex-Vivo Warm Cellular Perfusion of Swine Liver Using the Organ Care System (OCS™) Liver with Excellent Functional, Metabolic and Histological Outcomes (Abstract #277)
Joseph F. Magliocca, James F. Markmann, Marwan S. Abouljoud, Mark Gobrial, Anthony Demetris. Atlanta, GA; Boston, MA; Detroit, MI; Houston, TX; Atlanta, GA; Pittsburgh, PA.

3:06 pm  Improved Outcomes After Liver Transplantation from Controlled DCD Donors with Normothermic Regional Perfusion (Abstract #278)
Gabriel C. Oniscu, Fiona Hunt, Wendy Herries, Ian Currie, Andrew Sutherland, Craig Beattie, Euan Thomson. Edinburgh, United Kingdom.

3:18 pm  Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial (Abstract #279)
James F. Markmann, Mark Gobrial, Joseph F. Magliocca, Anthony Demetris, Marwan S. Abouljoud. Boston, MA; Detroit, MI; Houston, TX; Atlanta, GA; Pittsburgh, PA.

3:30 pm  Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology (Abstract #280)
Dhakshinamoorthy Vijayanand, Firas Zahreldeen, Jennifer Kingston, Shahid Farid, Tracy Mdlongwa, Anthony Ramsden, Sean Willis, Catherine Morenty, Magdy Attia. Leeds, United Kingdom.

3:42 pm  Ex-Situ Extended Limb Preservation: A Protocol for Porcine Limb Perfusion (Abstract #281)

Transplant Regulation and Management: Allocation, Access and Other Transplant Management Topics

Room E451B
Chairs: Gwen McNatt, RN, PhD, FNP-BC, Northwestern Memorial Hospital, Chicago, Illinois, United States and Anne Murphy, MBA, FACHE, University of Michigan, Ann Arbor, Michigan, United States

2:30 pm  Transplant Economics Post Implementation of the Affordable Care Act and the Budget Control Act Sequestration Adjustment on Medicare Reimbursement (Abstract #282)
Edward Zavala, John Rogers, Robert Howey, Seth Karp. Nashville; San Diego; Jacksonville.
2:42 pm  The Impact of the New Kidney Allocation System on Length of Dialysis Prior to Transplantation (Abstract #283)

2:54 pm  A New Methodology for Measuring and Monitoring Equity in Access to Deceased Donor Kidney Transplants (Abstract #284)

M. Usman Ahmad, Afif Hanna, Ahmed Mohamed, Rahul Mhaskar, Tambi Jarmi, Alex Schindwein, Caitlin Pley, Ingrid Bahner. Tampa, FL; Gulfport, FL; Cambridge, Cambridgeshire, United Kingdom.

3:18 pm  The Unfunded OPTN/UNOS Mandate of Living Kidney Donor Follow-Up: Fewer Than 50% of Centers in Compliance (Abstract #286)
Macey Henderson, Alvin Thomas, Allan Massie, Xun Luo, Ashton Shaffer, Courtenay Holscher, Dorry Segev. Baltimore, MD.

3:30 pm  Vendor to Center in 0-60: A Safe and Effective Blueprint for Creating an In-House On-Call System for Organ Offers (Abstract #287)
Krista Driggers, Jordan Davenport, Debra Cassidy, Lena Curry, Allison Milling, Amy Hauser, Heather Crego, Prabhakar Baliga, Nicole Pilch, Derek Dubay, Julie Anderson. Charleston, SC.

3:42 pm  We Wish This Would Never Happen Again! Implementation of an Adverse Event Review System to Improve the Safety of Pediatric Solid Organ Transplant (SOT) Patients (Abstract #288)
Joshua Gossett, Mike Lake, John Bucuvalas, Anjali Basu, Lauren Burkhart, Lara Danziger-Isakov, Angela Lorts. Cincinnati, OH.

Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients

Room E354A
Chairs: Donald Hricik, MD, Case Western Reserve, Cleveland, OH, United States and Eric Langewisch, MD, University of Nebraska Medical Center, Omaha, NE, United States

2:30 pm  Safety & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs) (Abstract #289)

2:42 pm  Composite Prognostic Score Improves Clinical Benefit in Kidney Recipients Receiving Standard of Care Therapy for Antibody-Mediated Rejection (Abstract #290)

2:54 pm  Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Molecular Phenotype of Rejection for Complement-Targeting Therapy (Abstract #291)

3:06 pm  Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial (Abstract #292)
Farsad A. Eskandary, Bernd Jilma, Jakob Muehlbacher, Markus Wahlmann, Heinz Regele, Nicolas Kozakowski, Sandip Panicker, Jeff Reeve, Philipp F. Halloran, James C. Gilbert, Georg A. Boehmig. Vienna, Austria; San Francisco; Edmonton, Canada.
3:18 pm Experience with Obinutuzumab (Type II Anti-CD20) in Kidney Transplant Patients with Donor Specific Antibody (DSA+) Antibody Mediated Rejection (Abstract #293)
Jua Choi, Ashley Vo, Edmund Huang, Sabrina Louie, Alexis Kang, Alice Peng, Reiad Najjar, Stanley C. Jordan. Los Angeles, CA.

3:30 pm Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation (Abstract #294)
Dhiren Kumar, Gaurav Gupta, Jeff Reeve, Pooja Sanghi, Sindhura Bobba, Marlon Levy, Chandra Bhati, Pamela Kimball, Hasan Fattah, Anne King, Hugh Massey, Philip Halloran. Richmond; Edmonton, Canada.

3:42 pm Rapid Depletion of Circulating DSA and Treatment of Acute Antibody-Mediated Rejection with the Combination of CTLA-4Ig/Belatacept and Bortezomib in Mouse and Man (Abstract #295)
James Young, Augustin Vannier, Ginny Bumgardner, Anita Chong, Ronald Pelletier. Chicago, IL; Columbus, OH.

Pediatric/Allied Health Symposium
2:30 pm – 6:00 pm
Room E253ABCD

Promoting Adherence in the 21st Century
Moderators: Marie Chisholm-Burns, PharmD, University of TN College of Pharm, Memphis, TN, USA and Hilda Fernandez, MD, MS, Columbia University, New York, NY, USA

2:30 pm Report from the AST Adherence Task Force – Real World Options for Promoting Adherence
Larissa Myaskovsky, PhD
University of Pittsburgh, School of Medicine
Pittsburgh, PA, USA

3:00 pm Use of Once Daily Immunosuppression Regimens to Promote Adherence in the Pediatric/Adolescent Population
Rochelle Liverman, PharmD
Children’s Healthcare of Atlanta
Atlanta, GA, USA

3:30 pm Technology Based Interventions to Promote Adherence in Adult and Pediatric Populations
John McGillicuddy, MD
Medical University of South Carolina
Charleston, SC, USA

4:00 pm Coffee Break

Transplantation and Generation Z
Moderators: Mary Moss, PharmD, Children’s Hospital Colorado, Denver, CO, USA and Amy Bobrowski, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago, Elmhurst, IL, USA

4:30 pm Lost in Translation, Speaking with Generation Z
Emily Fredericks, PhD
University of Michigan / C.S. Mott Children’s Hospital
Ann Arbor, MI, USA

5:00 pm Social Media and Peer Mentoring as Bridges to the Adult World
Heidi Yeh, MD
Massachusetts General Hospital
Boston, MA, USA

5:30 pm Are They Really Ready? Assessing Readiness for Transition to the Adult World
Beverly Kosmach-Park, DNP, RN, FAAN
Children’s Hospital Pittsburgh
Pittsburgh, PA, USA

Allied Health Symposium 2
2:30 pm – 6:00 pm
Room E258

Balancing Quality & Risk

The ABC’s in transplantation: UNOS, MPSC, SRTR, CMS
Moderators: Demetra Tsapepas, PharmD, New York-Presbyterian Hospital, New York, NY, USA and Brigitte Sullivan, MBA, NYU Langone Transplant Institute, New York, NY, USA

2:30 pm The Basics: Developing a QAPI Program
Tiffany Kaiser, PharmD
University of Cincinnati
Cincinnati, OH, USA

3:00 pm Survey Readiness: How Will You Make Your Allstar Team Shine
Meredith Aull, PharmD
Weill Cornell Medical College
New York, NY, USA
3:30 pm Data Analytics: Making Better Business Decisions and Expanding Your QAPI Program
Sumit Mohan, MD, MPH
Columbia University
New York, NY, USA

4:00 pm Coffee Break

MPSC: Friend or Foe? Current Status and The Future Of Transplant Program Oversight
Moderators: Jon Snyder, PhD, Minneapolis Medical Research Foundation, Minneapolis, MN, USA and Stuart Sweet, MD, Washington University/ St. Louis Children’s Hospital, St. Louis, MO, USA

4:30 pm – 5:00 pm Lesions from the Real World: An MPSC Transplant Center Case Study
Liise Kayler, MD, MS, FACS
Erie County Medical Center
Buffalo, NY, USA

5:00 pm – 5:30 pm Lesions from the Real World: A CMS Transplant Center Case Study
James Whiting, MD
Maine Medical Center
Portland, ME, USA

5:30 pm – 6:00 pm The OPTN Coin Project: Early Data From A New Approach To Program Oversight
David Klassen, MD
United Network for Organ Sharing
Richmond, VA, USA

Coffee Break with Exhibits
4:00 pm – 4:30 pm

Hall D1

Concurrent Oral Abstract Sessions
4:30 pm – 6:00 pm
Antibody Mediated Rejection in Kidney Transplant Recipients: Pathophysiology and Epidemiology

Room E354A
Chairs: Stanley Jordan, M.D., Cedars Sinai, Los Angeles, CA, United States and Carrie Schinstock, Mayo Clinic, Rochester, MN, United States

4:30 pm Lower Incidence of DSA-Induced Chronic Antibody-Mediated Rejection in Abo-Incompatible Renal Transplantation (Abstract #296)

4:42 pm Meta-Analysis of Clinical Significance of Complement Activating Anti-HLA DSA in Kidney Transplantation (Abstract #297)

4:54 pm Glomerular CD45 Immunostaining in Post Perfusion Graft Biopsies Predicting Rejection (Abstract #298)
Anand Yuvraj, Abheesh Prasad, Kishore Gopalakrishnan, Nithya Krishnan. Coventry, United Kingdom.

5:06 pm The Molecular Phenotypes of Rejection in Kidney Transplant Biopsies (Abstract #299)
Philip Halloran, J. Reeve, INTERCOMEX Study Group. Edmonton, AB, Canada.

5:18 pm The Natural History of Kidney Rejection: How Do Molecular Disease States Change Over Time in Patients with Repeat Indication Biopsies? (Abstract #300)
J. Reeve, Philip Halloran. Edmonton, AB, Canada.

5:30 pm Endocapillary NK Cells Are Increased in Indication Renal Transplant Biopsies with Antibody and T Cell Mediated Rejection (Abstract #301)
Ali Shammout, Jenna Barnes, Evan A. Farkash. Ann Arbor, MI.
5:42 pm Immunodominant Donor Specific Antibody Reduction with Proteasome Inhibitor Based Treatment: Clinical Variability and Implications for Long Term Graft Survival (Abstract #302)

B Cells and Antibody in Rejection
Room E350
Chairs: Lakshman Gunaratnam, MD, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada and Emmanuel Zorn, Columbia University Medical Center, New York, United States

4:30 pm Comprehensive Functional Assessment of the Pathogenic Potential of Immunodominant Donor Specific Antibody Following Treatment of Late Antibody Mediated Rejection or Mixed Acute Rejection (Abstract #303)

4:42 pm Strategy for Analysis of Donor-Specific Antibody Repertoire: Paired Immunoglobulin Heavy and Light Chain Analysis of Individual Memory B Cells (Abstract #304)
Marc Lucia, Alejandro Gomez, Sergi Luque, Oriol Bestard, William H. Robinson, Olivia M. Martinez. Stanford; Barcelona, Catalonia, Spain.

4:54 pm Generation of Natural Antibodies Post Transplant and Association with Kidney Allograft Loss (Abstract #305)
Sarah B. See, Alexandre Loupy, Olivier Aubert, Yokarla Veras, Xavier Lebreton, Baoshan Gao, Christophe Legendre, Dany Anglicheau, Emmanuel Zorn. New York, NY; Paris, France; Changchun, China.

5:06 pm B Cell Deficiency Inhibits Both Antibody Mediated Rejection and T Cell Mediated Acute Rejection in a Rat Kidney Transplant Model (Abstract #306)
Sarah Panzer, Shannon Reese, Nancy Wilson Schlei, Bret Verhoven, Ding Xiang, Weixiong Zhong, Arjang Djamali. Madison, WI.

5:18 pm Donor-Specific B Cell Responses: Predicting the Future of Kidney Transplants (Abstract #307)

5:30 pm Antibodies Specific for HLA Class I and Lung Associated Self-Antigens, Ka1Tubulin and Collagen V, Induces Exosomes Following In Vitro Binding to Human Airway Epithelial Cells (Abstract #308)

5:42 pm TIM-4 Identifies Pro-Inflammatory B Effector Cells That Are Potent Drivers of Alloimmunity and Allograft Rejection Through Expression of Both IFN-γ and IL-17 (Abstract #309)
Qing Ding, Kanish Mohib, David Rothstein. Pittsburgh.

Basic Chronic Rejection
Room E351
Chairs: Wink Baldwin, MD, PhD, Cleveland Clinic, Cleveland, Ohio, United States and Roslyn Mannon, MD, UAB, Birmingham, AL, United States

4:30 pm Macrophage Specific Deletion of RhoA Inhibits Fractalkine Signaling and Abrogates Chronic Rejection of Cardiac Allograft (Abstract #310)
Malgorzata Kloc, Yianzhu Liu, Wenhao Chen, Xian C. Li, Rafik Ghobrial. Houston.

4:42 pm Sulfatide-Selective NKT Cells Mediate M2 to M1 Polarization Resulting in Amelioration of Kidney Fibrosis (Abstract #311)
Sunhwa Lee, Mi-Yeon Yu, Yong Chul Kim, Seung Hee Yang, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim. Seoul, Republic of Korea.

4:54 pm HLA-DR Based Murine Transplant Model for Studying Collagen Type V Autoimmunity in Chronic Allograft Rejection (Abstract #312)
Vrushali V. Agashe, Ying Zhou, Ewa Jankowska-Gan, William J. Burlingham. Madison, WI.
5:06 pm  Podocyte-Specific Knockdown of SHROOM3 Causes Albuminuria and Foot-Process Effacement by Interaction with FYN (Abstract #313)
Madhav C. Menon, Nimrod Philippe, Chengguo Wei, Weijia Zhang, John C. He, Barbara Murphy. New York, NY.

5:18 pm  Podocyte Participates in the ST2 Related Renal Fibrosis (Abstract #314)

5:30 pm  Gene Expression During Development of Chronic Antibody-Mediated Rejection in Renal Allografts from Non-Human Primates: Validation of Markers Used in Humans and Sequential Changes in Protocol Biopsies (Abstract #315)
B. Adam, R. N. Smith, M. Matsunami, I. A. Rosales, B. Afzali, T. Oura, A. B. Cosimi, T. Kawai, R. B. Colvin, M. Mengel. Edmonton, Canada; Boston.

5:42 pm  The Degree of NK Cell Activation Determines the Ability of Donor-Specific Antibodies to Mediate Acute vs. Chronic Rejection of Kidney Allografts (Abstract #316)
Takafumi Yagisawa, Toshiaki Tanaka, Nina Dvorina, Anna Valujskikh, William M. Baldwin 3rd, Robert L. Fairchild. Cleveland, OH; Tokyo, Japan.

Disparities in Organ Transplantation

Room E353C
Chairs: Robert Gaston, MD, UAB, Birmingham, AL, United States and Daniela Ladner, Northwestern University, Chicago, IL, United States

4:30 pm  One-Year Graft and Patient Survival of Deceased Donor Kidney Transplants Under KAS (Abstract #317)
Amber R. Wilk, Darren E. Stewart, Mark I. Aeder, Anna Y. Kucheryavaya, David K. Klassen. Richmond, VA; Cleveland, OH.

4:42 pm  EPTS Is a Poor Predictor of Post-KT Mortality for Older Recipients (Abstract #318)
Mara McAdams DeMarco, Xun Luo, Allan Massie, Dorry Segev. Baltimore, MD.

4:54 pm  Impact of Bariatric Surgery on Risk of Organ Rejection Among Solid Organ Transplant Recipients (Abstract #319)
Max Soghikian, Dyanna Gregory, Jane E. Wilcox, Aneesha Shetty, Daniela P. Ladner, Lisa B. VanWagner. Chicago, IL.

5:06 pm  Training for Transplant: Frailty Assessment and Optimization in Kidney Transplant Candidates (Abstract #320)
Mary Mrdutt, Debra Doherty, Susan Tanner, Jacqueline Lappin. Temple, TX.

5:18 pm  Cumulative Deficits Frailty Index for Transplant Candidates Predicts Candidacy for Solid Organ Transplantation (Abstract #321)
Rhea A. Varughese, Olga Theou, Xiaojin Huang, Olusegun Famure, Yanhong Li, Noori Chowdhury, Eberhard Renner, Joseph Kim, Jane Macleay, Sunita Mathur, Kenneth Rockwood, Lianne G. Singer. Toronto, ON, Canada; Halifax, NS, Canada.

5:30 pm  A Cost Comparison for Telehealth Utilization in the Kidney Transplant Waitlist Evaluation Process at a VA Center (Abstract #322)

5:42 pm  Provision of Highly Specialized Aftercare by the Transplant Center Strongly Improves Patient and Allograft Survival in Long-Term Follow-Up After Kidney Transplantation (Abstract #323)
Thomas Schachtner, Petra Reinke. Berlin, Germany.
Donors with Acute Kidney Injury

Room E450A

Chairs: Vanessa Humphreville, MD FACS, University Hospitals Cleveland Medical Center, Cleveland, OH, United States and Lena Sibulesky, MD, University of Washington, Seattle, Seattle, WA, United States

4:30 pm A Humanized Anti-CD47 Monoclonal Antibody Therapy Alleviates Ischemia-Reperfusion Injury of Porcine Renal Allografts Donated After Cardiac Death (Abstract #324)

4:42 pm CD47 Blockade Reduces Ischemia/Reperfusion Injury in Donation After Cardiac Death Rat Kidney Transplantation (Abstract #325)

4:54 pm Donor Warm Ischemic Time >80 min Is an Important Predictor of Kidney Graft Survival from Donors After Cardiac Death (Abstract #326)

5:06 pm Five-Year Outcomes After Transplantation of Kidneys from Deceased Donors with Acute Kidney Injury (Abstract #327)

5:18 pm Outcomes with Kidney Transplant from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time: UNOS Analysis (Abstract #328)

5:30 pm Single Kidney Transplantation from DCD Maastricht Category 3 Donors ≥ 60 Years: Is It Safe? (Abstract #329)
Evaldo Favi, Carmelo Puliatti, Mariano Ferrarese, Samuele Iesari, Roberto Cacciola. Milan, Italy; London, United Kingdom; L’Aquila, Italy.

5:42 pm Assessment and Transplantation of Declined Human Kidneys Using Ex-Vivo Normothermic Kidney Perfusion (Abstract #330)
Sarah A. Hosgood, Mazin O. Hamed, Avi Sawpaol, Rodrigo Figueiredo, Kouros Saeb-Parsy, Colin Wilson, Michael L. Nicholson. Cambridge, United Kingdom; Newcastle, United Kingdom.

Health Services and Policy in Organ Transplantation

Room E271A

Chairs: Eric Tichy, PharmD, Yale New Haven Hospital, New Haven, CT, United States and Edward Zavala, MBA, Vanderbilt University, Nashville, TN, United States

4:30 pm The Cumulative United States Experience with Transplants (Txs) from Living Donors (LDs): 140,156 LD Txs in 28 Years (Abstract #331)

4:42 pm Intensive Care Unit Enhanced Recovery Pathway for Liver Transplant Recipients: A Prospective, Observational Study (Abstract #332)
Clark Kensinger, Adam King, Seth Karp, Pratik Pandharipande, Kelly Wright, Liza Weavind. Nashville.

4:54 pm Comparing the Role of Post-Transplant Readmissions and Bed Days on Total One Year Cost of Care (Abstract #333)
Wade M. Bannister, Mark A. Schnitzler, Jiang Tao, Anthony F. Bonagura, Bart Laihinen, Frank D. Irwin, Cecelia M. Horstman. Eden Prairie, MN; St. Louis, MO.
Effects of New KPD Histocompatibility Policy on Refusal Rate and Transplants (Abstract #334)
R. Leishman, M. Aeder, M. S. Leffell, C. Murphey, N. Reinsmoen, S. Saidman, T. Sandholm, A. Toll, A. Harper, N. Turgeon. Richmond, VA; Cleveland, OH; Baltimore, MD; San Antonio, TX; Los Angeles, CA; Boston, MA; Pittsburgh, PA; Atlanta, GA.

A Kidney Paired Donation Standard Acquisition Charge (Abstract #335)
Michael A. Rees, Laurie J. Reece, Susan E. Rees, Betty Crandall, Alan B. Leichtman. Toledo; Perrysburg; Winston Salem; Ann Arbor.

How Much Is a Kidney Worth? Comparing Kidney Transplant Strategies in Liver Transplant Candidates (Abstract #336)

HOPE Act – The First Year (Abstract #337)
Amber R. Wilk, Sarah Taranto, Read Urban, David K. Klassen. Richmond, VA.

Adoptive Immunotherapy with Liver Allograft-Derived Lymphocytes Compensate for the Susceptibility to Post-Liver Transplant Blood Stream Infection Associated with FCGR3A SNP (Abstract #338)

Gut Microbiota-Urinary Tract Infection Axis in Kidney Transplant Recipients (Abstract #339)

Fosfomycin Tromeltamol (FOS) Is an Effective Alternative in Post Renal Transplant Urinary Tract Infection Prophylaxis Caused by Escherichia coli and Enterococcus faecalis without Increasing Resistance Rate (Abstract #340)
Jose Manuel Arreola-Guerra, Josefina Alberu, Luis Eduardo Morales-Buenrostro, Ernesto Maravilla, Rodrigo Rosado, Jose Sifuentes. Aguascalientes, Mexico; Mexico, Mexico.

Importance of Acquisition of Carbapenemase (KPC)-Producing Enterobacteriaceae in Solid Organ Transplant Recipients: A Single-Center Experience (Abstract #341)

High Mortality in Transplant Recipients Associated with Coccioidiomycosis Derived from Organ Donors (Abstract #342)
Nikeshan Jeyakumar, Nikole Neidlinger, Michael Salvatore, Christopher Brown, Tamara Carpenter, Monica Fung, Peter Chin-Hong. San Francisco, CA; Miami, FL; San Ramon, CA; Oakland, CA.

The Clinical and Economic Burden of Pneumonia in Canadian Solid Organ Transplant Recipients (Abstract #343)

Effect of Academic Detailing with Prescribers as an Antimicrobial Stewardship Intervention in Solid Organ Transplant Patients (Abstract #344)
M. So, A. Morris, C. Bell, A. Humar, S. Husain. Toronto, ON, Canada.
Kidney Clinical Complications 2

Room E354B
Chairs: Mona Doshi, MD, Wayne State University, Detroit, MI, United States and Nicolae Leca, MD, University of Washington, Seattle, WA, United States

4:30 pm Performance-Based vs. Self-Reported Functional Assessment on Outcomes After Kidney Transplant (Abstract #345)
Kim N. Tibaldi, Navdeep Dhillon, Ryan Goldberg, Homero Paniagua, Anup M. Patel. Livingston, NJ.

4:42 pm Patient and Kidney Allograft Survival in Recipients with End Stage Renal Disease from Amyloidosis (Abstract #346)
Mary Ann Lim, Deirdre Sawinski, Jordana Cohen, Brendan Weiss, Jonathan Hogan, Laura Dember. Philadelphia, PA.

4:54 pm Neutropenia in Kidney Transplantation: A Hidden Threat to Graft Survival (Abstract #347)
Ana Vergottini, Abdullah Karabala, Peter Abrams, Jennifer Verbesey, Seyed Ghasemian, Jack Moore, Monica Grafals, Basit Javaid, Matthew Cooper, Alexander Gilbert. Washington, DC.

5:06 pm Quantitative Analysis of 10-Year Surveillance Renal Allograft Biopsies (Abstract #348)

5:18 pm VO2peak: A Significant Marker of All-Cause Mortality Among Patients with End-Stage Renal Disease Being Evaluated for Kidney Transplant (Abstract #349)

5:30 pm DNA Methylation Dynamics from Ischemia/Reperfusion Injury to Long-Term Allograft Function (Abstract #350)
Vineela Bontha, Daniel Maluf, Mikhail Dozmorov, Debalina Bagchi, Kellie Archer, Valeria Mas. Charlottesville; Richmond; Columbus.

5:42 pm Simple Kidney Transplant Graft Survival (KTGS) Calculator Predicts 5- and 10-Year Allograft Survival (Abstract #351)
Puneet Sood, Wida Cherikh, Rajil Mehta, Amit Tevar, Sundaram Hariharan. Pittsburgh; Richmond.

Kidney: Cardiovascular and Metabolic

Room E451B
Chairs: Michelle Josephson, University of Chicago, Chicago, IL, United States and Kimi Ueda, PharmD, FAST, California Pacific Medical Center, San Francisco, CA, United States

4:30 pm Impact of Type of Recipient Diabetes on 1 and 3-Year Kidney Allograft and Patient Outcomes (Abstract #352)

4:42 pm Beyond the Bones – The Association Between Vitamin D, Graft Outcomes, Malignancy and Vascular Disease (Abstract #353)
Adrienne Seitz, Aravind Cherukuri, Richard Baker. Leeds, West Yorkshire, United Kingdom; Pittsburgh, PA.

4:54 pm Kidney Transplant Recipient Intermediate and Long Term Outcomes for Living Donor Gifted Lithiasis (Abstract #354)
Simit Doshi, Muhammad S. Yaqub, Tim Taber, Muhammad Mujtaba, Dennis Mishler, Oluwafisayo Adebiyi, Chandru Sundaram, John Powelson, Asif Sharfuddin. Indianapolis.

5:06 pm Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study (Abstract #355)
5:18 pm The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing (Abstract #356)
Katerina Flabouris, Steven J. Chadban, Maleeka Ladhani, Matthew Cervelli, Philip A. Clayton. Adelaide, Australia; Sydney, Australia.

5:30 pm The Relationship Between Frailty and Decreased Physical Performance with Death on the Kidney Transplant Waiting List (Abstract #357)

5:42 pm Outcomes of Infraringuinal Revascularization in Renal Transplant Patients (Abstract #358)
Rebecca Craig-Schapiro, Besma Nejim, Mahmoud B. Malas. Baltimore, MD.

Liver Living Donors and Partial Grafts
Room E451A
Chairs: Julie Heimbach, Mayo Clinic, Rochester, MN, United States and Michael Zimmerman, MD, Medical College of Wisconsin, Milwaukee, WI, United States

4:30 pm Technical Refinement to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation: Simplified One-Orifice Venoplasty (Abstract #366)
Joo Dong Kim, Dong Lak Choi. Daegu, Republic of Korea.

4:42 pm Live Donor Liver Transplantation Using Grafts with More Than Two Bile Ducts – Does It Affect Patient Outcome? (Abstract #367)

4:06 pm Stable Deceased Donor Transplantation Rates Among Pediatric Candidates Post-KAS Implementation (Abstract #362)
Brittany A. Shelton, Christopher Ray, Deirdre Sawinski, Rhiannon D. Reed, Paul A. MacLennan, Jayme E. Locke. Birmingham; Philadelphia.

5:18 pm P-LKDI: A Donor Risk Index for Pediatric Recipients of Living Donor Kidney Transplantation (Abstract #363)

5:30 pm KDPI and Small (<20 kg) Pediatric Kidney Donors (Abstract #364)
Jodi M. Smith, Sally K. Gustafson, Andrew Wey, Jon J. Snyder, Ajay Israni. Seattle; Minneapolis.

5:42 pm Belatacept After Kidney Transplantation in Adolescents (Abstract #365)

Kidney: Pediatric Adherence and Allocation
Room E353AB
Chairs: Jens Goebel, MD, Children’s Hospital Colorado, Aurora, CO, United States and Beau Kelly, MD MBA FACS, DCI Donor Services, West Sacramento, California, United States

4:30 pm The TAKE-IT Intervention Improves Medication Adherence in Adolescent Kidney Transplant Recipients (Abstract #359)
Bethany Foster, Ahna Pai, Susan Furth, TAKE-IT Investigators. Montreal, Canada; Cincinnati; Philadelphia.

4:42 pm In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients (Abstract #360)

4:54 pm A Dedicated Young Adult Service with a Youth Worker Increases Engagement of Teenagers and Young Adults with Kidney Transplantation and Impacts Favourably on Clinical Outcomes (Abstract #361)
Daley P. Cross, Paul N. Harden. Oxford, United Kingdom.
4:54 pm Largest US Series of Minimally Invasive Full and Laparoscopy-Assisted Living Donor Hepatectomy (Abstract #368)

Logistic and Programatic Challenges in Kidney Living Donation
Room E450B
Chairs: Naim Issa, M.D., Mayo Clinic, Rochester, MN, United States and Jennifer Verbese, MD, MedStar Georgetown Transplant Institute, Washington DC, District Of Columbia, United States

5:06 pm Forty-Six Consecutive Cases of Pure Live Donor Right or Extended Right Hepatectomy: Single Surgeon Initial 1-Year Experience (Abstract #369)

4:30 pm State Population Health and Center-Level Variation in Rate of Living Kidney Donation (Abstract #373)
Rhiannon D. Reed, Brittany A. Shelton, Paul A. MacLennan, Michael Hanaway, Vineeta Kumar, Robert Gaston, Jayme E. Locke. Birmingham.

5:18 pm ABO-Incompatibility Using Rituximab Does Not Increase Hepatocellular Carcinoma Recurrence After Liver Transplantation (Abstract #370)

4:42 pm Is Reluctance to Accept Younger Kidney Donors Justified? (Abstract #374)

4:54 pm Socioeconomic Status and Perceived Donation-Related Financial Burden Among Living Kidney Donors (Abstract #375)
Jessica Ruck, Allan Massie, Macey Henderson, Dorry Segev. Baltimore.

5:06 pm Time to Kidney Transplantation Following Live Donor Candidate Referral (Abstract #376)

5:18 pm Living Kidney Donor Pharmaceutical Care Needs Identified Through Linked Transplant Registry and Pharmacy Claims Data (Abstract #377)
Krista Lentine, Sally Gustafson, Mark Schnitzler, Gregory Hess, Dorry Segev, Amit Garg, Ngan Lam, David Axelrod, Daniel Brennan, Henry Randall, Bertram Kasiske. St Louis, MO; Minneapolis, MN; Philadelphia, PA; Baltimore, MD; London, Canada; Edmonton, AB, Canada; Greenville, NC; St. Louis, MO.
5:30 pm Living Kidney Donors: Battling High Attrition Rates During Evaluation Process (Abstract #378)
Jennifer Verbesey, Adam Bacigalupo, Alexander Gilbert, Alex Li, Christine Zuttermeister, Monica Grafals, Jack Moore, Basit Javaid, Peter Abrams, Seyed Ghasemian, Matthew Cooper. Washington DC.

5:42 pm Financial Burden and Time to Returning to Work Among Living Kidney Donors (Abstract #379)

Regulatory Cells in Alloimmunity

Room E352
Chairs: Jamil Azzi, MD, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, United States and Jonathan Maltzman, Stanford University, Palo Alto, CA, United States

4:30 pm CCR7+CD8+ T Cell Suppresses Effector T Cell Related Allo-Immune Responses in Kidney Transplant Recipients (Abstract #380)
Byung Ha Chung, Kyoung Woon Kim, Bo-Mi Kim, Kyoung Chan Doh, Chul Woo Yang. Seoul, Korea.

4:42 pm A Regulatory T Cell (Treg)-Intrinsic Role for p27kip1 in Acquired Transplant Tolerance (Abstract #381)
Peter Morawski, Liqing Wang, Xue Yang, Yanqun Chen, Wayne Hancock, Andrew Wells. Philadelphia, PA.

4:54 pm Novel Cell Intrinsic Role of the Adaptor Protein TSAd in Maintaining Alloimmune T Regulatory Cell Function (Abstract #382)

5:06 pm Maximizing the Potential of Treg-Based Therapies for Transplant Rejection via Computational Immune-Modeling: Effect of Dose, Timing and Distribution (Abstract #383)
Giorgio Raimondi, Anirud Arun, Olga Dorabiala, Julia Arciero. Baltimore; Philadelphia; Indianapolis.

5:18 pm Utility of IL-2 Complexes in Promoting Vascularized Composite Allograft Survival (Abstract #384)
Heng Xu, Satinder Dahiya, Liqing Wang, Tatiana Akimova, Wayne W. Hancock, Scott L. Levin. Shanghai, China; Philadelphia.

5:30 pm The Phenotypic and Functional Characteristics of a Novel CD11b+CD11c+F4/80+ Monocytic Myeloid-Derived Suppressor Cell Subset (Abstract #385)

5:42 pm Early Evolution and Immunopathologic Phenotype of Treg-Rich Organized Lymphoid Structures (TOLS) Associated with Immunological Tolerance in Accepted Mouse Kidney Allografts (Abstract #386)

Poster Session C

6:00 pm – 7:00 pm

Hall D1

Poster Viewing: 9:30 am – 7:00 pm

Presenters in Attendance: 6:00 pm – 7:00 pm

Poster Session C can be found on pages 155-177.

AST Town Hall Meeting & Reception

5:45 pm – 7:00 pm

Cafe
AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Tuesday, May 2, 2017

7:00 am – 8:15 am  Sunrise Symposia
Page 76  Expanding the Liver Donor Pool: The Art of Allocation
Room E354A
Page 76  Clinical Xenotransplantation – Perpetual Myth or Potential Reality?
Room E451B
Page 76  Fine-tuning Immunosuppression in Liver Transplantation
Room E353AB
Page 76  Antifungal Testing, Prevention and Treatment Stewardship in SOT
Room E450B
Page 77  Special Deliveries: Pregnancy and Transplantation
Room E353C
Page 77  Social Media and Organ Donation – The Next Frontier
Room E451A
Page 77  Metabolic Control of Immune Responses: Why Does it Matter?
Room E350
Page 77  Transplant Team Leadership: Leading a Multidisciplinary Transplant Team
Room E354B
Page 78  Opioids and Opioid Substitution: Therapy in Transplant Candidates
Room E351
Page 78  Dendritic Cells in Solid Organ Transplant
Room E450A

8:30 am – 9:15 am  Plenary
Page 78  Joint Plenary Session III
Arie Crown Theater

9:15 am – 9:30 am  AST Awards
Page 78  Arie Crown Theater

9:30 am – 10:00 am  AST Presidential Address
Page 78  Arie Crown Theater

10:00 am – 10:30 am  Coffee Break with Exhibits
Hall D1

10:30 am – 11:15 am  Controversies in Transplantation
Page 79  Innate Allorecognition: Does it Exist or Even Matter?
Room E354A
Page 79  Using the Hepatitis C Infected Donor Organ in the Era of Direct Acting Antivirals: Access for All or Only for Some?
Arie Crown Theater

11:30 am – 1:00 pm  Midday Symposia
Page 79  Donors Should Not Have to Pay to Donate – Towards Financial Neutrality for Living Donors
Room E450B
Page 79  Transplant Therapeutics Consortium Update
Room E451B
Page 80  Alternatives to Liver Redistricting to Improve Fairness in Liver Allocation
Room E450A
Page 80  Beta-cell Replacement – Choices, Choices, Choices
Room E353C
Page 80  Infected Donors: Expanding the Donor Pool & the Risk of Avoiding All Risk
Room xx
Risky Business – BK Infection: Diagnosis, Treatment, & Immunosuppression Reduction
Arie Crown Theater

Parenthood after Transplantation
Room E351

Bench to Bedside – Mechanisms and Approaches to Reduce Organ Injury
Room E353AB

Cellular Alchemy – Engineering Functional Cell Types and Whole Organs from Progenitors
Room E350

Together Everyone Achieves More: The Multidisciplinary Approach to Generating Revenue, Increasing Transplant Referrals, Improving Outcomes and Performing Research
Room E451A

Regulatory T Cells – New Concepts and Mechanisms
Room E354B

Basic Transplant Tolerance II
Room E350

Diagnosis of Antibody Mediated Rejection in Kidney Transplant Recipients
Room E354A

Evaluation Decisions: Living Kidney Donors
Room E450B

Islet (Auto and Allo) and Pancreas Transplantation
Room E353C

Kidney Immunosuppression: Induction Therapy
Room E354B

Kidney Issues in Liver Transplantation
Room E451B

Kidney Optimizing Donor/Recipient Selection and Matching
Room E450A

Liver Waitlist Outcome and Risk Stratification
Room E271A

New Pathways in Allograft Rejection
Room E352

Optimizing Donor Utilization: All Organs
Room E353AB

Small Bowel: All Topics
Room E271B

Surgical Issues (Minimally Invasive/Open): All Organs
Room E451A

Xenotransplant
Room E351

1:00 pm – 2:15 pm Luncheon Workshops

10:00 am – 11:15 am Ticketed Events

2:30 pm – 4:00 pm Concurrent Oral Abstract Sessions

2:30 pm – 6:00 pm Allied Health Symposium 3

2:30 pm – 6:00 pm Pediatric Symposium 2

4:00 pm – 4:30 pm Coffee Break with Exhibits Hall D1

4:30 pm – 6:00 pm Concurrent Oral Abstract Sessions

B Cells: Regulation and Tolerance
Room E350

DCD and Infectious Risk Kidney Donors
Room E450B

Disparities in Kidney Transplantation
Room E451A
Economics and Outcomes in Organ Transplantation
Room E271A

Islet Transplant
Room E352

Kidney General Outcomes
Room E354A

Liver: Immunosuppression and Rejection
Room E451B

Long Term Kidney Grant Survival II
Room E450A

Novel Immunosuppression Regimens – Belatacept
Room E354B

Pathways in Ischemia Reperfusion
Room E351

PTLD
Room E271B

Late Breaking
Room E353C

5:45 pm – 7:00 pm ASTS Business Meeting

Cafe

6:00 pm – 7:00 pm Poster Session D

Presenters in Attendance
Hall D1

7:30 pm – 10:30 pm ATC Night Out

Offsite – River Roast
Sunrise Symposia
7:00 am – 8:15 am

Expanding the Liver Donor Pool: The Art of Allocation

Room E354A
Moderators: A. Benedict Cosimi, MD, MGH, Massachusetts General Hospital, Boston, MA, USA and TBD

7:00 am What Is Really an Extended Criteria Donor? Are All Extended Criteria Grafts Created Equal?
Peter Abt, MD
University of Pennsylvania
Philadelphia, PA, USA

7:20 am The Challenges Involved in Allocating Extended Criteria Donors
Adel Bozorgzadeh, MD
University of Massachusetts Worcester, MA, USA

7:40 am Planning a Strategy for Optimal Use of Extended Criteria Donors Based on the Last 15 Years of Experience
Joseph Tector, MD
University of Alabama Birmingham, AL, USA

8:00 am Discussion

Clinical Xenotransplantation – Perpetual Myth or Potential Reality?

Room E451B
Moderators: Andrew Adams, MD, PhD, Emory University School of Medicine, Atlanta, GA, USA and James Allan, MD, MBA, Massachusetts General Hospital, Boston, MA

7:00 am Immunologic Barriers to Clinical Xenotransplantation
Megan Sykes, MD
Columbia University
New York, NY, USA

7:20 am Infectious Barriers – Do They Really Exist?
Jay Fishman, MD
Massachusetts General Hospital – Harvard Med.
Boston, MA, USA

7:40 am Regulatory Barriers – Are There Solutions?
Richard Pierson III, MD
University of Maryland Baltimore, MD, USA

8:00 am Discussion

Fine-tuning Immunosuppression in Liver Transplantation

Room E353AB
Moderators: Helen S. Te, MD, Univ of Chicago, Chicago, IL, USA and Thomas Schiano, MD, FACS, Icahn School of Medicine, Mt. Sinai, New York, NY, USA

7:00 am Rejection in 2017: “Big” or “Little” Deal in Liver Recipients
Josh Levitsky, MD, MS
Northwestern
Chicago, IL, USA

7:25 am Complete Immunosuppression Withdrawal in Children and Adults – How Close Are We?
Sandy Feng, MD, PhD
UCSF
San Francisco, CA, USA

7:50 am Personalized Immunosuppression – Is it Ready for Prime Time and if Not, When?
Abraham Shaked, MD, PhD
Univ of Pennsylvania
Philadelphia, PA, USA

Antifungal Testing, Prevention and Treatment Stewardship in SOT

Room E450B
Moderators: Aruna Subramanian, MD, Stanford University, Stanford, CA, USA and Rachel Miller, MD, Duke University, Durham, NC, USA

7:00 am Fungal Diagnostics: One Case at a Time
John Baddley, MD, MSPH
University of Alabama at Birmingham
Birmingham, AL, USA

7:25 am Prophylaxis, Pre-emption and Treatment: Best Way to Get That “Fun-Guy”
Shahid Husain, MD, MS
University of Toronto
Toronto, ON, Canada
7:50 am Hot Updates: Emerging, Re-emerging (PJP) and Endemic Fungi
TBD

Special Deliveries: Pregnancy and Transplantation

Room E353C
Moderators: Christina Klein, MD, Piedmont Transplant Institute, Atlanta, GA, USA and Anita Patel, MD, Henry Ford Hospital, Detroit, MI, USA

7:00 am Issues of Childbearing: Fertility, Infertility and Assisted Reproduction in Transplant Recipients
Michael Moritz, MD
Gift of Life Institute
Philadelphia, PA, USA

7:25 am Pregnancy and Delivery Management
Veronica Gomez-Lobo, MD
Washington Hospital Center
Washington D.C., USA

7:50 am The Second and Third Generation: Children and Grandchildren of Transplant Recipients
Lisa Coscia, RN
Gift of Life Institute
Philadelphia, PA

Social Media and Organ Donation – The Next Frontier

Room E451A
Moderators: Talia B Baker, MD, University of Chicago Medicine, Chicago, IL, USA and Sander Florman, MD, Mount Sinai Hospital/Recant Miller Transplantation Institute, New York, NY, USA

7:00 am Financial Implications of An Anonymous, Non-Directed Living Donor Registry – Kickstarting Kidney Paired Donation Chains to Maximize the Impact of Individual Donations
Michael Rees, MD, PhD
University of Toledo
Toledo, OH, USA

7:25 am Ethical Implications Organ Donation Entering the Social Media “Space”
William Sanchez, MD
Mayo Clinic
Rochester, MN, USA

7:50 am Social Media and Organ Donation – Optimizing Impact
David Scott, MD
Oregon Health & Science University
Portland, OR, USA

Metabolic Control of Immune Responses: Why Does It Matter?

Room E350
Moderators: Wayne Hancock, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA and Laurence Turka, MD, Massachusetts General Hospital, Boston, MA, USA

7:00 am Overview of T Cell Metabolism
Greg Delgoffe, PhD
University of Pittsburgh
Pittsburgh, PA, USA

7:25 am Oxidative Phosphorylation and T Cell Responses
Laurence Turka, MD
Massachusetts General Hospital
Boston, MA, USA

7:50 am Modulation of Glycolytic Pathways to Modulate T Cell Responses
Ulf Beier, MD
Children’s Hospital of Philadelphia / University of Pennsylvania
Philadelphia, PA, USA

Transplant Team Leadership: Leading a Multidisciplinary Transplant Team

Room E354B
Moderators: Anne Murphy, MBA, FACHE, University of Michigan, Ann Arbor, MI, USA and Angelina Korsun, RN, MSN, MPA, University of Iowa, Iowa City, IA, USA

7:00 am The Transplant Administrator and Physician Director Partnership in Leading the Transplant Team
John Fung, MD, PhD
University Of Chicago Medicine
Chicago, IL, USA

7:25 am Leading Your Team Through Change
Rangaraj Ramanujam, PhD
Vanderbilt
Nashville, TN, USA

7:50 am “Keep Off of my Land!” Preventing and Resolving Boundary Conflicts in Transplant Multidisciplinary Teams
Gwen McNatt, RN, PhD, CNN, FNP-BC
Northwestern Memorial Hospital
Chicago, IL, USA
**Opioids and Opioid Substitution Therapy in Transplant Candidates**

**Room E351**
Moderators: Jennifer Lai, MD, MBA, University of California San Francisco, San Francisco, CA, USA and Ulas Camsari, MD, Mayo Clinic, Rochester, MN, USA

7:00 am Pharmacology of Opioids: Drug Interactions and Screening Methods
James Fleming, PharmD
MUSC
Charleston, SC, USA

7:25 am Opioid Substitution Therapy Use in Transplant Candidates: Transplant Psychiatrist/Addiction Specialist
Robert Weinrieb, MD
University of Pennsylvania
Philadelphia, PA, USA

7:50 am Integrated Care and Pain Management for Transplant Candidates
TBD

**Dendritic Cells in Solid Organ Transplant**

**Room E450A**
Moderators: Anthony Jevnikar, MD, London Health Sciences Ctr, London, ON, Canada and William Kitchens, MD, PhD, Emory Transplant Center, Atlanta, GA, USA

7:00 am Dendritic Cells and Allograft Rejection: Experimental Perspective
Martin Oberbarnscheidt, MD, PhD
University of Pittsburgh
Pittsburgh, PA, USA

7:25 am Translational Approaches to Dendritic Cell Therapy
Angus Thompson, PhD
Univ of Pittsburgh
Pittsburgh, PA, USA

7:50 am Tolerogenic DCs in Kidney Transplantation
Edward Geissler, PhD
University of Regensburg
Regensburg, Germany

**Joint Plenary Session III**

8:30 am – 9:15 am

**Arie Crown Theater**

Chairs: James S. Allan, MD, MBA, Massachusetts General Hospital, Boston, MA, USA and Ronald G. Gill, PhD, University of Colorado Denver, Denver, CO, USA

8:30 am Community Health, Center Proximity and Liver Transplant Waitlist Mortality (Abstract #387)
Raymond J. Lynch, Katie Ross, David S. Goldberg, Rachel E. Patzer. Atlanta, GA; Philadelphia, PA.

8:45 am Vital Role of the CoREST Complex as a Master Regulator of Foxp3+ T-Regulatory Cell Gene Expression and Suppressive Function (Abstract #388)
Liqing Wang, Arabinda Samanta, Matthew H. Levine, Ulf Beier, Rongxian Han, Jay Kalin, Edward Holson, Philip A. Cole, Wayne W. Hancock. Philadelphia, PA; Baltimore, MD; Cambridge, MA.

9:00 am A Multidimensional Prognostic Score and Nomogram to Predict Kidney Transplant Survival: The Integrative Box (iBox) System (Abstract #389)

**AST Awards**

9:15 am – 9:30 am

**Arie Crown Theater**

**AST Presidential Address**

9:30 am – 10:00 am

**Arie Crown Theater**

**Coffee Break with Exhibits**

10:00 am – 10:30 am

**Hall D1**
Controversies in Transplantation
10:30 am – 11:15 am

Innate Allorecognition: Does it Exist or Even Matter?
Room E354A
Moderators: Robert Fairchild, PhD, Cleveland Clinic, Cleveland, OH, USA and Mandy Ford, PhD, Emory University, Atlanta, GA, USA

10:30 am PRO: Innate Allorecognition
Fadi Lakkis, MD
Univ Pittsburgh
Pittsburgh, PA, USA

10:40 am CON: Innate Allorecognition
Anita Chong, PhD
The University of Chicago
Chicago, IL, USA

10:50 am PRO: Rebuttals
Fadi Lakkis, MD
Univ Pittsburgh
Pittsburgh, PA, USA

10:55 am CON: Rebuttals
Anita Chong, PhD
The University of Chicago
Chicago, IL, USA

11:00 am Discussion

Using the Hepatitis C Infected Donor Organ in the Era of Direct Acting Antivirals: Access for All or Only for Some?

Arie Crown Theater
Moderators: Elizabeth C. Verna, MD, MS, Columbia University, New York, NY, USA and Norah Terrault, MD, MPH, UCSF, San Francisco, CA, USA

10:30 am PRO: We Should Be Using HCV+ Organs in All Recipients
Peter Reese, MD
University of Pennsylvania
Philadelphia, PA, USA

10:40 am CON: HCV+ Organs Should Only Be Used in Recipients with Active HCV
Kimberly Brown, MD
Henry Ford Hospital
Detroit, MI, USA

10:50 am PRO: Rebuttals
Peter Reese, MD
University of Pennsylvania
Philadelphia, PA, USA

10:55 am CON: Rebuttals
Kimberly Brown, MD
Henry Ford Hospital
Detroit, MI, USA

11:00 am Discussion

Midday Symposia
11:30 am – 1:00 pm

Donors Should Not Have to Pay to Donate – Towards Financial Neutrality for Living Donors
Room E450B
Moderators: Gabriel Danovitch, MD, UCLA, Los Angeles, CA, USA and Arthur Matas, MD, University of Minnesota, Minneapolis, MN, USA

11:30 am The Very Real Costs of Living Kidney Donation
Rebecca Hays, MSW, APSW
University of Wisconsin Hospital and Clinics
Madison, WI, USA

12:00 pm More than Just Semantics – Where is the Line Between Disincentive and Incentives
Scott Klarenbach, MD, MSc
University of Alberta
Edmonton, AB, Canada

12:30 pm Financial Neutrality – Is it Ethical? Is it Legal?
I. Glen Cohen
Harvard University
Cambridge, MA, USA

Transplant Therapeutics Consortium Update
Room E451B
Moderators: Kenneth Newell, MD, PhD, Emory University School of Medicine, Atlanta, GA, USA and Mark Stegall, MD, Mayo Clinic, Rochester, MN, USA

11:30 am Where are the New Therapeutic Agents and How Can We Get More?
Roslyn Mannon, MD
University of Alabama, Birmingham
Birmingham, AL, USA

12:00 pm How Does Industry Make a Go/No Go Decision about Novel Therapies in Transplantation?
Ulf Meier-Kriesche, MD
Bristol-Myers Squibb
Lawrenceville, NJ, USA

12:30 pm Barriers to Off-Label Use and Repurposing Drugs For Use in Transplantation
Christin Rogers, PharmD
Beth Israel Deaconess Medical Center
Boston, MA, USA
Alternatives to Liver Redistricting to Improve Fairness in Liver Allocation

Room E450A
Moderators: Julie Heimbach, MD, Mayo Rochester, Rochester, MN, USA and Michael Charlton, MD, University of Chicago, Chicago, IL, USA

11:30 am  Alternative Models for Liver Allocation Using Nearest Neighbor Algorithms
Sanjay Mehrotra, SM
Northwestern
Evanston, IL, USA

12:00 pm  Burden of Liver Disease as a Measure of Disparity in Liver Allocation
David Goldberg, MD
University of Pennsylvania
Philadelphia, PA, USA

12:30 pm  Determining the True Potential of Organ Donation in a Community as a Way to Decrease Disparity in Liver Allocation
Richard Hasz, MFS, CPTC
Gift of Life Donor Program
Philadelphia, PA, USA

Infected Donors: Expanding the Donor Pool & the Risk of Avoiding All Risk

Room xx
Moderators: Michael Ison, MD, MS, Northwestern University Feinberg School of Medicine, Chicago, IL, USA and Cameron Wolfe, MD, Duke University Medical Center, Durham, NC, USA

11:30 am  PHS Increased Donors: Can We Do More?
Nicole Theodoropolous, MD, MS
University of Massachusetts Memorial Medical Center
Worcester, MA, USA

12:00 pm  DTAC Perspectives on Expanding the Donor Pool
Cameron Wolfe, MD
Duke University Medical Center
Durham, NC, USA

12:30 pm  Hepatitis C D+: The New Frontier?
Peter Reese, MD
University of Pennsylvania
Philadelphia, PA, USA

Beta-cell Replacement – Choices, Choices, Choices

Room E353C
Moderators: Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington DC, USA and Bernhard Hering, MD, Univ. of Minnesota, Minneapolis, MN, USA

11:30 am  Insulin Pump v. Transplantation
Celeste Thomas, MD, MS
University of Chicago
Chicago, IL, USA

12:00 pm  Solid Organ v. Islet Cell
Xunrong Luo, MD, PhD
Northwestern
Chicago, IL, USA

12:30 pm  Type 1 v. Type 2
Robert Stratta, MD
Wake Forest Baptist Health
Winston-Salem, NC, USA

Risky Business – BK Infection: Diagnosis, Treatment, & Immunosuppression Reduction

Arie Crown Theater
Moderators: David Wojciechowski, DO, Massachusetts General Hospital, Boston, MA, USA and Hans Hirsch, MD, MSc, University of Basel / Department Biomedicine, Basel, Switzerland

11:30 am  Is it BK or Rejection – Can Your Friendly Neighborhood Pathologist Help? Noninvasive and Traditional Pathology Approaches
Parmjeet Randhawa, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

12:00 pm  Walking a Fine Line – Optimal and Novel Treatments of BK Nephropathy: A Case Discussion
Joanna Schaeinman, MD, PhD
David Geffen School of Medicine at UCLA
Los Angeles, CA, USA

12:30 pm  Trouble on the Horizon? How to Monitor for Rejection in the Setting of BK Infection
Emilio Poggio, MD
Cleveland Clinic
Cleveland, OH, USA
Parenthood after Transplantation
Room E351
Moderators: Maha Mohamed, MD, University of Wisconsin, Madison, WI, USA and Michelle Josephson, MD, University of Chicago, Chicago, IL, USA

11:30 am Contraception: What is the Best Option for Transplant Recipients?
Martha Pavlakis, MD
Beth Israel Deaconess Med Ctr
Boston, MA, USA

12:00 pm Contemplating Conception: Preconception Guidelines for Transplant Recipients
Kate Bramham, PhD
King’s College London
London, United Kingdom

12:30 pm Pregnancies Fathered by Transplant Recipients: Immunosuppression and Outcomes
Serban Constantinescu, MD, PhD
Temple University
Philadelphia, PA, USA

Cellular Alchemy – Engineering Functional Cell Types and Whole Organs from Progenitors
Room E350
Moderators: Jason Wertheim MD, PhD, Northwestern University, Chicago, IL, USA and Harald Ott, MD, MGH, Harvard Medical School, Boston, MA, USA

11:30 am Recellularizing Liver Scaffolds from ES and iPS Cells
Alejandro Soto-Gutierrez, MD, PhD
University of Pittsburgh
Pittsburgh, PA, USA

12:00 pm Rebuilding a Kidney
Leif Oxburgh, DVM, PhD
Tufts University School of Medicine
Scarborough, ME, USA

12:30 pm Developing Pancreatic Tissue from ES and iPS Cells
TBD

Together Everyone Achieves More: The Multidisciplinary Approach To Generating Revenue, Increasing Transplant Referrals, Improving Outcomes and Performing Research
Room E451A
Moderators: A. Osama Gaber, MD, Houston Methodist Hospital System, Houston, TX, USA and Christina Doligalski, PharmD, Tampa General Hospital, Tampa, FL, USA

11:30 am Financial Impact of Transplant Specialty Pharmacy
Lonnie Smith, PharmD
University of Utah Hospitals and Clinics
Salt Lake City, UT, USA

12:00 pm Leveraging Knowledge, Innovation, Team Work and Technology in Referral Outreach
TBD

12:30 pm There’s No “I” in Research
E. Steve Woodle, MD
Univ of Cincinnati Clg of Med
Cincinnati, OH, USA

Bench to Bedside – Mechanisms and Approaches to Reduce Organ Injury
Room E353AB
Moderators: Dianne McKay, University of California San Diego, La Jolla, CA, USA and Matthew Levine, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

11:30 am Basic – Regulated Cell Death in Transplantation
Anthony Jevnikar, MD
London Health Sciences Ctr
London, ON, Canada

12:00 pm Translational – Approaches to Prevent Ischemia-Reperfusion Injury
Peter Friend
University of Oxford
Oxford, United Kingdom

12:30 pm Clinical – Clinically Applicable Strategies to Attenuate Ischemia-Reperfusion Injury
Markus Selzner, MD
Toronto General Hospital
Toronto, ON, Canada
**Regulatory T Cells – New Concepts and Mechanisms**

**Room E354A**
Moderators: Ana Maria Waaga-Gasse, PhD, University of Wuerzburg, Wuerzburg, Germany and Jonathan Maltzman, MD, PhD, Stanford University, Palo Alto, CA, USA

11:30 am **The Promise of Low-Dose IL-2 Therapy**
Leonardo Riella, MD, PhD
Brigham and Women's Hospital
Boston, MA, USA

12:00 pm **Regulatory T Cell Trafficking**
Jonathan Bromberg, MD, PhD
University of Maryland
Baltimore, MD, USA

12:30 pm **Regulatory T Cells as Therapy in Clinical Transplantation**
James Markmann, MD, PhD
Massachusetts General Hospital
Boston, MA, USA

**Luncheon Workshops – Ticketed Events**
1:00 pm – 2:15 pm

7. **Overcoming Early and Mid-Career Challenges in the Field of Transplantation**
Moderators: Nissreen Elfadawy, MD, MS, FASN, Case Western Reserve University, Cleveland, OH, USA and Kassem Safa, MD, Harvard Medical School Massachusetts General Hospital, Boston, MA, USA

8. **Quality Improvement and Clinical Research: Making the Pharmacist a Staple**
Moderators: Jennifer Luppa Melaragno, PharmD, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, NY, USA, Caitlin Mardis, PharmD, BCPS, Medical University of South Carolina, Charleston, SC, USA and Tiffany Kaiser, PharmD, University of Cincinnati, Cincinnati, OH, USA

**Concurrent Oral Abstract Sessions**
2:30 pm – 4:00 pm

**Basic Transplant Tolerance II**

**Room E350**

**Chairs:** Indira Guleria, Ph.D., Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States and Xunrong Luo, Northwestern University, Chicago, United States

2:30 pm **Mesenchymal Stem Cells Suppress T Cell Proliferation and Improve Allograft Survival in a Nonhuman Primate Transplant Model (Abstract #390)**
Steven Kim, David Mathews, Laura Higginbotham, Cynthia Breeden, Christian Larsen, Andrew Adams. Atlanta, GA.

2:42 pm **Maintenance of the Phenotype and Abundance of Islet-Resident Macrophages Promotes Islet Graft Survival and Appears to Prevent Type 1 Diabetes (Abstract #391)**
Periklis Kyriazis, Thomas Thornley, Krishna Agarwal, Lingzi Ma, Terry Strom, Maria Koulmanda. Boston, MA.

2:54 pm **Anti-CD40 mAb Promotes Kidney Immunoregulatory Capacity in NHP Transplants by Altering Kidney Tubular Cell (TEC) Expression of CD40 and IL-6 (Abstract #392)**
Jacqueline Arp, YueXia Ma, Hongji Yang, Alex El Warrak, Aaron Haig, Winnie Liu, Keith Reimann, Patrick Luke, Zhuxu Zhang, David Rothstein, Anthony M. Jevnikar. London, ON, Canada; Chengdu, Sichuan, China; Boston, MA; Pittsburgh, PA.

3:06 pm **Prominence of Graft-Infiltrating PD-L1hi Cross-Dressed Dendritic Cells in Mouse Liver Transplant Tolerance (Abstract #393)**
3:18 pm Combination αCD28+αCD40 Costimulation Blockade Attenuates Acute and Chronic Rejection in Non-Human Primates (Abstract #394)

2:54 pm Similar Elevation of Gene Expression Associated with Antibody-Mediated Rejection (ABMR) of Renal Allografts Can Be Detected in Both Plasma Exosomes (pExo) and Biopsies (Bx) by Assessing mRNA Transcript Profiles (Abstract #399)

3:30 pm Abrogating MyD88 Signaling in Donor Lung Resident Hematopoietic Cells Promotes Cell Based Tolerance Induction in Lung Allografts in Mice (Abstract #395)
Zhikun Zheng, JiaoJing Wang, Xin Yi Yeap, Lin Li, Lei Zhang, Miao He, Xunrong Luo, Zheng Zhang. Chicago, IL.

3:06 pm Specific Gene Expression Signature of Complement-Activating Donor Specific Anti-HLA Antibody-Mediated Rejection in Kidney Allografts (Abstract #400)
C. Lefaucheur, D. Viglietti, L. Hidalgo, O. Aubert, A. Zeevi, P. Halloran, A. Loupy. Paris, France; Edmonton, Canada; Pittsburgh.

3:42 pm Dual Costimulatory Blockades Failed to Achieve Transplant Tolerance Despite Induction of Mixed Chimerism in NHPs (Abstract #396)
Tetsu Oura, Kiyohiko Hotta, Ivy Rosales, Abbas Dehnadi, Ji Lei, James James Markmann, Masatoshi Matsunami, Joshua Paster, Isabel Hanekamp, Kurt Pruner, Kento Kawai, Dorothy Ndishabandi, Rex-Neal Smith, Benedict A. Cosimi, Tatsuo Kawai. Boston, MA.

3:18 pm C5b-9 Deposition in Glomerular Capillaries Is Responsible for Poor Allograft Survival in Antibody-Mediated Rejection (Abstract #401)
Valentin Goutaudier, Hélène Perrochia, Marie Marron-Wojewodzki, Florian Garo, Céline René, Nelly Pirot, Georges Mourad, Moglie Le Quintrec. Montpellier, France.

Diagnosis of Antibody Mediated Rejection in Kidney Transplant Recipients

Room E354A
Chairs: Stephan Busque, MD MSc, Stanford University, Palo Alto, CA, United States and Carl Cardella, MD, University of Toronto, Toronto, Ontario, Canada

2:30 pm Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts (Abstract #397)
Roy Bloom, Jonathan Bromberg, Emilio Poggio, David Hiller, Robert Woodward, John Sninsky, James Yee, Daniel Brennan. Philadelphia, PA; Baltimore, MD; Cleveland, OH; Brisbane, CA; St. Louis, MO.

3:30 pm Early and Late Antibody Mediated Rejection and Mixed Acute Rejection Are Clinically Distinct and Demonstrate Biologic Differences in Immunodominant Donor Specific Antibody Characteristics (Abstract #402)

2:42 pm A Molecular Approach to Chronic Rejection: Antibody or T-Cell Mediated? (Abstract #398)
L. Kamal, P. O Broin, M. Lubetzky, Y. Bao, E. Akalin. NY.

3:42 pm Pre-Transplant HLA-Specific B Cell Breadth of Reactivity in a Novel Multiplex Bead-Based Assay Predicts Rejection in Kidney Transplant Recipients (Abstract #403)
Evaluation Decisions: Living Kidney Donors

Room E450B
Chairs: Suphama Bunnapradist, David Geffen
Sch of Med @ UCLA, Los Angeles, CA, United States and Matthew Levine, MD PhD, University of Pennsylvania, Philadelphia, PA, United States

2:30 pm Inferior Graft and Patient Survival After Living Donor Renal Transplantation of Negatively Selected Right Kidneys (Abstract #404)

3:06 pm Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life (Abstract #407)
Thomas Schachtner, Petra Reinke. Berlin, Germany.

3:30 pm Temporal Trends and Variation in BMI Thresholds for Living Donation Across the US (Abstract #409)
A. S. Naik, D. M. Cibrik, A. Sakhuja, K. Lentine. Ann Arbor; Rochester; St Louis.

3:42 pm Evolution of Health Related Quality of Life (HRQOL) in Kidney Donors (Abstract #410)

Islet (Auto and Allo) and Pancreas Transplantation

Room E353C
Chairs: Srinath Chinnakotla, MD, University of Minnesota Medical School, Minneapolis, MN, United States and Ty Dunn, MD MS, University of Minnesota, Minneapolis, MN, United States

2:30 pm Assessment of Islet Damage During Isolation Utilizing miRNAs and Its Significance with Post-Transplant Outcome in TPIAT (Abstract #411)
Prathab Balaji Saravanan, Mazhar A. Kanak, Gumpei Yoshimatsu, Michael C. Lawrence, Bashoo Naziruddin. Dallas, TX; Richmond, VA.

3:06 pm Pregnancy After Kidney-Pancreas Transplantation: Maternal and Offspring Outcomes (Abstract #414)

3:30 pm Belatacept in Chronic Kidney Disease Stabilizes and Improves Renal Function in Pancreas Transplant Recipients: Intermediate Results (Abstract #415)
Jeanne Chen, Muhammad A. Mujtaba, Tim Taber, Muhammad S. Yaqub, John Powelson, Oluwafisayo Adebayi, Jonathan Fridell, Asif Sharfuddin. Indianapolis.
3:30 pm Assessment of Simple Indices Based on a Single Fasting Blood Sample in Search for an Optimal Tool to Estimate Beta Cell Function After Islet Transplantation (Abstract #416)
Justyna Golebiewska, Julia Solomina, Evelyn Konsur, Kamil Cieply, Lindsay Basto, Alexander Kotukhov, Karolina Golab, Celeste Thomas, Alicia Debska-Slizien, Piotr Witkowski. Gdansk, Poland; Chicago.

3:42 pm Type 1 Diabetic Patients Have Better Endothelial Function After Simultaneous Pancreas-Kidney Transplantation Than After Kidney Transplantation with Continued Insulin Therapy (Abstract #417)
Aureliusz Kolonko, Adrian P. Kowalik, Jacek Ziaja, Dorota Kamińska, Aleksander J. Owczarek, Agata Kujawa-Szewieczek, Mariusz A. Kuształ, Joanna Badura, Dominika Bozek-Pajak, Agnieszka Zakrzewska, Piotr Choreza, Robert Krol, Stefan Chlopicki, Marian Klinger, Andrzej Wiecek, Jerzy Chudek, Lech Cierpka. Katowice, Poland; Wroclaw, Poland; Sosnowiec, Poland; Krakow, Poland.

Kidney Immunosuppression: Induction Therapy
Room E354B
Chairs: Nicole Pilch, PharmD, MSCR, Medical University of South Carolina, Charleston, South Carolina, United States and Rick Stevens, MD PhD FACS FAST, University of Florida, Pensacola, Florida, United States

2:30 pm Benefits of Induction in Recipients of Acute Renal Failure Donor Kidneys (Abstract #418)

2:42 pm Outcomes with Steroid Avoidance Regimen After Kidney Transplantation without Induction Immunosuppression (Abstract #419)
Ankit Sakhuja, Abhijit Naik, Diane Cibrik, Hatem Amer. Rochester, MN; Ann Arbor, MI.

2:54 pm Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry (Abstract #420)
Isa Ashoor, Karen Martz, Robbie Beyl, Vikas Dharmidharka. New Orleans, LA; Rockville, MD; Baton Rouge, LA; St. Louis, MO.

3:06 pm Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors (Abstract #421)
Fawaz Al Ammary, Mara McAdams DeMarco, Qiong Huang, Elizabeth King, Sunjae Bay, Abimereki Muzaale, Alexander Wiseman, Dorry Segev. Baltimore; Denver.

3:18 pm IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts) (Abstract #422)
Shili Ge, Bong-Ha Shin, James Mirocha, David Thomas, Maggie Chu, Edgar Rodriguez, Christine Chao, Anna Petrosyan, Odette A. Galera, Ashley Vo, Jua Choi, Alice Peng, Joseph Kahwaji, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

3:30 pm Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients (Abstract #423)
Marissa Casagrande, Katie Cunningham, Christine Tseng, Carly D’Agostino, Lana Wong, Chad Richardson. Chicago, IL.

3:42 pm Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation (Abstract #424)
Srijana D. Jonchhe, Jennifer Husson, Jillian P. Casale, Ruth Adekunle, Poonam Mathur, Janet Gripshover, Bharath Ravichandran. Baltimore, MD.
Kidney Issues in Liver Transplantation

Room E451B
Chairs: Sumeet Asrani, MD MSc, Baylor University Medical Center, Dallas, TX, United States and Goran Klintmalm, MD PhD, Baylor University Medical Center, Dallas, TX, United States

2:30 pm Current Practice and Center-Level Variation in Simultaneous Liver-Kidney Listing (Abstract #425)

2:42 pm Delayed Renal Implantation Improves Survival Following Simultaneous Liver-Kidney Transplantation in High Acuity Recipients (Abstract #426)

2:54 pm Post-Liver Transplant (LT) Early Allograft Dysfunction (EAD) Modulates the Effect of Pre-LT Kidney Function on Post-LT Survival (Abstract #427)
Hani M. Wadei, Martin Mai, Burcin Taner, Kristopher Croome, Andrew Keaveny, Lorraine Mai, David Lee. Jacksonville, FL.

3:06 pm Hepatic Ischemia Reperfusion Injury After Liver Transplantation Is Associated with Acute Kidney Injury (Abstract #428)
Shekhar Kubal, Melissa Anderson, Jonathan Fridell, Burcin Ekser, Tim Taber, Ping Li, Marwan Ghabril, Marco Lacerda, Richard Mangus. Indianapolis, IN.

3:18 pm Renal Function After Liver Transplantation Alone in Patients Meeting the Proposed UNOS Simultaneous Liver-Kidney (SLK) Criteria (Abstract #429)
Kayvan Roayaie, Eric D. Langewisch, Jennifer M. Burg, Charles K. Enestvedt, Erin Maynard, David L. Scott. Portland, OR; Omaha, NE.

3:30 pm Effect of Hypothermic Pulsatile Machine Perfusion on Kidney Delayed Graft Function in Simultaneous Liver-Kidney Transplantation: A Single Center Study (Abstract #430)

3:42 pm Non-Renal Factors Predicting Combined Liver-Kidney Transplantation for Non-Dialysis-Requiring Wait-Listed End Stage Liver Disease Patients: 14 Years of US Experience (Abstract #431)
Alfonso H. Santos, Michael J. Casey, Kawther Alquadan, Jon A. Gregg, Karl L. Womer. Gainesville, FL.

Kidney Optimizing Donor/Recipient Selection and Matching

Room E450A
Chairs: Antonia Harford, MD, University of New Mexico, Albuquerque, NM, United States and Lucile Wrenshall, Wright State University, Dayton, OH, United States

2:30 pm Donor Recipient Matching Based on HLA Epitopes Improves Outcome in Kidney Transplant Recipients (Abstract #432)
Oliver Staeck, Matthias Niemann, Fabian Halleck, Dmytro Khadzhynov, Constanze Schönemann, Petra Reinke, Eric Spierings, Klemens Budde, Nils Lachmann. Berlin, Germany; Utrecht, Netherlands.

2:42 pm Improved Outcome of Kidney Transplants by Donor Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes (Abstract #433)
Oliver Staeck, Matthias Niemann, Fabian Halleck, Dmytro Khadzhynov, Constanze Schönemann, Petra Reinke, Eric Spierings, Klemens Budde, Nils Lachmann. Berlin, Germany; Utrecht, Netherlands.
2:54 pm  Procurement Kidney Biopsy versus KDRI for Predicting Graft Survival (Abstract #434)
Isaac E. Hall, Chirag R. Parikh, Bernd Schröppel, Francis L. Weng, Yaqi Jia, Heather Thiessen-Philbrook, Peter P. Reese, Mona D. Doshi. Salt Lake City, UT; New Haven, CT; Ulm, Germany; Livingston, NJ; Philadelphia, PA; Detroit, MI.

Liver Waitlist Outcome and Risk Stratification
Room E271A
Chairs: Derek Dubay, MD, MSPH, Medical University of South Carolina, Charleston, SC, United States and Alan Reed, MD MBA, University of Iowa Health Care, Iowa City, Iowa, United States

2:30 pm  Factors Associated with Death or Transplant in Low-MELD Patients (Abstract #439)
Ann Harper, Erick Edwards, Julie Heimbach. Richmond, VA; Rochester, MN.

2:42 pm  Life Threatening Disparities in Calculated MELD Due to Variation in Laboratory Methods within a UNOS Region (Abstract #440)

3:06 pm  Absence of Independent and Additional Predictive Ability of Preimplantation Kidney Allograft Biopsies for Long-Term Outcome: Population Based Study (Abstract #435)

3:18 pm  Elevated Donor HbA1C Confers Impaired Overall Survival Following Renal Allotransplantation in Recipients of Allografts from Donors with Diabetes Mellitus: A National Analysis (Abstract #436)
Michael S. Mulvihill, Babatunde A. Yerokun, Robert P. Davis, Andrew S. Barbas, Mathew G. Hartwig. Durham, NC.

3:30 pm  A Mutation of the Erythropoietin Receptor Correlates with Improved Function of Deceased-Donor Renal Transplants (Abstract #437)
Michael Fischereder, Sascha Friedrich, Ursula Klingmüller, Teresa Kauke, Thomas Breidenbach, Detlef Boesebeck, Eder Angelika, Clemens Cohen, Bernhard Banas, Markus O. Guba, Manfred Stangl, Bernhard K. Krämer, Christian Hugo, Kai Lopau, Maria Stadtler, Tom Mone. Munich, Germany; Heidelberg, Germany; Augsburg, Germany; Regensburg, Germany; Mannheim, Germany; Erlangen, Germany; Würzburg, Germany; Los Angeles.

3:42 pm  Transplant Readiness Assessment Clinic: A New Approach to Kidney Waitlist Management in the KAS Era (Abstract #438)
The Objective Liver Frailty Index Significantly Improves the Clinician “Eyeball Test” to Predict Mortality in Liver Transplant Candidates (Abstract #445)

New Pathways in Allograft Rejection
Room E352
Chairs: Reza Abdi, Bwh, Boston, Ma, United States and Martina McGrath, Brigham and Women’s Hospital, Boston, United States

Aquaporin 4 Blockade Alters T Cell Anatomical Distribution and Prolongs Cardiac Allograft Survival in Sensitized Recipients (Abstract #446)

Lymphotoxin (LT) β Receptor-Mediated Non-Classical NFκB Signaling in Lymphatic Endothelial Eells (LEC) is Required for Homeostatic T Cell Migration (Abstract #447)

Gut Microbial Metabolite Improves Function and Prolongs Kidney Allograft Survival in Mice (Abstract #448)

Extracellular Mitochondria Cause B7 Costimulation Blockade Resistant Allograft Rejection in Mice (Abstract #449)
Todd V. Brennan, Liwen Lin, Mingqing Song, Feifei Feng, Qi-Jing Li, Allan D. Kirk, He Xu. Durham, NC.

Donor Batf3-Dependent Dendritic Cells Initiate Acute Rejection in a Skin Transplantation Model (Abstract #450)

FcgRIIB-Mediated Coinhibition Attenuates Donor-Reactive CD8+ T Cell Responses (Abstract #451)
Anna B. Morris, David F. Pinelli, Danya Liu, Mandy L. Ford. Atlanta, GA.

Lymph Node Stromal Laminins Differentially Regulate T Cell Activation (Abstract #452)

Optimizing Donor Utilization: All Organs
Room E353AB
Chairs: David Foley, M.D., University of Wisconsin School of Medicine and Public Health, Madison, WI, United States and Jared White, MD, University of Alabama Birmingham, Birmingham, AL, United States

Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC) (Abstract #453)
Cameron Wolfe, Marissa Clark, Susan Tlusty, Dan Kaul, Marian Michaels. Richmond.

Modifiable Deceased Organ Donor Critical Care Parameters Impact Donor Lung Utilization (Abstract #454)
Aaron Spaugy, Mitchell Sally, Katie Ellis, Tahnee Groat, Madhukar Patel, Darren Malinoski. Portland; Boston.

Current Status of HIV-to-HIV Transplants in the United States (Abstract #455)
Christine Durand, Aaron Tobian, Niraj Desai, Andrew Cameron, Nabil N. Dagher, Diane Brown, Samantha Halpern, Serena Bagnasco, Darin Ostrander, Andrew Redd, Shirish Huprikar, Brandy Haydel, Susan Lerner, Sander Florman, Dorry Segev. Baltimore, MD; New York, NY; Bethesda, MD.

Proteomic Profiles of Deceased Donor Kidney Biopsies Obtained Prior to Transplantation Correlate with Allograft Function at One Year (Abstract #456)
Maria Kaisar, Leon van Dullemen, Zeeshan Akhtar, Honglei Huang, Benedikt Kessler, Rutger Ploeg. Oxford, United Kingdom.
3:18 pm Using Donors with False Positive HIV Tests – An Unexpected Benefit of the HOPE Act (Abstract #457)
Christine Durand, Samantha Halpern, Gilad Bismut, Brianna Doby, Niraj Desai, Andrew Cameron, Sander Florman, Susan Lerner, Shirish Huprikar, Jayme Locke, Shikha Mehta, Peter Stock, Nikole Neidlinger, Diane Brown, Brandy Haydel, Andrew Redd, Allan Massie, Aaron Tobian, Dorry Segev. Baltimore, MD; New York, NY; Birmingham, AL; San Francisco, CA; San Ramon, CA; Bethesda, MD.

3:30 pm Release of HMGB1 in Serum and Urine of Brain-Death Donors Is Associated with Delayed Graft Function (DGF) of the Kidney (Abstract #458)

3:42 pm Center Volume Does Not Influence the Risk Associated with Using High DRI Donor Livers (Abstract #459)
Sylvester M. Black, Eliza W. Beal, Khalid Mumtaz, Don Hayes Jr., Ashraf El-Hinnawi, Kenneth Washburn, Dmitry Tumin. Columbus, OH.

3:18 pm Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation (Abstract #464)
Mohamed Safwan, Michael D. Rizzari, Kelly M. Collins, Atsushi Yoshida, Sharon Skorupski, Omar Fagoaga, Marwan S. Abouljoud, Shunji Nagai. Detroit, MI.

3:30 pm Intraabdominal Infections (IAI) and Bloodstream Infections in Small Intestinal and Multivisceral Transplants (IMVTX) (Abstract #465)

2:30 pm Myeloid-Derived Suppressor Cells (MDSC) Accumulate in Intestinal Transplant (IT) Recipients (rc) and Suppress Recipient T-Cell (T) Response Against Donor Antigen (Abstract #460)
Shinji Okano, Danielle D. Kish, Karen Keslar, William Baldwin, Robert L. Fairchild, Charles Miller, Kareem Abu-Elmagd, Ajai Khanna, Masato Fujiki, John Fung, Guilherme Costa, Koji Hashimoto. Cleveland, OH.

2:42 pm Renal Outcomes Following Intestinal Transplantation (Abstract #461)
Chethan Puttarajappa, Abhinav Humar, Sundaram Hariharan, Ruy Cruz Jr, Armando Ganoza, Doug Landsittel, Xiaotian Gao, Manoj Bhattarai, Hiroshi Sogawa. Pittsburgh, PA; Valhalla, NY.
Surgical Issues (Minimally Invasive/Open): All Organs

Room E451A
Chairs: Lokesh Bathla, Methodist Specialty and Transplant Hospital, San Antonio, TX, United States and Sunil Geeverghese, MD, MSCI, FACS, Vanderbilt University Medical Center, Nashville, TN, United States

2:30 pm Retrospective Analysis of Multiple Hemodialysis Access Modalities (Abstract #467)
Victor Bowers, Heidi Pearson, James Huang, John Leone, Adam Taniros, Kristyn Dawley, Ebonie Rogers, Victor Camba, Christopher Albertson, Dylan Lahiff, Talha Rashid, Jacentha Buggs. Tampa, FL.

2:42 pm Five Year Experience with Laparoscopic Sleeve Gastrectomy in Obese Renal Transplant Candidates (Abstract #468)

2:54 pm Outcomes Following Cholecystectomy in Kidney Transplant Recipients (Abstract #469)

3:06 pm The Effect of the Procurement Surgeon on Transplanted Abdominal Organ Outcomes: An OPTN/SRTR Analysis to Evaluate Regional Organ Procurement Collaboration (Abstract #470)

3:18 pm Results of Biliary Reconstruction with PTFE Graft in Liver Transplantation (Abstract #471)

3:30 pm Robotic Kidney Transplantation: Bakirkoy Experience (Abstract #472)

3:42 pm When Does the Learning Curve End? A High-Volume Single Center Experience with Laparoscopic Donor Nephrectomy Over 16 Years (Abstract #473)

Xenotransplant

Room E351
Chairs: Mohamed Ezzelarab, MD, University of Pittsburgh, Pittsburgh, PA, United States and Richard Pierson, MD, University of Maryland, Baltimore, MD, United States

2:30 pm Autologous Expanded Tregs and Porcine Hematopoietic Cells to Prolong Xenogeneic Pig Skin Graft Acceptance in Baboons (Abstract #474)
Jeffrey M. Stern, Sigal Kofman, Paula Alonso-Guallart, Erik Berglund, Makenzie Danton, Josh Weiner, David Ayares, Robert Hawley, Kazuhiko Yamada, David Sachs, Megan Sykes, Adam Griesemer. New York, NY; Blacksburg, VA.

2:42 pm Addition of hEPCR.hCD55.hTFPI.hCD47 Modulates Multi-Lineage Cell Sequestration and Coagulation Activation by GalTKO.hCD46 Transgenic Pig Livers Perfused Ex Vivo with Human Blood (Abstract #475)
Arielle Cimeno, Lars Burdorf, Dawn M. Parsell, Carol Phelps, David Ayares, Agnes M. Azimzadeh, Robin N. Pierson III, Rolf N. Barth, John C. LaMattina. Baltimore, MD; Blacksburg, VA.

2:54 pm Prolonged Survival with Co-Stimulatory Blockade Based Immunosuppression in Pig-to-Primate Liver Xenotransplantation (Abstract #476)
3:06 pm Orthotopic Liver Transplantation of Xenogeneic Livers Repopulated with Autologous Hepatocytes: Proof of Normal Function and Consistent Survival (Abstract #477)

3:18 pm Early Detection of Xenograft Rejection or Injury by Donor Derived Cell Free DNA in Pig to Baboon Cardiac Xenotransplantation (Abstract #478)
Avneesh Singh, Sean Agbor-Enoh, Joshua Chan, Sasha Groham, Phillip Corcoran, Billeta Lewis, Marvin Thomas, David Ayares, Keith Horvath, Hannah Valantine, Muhammad Mohiuddin. Bethesda, MD; Blacksburg, VA.

3:30 pm CD4 Depletion Is Necessary and Sufficient for Long-Term Nonhuman Primate Xenotransplant Survival (Abstract #479)
Steven Kim, Laura Higginbotham, David Mathews, Cynthia Breeden, Allison Stephenson, Christian Larsen, Mandy Ford, Joseph Tector, Andrew Adams. Atlanta, GA; Birmingham, AL.

3:42 pm CD28 Directed Immunotherapy Is More Potent Than Belatacept in a Nonhuman Primate Xenotransplant Model (Abstract #480)
Steven Kim, Laura Higginbotham, David Mathews, Cynthia Breeden, Allison Stephenson, Christian Larsen, Mandy Ford, Joseph Tector, Andrew Adams. Atlanta, GA; Birmingham, AL.

Allied Health Symposium 3
2:30 pm – 6:00 pm
Room E258

Breaking News in Transplant Pharmacology: Reviewing the Year’s Top Publications Involving Pharmacotherapy
Moderators: Tracy Anderson-Haag, PharmD, BCPS, Hennepin County Medical Center, Minneapolis, MN, USA and Winston Ally, PharmD, University of Virginia Health System, Charlottesville, VA, USA

2:30 pm Newest Therapies for the Treatment of Hepatitis C
Joshua Wiegel, PharmD, BCPS
UW Health
Madison, WI, USA

2:50 pm Novartis: What Are the Latest Updates in Hepatitis B/C Treatment
Moderators: Justin Reddick, PharmD, BCPS, and Elizabeth Cohen, PharmD

3:00 pm Notable Updates in Cytomegalovirus (CMV) Infection
Moderators: Justin Reddick, PharmD, BCPS, and Elizabeth Cohen, PharmD

3:10 pm Novel Treatment Options For Acute and Chronic Humoral Rejection
Nicole Ejaz, PharmD
Johns Hopkins Hospital
Baltimore, MD, USA

3:30 pm Novel Treatment Interventions to Improve Medication Adherence and Outcomes
David Taber, PharmD
Medical University of South Carolina
Charleston, SC, USA

3:50 pm Coffee Break

What’s Your Protocol? Show Me the Data!
Moderators: Daniel Brennan, MD, FACP, Washington University in St. Louis, St. Louis, MO, USA and Lyndsey Bowman, PharmD, BCPS, Tampa General Hospital, Tampa, FL, USA

4:20 pm Kidney Transplant Induction in the Real World – Alemtuzumab
Kristen Szempruch, PharmD
University of North Carolina Hospital
Chapel Hill, NC, USA

4:30 pm Kidney Transplant Induction in the Real World – Rabbit Antithymocyte Globulin
Lindsey Pote, PharmD
The Johns Hopkins Hospital
Baltimore, MD, USA

4:50 pm Discussion
Beyond the “BENEFIT:” How Do You Use Belatacept?
Moderators: Elizabeth Cohen, PharmD, Yale New Haven Hospital, New Haven, CT, USA and Erika Meredith, PharmD, Emory University Hospital, Decatur, GA, USA

5:05 pm Belatacept – The Emory Experience
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA
5:15 pm  Belatacept – The Christ/Cincinnati Experience  
Adele Shields, PharmD  
The Christ Hospital/University of Cincinnati  
Cincinnati, OH, USA

5:25 pm  Basixilimab Induction and Delayed Calcineurin Inhibitors Introduction  
TrisAnn Rendulic, PharmD, BCPS  
University of Kentucky HealthCare  
Lexington, KY, USA

5:35 pm  Everolimus and Low Dose Tacrolimus  
Timothy Horwedel, PharmD  
Barnes-Jewish Hospital  
St. Louis, MO, USA

5:45 pm  Discussion

Pediatric Symposium 2  
2:30 pm – 6:00 pm  
Room E265

Transitions in Care in Pediatric Transplantation  
Moderators: Emily Fredericks, PhD, University of Michigan / C.S. Mott Children’s Hospital, Ann Arbor, MI and Amy Bobrowski, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago, Elmhurst, IL, USA

2:30 pm  Enhancing the Hospital to Home Transition for Families of Pediatric Solid Organ Transplant Recipients: Setting the Stage for Long-Term Success  
Stacee Lerret, PhD, RN, CPNP  
Medical College of Wisconsin/Children’s Hospital of Wisconsin  
Milwaukee, WI, USA

3:00 pm  Risky Business: How Can We Help Teens Navigate Common Lifestyle Challenges?  
Ian Chen, BScEng, DO  
SickKids Hospital  
Toronto, ON, Canada

3:30 pm  Transition From Pediatric To Adult Care: Customizing Patient and Hospital Resources to Foster Successful Outcomes  
Beverly Kosmach-Park, DNP, MSN, FAAN  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA, USA

4:00 pm  Coffee Break

Transplant Strategies from Pediatric Recipients  
Moderators: John Bucuvalas, MD, Cincinnati Children’s Hospital MC, Cincinnati, OH, USA and Srinath Chinnakotla, MD, University of Minnesota Medical School, Minneapolis, MN, USA

4:30 pm  Implications of KAS on Organ Allocation for Children  
Amy Gallo, MD  
Stanford University Medical Center  
Palo Alto, CA, USA

5:00 pm  Finding the Right Donor for the Infant Liver Recipient – Live Donor, Split, or Whole Organ?  
George Maziariegos, MD  
Pittsburgh  
Pittsburgh, PA, USA

5:30 pm  Stepping Up – Strategies to Enhance Live Donation in Pediatric Transplantation  
Amy Waterman, PhD  
UCLA  
Los Angeles, CA, USA

Coffee Break with Exhibits  
4:00 pm – 4:30 pm  
Hall D1

Concurrent Oral Abstract Sessions  
4:30 pm – 6:00 pm

B Cells: Regulation and Tolerance  
Room E350

Chairs: Anita Chong, PhD, The University of Chicago, Chicago, IL, United States and Irene Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, United States

4:30 pm  Emerging Before Detection of De Novo Humoral Alloimmunity in Kidney Transplant Recipients (Abstract #481)  
4:42 pm  IL-21R Antagonist Inhibits Differentiation of B Cells Towards Plasmablasts upon Alloantigen Stimulation (Abstract #482)
Kitty de Leur, Frank J. M. F. Dor, Marjolein Dieterich, Luc J. W. van der Laan, Rudi W. Hendriks, Carla C. Baan. Rotterdam, Netherlands; London, United Kingdom.

4:54 pm  Donor-Derived Cell-Free DNA Predicts Biopsy-Proven Acute Cellular Rejection in Pediatric Kidney Transplant Recipients (Abstract #483)
Dan J. Stoltz, Aleah Brubaker, Marica Grskovic, Robert Woodward, Amy E. Gallo. Palo Alto, CA; Brisbane, CA.

5:06 pm  CTLA4Ig Suppresses Memory Responses to HLA-A2+ Skin Grafts in a Mouse Model of Allosensitization by Reducing CD138+ Plasma Cells (Abstract #484)
Gordon Wu, Irene Kim, Ning-Ning Chai, Stanley Jordan, Andrew Klein. Los Angeles, CA.

5:18 pm  CD8+ TAb-supp Cells Suppress the Production of Multiple Alloantibody Isotypes in Response to MHC-Mismatched Cellular and Vascularized Allografts (Abstract #485)
Jason M. Zimmerer, Christina L. Avila, Steven M. Elzein, Bryce A. Ringwald, Ginny L. Bumgardner. Columbus, OH.

5:30 pm  B Cells in Liver Transplant Tolerance (Abstract #486)
Miwa Morita, Gospel Enyindah Asonye, Neetu Gupta, John J. Fung, Charles Miller, Shiguang Qian, Lina Lu. Cleveland; Chicago, MI; Cleveland, OH.

5:42 pm  Importance of B Cell Antigen Specificity in Breg Dependent Tolerance (Abstract #487)

DCD and Infectious Risk Kidney Donors

Room E450B
Chairs: Amy Evenson, MD, MPH, Beth Israel Deaconess Medical Center, Boston, MA, United States and Kenneth Woodside, MD, University of Michigan, Ann Arbor, MI, United States

4:30 pm  Delayed Graft Function—Less Ominous for ARF or DCD Recipients? (Abstract #488)

4:42 pm  Donation After Circulatory Death (DCD) Kidneys Are More Likely to Be Discarded than Kidneys from Neurologically Brain Dead Donors (NBD) (Abstract #489)
John Gill, Caren Rose, Julie Lesage, Yayuk Joffres, Jagbir Gill, Kevin O'Connor. Vancouver, Canada; Seattle.

4:54 pm  Donor Age Is the Most Important Predictor of Longterm Graft Function in Simultaneous Pancreas-Kidney Transplantation from Donors After Cardiac Death (Abstract #490)

5:06 pm  Higher Mortality Among Candidates Who Refuse to Accept DCD Kidney Offers (Abstract #491)
Mary Bowring, Allan Massie, Dorry Segev. Baltimore.

5:18 pm  Higher Mortality Among Candidates Who Refused Increased-Infectious Risk Kidney Offers (Abstract #492)
Mary Bowring, Lauren Kucirka, Allan Massie, Courtenay Holscher, Dorry Segev. Baltimore.

5:30 pm  Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis (Abstract #493)
Bryce Kiberd, Karen Doucette, Karthik Tennankore. Halifax, NS, Canada; Edmonton, AB, Canada.
5:42 pm Delayed Graft Function and Long-Term Graft Survival in DBD and DCD Kidney Recipients (Abstract #494)
Allan Massie, Dorry Segev. Baltimore.

Disparities in Kidney Transplantation
Room E451A
Chairs: Lauren Kucirka, PhD, John Hopkins, Baltimore, MD, United States and Joseph Melancon, MD, George Washington, Washington, D.C., United States

4:30 pm Just Keeps Getting Worse: Racial and Ethnic Disparities in Access to Live Donor Kidney Transplantation in the US Over the Last Twenty Years (Abstract #495)
Tanjala Purnell, Xun Luo, Lauren Kucirka, Macey Henderson, Elisa Gordon, L. Ebony Boulware, Dorry Segev. Baltimore; Chicago; Durham.

4:42 pm How to Improve Pre-Kidney Transplant Education for Hispanics: Preferences and Perceptions of Northwestern Memorial Hospital’s Hispanic Transplant Program (Abstract #496)
Helen B. Gomez, Erica Malagon-Blackwell, Juan Carlos Caicedo. Chicago, IL.

4:54 pm Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients (Abstract #497)
David Taber, M. Gebregziabher, L. Egede, P. Baliga. Charleston, SC.

5:06 pm At-Home Transplant Education Increases Black and Low-Income Dialysis Patients’ Transplant Knowledge, Attitudes, Informed Decision-Making and Pursuit: An Explore Transplant @ Home Randomized Controlled Trial (Abstract #498)
Amy Waterman, John Peipert, Anna-Michelle McSorley, Christina Goalby, Leanne Peace. Los Angeles, CA; Columbia, MO.

5:18 pm Dialysis Facility Providers’ Awareness of Racial Disparities in Kidney Transplantation (Abstract #499)
Joyce Kim, Mohua Basu, Laura Plantinga, Cam Escoffery, Stephen Pastan, Rachel E. Patzer. Atlanta.

5:30 pm Geographic Disparities in Access to Deceased Donor Kidney Transplant (Abstract #500)
Sally Gustafson, A. Wey, B. Thompson, A. Massie, S. Zhou, N. Salkowski, D. Segev, S. Gentry, Jon Snyder. Minneapolis; Baltimore; Annapolis.

5:42 pm Dramatic Shifts in Prognosis, Outcomes and Baseline Risk Among Wait Listed Kidney Transplant Candidates in the United States (Abstract #501)
Jesse Schold, Emilio Poggio, Laura Buccini, Stuart Flechner, Joshua Augustine, David Goldfarb. Cleveland, OH.

Economics and Outcomes in Organ Transplantation
Room E271A
Chairs: Elizabeth Cohen, PharmD, Yale New Haven Hospital, New Haven, CT, United States and Edward Zavala, MBA, Vanderbilt University, Nashville, TN, United States

4:30 pm Utility of Weighted Composite Endpoints in Kidney Transplantation (Abstract #502)
Jesse Schold, David Goldfarb, Stuart Flechner, Laura Buccini, Joshua Augustine, Emilio Poggio. Cleveland, OH.

4:42 pm Unexplained Cost Variation for Liver Transplantation: A National Study of US Transplant Centers (Abstract #503)
Carlos Santos, Bala Hota, Martin Hertl. Chicago.

4:54 pm “Donor Age or Quality” a Qualitative Analysis of Livers Declined for 830 (Abstract #504)

5:06 pm Cultural Competency of a Mobile, Customized Patient Education Tool for Improving Potential Kidney Transplant Recipients’ Knowledge and Decision-Making (Abstract #505)
David Axelrod, Crystal Kynard-Amerson, David Wojciechowski, Krista Lentine, Mark Schnitzler, John Peipert, Amy Waterman. Greenville, NC; Los Angeles, CA; Boston, MA; St. Louis, MO.
5:18 pm Analysis of Outcomes in High Risk Kidney Transplants (Abstract #506)

5:30 pm Outcomes of Organs Transplants When the Donor Is a Prior Recipient (Abstract #507)

5:42 pm The New Kidney Allocation System in France Meets it’s Targets: Improving Age and HLA DR-QD Matching for Young Adults (Abstract #508)
Christian Jacquelinet, Benoît Audry, Florian Bayer, Marie Alice Macher. Saint-Denis, France.

Islet Transplant
Room E352
Chairs: Paolo Fiorina, MD PhD, Harvard Medical School/Università degli Studi di Milano, Boston, MA, United States Minor Outlying Islands and Norma Sue Kenyon, Ph.D., University of Miami, Miami, FL, United States

4:30 pm Bioengineering Human Islets to Form Peri-Islet Vessels from Intraislet Endothelial Cells for Improving Human Islet Function (Abstract #509)

4:42 pm Islet Rejection in Autoimmune NOD Mouse Recipients: Implications for Stem Cell Therapies (Abstract #510)
Ronald G. Gill, Marilyne Coulombe, Tinalyn Kupfer, K. Scott Beard, Adam L. Burrack. Aurora, CO; Minneapolis, MN.

4:54 pm IgM Immunotherapy Restores Immune Homeostasis in Type 1 Diabetes (Abstract #511)
Preeti Chhabra, Christopher Wilson, Daniel Moore, Kenneth L. Brayman. Charlottesville, VA; Nashville, TN.

5:06 pm Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts (Abstract #512)
Maria Koulmanda, Vaja Chipashivili, Michael Duggan, Terry B. Strom. Boston, MA.

5:18 pm A Combination of Anti-CD40L-Ab, Rapamycin and Donor Apoptotic Cells Prolongs Allogeneic Pancreatic Islet Survival in Sensitized Mice by Regulating Memory Responses (Abstract #513)
Anil Dangi, Hee-Kap Kang, Xiaomin Zhang, Xunrong Luo. Chicago, IL.

5:30 pm Optimization of Pancreatic Islet-Like Clusters from hiPSCs for Cell Therapy in Type 1 Diabetes (Abstract #514)
Giuseppe Pettinato, Periklis Kyriazis, Melissa T. Thompson, Maria Koulmanda, Robert A. Fisher. Boston, MA.

5:42 pm Inhibition of Liver Natural Killer Cells Activation Through Co-Transplantation of Pre-Activated Mesenchymal Stem Cells Contributes to Improvement of Islet Graft Survival (Abstract #515)
Nobuki Ishida, Kohei Ishiyama, Yoshihiro Saeki, Yuka Tanaka, Hideki Ohdan. Hiroshima, Japan.

Kidney General Outcomes
Room E354A
Chairs: Clarence Foster, MD, TriStar Centennial Medical Center, Nashville, Tennessee, United States and David Leeser, MD, MBA, University of Maryland, Baltimore, Md, United States

4:30 pm The Impact of Delayed Graft Function on Long Term Graft Survival Adjusted for Donor Kidney Quality Assessed by the KDPI (Abstract #516)
Lukas J. Lehner, Fabian Halleck, Dmytro Khadzhynov, Eva Schrezenmeier, Michael Dür, Klemens Budde, Oliver Staeck. Berlin, Germany.

4:42 pm Belatacept Conversion in Kidney Recipients with Low GFR Does Not Improve Renal Function (Abstract #517)
Dina Abdelwahab, Smith Byron, Bruce Kaplan, Raymond Heilman. Scottsdale, AZ; Rochester, MN.
4:54 pm  Identifying the Specific Causes and the Determinants of Outcome in Kidney Recipients with Transplant Glomerulopathy: A Multicenter Study (Abstract #518)

Liver: Immunosuppression and Rejection

Room E451B

Chairs: JP Norvell, M.D., Emory University School of Medicine, Atlanta, GA, United States and Thomas Schiano, The mount Sinai medical center, NY, NY, United States

4:30 pm  Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection (Abstract #523)

4:42 pm  Long-Term Outcomes After Liver Transplantation (tx) with Everolimus (EVR) and Mycophenolic Acid (MPA) in a Calcineurin Inhibitor-Free Regimen: The CERTITUDE Trial (Abstract #524)
Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Fabienne Di Giambattista, Filomena Conti. Villejuif, France; Créteil, France; Lille, France; Lyon, France; Paris, France; Rueil-Malmaison, France.

5:06 pm  No Gains in Long-Term Survival Following Liver Transplantation Over the Past Three Decades (Abstract #526)

5:18 pm  FOXP3 rs3761548 A/C+A/A Genotype Is a Risk Factor for Steroid Resistant Rejection After Liver Transplantation (Abstract #527)
Long Term Kidney Graft Survival II

Room E450A
Chairs: Arjang Djamali, MD, MS, University of Wisconsin-Madison, Madison, WI, United States and John Friedewald, Northwestern University, Chicago, IL, United States

4:30 pm Acute Cellular Rejection Is Associated with Increased Risk of Early and Late Graft Failure (Abstract #530)

4:42 pm Immune Sensitization During Pregnancy Reduces Long-Term Benefit for Kidney Recipients of Offspring Living Donors (Abstract #531)

4:54 pm Determinants of Severe Interstitial Fibrosis in Kidney Allografts: Major Impact of Circulating Donor-Specific Anti-HLA Antibodies (Abstract #532)

5:06 pm Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study (Abstract #533)

Center-Level Differences in Outcomes Following High-KDPI Kidney Transplants (Abstract #534)
Linxuan Wu, Allan B. Massie, Xun Luo, Mary Bowring, Dorry L. Segev. Baltimore.

Prolonged Dialysis Prior to Renal Transplantation (Abstract #535)

Impact of a B-Cell Targeting Agent on Antibody Mediated Rejection and Graft Survival in Liver Transplantation with Preformed DSAs (Abstract #529)
Arnaud Del Bello, Valérie Dubois, Jerome Dumortier, Nicolas Congy-Jolivet, Nassim Kamar. Toulouse, France; Lyon, France.

Nephrectomy of the Failed First Kidney Allograft Predisposes Kidney Transplant Recipients to Presensitization with Alloreactive T-Cells and Inferior Allograft Survival After Retransplantation (Abstract #536)
Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.

Novel Immunosuppression Regimens – Belatacept

Room E354B
Chairs: Lorenzo Gallon, NWU, Chicago, IL, United States and Eliot Heher, MD, Massachusetts General Hospital, Boston, MA, United States

Experience with Belatacept (CTLA4-Ig) Conversion in Highly HLA Sensitized (HS) and ABO-Incompatible (ABOi) Patients Who Received Incompatible Kidney Transplants Post Desensitization (DES) (Abstract #537)
Jua Choi, Alice Peng, Ashley Vo, Edmund Huang, Reiad Najjar, Sabrina Louie, Allie Kang, Shili Ge, Mieko Toyoda, Xiaohai Zhang, Stanley Jordan. Los Angeles, CA.

Belatacept Conversion for Calcineurin Inhibitor (CNI) Toxicity: Our First 100 Patients (Abstract #538)

IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection (Abstract #539)
He Xu, Todd V. Brennan, Allan D. Kirk. Durham, NC.
5:06 pm A Novel Belatacept Regimen to Optimize Efficacy and Safety (Abstract #540)
David Wojciechowski, Sindhu Chandran, Minnie Sarwal, Joshua Yang, Flavio Vincenti. Boston; San Francisco.

5:18 pm Stability of Immune Phenotype, Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation (Abstract #541)

5:30 pm Impact of Belatacept Conversion on Kidney Transplant Function, Histology and Gene Expression (Abstract #542)
Pooja Sanghi, Gaurav Gupta, Dhiren Kumar, Jeff Reeve, Marlon Levy, Amit Sharma, Hasan Fattah, Pamela Kimball, Hugh D. Massey, Anne L. King, Philip Halloran. Richmond; Edmonton, Canada.

5:42 pm A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naive, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells (Abstract #543)

5:06 pm The mTOR Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury (Abstract #547)
Cheng Yang, Chao Zhang, Ruiming Rong, Tongyu Zhu. Shanghai, China.

4:30 pm TRPV4 Channels Mediate Pulmonary Edema and Inflammation During Ischemia-Reperfusion Injury (Abstract #544)

4:42 pm Myeloid HO-1 Orchestrates Liver Graft Function via SIRT1/p53 Signaling: From Mouse-to-Human (Abstract #545)

5:06 pm The mTOR Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury (Abstract #547)
Cheng Yang, Chao Zhang, Ruiming Rong, Tongyu Zhu. Shanghai, China.

5:18 pm Donor-Derived Nonclassical Monocytes Produce MIP-2 to Recruit Recipient Neutrophils and Cause Ischemia Reperfusion Injury After Lung Transplant (Abstract #548)
5:30 pm Accumulating Mitochondrial DNA in Aging Augments Inflammatory Responses Subsequent to IRI (Abstract #549)

5:42 pm Glucocorticoid Receptor – Relaxin Signaling in Liver Transplant Ischemia-Reperfusion Injury (IRI): From Bench-to-Bedside (Abstract #550)

PTLD
Room E271B
Chairs: Vikas Dharnidharka, MD, MPH, Washington University in St. Louis, Saint Louis, MO, United States and Jutta Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada

4:30 pm Inhibition of Multiple Nodes in the PI3K/Akt/mTOR Pathway Synergistically Suppresses Epstein-Barr Virus B Cell Lymphomas (Abstract #551)
Adam X. Sang, Geoff T. Ivison, Xiumei Qu, Carlos O. Esquivel, Sheri M. Krams, Olivia M. Martinez. Palo Alto, CA.

4:42 pm EBV-Specific CD8+ T Cells from Pediatric Thoracic vs Abdominal Transplant Recipients Are Shaped Differently by the Chronic EBV Loads with Potential Impact on the Risk of PTLD (Abstract #552)
Masaki Yamada, Macedo Camila, Paul Fadakar, Kimberly Hornor, Marian Michaels, Michael Green, Christina Nguyen, Brian Feingold, George Mazariegos, Diana Metes. Pittsburgh, PA.

4:54 pm The miRNome of EBV+ PTLD is Distinct from EBV+ Infectious Mononucleosis (Abstract #553)

5:06 pm Genomic Diversity of Epstein-Barr Virus in Post-Transplant Lymphoproliferative Disorder (Abstract #554)
Eden M. Maloney, Olivia M. Martinez. Stanford, CA.

5:18 pm Presence of Anellovirus Nucleic Acid Sequences in Involved Tissue Is Associated with Worse Patient Survival in Post-Transplant Lymphoproliferative Disorder (Abstract #555)

5:30 pm Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients (Abstract #556)
Bong-Ha Shin, Shili Ge, James Mirocha, David Thomas, Edgar Rodriguez, Christine Chao, Odette A. Galera, Ashley Vo, Jua Choi, Alice Peng, Joseph Kahwaji, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

5:42 pm Risk of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients (Abstract #557)
Eric A. Engels, Parag Mahale, Meredith S. Shielis. Bethesda, MD.

Late Breaking
Room E353C
Chairs: Reza Abdi, Bwh, Boston, Ma, United States and David Mercer, MD PhD, University of Nebraska Medical Center, Omaha, Nebraska, United States

4:30 pm Co-Stimulation Blockade to Minimize and Withdraw Long Term Calcineurin Inhibitors (CNI) in Simultaneous Pancreas and Kidney Transplant (SPK) (Abstract #566)
P. G. Stock, R. B. Mannon, B. Armstrong, D. Ikle, M. Robian, Y. Morrison, J. Odorico, J. Fridell, A. K. Mehta, K. A. Newell. San Francisco; Birmingham, AL; Chapel Hill, NC; Bethesda, MD; Madison, WI; Indianapolis, IN; Atlanta, GA.
4:42 pm  U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) (Abstract #567)
Brian Lee, N. Mehta, L. Platt, G. Im, G. Therapondos, H. Han, D. Victor, D. Dronamraju, I. Hanouneh, M. Voigt, M. Rinella, S. Eswaran, J. Hause, C. Hsu, J. Dodge, Z. Li, N. Terrault. SF; Baltimore; NYC; New Orleans; LA; Houston; Cleveland; Iowa City; Chicago; Philadelphia.

4:54 pm  Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes (T1D) Post Renal Transplantation (Abstract #568)

5:06 pm  Efficacy and Safety of Everolimus with Reduced-Exposure Tacrolimus and Corticosteroid Withdrawal in De Novo Pediatric Renal Transplant Recipients: 12-Month Results from the CRADLE Study (Abstract #569)

5:18 pm  Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates (Abstract #570)
Robert R. Redfield, Stanley C. Jordan, Thomas Schindler, Ha Tran, Caroline Looney, Cherie Green, Alyssa Morimoto, Richa Rajwanshi, Matthew D. Cascino, Paul Brunetta, Dominic Borie. Madison; Los Angeles; Basel, Switzerland; South San Francisco.

5:30 pm  A Novel Equation, GRAIL (GFR Assessment in Liver Disease) Correctly Classifies Patients with Reduced GFR and Predicts Development of ESRD (Abstract #571)
Sumeet Asrani, Linda Jennings, Mitra Nadim, Josh Levitsky, James Trotter, Goran Klintmalm. Dallas, TX; LA, CA; Chicago, IL.

5:42 pm  Blood and Biopsy Genomic Signatures of Acute Rejection in Liver Transplant Recipients (Abstract #572)
Josh Levitsky, Thomas Whisenant, Sunil Kurian, Sam Rao, Anthony Demetris, Michael Abecassis. Chicago; San Diego; Pittsburgh.

5:45 pm – 7:00 pm  ASTS Business Meeting

6:00 pm – 7:00 pm  Poster Session D

Hall D1
Poster Viewing: 9:30 am – 12:00 pm
2:30 pm – 7:00 pm

Presenters in Attendance: 6:00 pm – 7:00 pm
Poster Session D can be found on pages 178-204.

7:30 pm – 10:00 pm  ATC Night Out

Offsite - River Roast
8:00 am - 10:00 am  Plenary

Page 102  

**Joint Plenary Session IV**

Arie Crown Theater

10:00 am - 10:15 am  Coffee Break

Foyer

10:15 am - 11:30 am  What's Hot, What's New

Page 103  

Arie Crown Theater
### Joint Plenary Session IV

**8:00 am – 10:00 am**

**Arie Crown Theater**

**Chairs:** Josh Levitsky, MD, MS, Northwestern University, Chicago, IL, USA and David Mercer, MD PhD, University of Nebraska Medical Center, Omaha, Nebraska, United States

**8:00 am**

**Tissue Transcriptional Profile of Portal Inflammation with Interface Activity in Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests Closely Resembles T Cell Mediated Rejection (TCMR) (Abstract #558)**

A. Sanchez-Fueyo, S. Feng, A. Demetris, J. Bucuvalas, J. Lozano, J. Magee, K. Spain, S. Kanaparthi, iWITH Investigators. London, United Kingdom; SF; Pittsburgh; Cincinnati; Barcelona, Spain; Ann ArborChapel Hill; Bethesda.

**8:00 am**

**8:15 am**

**Costimulation Independent Acute Rejection Requires CD127 Signaling (Abstract #559)**

David Varkey Mathews, Ying Dong, Steven Charles Kim, Cynthia Breeden, Andrew B. Adams. Atlanta, GA.

**8:30 am**

**Outcomes from a Multinational Randomised Controlled Trial Comparing Normothermic Machine Perfusion with Static Cold Storage in Human Liver Transplantation (Abstract #560)**

David Nasralla, Consortium for Organ Preservation in Europe Liver Research Group, Rutger Ploeg, Constantin Coussios, Peter Friend. Oxford, United Kingdom.

**8:45 am**

**Etiology and Timing of ESRD After Kidney Donation (Abstract #561)**


**9:00 am**

**Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study (Abstract #562)**

Marcus R. Pereira, Fernanda P. Silveira, Genovefa Papanicolaou, Amelia Langston, Robin Avery, Anna Wijatky, Jingyang J. Wu, Michael Boeckh, Francisco M. Marty, Stephen Villano. New York, NY; Pittsburgh, PA; Atlanta, GA; Baltimore, MD; Lexington, MA; Seattle, WA; Boston, MA; Wayne, PA.

**9:15 am**

**Donor SIRPa Polymorphism Modulates the Innate Immune Response to Allogeneic Grafts (Abstract #563)**

Hehua Dai, Andrew Friday, Khodor Abou-Daya, Amanda Williams, Martin Oberbarscheidt, Jayne Danska, Fadi Lakkis. Pittsburgh, PA; Toronto, ON, Canada.

**9:30 am**

**Dysregulated Innate Immune Response Is a Robust Predictor of Allograft Injury and Survival Across All Transplanted Organs (Abstract #564)**

Tej D. Azad, Michele Donato, Line Heylen, Shai Shen-Orr, Timothy E. Sweeney, Maarten Naesens, Purvesh Khatri. Stanford, CA; Leuven, Belgium; Haifa, Israel.

**9:45 am**

**Inflammasome, Unfolded Protein Response and T Cell Immunity in DAIH (Abstract #565)**

Adam Arterbery, Mercedes Martinez, Steven Lobritto, Yaron Avitzur, Udeme Ekong. New Haven, CT; Toronto, ON, Canada; New York, NY.

---

**Coffee Break**

**10:00 am – 10:15 am**

**Foyer**
What's Hot, What's New – Overview of the Top Presented Abstracts
10:15 am – 11:30 am

Arie Crown Theater
Moderators: TBD

10:15 am  Basic
Xian Li, MD, PhD
Houston Methodist
Houston, TX, USA

10:45 am  Translational
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

11:00 am  Clinical
Matthew Cooper, MD
Medstar Georgetown Transplant Institute
Washington DC, USA
Antibody Mediated Rejection in Kidney Transplant Recipients

A1 Antibody-Mediated Vascular Rejection of Kidney Allografts: What Does It Happen After 15 Years?
Beatriz B. Rodriguez Cubillo, Isabel I. Perez Flores, Maria Angeles M. A. Moreno De La Higuera, Marta M. A. Calvo, Natividad N. Calvo Romero, Alejandro A. Pascual, Jose Antonio J. A. Cortes, Julia J. Blanco, Ana Isabel A. I. Sanchez-Fructuoso. Madrid, Spain.

A2 Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?
Abheesh Prasad, Anand Yuvaraj, David Briggs, Nithya Krishnan. Coventry, United Kingdom; Birmingham, United Kingdom.

A3 Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens
Basit Javaid, Sandra Rosen-Bronson, Dong Li, Mariam Awwad, Alexander Gilbert, Seyed Ghasemian, Jennifer Verbesey, Peter Abrams, Monica Grafals, Jill Fenton, Caroline Cannon, Joanne Rapisura, Jack Moore, Matthew Cooper. Washington, DC.

A4 Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience
Supreet Sethi, Ashley Vo, Edmund Huang, Laalasa Varanasi, Jua Choi, Alice Peng, Reiad Najjar, Stanley Jordan. Los Angeles, CA.

A5 Risk Factors of Treatment Failure in Antibody Mediated Rejection
Vincent Pernin, Ilan Szwarc, Tarik Kanouni, Valérie Garrigue, Jean Emmanuel Serre, Sylvie Delmas, Georges Mourad, Moglie Le Quintrec. Montpellier, France.

A6 Elevated Circulating AT1R Levels Indicate Heightened Risk for Antibody Mediated Rejection and Graft Failure
Pamela Kimball, Gaurav Gupta, Felecia McDougan. Richmond, VA.

A7 IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-CMV IgG, Resulting in Inhibition of Antibody (Ab)-Mediated NK Cell Activation in Kidney Transplant Patients (KTX Pts)
Bong-Ha Shin, Shili Ge, Maggie Chu, Jua Choi, Lena Winstedt, Christian Kjellman, Sabrina Louie, Ashley Vo, Alice Peng, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA; Lund, Sweden.

A8 Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients
Hyeyoung Lee, Eunhee Han, Ae-Ran Choi, Ki Hyun Park, Ji Hyeong Ryu, Byung Ha Chung, Chul Woo Yang, Eun-Jee Oh. Seoul, South Korea (KOR), Korea.

A9 † Graft Immunocomplex Capture Fluorescence Analysis to Detect Donor Specific Antibodies and HLA Antigen Complexes in the Renal Allograft
A10 † Steroid Withdrawal and De Novo Donor-Specific HLA Antibodies in Renal Transplant Patients: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results
Juana Alonso-Titos, Pedro Ruiz-Esteban, Eulalia Palma, Veronica Lopez, Abelardo Caballero, Myriam Leon, Maria Angeles Cobos, Josep Maria Cruzado, Joana Sellares, Armando Torres, Domingo Hernandez. Malaga, Spain; Tenerife, Spain; Barcelona, Spain.

A11 † Activated Th1 and Th17 cT_{FH} Phenotype Correlates with DSA Production in Kidney Transplant Recipients
Camila Macedo, Paul Fadakar, Kevin Hadi, Beth Ellinof, Adriana Zevei, Sundaram Hariharan, Diana Metes. Pittsburgh.

A12 † Early Antibody-Mediated Rejection C4d Status Remains a Marker of Prognosis in HLA-Incompatible Kidney Transplantation

A13 † Regulatory T Cells Inhibit Plasmablast Formation and IgG Production by Tempering T Follicular Helper Cell Function
Paul Fadakar, Camila Macedo, Masaki Yamada, Kevin Hadi, Diana Metes. Pittsburgh, PA.

A14 Urinary Proteomic Biomarkers Discovery for Prediction of Acute Rejection in Kidney Transplant Recipients

A15 Identification of Antibody-Mediated Rejection After Kidney Transplantation by Specific MicroRNAs

A16 Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA
Sergi Luque, Marc Lúcia, Marta Jarque, Elena Crespo, Edoardo Melilli, Jaume Martorell, Josep M. Cruzado, Joan Torras, Josep M. Grinyó, Oriol Bestard. Barcelona, Catalunya, Spain; Stanford.

A17 Single Nuclear Polymorphisms of Complement Component 4 and Component 5 in Renal Transplant Recipients with Antibody-Mediated Rejection
Zijie Wang, Zhijian Han, Jun Tao, Ruoyun Tan, Min Gu. Nanjing, Jiangsu, China.

A18 Gene Expression Signature of Subclinical Allograft Kidney ABMR Compared to Clinical ABMR

A19 Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients
Hasan Khamash, Logan Archambault, Matthew Buras, Heidi Kosiorek, Marcelo Pando, Kunam Reddy, Bruce Kaplan, Raymond Heilman. Phoenix, AZ.

A20 Poor Prediction of Rejection and Kidney Survival by Donor-Specific Antibodies Characterization
Lionel Couzi, Maxime Courant, Jonathan Visentin, Valérie Dubois, Sébastien Lepreux, Gwendaline Guidicelli, Olivier Thaunat, Pierre Merville, Jean-Luc Taupin. Bordeaux, France; Lyon, France; Paris, France.

A21 DSA Presence Does Not Affect Renal Histology and Clinical Outcome in Chronic Active Antibody Mediated Rejection
Kasia A. Sablik, Marian C. Clahsen–van Groningen, Caspar W. N. Looman, Jeffrey Damman, Dave L. Roelen, Madelon van Agteren, Michael Betjes. Rotterdam, Netherlands; Leiden, Netherlands.
A22 Microarray Analysis of Rejection in Formalin-Fixed Paraffin-Embedded Biopsies: Similarities and Disparities with Conventionally Stabilized Biopsies
Konrad S. Famulski, Jeff Revee, Philip F. Halloran. Edmonton, AB, Canada.

A23 Microcirculation Inflammation in Kidney Allograft Biopsies
Maria C. Giordani, Mariela I. Bedini Rocca, Silvia R. Groppa, Cesar A. Mombelli, Silvia B. Christiansen, Maria L. Ocampo, Guillermo J. Rosa Diez, Nora C. Imperiali. Buenos Aires, Argentina.

A24 Comparison Between IgG, C1q and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies
Manuel A. Moreno Gonzales, Donald G. Mitema, Byron H. Smith, Carrie A. Schinstock, Mark D. Stegall, Manish J. Gandhi. Lima, Peru; Jackson, MS; Rochester, MN.

A25 C3d-Binding Anti-DQ DSA Is Associated with a High Risk for Late ABMR and Graft Failure in Stable Kidney Transplant Recipients
Dong Ryeol Lee, Byung Chang Kim, Jong Pho Kim, In Guen Kim, Mi Young Chun. Busan, Republic of Korea.

A26 Mycophenolate Dose Reductions Are Not Associated with De Novo Donor-Specific Antibodies
Scott Davis, Jane Gralla, Patrick Klem, Alexander Wiseman, James Cooper. Aurora, CO.

A27 Blood Transfusion Before Organ Transplant: Patient Sensitization and Outcomes

A28 Banff 2013 Classification of Renal Allograft Pathology Is Superior to Banff 2007 in Detecting and Managing Milder and Earlier Cases of Antibody-Mediated Rejection
Jared Hassler, Venkatesh K. Ariyamuthu, Allen Hendricks, Bekir Tanriover, Jose R. Torrealba. Dallas, TX.

A29 HLA Donor-Specific Antibody (DSA) Negative Antibody-Mediated Rejection (AMR): Incidence, Treatment and Outcomes

A30 † A Novel Computational HLA Matching Algorithm for Improving Donor-Recipient Histocompatibility and Graft Outcomes After Kidney Transplantation
Vasilis Kosmoliaptsis, Dermot H. Mallon, Susan Fuggle, Rachel Johnson, Christopher J. E. Watson, J. Andrew Bradley, Craig J. Taylor. Cambridge, United Kingdom; Bristol, United Kingdom.

Cellular & Bone Marrow Transplantation Session I

A31 † Combining Neural Stem Cell Transplantation with Mixed Hematopoietic Chimerism Promotes Restoration of Self-Tolerance in Established Experimental Autoimmune Encephalomyelitis
William Orent, Jose Marino, Bruno Gonzalez Nolasco, Joshua Paster, Aycen Harney, David Sachs, Gilles Benichou. Boston, MA.

A32 † The Beneficial Effect of Janus Kinase 3 Inhibitor on Transplanted Islet via Protection from Oxidative Stress-Induced β Cell Death

A33 † The Role of Toll-Like Receptor 4 in Islet Transplantation and a Novel Method of Protection Using Chemical Surface Modification
Charles A. Chang, Gumpei Yoshimatsu, Babatope Akinbobuyi, Michael C. Lawrence, Robert R. Kane, Bashoo Naziruddin. Waco, TX; Dallas, TX.
A34 † Transplantation of Chimeric Cells of Myoblast and Mesenchymal Stem Cell Origin for Restoration of Muscle Function
Maria Siemionow, Erzsebet Szilagy, Joanna Cwykiel, Anna Domaszewska-Szostek, Ahike Heydemann, Jesus Garcia-Martinez. Chicago.

A35 Timing of Mesenchymal Stem Cell Infusions Affects Rejection Free and Overall Islet Allograft Survival
Norma S. Kenyon, Melissa Willman, Dongmei Han, Alexander Rabassa, Waldo Diaz, Rachel Leeman, Kenton McHenry, Daniel Salomon, Amelia Bartholomew, Norman M. Kenyon, Dora M. Berman. Miami, FL; Champaign, IL; La Jolla, CA; Chicago, IL.

A36 Liver Mesenchymal Stem Cells Inhibit T Cell Alloresponses

A37 Donor Lymphoid Chimerism in Early Recognition and Prediction of Clinical Outcome Caused by Acute Graft versus Host Disease After Solid Organ Transplant
Aiwen Zhang, Yuchu Sun, Koji Hashimoto, Masato Fujiki, Medhat Askar, John Fung, Charles Miller, Kareem Abu-Elmagd, Bijan Eghtesad. Cleveland, OH; Willemstad, Netherlands Antilles; Dallas, TX; Chicago, IL.

A38 iNKT Cell Activation Plus Veto Cell Transfer Yields Complete Chimerism in a Murine Sub-Lethal Bone Marrow Transplant Model
Rumi Ishii, Toshihito Hirai, Yasuyuki Ishii, Masayoshi Okumi, Kazunari Tanabe. Tokyo, Japan; Yokohama, Japan.

A39 Naïve and Interferon-gamma Activated Mesenchymal Stem Cells Differentially Affect Immune Responses In Vitro and In Vivo

A40 PTEN Inhibition in MSC Upregulates PD-L1 and Enhances Their Immunomodulatory Capacity Prolonging Skin Allograft Survival

A41 Inflammatory Conditions Dictate the Effect of MSC on B Cell Function
Franka Luk, Laura Carreras-Planella, Sander S. Korevaar, Samantha F. H. de Witte, Francesc E. Borràs, Michiel G. H. Betses, Carla C. Baan, Martin J. Hoogduijn, Marcella Franquesa. Rotterdam, Netherlands; Badalona, Spain.

A42 Antioxidant Thermoresponsive Hydrogel as a Versatile Islets Scaffolds for Treating Type I Diabetes
Yunxiao Zhu, Xiaoming Zhang, Guillermo Antonio Ameer, Xunrong Luo. Evanston, IL; Chicago, IL.

A43 Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation
Laura de Ramon, Ana Merino, Elia Ripoll, Nuria Bolaños, Montse Gomà, Josep M. Cruzado, Josep M. Grinyó, Juan Torras. Hospitalet Llobregat, Barcelona, Spain; Hospitalet Llobregat, Barcelona, Spain.

A44 Cibinetide (ARA 290), the Innate Repair Receptor Ligand, Improves Engraftment in Pancreatic Islet Transplantation by Protecting Islets and Reducing Inflammatory Reactions
Masaaki Watanabe, Ming Han Yao, Helen Zemack, Bo-Göran Ericzon, Anthony Cerami, Michael Brines, Torbjörn Lundgren, Makiko Kumagai-Braesch. Stockholm, Sweden; Tarrytown, NY.

A45 CXCL12 Modulation of Localized Immune Responses to Subcutaneous Islet Macrocapsulation
Madeline F. E. Penson, Marinko Sremac, Ruxandra Sirulescu, Timothy Brauns, Fiona Harrington, Mark Poznansky. Boston, MA.
A46  Suppression of Inflammation by Withaferin A in Cerulein-Induced Pancreatitis Model Results in Improved Syngeneic Islet Engraftment
Gumpei Yoshimatsu, Mazhar A. Kanak, Charles A. Chang, Carly M. Darden, Michael C. Lawrence, Bashoo Naziruddin. Dallas, TX; Richmond, VA.

A47  † Human Islet-Derived Extracellular Vesicles Stimulate CD14+ Monocytes Resulting in Proinflammatory Cytokine Production
Alissa K. Rutman, Sarita Negi, Craig Hasilo, Marco Gasparini, Jean Tchervenkov, Steven Paraskevas. Montreal, QC, Canada.

Clinical Science: Kidney Immunosuppression: Desensitization

A48  † The Impact of Belatacept on Anti-HLA Antibodies of Highly Sensitized Kidney Transplant Recipients

A49  † Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation

A50  Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients

A51  Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation

A52  Prognostic Tools to Choose Candidates for Successful Desensitization
David F. Pinelli, Andrea A. Zachary, John J. Friedewald, Mary S. Leffell, Donna Lucas, Robert Montgomery, Anat R. Tambur. Chicago, IL; Baltimore, MD.

A53  Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization
Shree Patel, Jamie Benken, Sanjeev Akkina, Patricia West-Thielke, James Thielke, Maya Campara, Jose Oberholzer, Enrico Benedetti. Chicago; Maywood.

A54  Presence of Complement Activating Donor Specific Antibodies Is Associated with Poor Renal Allograft Survival: Two Centre Retrospective Study
Adarsh Babu, Olivia Shaw, Louise Howe, Nicos Kessaris, Anthony Dorling, Nizam Mamode, Robert Vaughan, Nithya Krishnan, Rob Higgins, Dan Mitchell, David Briggs, Sunil Daga. Coventry, United Kingdom; London, United Kingdom; Birmingham, United Kingdom; Leeds, United Kingdom.

A55  Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience
Supreet Sethi, Ashley Vo, Edmund Huang, Laalasa Varanasi, Jua Choi, Alice Peng, Reiad Najjar, Stanley Jordan. Los Angeles, CA.

A56  Effect of Induction Therapy in ABO Incompatible Living-Donor Kidney Transplantation: A Single Center Experience
Luca Lanfranco, Laure Esposito, Arnaud Del Bello, Olivier Cointault, Asma Allal, Lionel Rostaing, Nassim Kamar. Toulouse, France.
A57  Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab

A58  Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center

A59  Complement Markers in Immunoadsorption Combined with Membrane Filtration
P. Malvezzi, F. Defendi, F. Eskandary, T. Jouve, L. Rostaing, C. Demestre-Perard, G. Böhmig. Grenoble, France; Vienna, Austria.

A60  Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization

A61  Factors Affecting Desensitization Outcome
Andrea A. Zachary, Robert A. Montgomery, Mary S. Leffell. Baltimore, MD; New York, NY.

A62  Comparing Outcomes of ABO Incompatible to DSA Positive/CDC-AHG Negative Kidney Transplantation

A63  Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center
Daigo Okada, Masayoshi Okumi, Kohei Unagami, Tomokazu Shimizu, Hideki Ishida, Kazunari Tanabe. Tokyo, Japan.

Clinical Science: Liver – Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

A64† Women in the United States Receive More Resections and Ablations for Hepatocellular Carcinoma Than Men
Lindsay Sobotka, Alice Hinton, Lanla Conteh. Columbus.

A65† Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria
Su-Kyung Kwon, Jae Geun Lee, Seung Hwan Song, Jee Youn Lee, Deok Gie Kim, Jun Jung Lee, Myoung Soo Kim, Gi Hong Choi, Jin Sub Choi, Dai Hoon Han, Soon Il Kim, Dong Jin Joo. Seoul, Korea; Bundang, Korea.

A66  The Impact of the Donor Risk Index on Tumor Free Survival in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma
Dilip K. Moonka, Shunji Nagai, Ann M. Harper, Reena J. Salgia. Detroit, MI; Richmond, VA.

A67  Effect of Embolization History and Tumor Treatment Response on Plasma TGFβ in HCC Patients Listed for Liver Transplantation
Paul Thevenot, Kelley Núñez, Janet Gonzalez-Rosario, Tyler Sandow, Anas Alharbi, Amjad Bokhari, Dorota Wyczewskas, Augusto Ochoa, Ari Cohen. New Orleans, LA.

A68  Hepatic Artery and Biliary Complications in Liver Transplant Recipients with Radioembolization Bridging Treatment for Hepatocellular Carcinoma
Sonia Radunz, Jürgen Treckmann, Fuat H. Saner, Stefan Müller, Jens M. Theysohn, Andreas Paul, Tamás Benkő. Essen, Germany.

109
Different Prognostic Factors for Early and Late Recurrence After Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma

The Glasgow Prognostic Score and Its Variants Predict Mortality in Living Donor but Not in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Double-Center Validation Study

Incidental Hepatocellular Carcinoma in Explanted Livers: An Assessment After LIRADS Introduction
Sandra Garcia Aroz, Daniel Ludwig, Kathryn Fowler, Neeta Vachharajani, Min Xu, Yying Lin, Majella Doyle, William Chapman. St. Louis, MO.

A New Strategy for Loco-Regional Therapy of Hepatocellular Carcinoma: Stereotactic Body Radiotherapy as a Bridge to Liver Transplantation

Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation
Hala Muaddi, David Al-Adra, Joshua Shaw, David Grant, Paul D. Greig, Ian McGilvray, Mark Cattral, Alice Wei, Carol-Anne Moulton, John Kachura, Rob Beecroft, Markus Selzner, Anand Ghanekar, Steve Gallinger, Sean P. Cleary, Gonzalo Sapisochin. Toronto, ON, Canada.

Which Way to Go, Liver Resection or Liver Transplantation for Hepatocellular Carcinoma in Child A Liver Cirrhosis

Outcome After Living Donor Liver Transplantation for Hepatocellular Carcinoma in Elderly Patients > 65 Years: Assessing the Long Term Survival
Ashok Thorat, Shih-Chao Hsu, Long-Bin Jeng, Hong-Ren Yang, Ping-Chun Li, Chun-Chieh Yeh, Te-Hung Chen, Kin-Shing Poon. Taichung, Taiwan.

Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant
Tyler Sandow, Humberto Bohorquez, David Kirsch, Abeer Albar, Paul Thevenot, Kelley Nunez, Daniel DeVun, Juan Gimenez, Gretchen Galliano, Ari Cohen, George Loss, Dennis Kay, Paul Gulotta. New Orleans, LA.

Re-Evaluation of Imaging Studies in Patients with Hepatocellular Carcinoma at a Transplant Center Impacts Patient Care
Ara A.ardashian, Bahar Madani, Catherine Frenette. La Jolla, CA.

Comparison of Locoregional Therapies for Hepatocellular Carcinoma in Liver Transplant Recipients
Melissa Chen, Benjamin Philosophe. Baltimore, MD.

Predicting Recurrence Prior to Transplant: The Response of HCC to Chemoembolization
Tyler Sandow, Humberto Bohorquez, David Kirsch, Paul Thevenot, Kelley Nunez, Abeer Albar, Daniel DeVun, Juan Gimenez, Gretchen Galliano, Ari Cohen, George Loss, Dennis Kay, Paul Gulotta. New Orleans, LA.
**A80** Serum AFP Greater Than 200 ng/ml as a Predictor for Low Survival in Patients with Hepatocellular Carcinoma Recurrence in a Brazilian Multicentric Study
Ilka F. S. F. Boin, Mariana Bina Possatto, Elaine Cristina Aitaide, Renato Ferreira Silva, Rita C. M. A. Silva, Helem C. Felicio, Leandro R. N. Amado, Agnaldo Soares Lima, Tiago Seva-Pereira. Campinas, SP, Brazil; Rio Preto, SP, Brazil; Federal University of Minas Gerais, Minas Gerais, Brazil.

**A81** Comparison of Long-Term Survival Outcome Between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria – A Single-Center Experience

**A82** Comparison of Local Recurrence Rates Between Endhole vs Anti-Reflux Catheters in Patients Undergoing DEB-TACE for Solitary LR-5 HCC Tumors
Aravind Arepally, Lance Stein, Roshan Shrestha, Madeline Tully, Steve Citron, Arnav Cherian, Harrison Pollinger, Michael Bosley, Rubin Raymond. Atlanta, GA.

**A83** Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect
Jee Youn Lee, Jae Geun Lee, Seung Hwan Song, Su-Kyung Kwon, Deok Gie Kim, Jung Jun Lee, Myoung Soo Kim, Gi Hong Choi, Jin Sub Choi, Dai Hoon Han, Soon Il Kim, Dong Jin Joo. Seoul, Korea; Bundang, Korea.

**A84** Outcomes Following Transplantation for Hepatocellular Carcinoma

**A85** Expanded Criteria for HCC in Liver Transplantation

**A86** Favorable Long-Term Prognosis of Hepatitis B Surface Antigen Positive Intrahepatic Cholangiocarcinoma for Both Hepatic Resection and Incidental Liver Transplantation via Inhibiting Cancer-Associated Lymphangiogenesis
Jinyang Gu, Seogsong Jeong, Meng Sha, Jianjun Zhang, Qiang Xia. Shanghai, China.

**A87** HCC and Cardiac Cirrhosis After the Fontan Procedure in a Patient with Congenital Heart Disease and Situs Inversus
Patrick N. Nguyen, N. Thao N. Galvan, Michael L. Kueht, Christine A. O'Mahony, Ronald T. Cotton, Abbas Rana, John A. Goss. Houston, TX.

**Deceased Donor Issues I: Allocation, KDPI and Recipient Selection**

**A88** The American Transplant Congress Effect on Kidney Discard Rates in the United States
Dina E. Abdelwahab, Guo Wei, Isaac E. Hall. Scottsdale, AZ; Salt Lake City, UT.

**A89** Variations in Risk-Appetite Between UK Kidney Transplant Centres and Impact on Patient and Graft Outcomes
Patrick B. Trotter, Matthew Robb, Dominic M. Summers, J. A. Bradley, James Neuberger, Chris Callaghan. Cambridge, United Kingdom; Bristol, United Kingdom; London, United Kingdom; Birmingham, United Kingdom.

**A90** Program-Specific Offer Acceptance Behavior for Kidney Programs Across the Spectrum of KDPI
Andrew Wey, Nicholas Salkowski, Bertram Kasiske, Ajay Israni, Jon Snyder. Minneapolis, MN.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>A92</td>
<td>An OPO Offer Acceptance Report for Hard-to-Place Kidneys</td>
<td>Andrew Wey, Nicholas Salkowski, Bertram Kasiske, Ajay Israni, Jon Snyder.</td>
<td>Minneapolis, MN.</td>
</tr>
<tr>
<td>A93</td>
<td>OPO-Wide Waitlist Size and Deceased Donor Kidney Transplant Rate</td>
<td>Sheng Zhou, Allan Massie, Sommer Gentry, Dorry Segev.</td>
<td>Baltimore, MD;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Annapolis, MD.</td>
</tr>
<tr>
<td>A94</td>
<td>OPO Performance Metrics: Relationship with Kidney Transplant Program Performance Metrics and Kidney Utilization</td>
<td>Andrew Wey, Nicholas Salkowski, Bertram Kasiske, Ajay Israni, Jon Snyder.</td>
<td>Minneapolis, MN.</td>
</tr>
<tr>
<td>A95</td>
<td>A Multistate Modeling Analysis of Time-Varying CPRA States and Its Impact on Kidney Transplant: A Focus on KAS Implementation</td>
<td>Sanjay Kulkarni, Isaac Hall, Richard Formica, Darren Stewart, Eric Greene, Yanhong Deng.</td>
<td>New Haven, CT;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Salt Lake City, UT; Richmond, VA.</td>
</tr>
<tr>
<td>A97</td>
<td>Donor/Recipient Matching Using the Creatinine Clearance Match Ratio (CCMR) Is Superior to the Kidney Donor Profile Index (KDPI) Predicting Early but Not Late Outcomes for Deceased Donor Kidney Transplantation</td>
<td>Jeffrey Halldorson, Naser Karimi. San Diego, CA; Dublin, Ireland.</td>
<td>San Diego, CA;</td>
</tr>
<tr>
<td>A98</td>
<td>KDPI Obscures Trends in Absolute Donor Risk</td>
<td>Nicholas Salkowski, Sally Gustafson, Andrew Wey, Jon Snyder.</td>
<td>Minneapolis, MN.</td>
</tr>
<tr>
<td>A99</td>
<td>Lack of Utility of KDPI in Dual Kidneys from Donors at the Extremes of Age</td>
<td>Debra Felts, Muhammad Khan, Baha Alradawna, Alan Farney, Jeffrey Rogers, Giuseppe Orlando, Amber Reeves-Daniel, Amudha Palanisamy, William Doares, Scott Kaczmorski, Robert J. Stratta.</td>
<td>Winston-Salem, NC.</td>
</tr>
<tr>
<td>A100</td>
<td>The Impact of the Kidney Allocation System on Outcomes for Kidneys with KDPI &gt; 85%</td>
<td>Andrew Perry, Junichiro Sageshima, Chandrasekar Santhanakrishnan, John McVicar, Christoph Troppmann, Angelo De Mattos, Jakub Woloszyn, Richard Perez.</td>
<td>Sacramento, CA.</td>
</tr>
<tr>
<td>A101</td>
<td>Outcome of Kidney Transplantation Using Deceased Octogenarian Donors</td>
<td>Paola Donato, Lucrezia Furian, Cristina Silvestre, Flavia Neri, Caterina Di Bello, Marianna Di Bello, Paolo Rigotti.</td>
<td>Padua, Italy.</td>
</tr>
<tr>
<td>A102</td>
<td>Accepting a High-KDPI Kidney versus Waiting for Another Offer Can Improve Chances of a Functioning Graft</td>
<td>Andrew Wey, N. Salkowski, W. Kremers, A. Israni, B. Kasiske, Jon Snyder.</td>
<td>Minneapolis, MN; Rochester, MN.</td>
</tr>
<tr>
<td>A103</td>
<td>Outcomes of Kidney Transplantation Using Deceased Diabetic Donors</td>
<td>Faiza N. Khan, Wadi N. Suki, Duc T. Nguyen, Edward A. Graviss.</td>
<td>Houston, TX.</td>
</tr>
<tr>
<td>A105</td>
<td>Successful Utilization of Deceased Donor Kidney Allografts with KDPI&gt;85: A Single Center Experience</td>
<td>Avinash Agarwal, Winston Ally, Kenneth Brayman.</td>
<td>Charlottesville, VA.</td>
</tr>
</tbody>
</table>
A106 The Use of Kidneys from Deceased Donors Over 80 Years in Kidney Transplantation

A107 Charlson Comorbidity Index (CCI) as Prognostic Indicator of Outcomes in Older Patients Undergoing Renal Transplantation
Argiris Asderakis, Ummul Contractor, Usman Khalid, Paola Donato, Laszlo Szabo. Cardiff, United Kingdom.

Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.

A109 Outcomes of Deceased Donor Kidney Transplantation in Elderly Recipients Aged 70 Years and Older
Anna M. Adamusiak, Tracey Salter, Peter Andrews, Christopher Callaghan. London, United Kingdom.

A110 Impact of a Novel Prehabilitation Program in Kidney Transplant Candidates
Mara McAdams DeMarco, Hao Ying, Anthony Nastasi, Dorry Segev. Baltimore, MD.

A111 Short- and Long-Term Graft Survival After Kidney Transplantation in Western Europe
Maarten Coemans, Geert Verbeke, Dany Anglicheau, Oriol Bestard, Magali Giral, Maarten Naesens. Leuven, Belgium.

A112 Intended and Unexpected Impact of the New Kidney Allocation System on a Large Volume Transplant Program

A113 Estimating Donor Organ Quality with Baseline Histology and Kidney Donor Risk Index for Predicting Graft Outcomes in Deceased Donor Kidney Transplantation

A114 Correlation of Donor Clinical and Histopathological Characteristics with Graft Function in Kidney Transplant Recipients

A115 Reliability of Donor Kidney Biopsies from Time of Organ Recovery Compared to Immediate Post-Reperfusion Biopsies

Yosu Luque, Olivier Aubert, Frank Martinez, Lucile Amrouche, Claire Tinel, Louise Galmiche, Laure-Hélène Noel, Jean-Paul Duong, François Audenet, Christophe Legendre, Dany Anglicheau, Marion Rabant. Paris, France.

Diagnostics/Biomarkers Session I

A117 Identification of Kidney Transplant Patients at Risk for Skin Cancer by Differentially Methylated Regions in T Cells
A118 † mRNA Biomarkers in Renal Allograft Protocol Biopsies Detected by the Nanostring Platform Predict Tolerance in Non-Human Primates
Masatoshi Matsunami, Tetsu Oura, Ivy A. Rosales, Rex-Neal Smith, Benjamin Adam, Michael Mengel, A. Benedict Cosimi, Robert B. Colvin, Tatsuo Kawai. Boston, MA; Edmonton, AB, Canada.

A119 † Urinary Renal Progenitors Isolation: A Novel Predictor of Kidney Graft Outcome
Anna Manonelles, O. Bestard, M. Goma, P. Romagnani, J. M. Cruzado. Barcelona, Spain; Firenze, Italy.

A120 † Identification of NKG2D as Senescence Marker in Zero-Hour Kidney Biopsies Is Indicative for Clinical Outcome
Thomas Resch, Julia Günther, Hubert Hackl, Arne Sattler, Susanne Ebner, Paul Ritschl, Matthias Biebl, Robert Öllinger, Stefan Schneeberger, Gerald Brandacher, Hubert Schwaiberger, Bettina Zelger, Diana Stauch, Andreas Pascher, Johann Pratschke, Katja Kotsch. Innsbruck, Austria; Berlin, Germany; Baltimore.

A121 MicroRNAs Differentiate Between Antibody and T-Cell Mediated Renal Allograft Rejection

A122 Clusterin Levels at 3-Months Associate with DGF and 12-Month Fibrosis – Reinforcing the Early Injury to Fibrosis Continuum

A123 Validation of CYP4F11 as a Marker of Accommodation in Biopsies from Recipients of an ABO-Incompatible Renal Transplant
Katherine M. Dominy, Michelle Willicombe, Tariq Al Johani, Jack Galliford, Adam McLean, Terence Cook, Candice Roufosse. London, United Kingdom; Riyadh, Saudi Arabia.

A124 Plasma Extracellular Vesicles MicroRNA Signatures Associate with Graft Function Recovery Post-Acute Renal Allograft Injury
Vineela Bontha, Angela Fernandez-Pineros, Debalina Bagchi, Daniel Maluf, Erika Rhone, Valeria Mas. Charlottesville.

A125 Human Transitional B Cell Cytokine Profile Predicts Renal Allograft Rejection and Clinical Course

A126 Genome-Wide Genotyping in > 1500 Liver Allograft Recipient and Donor Pairs Reveals Several Associations with Acute Cellular Rejection
Brendan J. Keating, Bao-Li Chang, Jessica van Setten, Brian Cole, Linda W. Jennings, Goram B. Klintmalm, Abraham Shaked. Philadelphia, PA; UtrechT, Netherlands; Dallas, TX.

A127 Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis
Sung Shin, Yu-Mee Wee, Monica Young Choi, Yong Mee Cho, Heounjeong Go, Young Hoon Kim, Duck Jong Han. Seoul, Korea.

A128 T Cell Responses to Viral Peptide Stimulation Predict Influenza Vaccine-Induced Seroconversion in Pediatric Solid Organ Transplant Recipients
Erick Mayer, Michelle Altrich, Christine Cordes, Stephanie Fausett, Jonathan Tepp, Randy Albrecht, Ana Fernandez-Sesma, Betsy Herold, Irene Ramos, Rebecca Madan. Bronx, NY; Lee’s Summit, MO; New York, NY.

A129 Identification of Novel Diagnostic Biomarkers in Liver Transplantation Tolerance
Gong-Qing Shen, Miwa Morita, Charles Miller, Koji Hashimoto, Lina Lu, Shiguang Qian, John Fung. Cleveland; Chicago.
A130 Validation of a Novel Computational Approach for Predicting HLA
Immunogenicity Based on Quantification of Structural and Surface Electrostatic Potential Differences Between Donor and Recipient HLA
V. Kosmoliaptsis, C. Kling, M. Robb, D. Collett, J. A. Bradley, C. J. Taylor, D. Kabelitz, D. H. Mallon. Cambridge, United Kingdom; Kiel, Germany; Bristol, United Kingdom.

A131 Quantitative Gene Expression Analysis of CRM-Panel Genes Using FFPE Kidney Tissues for Transplant Injuries
Tara Sigdel, Mark Nguyen, Dejan Dobi, Szu-Chuan Hsieh, Juliane Liberto, Flavio Vincenti, Minnie Sarwal, Zoltan Laszik. San Francisco.

A132 The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction
Stephanie Chong, Raymond Fernando, Mark Harber, Ciara N. Magee. London, United Kingdom.

A133 Testing the Efficacy of Contrast Enhanced Ultrasound in Detecting Transplant Rejection Using a Murine Model of Heart Transplantation

A134 Assessment of Donor-Reactive T-Cell Immunity by the Novel Urine Cell-Derived Alloantigen Assay Allows Prediction of Acute Rejection in Renal Transplant Patients
Constantin J. Thieme, Benjamin Weist, Annemarie Müskes, Petra Reinke, Timm Westhoff, Nina Babel. Berlin, Germany; Bochum, Germany.

A135 Intravoxel Incoherent Motion MRI Is an Effective Way to Monitor Acute Allograft Rejection in Rat Models
Song Zeng, Xiaopeng Hu. Beijing, China.

Immunosuppression

A136 Kidney-Specific Immunosuppression without Adverse Systemic Effects
Dominik Kentrup, Katharina Schuette-Nuetgen, Helga Pawelski, Hermann Pavenstädt, Sven Hermann, Michael Schaefer, Gregor Larbig, Armin Kuebelbeck, Stefan Reuter. Muenster, Germany; Darmstadt, Germany.

A137 Medicinal Herb Cordyceps Sinensis Promotes Long-Term Allograft Survival by Tipping the Balance Between CD4+FoxP3+ Tregs and CD8+ Tcm Cells
Zhenhua Dai, Hehua Dai. Guangzhou, China; Pittsburgh, PA.

A138 Immunosuppressive Treatment Alters Gut Microbiota and Modified Gut Microbiota Affects Immune Status
Zijian Zhang, Yue Xu, Qiang Zhang, Xiaopeng Hu. Beijing, China.

A139 Clinically Relevant Immunosuppression Promotes MCMV Reactivation and Dissemination Following Transplantation of Latently Infected Kidneys
Zheng Zhang, Shixian Yan, Lihai Zhao, Sunil Kurian, Mary Hummel, Daniel Salomon, Michael Abecassis. Chicago; La Jolla.

A140 Blockade of Tim-3 and PD-1 Reverses Dysfunctions of Tumor Infiltrating Lymphocytes in HBV Related Hepatocellular Carcinoma
Anbin Hu, Furong Liu, Xiaofeng Zhu, Xiaoshun He. Guangzhou, China.

A141 Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients
Hong Xu, Andrea Merchak, Manting Xu, Claudia Mort, Tia Dowling, Larry Kahn, Melissa Binion, Anita Chhabra, Yujie Wen, Yiming Huang, Suzanne Ildstad. Louisville, KY.

A142 Novel Therapies for Diabetic Kidney Disease
Mark Nguyen, Keiichi Kodama, Minnie Sarwal. San Francisco, CA.
A143  Differential Effects of Immunosuppressive Drugs on DNA Methylation in T Cells  

A144  Dexamethasone Prolongs Cardiac Allograft Survival in a Murine Model Through Myeloid-Derived Suppressor Cells  

A145  D-Dimer Level, in Association with Humoral Responses, Negatively Correlates with Survival of Porcine Islet Grafts in Nonhuman Primates with Immunosuppression  
Hee Jung Kang, Haneulnari Lee, Eun Mi Park, Jong Min Kim, Byoung Hoon Min, Chung-Gyu Park. Anyang, Korea; Seoul, Korea.

A146  Mycophenolic Acid Needs Ca\(^{2+}\) to Exert Its Anti-inflammatory Action via Shedding of Toll-Like Receptor4 and Tumor Necrosis Factor Receptor 1  
Ji Hyun Kim, Won Seok Yang, Chung Hee Baek, Nam Jeong Han, Su-Kil Park. Seoul, Republic of Korea.

A147  Immunosuppressive Ability of NFkB Inhibitor: Withaferin A  
Mazhar A. Kanak, Yoshitaro Shindo, Marlon Levy, Bashoo Naziruddin. Richmond, VA; Dallas, TX.

A148  Short-Term Combination Treatment of FK506 and Anti-CD40 Ligand Remarkably Prolong Allograft Survival Time in Mouse Skin Transplantation  
Xue Zhang, Zuoquan Ding, Min Yang, Yan Miao, Yang Yang, Ping Zhou. Wuhan, Hubei, China.

A149  Tacrolimus Suppresses Calcineurin Activity and Ca\(^{2+}\) Influx Age-Specifically  
Felix Krenzien, Markus Quante, Hirofumi Uehara, Reza Abdi, Hector Rodriguez Cetina Biefer, Moritz Schmelzle, Johann Pratschke, Abdallah Elkhal, Stefan G. Tullius. Boston; Berlin, Germany.

A150  Tacrolimus and Mycophenolic Acid Have a Limited Inhibitory Effect on Monocyte Signaling Pathway Phosphorylation, Function and Differentiation  

A151  New Approach for Targeted Immunotherapy in Vascularized Composite Allografts  
Firuz G. Feturi, Hua Wang, Yevgeny Brudno, Vasil Erbas, Zhaoxiang Zhang, Huseyin Sahin, David J. Mooney, Vijay S. Gorantla, Raman Venkataramanan. Pittsburgh, PA; Boston, MA.

Ischemic Injury and Organ Preservation Session I

A152  CD4 T Cell Depletion Mitigates Ischemic Hepatocellular Damage and Promotes Immune Regulation in Mouse Liver Allografts  

A153  Hypoxia Induces Tissue Factor Upregulation in Isolated Human Islets  

A154  Twelve Hour Ex Vivo Normothermic Perfusion for the Assessment of High-Risk Discarded Deceased Donor Kidneys  

A155  Enhanced Liver Regeneration After Partial Hepatectomy in Mice Treated with a Prolyl Hydroxylase Inhibitor  
Jessica Latona, Ashesh Shah, Jing Cheng, Phillip Messersmith, Ellen Heber-Katz. Philadelphia, PA; Berkeley, CA; Wynnewood, PA.
A156  Neutering Worsens Liver Ischemia/Reperfusion Injury in Both Male and Female Mice

A157  Contribution of γΔ T-Cell Subsets and IL-17A Release to Ischemia Reperfusion Injury (IRI) and Kidney Allograft Rejection in Mice

A158  The Use of a Furosemide Stress Test (FST) for Assessment of Discarded Deceased Donor Kidneys in an Ex-Vivo Normothermic Perfusion Model

A159  Direct Intrahepatic Delivery of Pegylated-Catalase Is Protective in a Rat Ischemia-Reperfusion Injury Model
Eliza W. Beal, Sylvester M. Black, Jung Lye Kim, Victoria M. Velazquez, Kenneth Washburn, Don Hayes Jr., Bryan A. Whitson. Columbus, OH.

A160  A Promising MyD88 Inhibitor TJ-M2010-2 Protects Heart from Myocardial Ischemia Reperfusion Injury
Yan Miao, Lin Xie, Xue Zhang, Zuo-chuan Ding, Min Yang, Yang Yang, Ping Zhou. Wuhan, Hubei, China.

A161  Role of Protease Activated Receptor 1 and Sphingosine-1-Phosphate Receptor 1 in Mice Hepatic Ischemia-Reperfusion Injury for Targeting Cell Signal Pathways of Activated Protein C
Takahiro Ito, Naohisa Kuriyama, Hiroyuki Kato, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Yoshinori Azumi, Masashi Kishiwada, Shugo Mizuno, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji. Tsu, Japan.

A162  Nox4 and Oxidative Stress Mediate TGF-b1 Induced Human Kidney Proximal Cell Apoptosis in Ischemic Reperfusion Injury

A163  GSK3β and VDAC in Endoplasmic Reticulum Stress and Apoptosis Modulation During Orthotopic Liver Transplantation
Mohamed Amine Zaouali, Arnau Panisello Roselló, Emma Folch Puy, Alexandre Lopez, Anabela Pinto Rolo, Carlos Castro, Carlos Marques Palmeira, Agustín Garcia-Gil, René Adam, Joan Roselló-Catafau. Barcelona, Spain; Paris, France; Coimbra, Portugal; Zaragoza, Spain; Monastir, Tunisia.

A164  How to Promote Regeneration After Ischemic Reperfusion Injury: Dual Role of CD 137 Agonistic Antibody

A165  Nafamostat Mesilate Ameliorates Ischemia-Reperfusion Renal Injury via Anti-Apoptotic Mechanism
Dae Eun Choi, Jying Young Jeong, Hong Jin Bae, Young Rok Ham, Kang Wook Lee, Ki Ryang Na. Daejeon, Korea.

A166  Down-Regulation of Nuclear HMGB1 by Small Interfering RNA Protects Against Liver Ischemia-Reperfusion Injury

A167  Steatotic Human Livers Show Inferior Function Compared to Non-Steatotic Livers During Ex-Situ Viability Assessment by Oxygenated Machine Perfusion
Negin Karimian, Viola Huang, Fermin Fontan, Mohamed M. Aburawi, Sharon Geerts, Safak Mert, Irene Beijert, Robert J. Porte, Martin Yarmush, Korkut Uygun, James F. Markman, Heidi Yeh. Boston; Groningen, Netherlands.
A168 Succinate Accumulation During Warm and Cold Ischemia in Mouse, Pig and Man: Mechanistic and Therapeutic Implications for Transplant Ischemia-Reperfusion Injury
Jack Martin, Ana Costa, Anja Gruszczyk, Mazin Hamed, Nikitas Georgakopoulos, Gavin Pettigrew, Andrew James, Christian Frezza, Mike Murphy, Kouros Saeb-Parsy. Cambridge, United Kingdom.

A169 Protective Effect of Crepidiastrum denticulatum Extract Pretreatment Against Hepatic Ischemia-Reperfusion Injury in Mice
Hyuk Jai Jang, Hwa Mee Lee, Cheon Soo Park, Dae Un Eom, Ji Hwan Lee, Mee Young Oh, Ji Hye Yoo, Chu Won Rho. Gangneung, Gangwon, Korea.

A170 Protective Effects of Bryostatin-1 on Neutrophil Migration in an In Vitro Model of Ischemia Reperfusion Injury: Impact for Therapy
Felix Becker, Linus Kebschull, Trevor Castor, Daniel Palmes, Steve Alexander, Felicity Gavins. Münster, Germany; Shreveport, LA; Woburn, MA.

A171 Clearance of Transaminases During Normothermic Ex Vivo Liver Perfusion

A172 Liver Regeneration in Porcine Hepatectomy Model
Harvey S. Chen, DongJin Joo, Mohammed Shaheen, Jian Yang, Scott L. Nyberg. Rochester, MN.

A173 Ischemia Reperfusion Injury (IRI) Causes Local Release of Free Heme Which Aggravates Inflammation and Contributes to Delayed Graft Function

Kidney Complications I

A174 Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation
Patrick Klem, Lana Al-Omar, James Cooper, Scott Davis, Jane Gralla, David Choe, Alexander Wiseman. Aurora, CO; Aurora.

A175 Results of Stem Cell and Renal Transplantation in Patients with End Stage Renal Disease After Plasma Cell Dyscrasias

A176 On the Pathogenesis of Post-Transplant Diarrhea in Kidney Transplant Recipients
John Lee, Matthew Mcgruder, Lisa Zhang, Muthukumar Thangamani, Darshana Dadhania, Lars Westblade, Michael Satlin, Amy Robertson, Lilan Ling, Ying Taur, Eric Pamer, Manikkam Suthanthiran. NY, NY.

A177 NKG2C+ NK Cell Adaptive Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients
Dolores Redondo, Marta Crespo, Jose Yélamos, Aura Muntasell, María José Pérez-Sáez, Carlos Vilchez, Julio Pascual, Miguel López-Botet. Barcelona, Spain.

A178 The Feared Five Fungal Infections in Kidney Transplant Recipients: 20-Year Experience at a Midwestern Center
Sandesh Parajuli, Alexandra Wick, Sameer Pandeya, Brad C. Astor, Jeannina Smith, Arjang Djamali, Didier Mandelbrot. Madison, WI.

A179 Postoperative Serum Lactate Dehydrogenase Is a “Troponin-Like” Marker of Renal Transplant Distress
Robert Steiner, Jeffrey Halldorson. San Diego, CA.
A180  Risk Factors for Hospital Readmission with Urinary Tract Infections (UTIs) Following Kidney Transplantation (KT)
E. Minja, S. Jackson, Arthur Matas. Mpls, MN.

A181  Course and Outcome of Renal Transplant Recipients Admitted to the Intensive Care Unit (ICU): Long Term Follow-Up

A182  Chronic Hepatitis E-Genotype 3 Infection in Transplant Recipients: A Single Kidney and Pancreas Transplant Centre Experience

A183  Impact of Cytokine Gene Polymorphism on Clinical Outcome of Renal Transplantation

A184  Transcriptomic Analysis Revealed a Fibrotic Role of Epithelial Cells Originated from the Recipient in Kidney Transplant
Weijia Zhang, Zhengzi Yi, Eli Stahl, Madhav Menon, Karen L. Keung, Ke Hao, Philip J. O’Connell, Barbara Murphy. New York, NY; Sydney, Australia.

A185  Bacteremia in Kidney Transplant Recipients: Incidence, Risk Factors and Outcomes
Sandeep Brar, Yue Wang, Alyssa Cannitelli, Yanhong Li, Olusegun Famure, Shahid Husain, Joseph Kim. Toronto, ON, Canada.

A186  Antibiotic Prophylaxis Against Urinary Tract Infections After Renal Transplant
Patrick Klem, Jane Gralla, Davis Chang, Alexander Wiseman, Scott Davis, James Cooper. Aurora, CO.

A187  Solid Organ Cancer After Kidney Transplantation: Risk Factors and Long Term Impact
Anna Buxeda, Dolores Redondo, Maria José Pérez-Sáez, Alvaro Bartolomé, Marisa Mir, Ana Pascual, Anna Sans, Marta Crespo, Julio Pascual. Barcelona, Spain.

A188  Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

A189  Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant

A190  Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs
Joseph B. Lockridge, Eric D. Langewisch, Debargha Basuli, Ali Olyaei, Carley Shaut, Douglas J. Norman. Portland, OR; Omaha, NE.

A191  De Novo DSA Positivity Is Associated with a Higher Rate of Post-Transplant Bacterial and Viral Infections
Amanda Brooks, Lorita Rebellato, Kimberly Briley, Paul Bolin, Scott Kendrick, Angela Maldonado, Carl Haisch, Matthew Everly. Los Angeles; Greenville, NC.

A192  Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients
Joseph B. Lockridge, Eric D. Langewisch, Debargha Basuli, Ali Olyaei, Carley Shaut, Douglas J. Norman. Portland, OR; Omaha, NE.
The Impact of Elevated Doppler Resistive Indices in Renal Transplant Recipients with Delayed Graft Function

Occult Hepatitis C Virus in Recipients of Kidney Transplantation: Prevalence and Clinical Implications

Diagnostic Bronchoscopy in Kidney Transplant Recipients with Acute Respiratory Failure: Risk or Value?
Dmytro Khadzhynov, Jonas Deissler, Fabian Halleck, Lukas Lehner, Klemens Budde, Oliver Staack. Berlin, Germany.

Kinetic Estimation of Glomerular Filtration Rate and Urine Creatinine as Predictors of Delayed Graft Function in Kidney Transplantation from Non-Heart Beating Donors

Post Transplant Outcomes in Hepatitis C Positive Patients

Silvana Costa, Taina Sandes-Freitas, Elizabeth Daheer, Ronaldo Esmeraldo. Fortaleza, Brazil.

Sexual Acquisition of HIV-Infection After Kidney Transplantation: Late Presentation and Potentially Fatal Complications
Marina P. Cristelli, Marcello S. J. Ribeiro, Daniel W. C. L. Santos, Milene A. Mazolin, Helio Tedesco-Silva, Jose O. Medina-Pestana. Sao Paulo, Brazil.

Highly Sensitized Patients and the Association of Early Cardiovascular Disease: Analysis of Korean Organ Transplantation Registry(KOTRY) Data
Jong Cheol Jeong, Jaeseok Yang, Myoung Soo Kim, Sung Shin, Byung Ha Chung, Seungyeup Han, Curie Ahn. Suwon, Korea; Seoul, Korea; Daegu, Korea.

Prediction of Delayed Graft Function in Chinese Kidney Allograft Recipients

HIV and Cognitive Impairment in Kidney Transplant Candidates
Ashton Shaffer, Hao Ying, Christine Haugen, Mara McAdams DeMarco, Dorry Segev. Baltimore.

Ciprofloxacin for Urinary Tract Infection Prophylaxis in Post-Renal Transplant Patients with Ureteral Stent Placement
Payal P. Kakadiya, Marlon F. Levy, Gaurav Gupta, Anne L. King, Spencer B. LeCorchick. Richmond, VA.

Impact of Filgrastim Use on Maintenance Doses of Immunosuppressants and Clinical Outcomes in Renal Transplant Patients
Clare Kane, Kyle Lang, TrisAnn Rendulic, Megan E. Goetz, Rickey A. Evans, Kimberly Trobaugh, Jonathan C. Berger. Lexington, KY.

Poor Predictability of Quantiferon-TB Assay in Recipients and Donors for Tuberculosis Development After Kidney Transplantation in an Intermediate-TB-Burden Country
A206  Cost Effectiveness of Post-Prophylaxis Screening Strategies for Cytomegalovirus Viremia in CMV D+R-Kidney Transplant Recipients
Chethan M. Puttarajappa, Sundaram Hariharan, Kenneth J. Smith. Pittsburgh, PA.

Kidney: Polyoma

A213  Which Is More Nephrotoxic to Kidney Transplants: BK Nephropathy or Rejection?

A214  Alemtuzumab Induction Is Associated with a Lower Incidence of BK Virus Nephropathy Compared with IL2RA Induction

A215  Full Dose Cyclosporine Permanently Reverses Uncontrolled BK Viremia That Is Refractory to Tacrolimus Minimization
Andres R. Caero, Mita Shah, Dianne McKay, Janice Kerr, Jennifer Joliat, Eileen Chatfield, Robert Steiner. San Diego, CA.

A216  Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study

A217  Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant

A218  BK Polyoma Virus and Malignancy: Cause or Co-Incidence?
Rohini Prashar, Alpa Shah, Diana Stewart, Sean Williamson, Anita Patel. Detroit, MI.

A219  BK Viruria Levels within 3 Months Post Renal Transplantation Can Predict the Development of BK Viraemia
Nicole M. Lioufas, Rosemary Masterson, Peter Hughes. Parkville, Victoria, Australia.
<table>
<thead>
<tr>
<th>A220</th>
<th>Increased Gene Expression of TGF-β in Peripheral Blood Mononuclear Cells from Renal Transplant Patients with Polyomavirus BK Viremi</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wen Yao Yin. Dalin, Taiwan; Hualien, Taiwan.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A221</th>
<th>Poor Outcome of Polyomavirus-Associated Nephropathy with Glomerular Parietal Epithelial Cells Infected by Polyomavirus</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A222</th>
<th>Defining a BKV Cutt-Off and Profile for Early Detection of BKV Associated Nephropathy</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A223</th>
<th>Does Histologic Grade in BK Polyoma Nephropathy Associate with Viral Load, Allograft Dysfunction or Allograft Loss? A Single Center Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Melissa L. Swee, Sarat Kuppachi, Mony Fraer, Prerna Rastogi, Patrick Ten Eyck, M. Lee Sanders. Iowa City, IA.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A224</th>
<th>Treatment and Outcomes of Simultaneous Acute Rejection and Polyomavirus Allograft Nephropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tracy M. Sparkes, Sara Hammad, Cinthia B. Drachenberg, Abdolefza Harian. Baltimore, MD.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A225</th>
<th>Role of Chemokines in Resolution of BK Virus-Associated Nephropathy and Chronicity of Pathology Changes in Kidney Transplant Recipients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A226</th>
<th>Improvement in Inflammatory Response Follows Clearance of BKVN</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A227</th>
<th>Clinical Utility of Viral miRNA in Urinary Exosomes to Diagnose BK Virus Nephropathy After Kidney Transplantation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A228</th>
<th>The Search for a Polyomavirus BK Nephropathy (BKPyVN)-Specific Transcriptomic Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ling Pan, Gang Zeng, Zili Lyu, Yuchen Huang, Parmjeet Randhawa. Nanning, Guangxi, China; Pittsburgh, PA.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A229</th>
<th>Impact of Pre-Donation eGFR on Long-Term Post-Donation eGFR in Younger Living Kidney Donors</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A230</th>
<th>Cross-sectional and Serial Evolution of Quality of Life in Elderly Kidney Donors</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>A231</th>
<th>Predictive Value of Pre-Transplant Cross-Match Techniques on Living Donor Kidney Transplant Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maria Meneghini, Edoro Melilli, Ignacio Revuelta, Raja Rajalingam, Elizabet Rigol, Sindhu Chandran, Fritz Diekmann, Flavio Vincenti, Josep Maria Cruzado, Jaume Martorell, Oriol Bestard. Barcelona, Spain; San Francisco.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A232</th>
<th>Impact of Post Kidney Donation Gout on eGFR and Kidney Stones</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B. Sengupta, J. Menk, Arthur Matas. Mpls, MN.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A233</th>
<th>Fibromuscular Dysplasia in Living Kidney Donors: Characteristics and Recipient Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maria L. Gonzalez Suarez, Hatem Amer, Insara Jaffer, Terri Vrtiska, Andrew Rule, Mikel Prieto, Stephen Textor. Rochester, MN.</td>
</tr>
</tbody>
</table>
A234 Impact of Race on Selection of the Living Donor Candidate

A235 Outcome of Adult Living Donor Renal Transplants in Different Era: Analysis of UNOS Database
Vaughn E. Whittaker, Rainer Gruessner, Mark Laftavi, Zeki Acun, Angelika Gruessner. Syracuse, NY.

A236 Reasons for Ineligibility for Kidney Donation by Race: Gap for Blacks Represented by Modifiable Factors, However Are Big Hurdles to Overcome

A237 Minor Degree of Persistent Microscopic Hematuria in Potential Living Kidney Donors Is Associated with Pathology

A238 Functional Gain in eGFR Among Living Kidney Donors and Its Association with Remaining Kidney Volume

A239 Predicting Residual Renal Compensation in Living Kidney Donors Post-Donation
Alejandro Diez, Garrett Diltz, Jon Von Visger, Uday Nori, Todd Pesavento, Ronald Pelletier. Columbus, OH.

A240 Retroactive Application of a New Risk Index for Living Donor Kidney Transplantation (LKDPI) to Renal Transplants in Veracruz, Mexico

A241 Donor Kidney Volume Predicts One and Three Month eGFR in Live Donor Kidney Transplant Recipients
David Al-Adra, Maria Lambadaris, Andrew Barbas, Yanhong Li, Nicolas Goldaracena, Olusegun Famure, S. Joeceph Kim, Anand Ghanekar. Toronto, ON, Canada.

A242 Donor and Recipient Outcomes with Trans-Umbilical Laparoendoscopic Single-Site Donor Nephrectomy

A243 Benefits of Expanding Options for Patients Registered in the Kidney Paired Donation Program
Stanislaw Stepkowski, Beata Mierzejewska, Dulat Belbolsynov, Caitlin Baum, Jonathan Kopke, Robert Brunner, Susan Rees, Michael Rees. Toledo, OH.

A244 IgG Antibody Subclasses in Potential Renal Transplant Recipients with DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors
Alan G. Contreras, Aurora Casillas, Luis Llorente, Guadalupe Lima, Adriana Arvizu, Adrian De Santiago, Mario Vilatoba, Josefina Alberu, Jose M. Arreola-Guerra. Mexico City, Mexico.

A245 Renal Function Outcomes of Hypertensive Living Kidney Donors (HLD) and Recipients of HLD Kidneys: Results of a Case-Control Study
Todd E. Pesavento, A. Diez, R. Pelletier, U. Nori, J. VonVisger. Columbus, OH.

A246 Influence of an Enhanced Recovery Protocol in Laparoscopic Living Donor Nephrectomy
Aparna Rege, Deepak Vikraman, Kadiyala Ravindra, Todd Brennan, Harold Leraas, Debra Sudan. Durham, NC.
A247  C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors
Alan G. Contreras, Aurora Casillas, Natalia Castelan, Norma Gonzalez-Tableros, Mayra Lopez, Adriana Arvizu, Adrian De Santiago, Josefina Alberu, Jose M. Arreola-Guerra. Mexico City, Mexico.

A248  The Impact of Marginal Factors on the Postoperative Kidney Function of Complex Living Donors for Kidney Transplantation

A249  Living Kidney Transplant: The Influence of Intraoperative Hemodynamics on Delayed Graft Function
Ryan Schutt, Jamie Case, Bethany Barrick, Alice Toll, Christopher Marsh. La Jolla, CA; Richmond, VA.

A250  Longer Pre-Transplant Dialysis Exposure Is More Frequent in Living Donor Kidney Transplantation (LDTX) Involving Lower Income Donor and Recipients and Is Associated with an Increased Risk of LDTX Failure
Jagbir Gill, Caren Rose, Julie Lesage, Yayuk Joffres, John Gill. Vancouver, Canada.

A251  Non-Directed Donors (NDD) Less Than 25 Years

A252  Integration of Kidney-Exchange, (Un)Specific Living Donor Transplantation, ABO Incompatible and Desensitisation Programs in a Computerized Allocation Program: A Simulation

A253  Risk Factors and 2 Year Outcomes of Low Estimated Glomerular Filtration Rate in the Immediate Post-Operative Period for Living Kidney Donors

A254  Obesity Predicts New-Onset Diabetes After Live Kidney Donation

Organ Preservation and Reperfusion

A255  α-Lipoc Acid Improve the Short Term Outcomes in Human Liver Transplantation
Paola C. Casciato, Nella Ambrosi, Caro Fiorella, Monica Vasquez, Adrian C. Gadano, Martín de Santibañes, Eduardo de Santibañes, Marcos Zandomeni, Magali Chahi, Juan Cruz Laquinandi, Patricia Santolimia Castaño, Juan Iovanna, Eduardo Chuluyan, Claudio Incardona. Buenos Aires, Argentina; Marseille, France.

A256  The Use of an Haemoglobin Based Oxygen Carrier in a Human Liver Model of Normothermic Machine Perfusion

A257  Impact of Early Allograft Dysfunction on Graft and Patient Outcomes After Liver Transplantation
Zhiyong Guo, Danping Zheng, Xiaoshun He, Guodong Chen. Guangzhou, China.
A258 The Delivery of Stem Cell Therapy to Extended Criteria Donor Human Livers Using Normothermic Machine Perfusion  
Richard W. Laing, Samantha R. Stubblefield, Bhogal H. Ricky, Stephenson T. F. Barnaby, Mohammed Alfaifi, Anthony E. Ting, Darius F. Mirza, Philip N. Newsome, Hynek Mergental, Simon C. Afford. Birmingham, United Kingdom; Cleveland, OH.

A259 Development of an Automatic Regulated Normothermic Kidney Preservation Device for Long-Term Organ Perfusion  

A260 Effect of Epigenetic Modifications in Ischemia-Reperfusion-Injury Post Liver Transplantation: An Integrative Approach  
Debalina Bagchi, Sai Vineela Bontha, Mikhail Dozmorov, Angela Fernandez, Valeria Mas, Daniel Maluf. Charlottesville; Richmond.

A261 Human Organs Allocated for Research – Maximising Use of a Precious Resource Using a New Ex Vivo Model of Reperfusion Injury  

A262 Modulating Ischemia-Reperfusion Injuries with Pharmacological Agents: A Bench-to-Bedside Approach  
Meryl Thomas, Gwenaëlle Tardif, Antoine Melanger, Patrick Berna. Marseille, France.

A263 Effect of Bone Marrow Derived Mesenchymal Stem Cells on Renal Ischemia-Reperfusion Injury in Rabbit  
JongSu Jang, HyongGun Ri, In Chul Hong. Pyongyang, Democratic Peoples Republic of Korea.

A264 A Study on Gene Expression of the Protective Effect of Nitric Oxide Releasing Nanofiber in Rat Renal Ischemia-Reperfusion Injury  

A265 Using Scheduled Commercial Flights for Transport of Liver for Transplant  
Vivek Gupta, Abhijit Chandra, Manmeet Singh, Vishal Gupta, Saket Kumar, Pradeep Joshi, Partha Sarthi Sen Sharma, Habibul Hasan, P. K. Srivastava, Mohammed Parvez Khan, Zia Arshad, Ravi Kant. Lucknow, Uttar Pradesh, India.

A266 Long-Term Outcomes of Renal Function in Pediatric Living Related Intestinal Transplantation  
Sandra Garcia Aroz, Kimberly Czech, Leslie Briar, Giuliano Testa, Enrico Benedetti, Eunice John. Chicago, IL; Texas.

A267 Achieving Ideal Outcome After Intestinal Transplantation: How Close Are We?  

A268 Impact of Donor Asystole in Intestine Transplant  
Joel Schroering, Chandrashekhar Kubal, Richard Mangus. Indianapolis, IN.

Small Bowel: All Topics

A269 Vendor to Center in 0-60: A Cost-Effective Blueprint for Creating an In-House On-Call System for Abdominal Organ Offers  
Jordan Davenport, Debra Cassidy, Amy Hauser, Allison Milling, Krista Driggers, Heather Crego, Julie Anderson, Lena Curry, Prabhakar Baliga, Nicole Pilch, Derek Dubay. Charleston, SC.
A270 † Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients

A271 Associations Between Provision of Transplant Pharmacy Services and Center-Level Patient and Graft Outcomes in U.S. Adult Kidney Transplant Programs
J. Park, J. Trofe-Clark, T. Kaiser, N. Pilch, D. Taber. Ann Arbor; Philadelphia; Cincinnati; Charleston.

A272 Assessment of a Medication Education Program Among New Transplant Recipients at a Large Academic Health Center
Ginny Tyler G. Meadows, Juliana Kyle, Adam Dodson, Kristofer Gutierrez, Paul A. MacLennan, Fatima Iqbal, Lisa Weldon, DeAnn Jones, Alexandra James. Birmingham, AL.

Viral Conundrums

A273 † Sequential Monitoring of Natural Killer Cell Reconstitution Against CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation

A274 † Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients

A275 CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms

A276 Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience
Adam Baghban, Kristen D. Belfield, Marwan M. Azar, Elizabeth Cohen, Maricar F. Malinis. New Haven, CT.

A277 Kinetics of Cytomegalovirus (CMV) DNAemia in CMV Mismatch Solid Organ Transplant Patients with Primary CMV Infection
Cristina Hernandez, Diana Chiang, Sonia Fuentes, Carlos Cervera. Edmonton, Canada.

A278 ASP0113 Elicits an Immune Response in CMV-Seronegative Dialysis Patients: Comparison to Healthy Subjects
Peter Bonate, Charles Van Sant, Kathy Cho, Erin Zook, Larry Smith, Sou Boutsaboualoy, Xuegong Wang, Ruishan Wu, Anne Koester, Diane Rammelsberg, Ronald Goldwater, Thomas Marbury. Northbrook; Skokie; San Diego; Baltimore; Orlando.

A279 Evaluation of Immunological States of Patients with Cytomegalovirus Infection After Kidney Transplantation
Asuka Tanaka, Kentaro Ide, Yuka Tanaka, Kohei Ishiyama, Masahiro Ohira, Hiroyuki Tahara, Seiichi Shimizu, Das Lalit Kumar, Hideki Ohdan. Hiroshima, Japan.

A280 Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients
Sandra El Hajj, Miae Kim, Jamil Azzi, Steven Gabardi. Boston, MA.

A281 Cytomegalovirus Viral Load: Characterization of Results from Clinical Specimens
Steven B. Kleiboeker. Lees Summit, MO.

A282 Ganciclovir Resistant Cytomegalovirus Infection in Abdominal Transplant Recipients
Jillian Fose, Margaret Jorgenson, Kate Rolling, Erin McCready, Didier Mandelbrot, Jeannina Smith. Madison.
A283 High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients
Jillian Fose, Erin McCreary, Margaret Jorgenson, Michael Lucey, Jeannina Smith. Madison, WI.

A284 Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients
Kerri Roach, Helen Triemer, Michael Hurtik, Aneesh Mehta. Atlanta, GA.

A285 Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen
Corey C. Burrelli, Michelle H. Bradley, Stephanie M. Pouch, Elmahdi A. Elkhhammas, Holli A. Winters. Columbus, OH.

A286 Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?
Harry E. Prince, Marek J. Nowicki. Los Angeles, CA.

A287 Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV)
Paul Baum, Joseph Yao, Ann Butcher, Pari Hemyari, Alexandra Valsamakis, Stephen Young. Pleasanton, CA; Rochester, MN; Baltimore, MD; Albuquerque, NM.

A288 Cytomegalovirus Renal Infection: Rare Manifestation of a Common Post-Transplant Viral Infection -- A Case Series
Maria Aurora Posadas Salas, Jennifer Thompson, Tue Ngo, Sally Self. Charleston, SC.

A289 Immediate vs Delayed Initiation of CMV Prophylaxis...Safe and Cost Beneficial?
Laura Cotiguala, Adrian Carlson, Crystal Truax, Bhanupriya Sirandas, Isaac Hall, Lonnie Smith. Salt Lake City, UT.

A290 Risk Factors for Polymavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis

A291 Lack of Specificity of LC-MS/MS Based Urinary Biomarkers for Polymavirus BK Nephropathy (BKPyVN)
Gang Zeng, Ling Pan, Zili Lyu, Yuchen Huang, Farmjeet Randhawa. Pittsburgh, PA; Nanning, Guangxi, China.

A292 Does EBV Viremia at Time of Transplant Have a Negative Impact on Transplant Outcomes?

A293 † Pharmacokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients
Eva Schrezenmeier, Petra Galander, Friederike Hoffmann, Carsten Jaeger, Jan Lisec, Jens Schrezenmeier, Oliver Staeck, Lukas Lehner, Dmytro Khadzhynov, Fabian Halleck, Michael Duerr, Klemens Budde. Berlin, Deutschland, Germany; Berlin, Deutschland (DEU), Germany.

A294 The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients
Jennifer Husson, Ruth Adekunle, Bharath Ravichandran, Poonam Mathur, Srijana Jonchhe, Kristen Stafford. Baltimore, MD.

A295 Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients

A296 Kidney Transplantation in HCV+ Recipients in a New Era of Diagnostics and Therapeutics
A297 Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney

A298 Risk Factor for Hepatitis E Virus Infection Among Solid-Organ-Transplant Patients
Nassim Kamar, Sebastien Lhomme, Florence Abbravanel, Laure Esposito, Anne Laure Hebral, Olivier Marion, Arnaud Del Bello, Jacques Izopet. Toulouse, France.

A299 Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission
Marek Nowicki, Harry Prince, Claudia Chinchilla, Claudia De Los Santos, Jeffrey Trageser, Lisa Stocks. Los Angeles, CA; San Diego, CA.

A300 The Evolution of Hepatitis B Surface Antibody (Anti-HBs) Titer of the Kidney Transplant Recipients: A 5-Year Experience Guideline for the Optimal Maintaining Immunization

A301 Low Incidence of Acute Rejection within the Six Months After Transplantation in HIV Recipients Treated with Raltegravir, the ANRS 153 Treve Trial
Marie Matignon, A. Lahiani, Jean Daniel Lelievre, Dominique Desvaux, Khadidja Abassi, A. Diallo, Marie Noelle Peraldi, Anne Marie Taburet, Juliette Saillard, Constance Delaugerre, Lambert Assoumou, Philippe Grimbert, TREVE ANRS Study Group. Créteil, France; Paris, France; Le Kremlin-Bicêtre, France.

A302 Antiretroviral Therapy Modification of HIV+ Patients Listed for Kidney Transplantation

A303 Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients

A304 High-Risk Human Papillomavirus Associated with Genital Squamous Cell Carcinoma in Nonwhite Organ Transplant Recipients
Kumar S. Nadhan, Mary E. Larijani, Lauren M. Ogrich, Christine M. Shaver, Alden Doyle, Christina L. Chung. Philadelphia, PA; Charlottesville, VA.

A305 Effect of Influenza Vaccination in the Severity of Illness in Hospitalized Transplant Recipients with Laboratory-Confirmed Influenza
Amy L. Bagenski, Fernanda P. Silveira. Pittsburgh, PA.

A306 Measles Screening and Vaccination in Solid Organ Transplant Recipients: Adherence to Infectious Disease Community of Practice (IDCOP) Recommendations
Faria A. Irani, Robert Butler, Christopher Kovacs. Cleveland.

A307 Emerging Variables Which May Enhance Care of HIV Positive Renal Transplant Recipients
Deanne Leonard, Mary B. Prendergast. Jacksonville, FL.

A308 Willingness to Donate Organs Among Persons Living with HIV
Samantha Halpern, Komal Kumar, Anh Nguyen, Sarah Rasmussen, Saad Anjum, Allan Massie, Aaron Tobian, Dorry Segev, Jeremy Sugarman, Christine Durand. Baltimore, MD.
A309  Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis
Kristen D. Belfield, Elizabeth Cohen, Maricar Malinis, Adam Baghban. New Haven, CT.

A310  Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy
Eun Jeong Ko, Ju Hyun Yu, Beom Soon Choi, Cheol Whee Park, Yong Soo Kim, Chul Woo Yang, Byung Ha Chung. Seoul, Korea.
Poster Session B
Poster Viewing: 9:30 am – 12:00 pm and 2:30 pm – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm
Hall D1

B# indicates the board location where the poster will be displayed.
† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

Acute and Chronic Rejection

B1 † Donor Genetic Background Determines the Severity of Delayed Graft Function Following Kidney Transplantation in Mice

B2 Inhibition of Bruton Tyrosine Kinase Blocks Sensitization in Response to Allogeneic Skin Transplantation and Prolong Skin Graft Survival

B3 Evaluating T Cell Repopulation Post Alemtuzumab Induction with a Belatacept-Based Regimen
Victoria A. Bendersky, He Xu, Allan D. Kirk. Durham, NC.

B4 Lymphoid Isolation as an Adjuvant Maneuver for Belatacept-Based Immunotherapy
Michael S. Mulvihill, Kannan P. Samy, Robert P. Davis, Francis V. Leopardi, Bradley H. Collins, Allan D. Kirk. Durham, NC; Indianapolis, IN.

B5 Type-1 Interferon Impairs the Immunoregulatory Activity of IL-10: A Mechanism in the Abrogation of Transplant Tolerance

B6 Evaluation of Function and TCR Signaling Profile of CD57+ T Cells in Allo-Specific Immunity
He Xu, Todd V. Brennan, QiJing Li, Allan D. Kirk. Durham, NC.

B7 Deleting LAG-3 Accelerates Cardiac Allograft Rejection and Augments T Cell Memory in Mice
J. Mark Erfe, Chao Yang, Dorothy Ndishabandi, Ivy Rosales, Rebecca White, Paul S. Russell, Robert B. Colvin, Joren C. Madsen, Alessandro Alessandrini. Boston, MA; New Haven, CT.

B8 Differences in Kinetics of IFN-γ Production Between Endogenous and Allotransplant-Induced Memory T Cells
Bruno Gonzalez-Nolasco, Jose Mariano, William Orent, Gilles Benichou. Boston, MA.

B9 Patients with Renal Failure Have a pERK-Dependent Defective TCR-Mediated Activation of CD4+ T Cells
Ling Huang, Nicolle H. R. Litjens, Nynke M. Kannegieter, Mariska Klepper, Carla C. Baan, Michael Betjes. Rotterdam, Netherlands.

B10 A Novel Microsurgical Penis Transplant Model to Study Distinct Immunologic Features of Urogenital Tissues

B11 Is Thymic Function Determining Rejection Onset in Heart Transplantation?

B12 Immune Activation and Rejection Risk in HIV-Positive Kidney Transplantation
Steven A. Wisel, Brian Shaw, Linda Lee, Karim Lee, Chung Yee Leung, Peter G. Stock, Qizhi Tang. San Francisco, CA.
B13 Apoptotic Exosome-Like Vesicles Released During Tissue Injury Trigger IL23/IL-17 Autoimmune Axis and Accelerate Rejection
Mélanie Dieudé, Julie Turgeon, Annie Karakeussian-Rimbault, Luc Pomerleau, Alexa Robitaille, Nathalie Grandvaux, Éric Boilard, Marie-Josée Hébert. Montreal, Canada; Québec, Canada; Montreal, QC, Canada; Edmonton, Canada.

B14 Mitochondrial Permeability Can Regulate Endothelial Cell Necroptosis and Promote Cardiac Allograft Rejection

B15 Inhibition of Heat Shock Protein 90 Suppresses the Expression of MHC Class I Molecules, but Not MHC Class II Molecules, on Endothelial Cells in Allografts
Toshiaki Tanaka, Takeshi Maehana, Naoya Masumori. Sapporo, Japan.

B16 BKV Clearance Time Correlates with T-Cell Receptor Repertoire Shape and Exhaustion State of BKV-Specific T-Cells in Renal Transplant Patients with Severe BKV Infection
Ulrik Stervbo, Mikalai Nienen, Benjamin J. D. Weist, Patrizia Wehler, Timm H. Westhoff, Hans-Dieter Volk, Petra Reinke, Nina Babel. Bochum, Germany; Berlin, Germany.

B17 Allograft Cytokine Activation and Elevated Tissue Indoleamine 2,3-Dioxygenase Gene and Protein Expression in Rejecting Pig Transplants
Todd Merchen, Youli Wang, Randi Lassiter, Dan Kleven, Ryan Jajosky, Matt Winn, Chak-Sum Ho, N. Stanley Nahman. Augusta, GA; Ann Arbor, MI.

B18 Recipient iNOS Deficiency Reduces Spontaneous Kidney Allograft Acceptance by Accelerating Allograft Loss
Imad Aljabban, Bo Jiang, Chao Yang, Dorothy K. Ndishabandi, Rebecca White, Paul S. Russell, Joren C. Madsen, Robert B. Colvin, Alessandro Alessandrini. Boston, MA.

B19 Immune Monitoring-Guided Treatment of a Pediatric Patient with Sequential GvHD, Acute Rejection and CMV Infection Following Lung Transplantation
Christine S. Falk, Schwerk Nicolaus, Müller Carsten, Tudorache Igor, Sommer Wiebke, Daemen Kerstin, Keil Jana, Hansen Gesine, Havercich Axel, Warnecke Gregor. Hannover, Germany; Hannover, Deutschland, Germany.

B20 Generation of Autologous CMV and EBV-Specific T-Cell Lines from Seronegative Patients for Cell Therapy of Opportunistic Infections Following Kidney Transplantation
Caroline Lamarche, Thomas Pincez, Julie Orio, Cedric Carli, Atul Humar, Jean-Sébastien Delisle. Montreal, QC, Canada; Toronto, ON, Canada.

B21 CMV-Specific CD4+ T Cells in CMV-IgG-Seronegative Individuals Protect from CMV Viremia Following Transplantation with a CMV-Seropositive Donor Kidney
Nicole H. R. Litjens, Ling Huang, Burc Dedeoglu, Ruud W. J. Meijers, Michiel G. H. Betjes. Rotterdam, Netherlands.

B22 RAS Inhibition Attenuates Urine Angiotensin II-Regulated Proteins Associated with Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients
Zahraa Mohammed-Ali, Shelby Reid, Paul Yip, Heloise Cardinal, Marie-Josée Hébert, Yanhong Li, S. Joseph Kim, Ana Konvalinka. Toronto, ON, Canada; Montréal, QC, Canada.

B23† TGF-b1 Induces Transplant Kidney Interstitial Fibrosis Through Endothelial-to-Mesenchymal Transition via TGF-β/Smad and Akt/mTOR/p70S6K Pathways
Zijie Wang, Zhijian Han, Jun Tao, Ruoyun Tan, Min Gu. Nanjing, Jiangsu, China.

B24 Mechanisms of Fibrosis in the Allograft Kidney: RNA-seq Based Analysis Using Formalin Fixed Biopsies
Gang Zeng, Ling Pan, Zili Lyu, Yuchen Huang, Parmjeet Randhawa. Nanning, Guangxi, China; Pittsburgh, PA.
B25 Kidney Recipients with 10 Year Belatacept-Treatment Display an Altered T Cell Subset Composition and Low Plasma Cytokine Levels Compared to Matched Patients with CNI-Based Immunosuppression
Christine S. Falk, Christine Neudörfl, Anne Scherf, Kerstin Daemen, Jana Keil, Jürgen Klempnauer, Frank Lehner, Gerrit Grannas. Hannover, Germany.

B26 IL-3 Contributes to Development of Basophil-Triggered Cardiac Allograft Fibrosis Development

B27 Donor Macrophage Depletion from CMV-Latently Infected Hearts Abrogates CMV-Accelerated Chronic Rejection
Jennifer M. Burg, Takeshi F. Andoh, Nicole N. Haese, Iris K. A. Jones, Susan L. Orloff, Daniel N. Streblow. Portland, OR; Hillsboro, OR.

B28 Vimentin Regulates β-Catenin Translocation During Epithelial to Mesenchymal Transition in Renal Fibrosis
Reynold Lopez-Soler, Zhen Wang, Alex Divanyan. Albany, NY.

B29 Trafficking of Donor Leukocytes and Recipient Cells Cross-Dressed with Donor MHC Molecules After Transplantation of Cardiac Allografts in Monkeys
Jose Marino, Kortney Robinson, Joshua Paster, Isabel Hanekamp, Joren C. Madsen, Gilles Benichou. Boston, MA.

B30 HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation
Yi-Ping Jin, Eline F. Reed. Los Angeles, CA.

B31 mTORC1 and 2 Regulate Dendritic Cell (DC) Metabolism and Allostimulatory Function of Donor DCs in Skin Transplantation

B32 Fate and Function of CD8+ T Cells Primed by Fetal Antigen During Pregnancy
Paige Porrett, Rong Xu, E. John Wherry. Philadelphia, PA.

B33 Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting

B34 Suppression of T Cell Proliferation by CpG-Activated B Cells Depends on Granzyme-B and Cell-Cell Contact, but Not on IL-10
Lisa Kojima, Shoko Kimura, Kang Mi Lee, Christian Schuetz, Laura Washburn, Kevin Deng, Haley Tector, Beth Amundsen, Dorothy Ndishabandi, Alexandra Markmann, Madeleine Markmann-Porch, Tetsu Oura, Alessandro Alessandrini, James Kim, Heidi Yeh, James Markmann. Boston, MA.

B35 The Treg/Th17 Axis: A Dynamic Balance Regulated by Stromal Laminins

B36 Non-Human Primate Auto-Immune Responses to Col V, Ko-1 Tubulin and Vimentin Are P2X7R Dependent

B37 Persistent Donor Antigen Leads to Dysfunctional CD4+ Memory T Cell Development
Michelle L. Miller, Ying Wang, Luqiu Chen, Yuk Man Lei, Melvin D. Daniels, Elyse Watkins, Carolina Mora Solano, Christine McIntosh, Noel Isaad, Anita S. Chong, Maria-Luisa Alegre. Chicago, IL.
B38 Modification of Human Endothelial Cells by CRISPR/Cas9-Mediated Ablation of Class I and II Major Histocompatibility Complex Antigen Expression
Jonathan Merola, Christopher Anderson, Hao Xu, Thomas Manes, Jordan S. Pober. New Haven, CT.

B39 Two Promoter Polymorphisms in the Genes Encoding for Complement Regulating Proteins CD46 and CD59 in Kidney Donors Are Associated with Biopsy Proven Acute Rejection

B40 Placental Leukocytes Are Maternally Derived: Implications for Pregnancy-Induced Alloimmunization
Paige Porrett, Emma Lewis, Rong Xu, Amy Brown, E. John Wherry, Michal Elovitz. Philadelphia, PA.

B41 SIRPα+ DCs and the Time-Dependent CD4+CD8+ Double Positive T Cell Infiltration in Accepted Renal Allografts

B42 CD4 T Cells and Co-Engagement with Foreign Protein Are Required in Antibody Response to Non-Self Blood Group A-Antigen
Ibrahim Adam, Bruce Motyka, Lori West. Edmonton, AB, Canada.

B43 Assessment of Cardiosphere-Derived Cell Exosomes as Possible Modulator of Alloimmunity in a Mouse Model of HLA-A2 Allosensitization
Irene Kim, Gordon Wu, Ning-Ning Chai, Geoffrey De Couto, Eduardo Marban, Andrew Klein, Stanley Jordan. Los Angeles, CA.

B44 Vascularized Bone Marrow Mechanisms of Immunomodulation

B45 HLA-DPA1 and HLA-DPB1 Frequencies in the US Populations
Zeying Du, Jaishree Patel, Christine Braun, Brian Norton. Maywood, IL.

B46 Phenotypic and Functional Assessment of T Cell Alloimmunity After Liver Transplantation
T. Taner, M. Hansen, W. Park, M. Stegall. Rochester, MN.

B47 T-Cell Aging Parameters in the Lymph Node and Peripheral Blood Are Strongly Associated but Terminally Differentiated T Cells Are Mainly Located within the Circulation

B48 Quantity and Functions of CD4+CD8- Double Negative (DN) αβ T Cells in Kidney Is MHC Dependent

B49 A New and Potent Distal Enhancer of the IL2 Gene

B50 Ex-Vivo Mitomycin-C Exposure Reduced Immunogenicity and Prolonged Survival of Islets by Suppressing the Secretion of Multiple Chemotaxis Factors

B51 Donor Leukocytes Are Eliminated by the Host's Immune System Shortly After Skin Transplantation in Mice
Jose Marino, Bruno Gonzalez-Nolasco, Gilles Benichou. Boston, MA.
B52 Increased T Cell Exhaustion in Dialysis Patients
Mark A. Bastiaansen, Audrey Uffing, Leonardo V. Riella. Boston, MA.

B53 The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti-Rejection Therapy
Alain G. Assounga, Saleha Omarjee. Durban, South Africa.

B54 Memory T Cells Are Decreased in Transplant Recipients Deficient in miR-182
Vandana Kaul, Liang Wei, Xiumei Qu, Olivia M. Martinez, Sheri M. Krams. Stanford.

Antibody Mediated Rejection in Kidney Transplant Recipients II

B55 A Lower Mean Exposure to Tacrolimus, Not Intra-Patient Variability Is Associated with Chronic Active Antibody Mediated Rejection
Kasia A. Sablik, Marian C. Claesen-van Groningen, Teun Van Gelder, Michael Betjes. Rotterdam, Netherlands.

B56 Development of Transplant Glomerulopathy in Recipients with Antibody Mediated Rejection: Activation of Inflammatory Pathway Through Renal Poly (ADP-Ribose) Polymerase (PARP)

B57 Impact of Complement Component 3 Single Nuclear Polymorphisms on Renal Transplant Recipients with Antibody-Mediated Rejection
Zijie Wang, Zhijian Han, Jun Tao, Ruoyun Tan, Min Gu. Nanjing, Jiangsu, China.

B58 Molecular Classifier of Antibody-Mediated Rejection Is a Better Predictor of Histologic Rejection Than a Corresponding Transcript Set and Is Further Improved When Combined with Classifiers of Rejection Syndromes
Konrad S. Famulski, Philip F. Halloran. Edmonton, AB, Canada.

B59 Clinical and Molecular Significance of Microvascular Inflammation Negative Transplant Glomerulopathy
M. Lubetzky, N. Hayde, P. O Brolin, Y. Bao, E. Akalin. Bronx; Galaway, Ireland.

B60 Molecular Significance of Peritubular Capillaritis in Early Transplant Kidney Biopsies of Donor-Specific Antibody Negative Patients
Maria Ajaimy, Pilib O Broin, Yi Bao, Enver Akalin. Bronx.

B61 Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant
Silvia Pineda, Tara Sigdel, Annette Jackson, Marina Sirota, Minnie Sarwal. San Francisco, CA; University of California, San Francisco (UCSF), CA; Baltimore, MD.

B62 IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-HLA Antibody (Ab), Resulting in Inhibition of Anti-HLA Ab-Mediated NK Cell Activation and Ab-Dependent Cell-Mediated Cytotoxicity (ADCC) in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts)
Shili Ge, Maggie Chu, Jua Choi, Sabrina Louie, Alexis G. Kang, Ashley Vo, Alice Peng, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

B63 Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study

B64 Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients
B65  Microvascular Inflammation at 4 Months Posttransplant Is Associated with Transplant Glomerulopathy at One and Two Years Independent of Rejection and Donor Specific Antibodies

B66  Pre-Transplant Non-Cytotoxic Donor Specific HLA Antibodies Do Not Increase the Risk of Graft Dysfunction in Kidney Transplant Recipients with Thymoglobulin and IVIG Induction

B67  Prospective Monitoring of De Novo Donor-Specific Antibodies: Incidence, Clinical Outcomes and Dynamic Changes Over 5 Years After Kidney Transplantation
Maria Ajaimy, Adriana Colovai, Nicole Hayde, Jay Graham, Michelle Lubetzky, Layla Kamal, Graciela De Bocardo, Enver Akalin. Bronx.

B68  C1q+ and IgG3+ De Novo Donor Specific Antibody Are Associated with Allograft Failure in a Multicenter Cohort
Carrie A. Schinstock, Matthew Everly, Milagros Samaniego, Manish Gandhi, Ruchang Parikh, Vijay Sharma, Mark Stegall, Darshana Dadhania. Rochester, MN; Los Angelos, CA; Ann Arbor, Mi; New York, NY.

B69  Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center
Shirley Chang, Indika Mallawarachchi, Cindy Yip, Thomas Shanahan, Ajaz Gundroo, Alok Dwivedi, Sunil Patel, Mareena Zachariah. Buffalo, NY; El Paso, TX.

B70  Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants
Raja Rajalingam, Dessislava Kopchaliiska, Owen Buenaventura, Manpreet Singh, Stephen Tomlanovich. San Francisco, CA.

B71  Retrospective Analysis of Kidney Transplant Recipients with Antibody-Mediated Rejection

B72  C-C Chemokine Receptor 5 Polymorphisms and Risk of Antibody-Mediated Rejection in Renal Transplantation

B73  Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts
Daniel Brennan, Jonathan Bromberg, Emilio Poggio, David Hiller, John Sninsky, Robert Woodward, James Yee, Roy Bloom. St. Louis, MO; Baltimore, MD; Cleveland, OH; Brisbane, CA; Philadelphia, PA.

B74  IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation
Reiad Y. Najjar, Edmund Huang, Ashely A. Vo, Jua Cho, Sabrina Louis, Aleix Hang, Alice Peng, Stanley Jordan. Los Angeles, CA.
B75 Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR) Bong-Ha Shin, Matthew Everly, Jua Choi, Shili Ge, Anna Petrosyan, Ashley Vo, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA; Los Angeles.

B76 Preformed HLA Donor-Specific Antibodies Disappearance After Kidney Transplantation: Significance and Comparison with Persistent DSA Dolores Redondo, Marí José Pérez-Sáez, Marisa Mir, Javier Gimeno, Carme García, Juan José Hernández, José Yélamos, Julio Pascual, Marta Crespo. Barcelona, Spain.


B78 Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population Jonathan Bromberg, Daniel Brennan, Emilio Poggio, David Hiller, Robert Woodward, James Yee, John Sninsky, Roy Bloom. Baltimore, MD; St. Louis, MO; Cleveland, OH; Brisbane, CA; Philadelphia, PA.


B81 Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation Nassim Kamar, Valérie Hajj, Inès Ferrandiz, Eliane Younes, Laure Esposito, Anne Laure Hébral, Arnaud Del Bello. Toulouse, France.

B82 Biopsies (Bx) of Renal Allografts with Antibody- + Cell-Mediated Rejection (ABMR/CMR) Exhibit Gene Expression Signatures from Both Types of Rejection Hao Zhang, Cynthia C. Nast, Janice Doldron, Mandy Cheung, James Mirocha, Joseph Kahwaji, Ashley A. Vo, Stanley C. Jordan, Mieko Toyoda. Los Angeles.


B84 Transcript Changes Associated with Graft Rejection Are Not Specific for Rejection Because They Are Shared with Tissue Responses to Wounding Philip Halloran, K. S. Famulski, INTERCOMEX Study Group. Edmonton, Canada.

B85 Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes Adarsh Babu, David Briggs, Dan Mitchell, Nithya Krishnan, Rob Higgins, Sunil Daga. Coventry, United Kingdom; Birmingham, United Kingdom; Leeds, United Kingdom.

Bacteria, Fungi, Parasites

B86 Epidemiology and Clinical Outcomes of Mycobacterium tuberculosis in Liver Transplant Recipients in an Intermediate Tuberculosis-Endemic Area Sang Il Kim, Yoon Jeong Kim, Jong Young Choi, Seung Kyu Yoon, Ji Il Kim, In Sung Moon, Yung Kyung Yoo, Dong Goo Kim. Seoul, Republic of Korea.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B87</td>
<td>TB Chemoprophylaxis Post Transplantation in West London</td>
<td>Yasser W. Al-Mula Abed, Rawya Charif, Onn Min Kon, David Taube. Stevenage, United Kingdom; London, United Kingdom.</td>
<td></td>
</tr>
<tr>
<td>B88</td>
<td>Incidence and Clinical Outcomes of Active Tuberculosis in Transplant Recipients from a Low Prevalence Region</td>
<td>Yoichiro Natori, Atul Humar, Shahid Husain, Deepali Kumar. Toronto, Canada.</td>
<td></td>
</tr>
<tr>
<td>B90</td>
<td>\textit{Clostridium difficile} Infection in Intestinal Transplant Recipients</td>
<td>Vanessa Goldenberg, Ana Berbel, Jose F. Camargo, Jacques Simkins. Miami, FL.</td>
<td></td>
</tr>
<tr>
<td>B91</td>
<td>Vancomycin Prophylaxis for Prevention of \textit{Clostridium difficile} Recurrence in Renal Transplant Patients</td>
<td>Lindsey Spliner, Jillian Fose, Glen Leverson, Jeannina Smith, Christopher Saddler, Margaret Jorgenson. Madison, WI.</td>
<td></td>
</tr>
<tr>
<td>B92</td>
<td>Outcomes of Recurrent \textit{Clostridium difficile} Infection in Solid Organ Transplant Recipients</td>
<td>Mika Shiotsuka, Yo Natori, Deepali Kumar, Atul Humar, Coleman Rotstein, Shahid Husain. Toronto, ON, Canada.</td>
<td></td>
</tr>
<tr>
<td>B97</td>
<td>Evaluation of Vancomycin Resistant Enterococcus (VRE) Colonization and Infection Rate in Adult Liver Transplant Patients</td>
<td>Erika Aldag, Garrett Fouth, Rachel Pedersen, Lynne Fehrenbacher, Ajay Sahajpal, Vikraman Gunabushanam, David J. Kramer. Milwaukee; Mequon.</td>
<td></td>
</tr>
<tr>
<td>B98</td>
<td>Describing the Effects of the Antibiotic Regimen Immediate Post Multi-Visceral Transplant in the Pediatric Population on the Time to First Serious Bacterial Infection</td>
<td>Brandon M. Chatani, Jennifer Garcia, Chiara Biaggi, Thiago Beduschi, Akin Tekin, Rodrigo Vianna, Ivan Gonzalez. Miami, FL.</td>
<td></td>
</tr>
</tbody>
</table>
B100  Antibiotic Conservatorship in Orthotopic Liver Transplantation
Jonson M. Yee, Damon Clark, Rachel Hogen, Kiran Dhanireddy, Subarna Biswas, J. Perren Cobb, Kazuhide Matsushima, Daniel Grabo, Aaron Strumwasser. Los Angeles, CA.

B101  Increased Pro-Inflammatory and Decreased Interferon-Related Gene Expression in Older as Compared with Younger Kidney Transplant Recipients

B102  Does an Indeterminate Result on Pre-Transplantation Tuberculosis Interferon Gamma Release Assay Predict Risk for Post-Transplantation Infection or Rejection?
Andrea J. Zimmer, Raymond R. Razonable. Omaha, NE; Rochester, MN.

B103  Trends in Infection Among Kidney Transplant Recipients, 1999-2013
Sunjae Bae, Christine Durand, Lauren Kucirka, Sandra DiBrito, Robin Avery, Jacqueline Garonzik Wang, Dorry Segev. Baltimore, MD.

B104  Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis for Nocardia in Solid Organ Transplant Recipients (SOTRs): Systematic Review and Meta-Analysis
Aynaa Alsharidi, Arnoldo Adrian Gonzalez, Coleman Rotstein, Atul Humar, Deepali Kumar, Shahid Husain. Hamilton, ON, Canada; Gainesville, FL; Toronto, ON, Canada.

B105  Outcomes Following Reduction of Immunosuppression in Solid Organ Transplant Recipients with Cryptococcosis
Paul Bryant, Peter Pappas, Carrie Huisingh, Roslyn Mannon, Jayme Locke, Keith Wille, Devin Eckhoff, Jose Tallaj, John Baddley. Birmingham, AL.

B106  MicroRNAs and Long Non-Coding RNAs as Potential Novel Biomarkers in Transplanted Patients with Candida Infection
Anli Yang, Chan Zhou, Dian Li, Weiqiang Ju, Zhiyong Guo, Linwei Wu, Anbin Hu, Yi Ma, Dongping Wang, Xiaofeng Zhu, Xiaoshun He. Guangzhou, Guangdong, China; Boston, MA.

B107  Incidence of Fungal and Viral Infections Following Rituximab Use in Kidney Transplant Recipients
Lana Wong, Michael Ison, Chad Richardson, Katie Cunningham, Carly D'Agostino, Christine Tseng, Aneesh Shetty. Chicago, IL.

B108  Identifying Risks and Screening Deceased Organ Donors in the UK for Trypanosoma cruzi
Ines Ushiro-Lumb, Mhairi Webster, Alan Kitchen. London, United Kingdom.

B109  Strongyloides Infection in Solid Organ Transplant Recipients: A Single Center Experience and Review of the Literature
Hanine E. El Haddad, Vagish S. Hemmige, Amelia K. Sofjan, Todd M. Lasco, Alejandro Restrepo. Houston, TX.

B110  Risk Factors for Cryptococcal Disease in Transplant as Compared with Non-Transplant Patients: A Single Center Study
O. Beiard, O. Garner, R. Humphries, J. Schaenman. Los Angeles, CA.

B111  Prevalence of Cutaneous Disease in Solid Organ Transplant Recipients: A 5-Year Study from a Medical -Surgical Transplant Dermatology Center

B112  The Incidence and Outcomes of Fever of Unknown Origin After Pancreas Transplantation
Robin Klasek, Samantha A. Kuten, Samir J. Patel, Duc T. Nguyen, Edward A. Graviss, A. Osama Gaber, Richard J. Knight. Houston, TX; Cary, NC.
Ischemic Injury and Organ Preservation Session II

B113 † AAV8 Delivery of TIMP-1 Prevents Hepatocyte Apoptosis After Liver Ischemia/Reperfusion Injury
Sergio Duarte, Patrick Matian, Mary Miller, Ronald W. Busuttil, Ana J. Coito. Los Angeles.

B114 † Estrogen Receptor Alpha Mediates Female Protection from Renal Ischemia-Reperfusion Injury Through Mechanisms Extrinsic to the Kidney

B115 Myeloid HO-1 Regulates M2 Macrophage Activation in Liver Ischemia-Reperfusion Injury (IRI)
Kojiro Nakamura, Min Zhang, Shoichi Kagayama, Bibo Ke, Rebecca A. Sosa, Elaine F. Reed, Ali Zarrinpar, Ronald W. Busuttil, Jesus A. Araujo, Jerzy W. Kupiec-Weglinski. Los Angeles, CA.

B116 Impact of STEEN vs Gelofusine as Perfusate During Normothermic Ex Vivo liver Perfusion on Outcome of Pig Liver Transplantation
Ivan Linares, Dagmar Kollmann, Juan Echeverri, Moritz Kaths, Roizar Rosales, Claudia Brugueras, Matyas Hamar, Peter Urbanellis, Sujani Ganesh, Nazia Selzner, Markus Selzner. Toronto, ON, Canada.

B117 Effects of the Gut-Liver Axis on Ischemia-Mediated Hepatocellular Carcinoma Recurrence in the Mouse Liver
Lorenzo A. Orci, Stéphanie Lacotte, Vaihere Delaune, Graziano Oldani, Florence Slits, Carlo Rossetti, Laura Rubbia-Brandt, Philippe Morel, Christian Toso. Geneva, Switzerland; Varese, Italy.

B118 DNA Hypermethylation Caused by Ischemia in Kidney Transplants Predicts Future Chronic Injury to the Allograft

B119 Combined Perfusion of Liver and Kidney Enhances the Protective Effects of Normothermic Perfusion on Donation After Cardiac Death Porcine Livers
Zhiyong Guo, Fei Ji, Xiaoshun He, Guodong Chen. Guangzhou, China.

B120 Extended Ex Vivo Kidney Perfusion Using Hemopure as an Oxygen Carrier: A Method to Preserve, Assess and Repair Discarded Organs
Fermin M. Fontan, Mohamed M. Aburawi, Negin Karimian, Korkut M. Uygun, Francis L. Delmonico, Heidi Yeh, James F. Markmann. Boston, MA.

B121 Normothermic Ex-Vivo Kidney Perfusion Improves Function of Extreme Marginal Renal Grafts Subjected to Prolonged Ischemia

B122 TIMP-3 Plays a Key Regulatory Role in the Cleavage of E-Cadherin and Has an Essential Protective Function in Hepatic IRI
Takehiro Fujii, Sergio Duarte, Ronald W. Busuttil, Ana J. Coito. Los Angeles, CA.

B123 Histone Deacetylase Inhibition Mitigates Liver Ischemia/Reperfusion Injury in Mice
B124 Dual Role for Caspase-3 in the Regulation of Tubular and Microvascular Damage Post-Renal Ischemia-Reperfusion Injury
Bing Yang, Shanshan Lan, Natalie Patey, Julie Turgeon, Mélanie Dieudé, Marie-Josée Hébert. Montreal, QC, Canada; Edmonton, AB, Canada.

B125 Isoflurane Precondition Alleviated Murine Liver Ischemia and Reperfusion Injury by Restoring AMPK/mTOR-Mediated Autophagy
Zhuqing Rao, Haoming Zhou, Xiongxiong Pan, Meizi Gao, Zhongyun Wang, Jie Sun, Cunming Liu, Zhengnian Ding. Nanjing, Jiangsu, China.

B126 Proteasome Modulation an Effective Strategy to Ameliorate Steatotic Liver Grafts Viability After Preservation

B127 Gene Editing of Keap1/Nrf2 in Human T Cells Using CRISPR-Cas9 to Improve Outcome from Ischemia Reperfusion Injury and Other T Cell Mediated Diseases

B128 Novel Application of Localized Nanodelivery of Anti-IL6 Protects Organ Transplant from Ischemia Reperfusion Injuries

B129 Nuclear Co-Repressor Complex Inhibition Reverses Benefit of HDAC2 Deletion in Renal Ischemia
B136 Longer Anastomotic Time Leads to Delayed Graft Function
Munish Kumar Heer, Paul Raymond Trevillian, Adrian Donald Hibberd.
Newcastle, NSW, Australia.

B137 Outcome and Risk Factors of Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplantation

B138 Angioplasty versus Stent in the Treatment of Transplant Renal Artery Stenosis
Ling-Xin Chen, Ghaneh Fananapazir, Heejung Bang, Mehul Gandhi, Muna Alnimri, Brian Gallay, Angelo De Mattos. Sacramento, CA; Davis, CA.

B139 Short Term Renal Allograft Outcomes Following Treatment of Early Subclinical Borderline Changes on Surveillance Biopsies
Chrstina James, Kenneth Woodside, Jeong Park, Abhijit Naik, Evan Farkash, Randall Sung, Milagros Samaniego, Yihung Huang. Ann Arbor, MI.

B140 Predictive Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy After Kidney Transplantation
Nicolas Maillard, Hitoshi Suzuki, Hesham Mohey, Christophe Mariat, Jan Novak, Bruce Julian, Francois Berthoux. Saint Etienne, France; Tokyo, Japan; Birmingham, AL.

B141 A2 Incompatible Kidney Transplantation: A Single Center Experience

B142 Outcomes of Renal Disease Related to Monoclonal Gammopathy After Kidney Transplantation: A Single Center Experience

B143 Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study

B144 Contrast-Induced Acute Kidney Injury in Kidney Transplant Recipients: A Meta-Analysis

B145 Model to Predict Prolonged Delayed Graft Function (DGF) Following Kidney Transplantation from Deceased Donor with Acute Kidney Injury (AKI Tx)
R. Heilman, B. Smith, C. Johnson, H. Khamash, K. Reddy, W. Kremers, B. Kaplan. Phoenix, AZ; Rochester, MN.

B146 Graft Loss from Anti-GBM Nephritis: A Rare Event in Alport Syndrome, Even with a Severe COL4A5/A4/A3 Mutation
Valentine Gillion, Karin Dahan, Eric Goffin, Jean-Pierre Cosyns, Michel Jadoul, Martine De Meyer, Michel Mourad, Yves Pirson, Nada Kanaan. Brussels, Belgium; Gosselies, Belgium.

B147 Predictive Value of Renal Transplant Scintigraphy for the Duration of Delayed Graft Function

B148 Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation
B149  *De Novo Donor-Specific Antibody Formation After Kidney Retransplant Is Associated with Specificity Against Class I*

B150  *Acthar in Recurrent Focal Segmental Glomerular Sclerosis After Kidney Transplantation*

B151  *Recurrent Lupus Nephritis in a Multi-Ethnic Kidney Transplant Population*

B152  *Significance of Thrombotic Microangiopathy in Renal Allografts*
B. Handan Ozdemir, Alev Ok Atilgan, Mehmet Haberal. Ankara, Turkey.

B153  *Long-Term Outcomes Among Slow versus Delayed or Immediate Graft Function Kidney Transplant Recipients: A Single-Center Experience*
Iman Bajjoka, Alexander S. Yaldo, Catherine Crombez, Marwan S. Abouljoud. Detroit, MI.

B154  *Long-Term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology*

B155  *Streamlining Discharge Pathways in Kidney Transplant Recipients with Delayed Graft Function*
Emilie Chan, Joseph Kim. Toronto, ON, Canada.

B156  *Acute Rejection in 6 Antigen HLA Matched Kidney Transplant Recipients: Risk Factors and Outcomes*
Amanda Condon, Brad Astor, Kim Holdener, Tom Ellis, Arjang Djamali. Madison, WI.

B157  *Eculizumab Treatment on GC3 Recurrence on Renal Graft*
Guillaume Jeantet, Dominique Bertrand, Arnaud Lionet, Dany Anglicheau, Veronique Fremeaux-Bacchi, Moglie Le Quintrec. Montpellier, France; Lille, France; Rouen, France; Paris, France.

B158  *The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database*
Q. Liu, A. Smith, J. Park, M. Oguntimein, S. Dutcher, G. Bello, M. Helmuth, M. Turenne, R. Balkrishnan, M. Fava, P. Sharma, C. Beil, A. Leichtman, J. Zee. Ann Arbor, MI; Silver Spring, MD; Charlottesville, VA.

B159  *Immunosuppressant Costs for Medicare Part D and Kidney Transplant Recipients Since the Introduction of Generic Formulations in an Incident Kidney Transplant Population*
M. Helmuth, M. Turenne, J. Park, Q. Liu, M. Oguntimein, S. Dutcher, R. Balkrishnan, J. Zee, A. Smith, A. Leichtman. Ann Arbor, MI; Silver Spring, MD; Charlottesville, VA.

B160  *A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease*

B161  *Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry*
Sarah Cormican, Claire Kennedy, Patrick O’Kelly, Brendan Doyle, Anthony Dorman, Peter Conlon. Dublin, Ireland.

B162  *Continuation of ImmunosuppressionAppears to Protect Against Allosensitization in Patients Listed for a Second Kidney Transplant*
Sarat Kuppachi, Marion Sanders, Roberto Kalil, Zoe Stewart, Christie Thomas. Iowa City, IA.
B163 Treatment of Post-Transplant Nephrotic Syndrome with Adrenocorticotropic (ACTH) Gel

B164 Evaluating Patients’ Experiences Towards Their Immunosuppressive Treatment: A Way to Improve Adherence
Claire Villeneuve, Muriel Grau, Marie Essig, Stéphanie Hegarat, Justine Zoughbi, Pierre Marquet, Caroline Monchaud. Limoges, France.

B165 Long-Term Outcomes of Kidney Transplant Recipients with Primary Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Dmytro Khadzhynov, Fabian Halleck, Lukas Lehner, Eva Schrezenmeier, Klemens Budde, Oliver Staeck. Berlin, Germany.

B166 Costimulatory Blockade in Delayed Graft Function
Jon Von Visger, Alejandro Diez, Uday Nori, Todd Pesavento, Ronald Pelletier, Amer Rajab, Ashraf El Hinnawi, Holli Winters. Columbus, OH.

B167 Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays

B168 Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy

B169 Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID)
Sanjiv Anand, Dylan Miller, Gregory Chipman, Donald Morris, Titte Srinivas. Salt Lake City, UT.

B170 † The Value of Protocol Biopsy at Third Month After Kidney Transplant: A Single-Center Cohort Analysis

B170.1 † Classification of Fibromuscular Dysplasia in Kidney Donors Based on Severity and Extent of Lesion

Kidney Immunosuppression: Induction Therapy

B171 † Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients

B172 † Course of Donor Specific Anti-HLA Antibodies After Induction Therapy with Rituximab in Renal Transplantation
Marije C. Baas, Wil A. Allebes, Martijn van den Hoogen, Irma Joosten, Luuk B. Hilbrands. Nijmegen, Netherlands; Nijmegen, Netherlands; Rotterdam, Netherlands.

B173 Does Choice of Induction Agent Affect Outcomes in Kidney Transplants from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time?

B174 Understanding the Role of Induction Agents in Older versus Younger Kidney Transplant Recipients
Qiong Huang, Fawaz A. I. Ammary, Mara McAdams-DeMarco, Dorry Segev. Baltimore, MD.
B175  Long-Term Persistence of Anti-HLA Antibodies in Renal Transplant Recipients: Risk Factors and Impact on Clinical Course

B176  Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin and Rituximab Induction for High Risk DSA Positive Recipients
Elizabeth M. Lessmann, Mozhgon Moaddab, Melissa Manson, Adith Ram, Ronald H. Kerman, Peter Jindra. Houston, TX.

B177  De Novo Malignancy Occurrence After Kidney Transplantation in HLA-Sensitized Patients Treated with B-Cell Targeting Therapy

B178  Optimal Induction Therapy for Kidney Transplantation in Previous Heart Transplant Recipients: Analysis of OPTN/UNOS Registry
Marcelo S. Sampaio, Sabiha M. Hussain, Bhavna Chopra, Kalathil K. Sureshkumar. Pittsburgh, PA.

B179  Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients: A Match Kidney Analysis
Marcelo S. Sampaio, Kalathil K. Sureshkumar. Pittsburgh, PA.

B180  Alemtuzumab Induction Is Safe and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients
Adrienne Seitz, Matthew Robb, Niaz Ahmad, Adam McLean, David Taube, Rachel Johnson, Richard Baker. Leeds, United Kingdom; Bristol, United Kingdom; London, United Kingdom.

B181  A Comparison of Medical Costs Among ABO-Compatible, -Incompatible and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study
Daiji Fujiromi, Masayoshi Okumi, Kohei Ungami, Hideki Ishida, Kazunari Tanabe. Tokyo, Japan.

B182  National Variation in US Kidney Transplant Induction Therapy
Vikas Dharnidharka, A. Naik, T. Alhamad, D. Axelrod, M. Schnitzler, Z. Zhang, S. Bae, D. Brennan, D. Segev, H. Randall, M. Nazzal, R. Ouseph, B. Kasiske, K. Lentine. St. Louis, MO; Ann Arbor, MI; Greenville, NC; Baltimore, MD; Minneapolis, MN.

B183  Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?

B184  Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-Free and CNI Minimization Maintenance Immunosuppressive Regimen
Tainá Sandes-Freitas, Jeronimo Junqueira, Jr, Celi Girão, Maria Luiza Oliveira, Ronaldo Esmeraldo. Fortaleza, Brazil.

B185  Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation

B186  Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal
Steven Gabardi. Boston.
Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results
Katie Korneffel, Bradley Gehring, Graham Mitro, Olanrewaju Aboderin, Sarabjot Singh Makkar, Woojin Han, Michael Rees, Jorge Ortiz. Toledo, OH.

The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys
Thomas E. Butler, Nicole Hayde. Bronx, NY.

Early Rejection in the Elderly: Is It Predictable?

Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients
Marie Marron-Wojewodzki, Ilan Szwarc, Céline Rene, Jean-Francois Eliaou, Georges Mourad, Moglie Le Quintrec. Montpellier, France.

Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction

Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy
Olivier Marion, Arnaud Del Bello, Ines Ferrandiz, Laure Esposito, Nicolas Congy, Anne-Laure Hebral, Nassim Kamar. Toulouse, France.

Liver Retransplantation and Other Complications

Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis
Omar Y. Mousa, Neej Patel, Juan E. Corral, David D. Lee, Justin H. Nguyen, Kristopher Croome, Denise Harnois. Jacksonville, FL.

Reduced Rituximab with Prophylactic Antibiotic Treatment Improves the Infectious Complications in Patients Undergoing ABO-Incompatible Living Donor Liver Transplantation
Shih-Chao Hsu, Ashok Thorat, Long-Bin Jeng, Horng-Ren Yang, Ping-Chun Li, Chun-Chieh Yeh, Te-Hung Chen, Kin-Shing Poon. Taichung, Taiwan.

Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients
Chelsey E. Payne, Jennifer I. Melaragno, David Hutchinson, Tara M. Babu, Paritosh Prasad, Travis B. Dick. Rochester, NY.

Outcomes Following Colectomy in Liver Transplant Recipients

Effect of Initial Hepatic Arterial Followed by Portal Reperfusion on Outcomes After Liver Transplantation
Raul Shahbazov, Feredun Azari, Jennifer Alejo, Michael Talanian, Michael Fox, Krista Kennedy, Samuel Kessel, Arash Nickholgh, Daniel Maluf, Shawn Pelletier. Charlottesville, VA.
B199  Identifying Independent Risk Factors for Graft Loss After Primary Liver Transplantation: A Propensity Score Matched Analysis
Jill Gwiasda, Harald Schrem, Alexander Kaltenborn. Hannover, Germany.

B200  Tenofovir Use Is Not Associated with Reduced Bone Density or Fractures in Liver Transplant Recipients
Nicholas Lim, Conrad Engler, John R. Lake. Minneapolis, MN.

B201  Optimizing Survival Outcomes for Advanced Age Patients Undergoing Liver Transplant

B202  Readmissions After Liver Transplantation–They May Be Predictable, but Are They Inevitable?

B203  Predictive Value of Post Reperfusion TEG in Peri-Operative Outcomes During Liver Transplant
Patricia Sheiner, Amelia Sulejamovnic, Justin Salm, Elizabeth Silver, Caroline Rochon. Hartford, CT.

B204  Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery
Mohamed Safwan, Marwan S. Abouljoud, Reena Salgia. Detroit, MI.

B205  Lactate Level Immediate Post-Liver Transplantation Is a Predictor of Early Allograft Dysfunction

B206  Endoscopic Therapy of Bile Duct Strictures After Liver Transplant
Heather L. Woller, Parvez Mantry, Alejandro Mejia, Stephen Cheng, Carlos Fasola. Dallas, TX.

B207  Combined Endoscopic and Percutaneous Cholangiography for Biliary Anastomotic Stricture in Adult Right-Lobe Living-Donor Liver Transplantation

B208  Risk Factors and Outcomes of Intracardiac Thrombosis During Orthotopic Liver Transplantation

B209  Effective Thrombolytic Therapy of Hepatic Artery Thrombosis After Liver Transplantation – A Single-Center Experience
Maogen Chen, Xiaohong Lin, Weiqiang Ju, Dongping Wang, Yi Ma, Linwei Wu, Xiaoshun He, Guodong Chen. Guangzhou, Guangdong, China.

B210  Risk Analysis of Patients with Proven Coronary Artery Disease Undergoing Liver Transplant

B211  Complications Requiring Reoperation After Pediatric Liver Transplantation
Dor Yoeli, Jennifer M. Moffett, Kathleen E. Hosek, Ruth L. Ackah, Rohini R. Sigireddi, Michael L. Kueht, N. Thao N. Galvan, Ronald T. Cotton, Abbas Rana, Christine A. O’Mahony, John A. Goss. Houston, TX.

B212  Relationship of Liver Extraction Times to Early Allograft Dysfunction and Post-Transplant Kidney Injury
<table>
<thead>
<tr>
<th>Poster Session B</th>
<th>Sunday, April 30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B214</strong> Molecular Adsorvent Recirculating System (MARS) Effectively Replaces Hepatic Function in Severe Acute Liver Failure&lt;br&gt;Steven I. Hanish, Rolf N. Barth, Deborah M. Stein, Enonobong Essien, Paul Thurman, Thomas M. Scalea, Stephen T. Bartlett. Baltimore, MD.</td>
<td><strong>B21</strong> Desensitization Regimen for the Patients with High Isoaglutinin Titors to Undergo Adult ABO-Incompatible Living Donor Liver Transplantation&lt;br&gt;Wei-Chen Lee, Chen-Fang Lee, Tsung-Han Wu, Yu-Chao Wang, Chih-Hsien Cheng, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan. Taoyuan, Taiwan.</td>
</tr>
<tr>
<td><strong>B215</strong> A Novel Method for Detecting and Monitoring Chimerism in Patients with Graft versus Host Disease After Liver Transplantation&lt;br&gt;Bo Peng, Hong Liu, Ke Cheng, Yujun Zhao, Xingguo She, Ying Niu, Quan Zhuang, Yingzi Ming. Changsha, Hunan, China.</td>
<td><strong>B22</strong> Extending the Limit for Living Donor Liver Transplantation: Similar Outcomes After Left vs. Right Lobe Graft, a Propensity Score Analysis&lt;br&gt;T. C. L. Wong, K. K. C. Ng, J. Y. Y. Fung, K. S. H. Chok, A. C. Y. Chan, C. M. Lo. Hong Kong, Hong Kong.</td>
</tr>
<tr>
<td><strong>B218</strong> Safety of Statin Therapy After Liver Transplantation&lt;br&gt;Meghan Glynn, Arin Jantz, Bryant Summers, Reena Salgia, Nimisha Sulejmani. Detroit, MI.</td>
<td><strong>B222</strong></td>
</tr>
</tbody>
</table>
B225 Recovery from Hypophosphatemia as a Predictor of Post-Operative Morbidity in Live Donor Hepatectomy

B226 Patency of Autologous Portal Vein “Y” Graft in Anterior Sector Outflow Reconstruction in Adult Living Donor Right Lobe Grafts
Sorabh Kapoor, Barun Nath, Vibha Varma, Shailesh Sable, Ashutosh Chauhan, Vinay Kumaran. Mumbai, Maharashtra, India.

B227 Safety of Liver Donation from Living Donors with Sickle Cell Trait

B228 Incidence and Outcomes of Re-Explorations in Living Donor Liver Transplantation
Vibha Varma, Shailesh Sable, Sorabh Kapoor, Ashutosh Chauhan, Vinay Kumaran. Mumbai, Maharashtra, India.

B229 Surgical Outcomes of Pair-Watch Suturing Technique (PWST) for Duct-To-Duct Biliary Anastomosis in an Attempt to Reduce the Biliary Complications in Living Donor Liver Transplantation
Akihiro Tanemura, Yusuke Iizawa, Hiroyuki Kato, Yasuhiro Murata, Naohisa Kuriyama, Yoshinori Azumi, Masashi Kishiwada, Shugo Mizuno, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji. Tsu, Japan.

B230 Incidence of Late-Onset Complications Related to Immunosuppressive Drugs Following Adult to Adult Living Donor Liver Transplantation, Especially Focusing on De Novo Malignancy
Shugo Mizuno, Yusuke Iizawa, Hiroyuki Kato, Yasuhiro Murata, Akihiro Tanemura, Naohisa Kuriyama, Masashi Kishiwada, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji. Tsu, Japan.

B231 The ‘W’ Technique: A Safe and Reproducible Technique for Hepatic Arterial Reconstruction in Living Donor Liver Transplantation
Vinay Kumaran, Vibha Varma, Sorabh Kapoor, Barun Nath, Ashutosh Chauhan, Shailesh Sable, Kapildev Yadav, Suneed Kumar, Swapnil Sharma. Mumbai, India.

B232 Living Donor Liver Transplantation for Alcoholic Liver Disease

B233 Readmission and Reoperation After Living Donor Hepatectomy
Sorabh Kapoor, Barun Nath, Vibha Varma, Shailesh Sable, Ashutosh Chauhan, Vinay Kumaran. Mumbai, Maharashtra, India.

B234 Are Drains Required After Donor Hepatectomy?
Swapnil Sharma, Suneed Kumar, Kapildev Yadav, Shailesh Sable, Ashutosh Chauhan, Sorabh Kapoor, Vibha Varma, Vinay Kumaran. Mumbai, Maharashtra, India.

B235 Technique and Result of Anastomosing Right Hepatic Vein to Inferior Vena Cava with a Separate Cavotomy Inferior to Right Hepatic Vein Orifice

B236 Heterotopic Auxiliary Liver Transplantation(ALTx) – Revisited
Varvara Kirchner, Emmanuel Minja, Srinath Chinnakotla, Raja Kandaswamy, William Payne, Timothy Pruett. Minneapolis.

B237 Reasons for Racial Disparities in Living Donor Liver Transplants (LDLT)

B238 Kinetics of Liver regeneration in Donors After Living Donor Living Transplant
Shailesh Sable, Sharad Maheshwari, Rahul Jadhav, Kapildev Yadav, Swapnil Sharma, Suneed Kumar, Ashutosh Chauhan, Sorabh Kapoor, Vibha Varma, Vinay Kumaran. Mumbai, Maharashtra, India.
Lung Transplantation Poster Session

B239 † The Impact of Insurance Status on Waiting List and Post-Lung Transplant Survival in Patients with Cystic Fibrosis
Carli Lehr, M. Skeans, E. Dasenbrook, Maryam Valapour. Cleveland, OH; Minneapolis, MN.

B240 † Outcomes After Lung Transplant: Being a Teenager Does Not Stop at Age 18
R. Scott Baker, Raheel Rizwan, Roosevelt Bryant III, Marc G. Schecter, Christopher Towe, James S. Tweddell, Farhan Zafar, David L. S. Morales. Cincinnati, OH.

B241 † Waitlist and Post-Lung Transplant Mortality Vary by Diagnosis for a Given Lung Allocation Score

B242 † Felodipine Diminishes Decline in Glomerular Filtration Rate in Lung Transplanted Patients Treated with Cyclosporine: A Randomized Placebo Controlled Trial
Mads Hornum, Martin Iversen, Peter Oturai, Mads J. Andersen, Mikhail Zemtsovski, Pia Bredahl, Nina H. Bjarnason, Karl B. Christiansen, Jørn Carlsen, Christian H. Möller, Bo Feldt-Rasmussen, Michael Perch. Copenhagen, Denmark.

B243 † Preoperative Pulmonary Hypertension Is Not Associated with Adverse Outcomes After Lung Transplantation

B244 † Age and Gender Disparities in Post-Lung Transplant Mortality

B245 Eliminating False Positive Virtual Crossmatch Results for Lung Transplant Candidates by Using Multiple Antibody Testing Platforms
Olga A. Timofeeva, Mohammed A. Kashem, Steven Geier, David Grogan, Suresh Keshavamurthy, Jesus Gomez-Abraham, Yoshiya Toyoda, Francis Cordova. Philadelphia, PA.

B246 Is Lung Allocation Score Associated with Waitlist and Post-Transplant Survival?

B247 Age and Race Disparities Among Pediatric and Adult Cystic Fibrosis Lung Transplant Recipients

B248 Effect of Statins on Influenza Vaccine Antibody Concentrations in Lung Transplant Recipients
Amanda J. Condon, Christine A. Garmoe, Mary S. Hayney. Madison, WI.

B249 Donor Smoking History Associated with Increased Risk of Death Following Lung Transplantation, but Lower Risk of Bronchiolitis Obliterans Syndrome
Sarah Burger, Michael Eberlein, John Keech, Evgeny Arshava, Tahuanty Pena, Sharon Larson, Julia Klesney-Tait, Kalpaj Parekh. Iowa City, IA.

B250 Role of HMG CoA Reductase Inhibitors on Time to Development of Chronic Lung Allograft Dysfunction Post-Lung Transplant

B251 Propensity-Score Matched Comparison of Lung Transplant Recipients of Age <70 and ≥70 Years
Abul Kashem, Suresh Keshavamurthy, Jesus Gomez-Abraham, Tomo Yoshizumi, Huaqing Zhao, Francis Cordova, Gerard Criner, Yoshiya Toyoda. Philadelphia, PA.
B252  Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?
Aiwen Zhang, Yuchu Sun, Kenneth McCurry, Marie Budev. Cleveland, OH; Willemstad, Netherlands Antilles.

B253  Lung Transplant Recipient Travel Distance to Transplant Center Does Not Impact Survival
Wayne M. Tsuang, Songhua Lin, Jesse Schold, Maryam Valapour. Cleveland, OH.

B254  Long-Term Analysis of Combined Liver-Lung Transplant Outcomes at a Single-Center
Kyle Freischlag, Brian Ezekian, Michael Mulvihill, Stuart Knechtte. Durham, NC.

B255  The Impact of Scleroderma Diagnosis on Lung Transplant Outcomes: A Single Center’s Experience

B256  Outcomes of Combined Liver/Lung Transplantation for Cystic Fibrosis Using SRTR Analysis
Jeffrey Halldorson, Khalid AlQahtani. San Diego, CA; Birmingham, AL.

B257  Impact of Pediatric Lung Transplant on Quality of Life Outcomes
Tanya Lazor, Hartmut Grasemann, Melinda Solomon, Samantha J. Anthony. Toronto, ON, Canada; Toronto, Canada.

B258  C4d Immunohistochemistry in Lung Allograft Interstitial Capillaries Lacks Linear Correlation with Donor Specific Antibodies, yet It Is Still Diagnostically Relevant
Yasmeen M. Butt, Tunc Gokaslan, Vaidehi Kaza, Fernando Torres, Jose R. Torrealba. Dallas, TX.

B259  HLA, ANA and ANCA Negative Vasculitis in Lung Transplantation Due to Overexpression of a1 Collagen V
Elena Daoud, Yasmeen M. Butt, Fernando Torres, Torrealba R. Jose. Dallas, TX.

B260  Improving Vaccination Rates for Lung Transplant Candidates
Manuel G. Cortez, Remzi Bag, Lisa Potter. Chicago, IL.

B261  Echinocandins in Lung Transplant Recipients (LTRs)
Yamama AlJishi, Coleman Rotstein, Deepali Kumar, Atul Humar, Lianne G. Singer, Shaf Keshavjee, Shahid Husain. Toronto, ON, Canada.

B262  Risk of Venous Thromboembolism After Lung Transplant
Rebecca Felkner, Amanda J. Condon, Katherine E. Rolling, Mary Hayney. Madison, WI.

Pediatric Liver Transplant – Clinical

B263  Liver Transplantation for Adolescents with Biliary Atresia in the PELD/MELD Era: An Analysis of the UNOS Database
Jaime Chu, Rachel Annunziato, Daisy Reinoso, Archana Ramaswami, Ronen Arnon. New York, NY; Bronx, NY.

B264  Inflammation, Impaired Energy Metabolism and Synthetic Failure Characterize the Liver Transcriptome of End-Stage Idiopathic Pediatric Acute Liver Failure (PALF)
Mylarappa Ningappa, Patrick McKiernan, Robert H. Squires, Qing Sun, Brandon W. Higgs, Kyle Soltys, Geoffrey Bond, Chethan Ashokkumar, George Mazariagos, Rakesh Sindhi. Pittsburgh, PA.

B265  Identify Clinical and Masked Hypertension and Management Strategies in Pediatric Liver Transplant Patients

B266  MMR and Varicella Immunity After Pediatric Liver Transplant
B267 A Pilot Test of the “Individualized Self-Management Training in Adolescent/Young Adult Recipients of Transplantation (iSTART)” Program

B268 Biliary Complications After Pediatric Liver Transplantation: A High Volume Living Donor Liver Transplantation Center Study of 237 Patients Over 27 Years
Dongkyu Oh, Nam-Joon Yi, Sung Woo Ahn, Suk Kyun Hong, Kyung Chul Yoon, Hyo-Sin Kim, Hyeyeong Kim, Kwang-Woong Lee, Kyung-Suk Suh, Joon Koo Han, Min Uk Kim, Jeong Min Lee. Seoul, Korea.

B269 Liver Transplantation for Babies Weighing Less Than 10 kg

B270 Use of Biodegradable Stents for the Treatment of Anastomotic Biliary Strictures in Pediatric Liver Transplant Patients
Jesus Quintero, Javier Juamperez, Vanessa Cabello, Maria Mercedes Perez, Itxarone Bilbao, Jose Andres Molino, Ramon Charco. Barcelona, Catalunya, Spain.

B271 Comparing Outcomes Between Technical Variant Liver Allografts and Whole Allografts in Pediatric Liver Transplantation: A Single Center’s Experience
Amy E. Gallo, Jacqueline Lee, Mihaela Damian, Dan J. Stoltz, Clark A. Bonham, Carlos Esquivel, Julianne Mendoza. Palo Alto, CA.

B272 Biliary Complications in Pediatric Liver Transplantation for Cystic Fibrosis: A Single-Center Experience with Choledochocholedochostomy

B273 Acute Renal Replacement Therapy in Pediatric Liver Transplantation: A Predictor of Increased Risk

B274 Long-Term Pediatric Live-Donor Liver Transplantation Survivors: Patient and Allograft Outcomes

B275 Conservative Management of Pneumatosis Intestinalis After Pediatric Liver Transplantation

B276 Variability in Tacrolimus Concentrations Across Pediatric Solid Organ Transplants
Sandar Min, Tanya Daljevic, Odelia Lee, Marie-Eve Alary, Faye Murdoch, Rulan Parekh, Vicky Ng, Diane Hebert, Lorraine Hamioka, Tom Blydt-Hansen, Veronique Phan, Patricia Birk, Upton Allen, Simon Urschel, CNTRP POSITIVE Research Group, Bethany Foster, Seema Mital. Toronto, Canada; Calgary, Canada; Winnipeg, Canada; Montreal, Canada; Edmonton, Canada; Montreal, Canada.

B277 Transcatheter Relief of Symptomatic Hepatic Venous Outflow Obstruction Following Pediatric Liver Transplantation

B278 Percutaneous Direct Intrahepatic Portosystemic Shunt as a Bridge to Liver Transplantation in Pediatric Patients with Variceal Bleeding
B279 Gastrointestinal Perforation After Liver Transplantation in Pediatric Patients
Mahir Kirnap, Sedat Yildirim, Gokhan Moray, Adhan Torgay, Mehmet Haberal. Ankara, Turkey.

B280 Ornithine Transcarbamylase Deficiency (OTC) in the Donor Liver, the Importance of Ascertaining the Cause of Death in the Brain Dead Donor
Mathew George, Gordon Thomas, Albert Shun, Michael Stormon. Sydney, NSW, Australia.

B281 Infectious Complications Following Hepatectomy for Pediatric Hepatoblastoma
Sarah Jane Commander, Michael Kueht, Tu-Anh Ha, Abbas Rana, John Goss, Sanjeev Vasudevan. Houston, TX.

B282 Porta Systemic Shunts Helps Us to Delay or Avoid Liver Transplantation in Patients with Portal Hypertension Post Kasai Operation for Biliary Atresia
Mathew George, Gordon Thomas, Albert Shun. Sydney, NSW, Australia.

B283 Rapid Regression of Xanthomata After Orthotopic Liver Transplantation for Alagille Syndrome
Nhu Thao N. Galvan, Patrick Nguyen, Sarah Koohmaraei, Ronald T. Cotton, Abbas Rana, Christine A. O’Mahony, John A. Goss. Houston, TX.

B284 Digital Image Analysis of Pediatric Liver Allograft Biopsies Correlates with METAVIR Fibrosis Score

B285 Pediatric Liver Transplantation for Alpha-1 Antitrypsin Deficiency: A UNOS Database Analysis
Jacqueline Jossen, Rachel Annunziato, John McShane, Jaime Chu, Ronen Arnon. New York, NY; Bronx, NY.

B286 Modular Training in Organ Procurement, in the Present Era of High BMI Donors: Validation by Results

B287 Long-Term Follow-Up of the Safety and Effects of Bariatric Surgery on Immunosuppression in Post-Transplant Patients
Andrei Keidar, Renana Yemini, Idan Carmeli, Eviatar Nesher, Janos Vinkler, Eytan Mor, Matan Bendavid. Tel Aviv, Israel.

B288 Bariatric Operations at a Service of the Transplant Surgery
Andrei Keidar, Renana Yemini, Matan Ben David, Eviatar Nesher, Janos Vinkler, Marius Broun, Eytan Mor. Tel Aviv, Israel.

B289 Review of UK-Wide Practice of Pancreas Transplantation: Donor Selection, Back-Bench Preparation & Implantation Technique
Hemant Sharma, Shiv Bhutani, David Vandellen, Tunde Campbell, Ravi Pararajasingham, Bence Forgacs, Afshin Tavakoli, Peter Friend, Titus Augustine, Raman Dhanda. London, ON, Canada; Manchester, United Kingdom; Toronto, Canada; Oxford, United Kingdom.

B290 Kidney Insertion Through Vagina and Robotic Assisted Laparoscopic Kidney Transplantation: A Pilot Study

B291 Impact of Pretransplant Panel-Reactive Antibody Level on Ocular Surface Stem Cell Survival and Visual Outcome
Amit Govil, Albert Y. Cheung, Enrica Sarnicola, Brad M. Genereux, Edward J. Holland. Cincinnati, OH.
B292 † Distinctive Molecular Features of Antibody-Mediated versus T-Cell Mediated Rejection in Facial Transplantation
Rachel Lopdrup, Thet Su Win, Naoka Murakami, Jessica Teague, Anil Chandraker, George Murphy, Christine Lian, Ericka Bueno, Bohdan Pomahac, Rachael Clark, Leonardo Riella. Boston, MA.

B293 The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response

B294 Contribution of Donor versus Recipient T Cells in Face Transplant Rejection

B295 Transient High Dose Tacrolimus Allows Tolerance of a Vascularized Composite Allograft Tolerance Across a Full MHC Mismatch

B296 Ex vivo Expanded Regulatory T cells Combined with Short-Term Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts

B297 CTLA4-Ig, Vascularized Bone Marrow and Donor Bone Marrow Cells Successfully Negate the Development of Acute Skin Rejection of Vascularized Composite Allografts in MHC Class I Mismatched Recipients
Ilse M. Schol, Zhi Y. Ng, Alexandre G. Lellouch, Amon-Ra Gama, Josef M. Kurtz, Curtis L. Cetrulo. Boston.

B298 Preservation of Musculoskeletal Components in Vascularized Composite Allograft Skin Rejection

B299 A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using a Single Dose of AMD3100 for Stem Cell Mobilization
Bruce J. Swearingen, Scott S. Graves, Rainer Storb, David W. Mathes. Aurora, CO; Seattle, WA.

B300 Systemic Immunosuppression in the Setting of Ocular Surface Stem Cell Transplantation
Amit Govil, Albert Y. Cheung, Enrica Sarnicola, Edward J. Holland. Cincinnati, OH.

Xenotransplantation

B301 Xenogeneic Lung Transplantation: Identifying Transgenes and Supportive Drug Treatments to Achieve Long-Term Survival

B302 Recognition of Islet Xenografts In Vivo by Non-Obese Diabetic (NOD) Insulin-Specific CD4 T Cells
Ronald G. Gill, Wegemann Dale, Megan Crawford. Aurora, CO.
B303  A Swine for Human MHC Class I Swap: Implications for Xenotransplantation

B304  Binding of Human Neutrophils to Activated Porcine Endothelium Is Mediated by E-Selectin

B305  Coagulation Pathway Perturbations Associated with Pig-to-Baboon Lung Xenotransplantation

B306  Lack of Xenograft Recipient Monitoring by Telemetry Lets Infection Go Unchecked and Trigger Coagulopathy
Muhammad Mohiuddin, Avneesh Singh, Joshua Chan, Philip Corcoran, Billeta Lewis, Marvin Thomas, David Ayares, Keith Horvath. Bethesda; Blacksburg.

B307  The Role of Anti-Neu5Gc IgM in Xenograft Antibody Mediated Rejection

B308  Thrombalexin and Mirococept Synergistically Reduce IBMIR in a Porcine to Rhesus Xenoislet Model

B309  CD4+/CD8+ T Cell Ratio as a Predictive Marker for Early Graft Failure in Pig to Non-Human Primate Islet Xenotransplantation with Immunosuppression
Poster Session C

Poster Viewing: 9:30 am – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm
Hall D1

C# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

Antibody and B Cell

C1 Detection of Specific B Cell Memory to the Perlecan LG3 Antigen in the Normal Immune Repertoire
Lauriane Padet, Melanie Dieude, Bing Yang, Julie Turgeon, Heloise Cardinal, Marie-Josee Hebert. Montreal, Canada; Edmonton, Canada.

C2 Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation
Juan S. Danobeitia, Peter J. Chlebeck, Jose R. Torrealba, Tiffany Zens, Laura J. Zitur, Anthony M. D’Alessandro, Luis A. Fernandez. Madison, WI.

C3 Effects of Tofacitinib (JAK-3 Inhibitor) on De Novo HLA-A2 Antibody Production in a Mouse Model of Allo-Sensitization
Ning-Ning Chai, Gordon Wu, Irene Kim, Andrew Klein, Stanley Jordan. Los Angeles, CA.

C4 Differential Effect of Antibody Removal on ABO Blood Group Type Chain Specific Antibodies Over Time
Andrew Bentall, Mylvaganam Jeyakanthan, Jean Pearcey, Bruce Motyka, Chris Cairo, Todd Lowary, Jillian Buriai, Lori West, Simon Ball. Birmingham, United Kingdom; Edmonton, Canada.

C5 Development of an Anti-HLA Antibody-Producing Humanized Mouse Model

C6 Triptolide Alleviating Acute Antibody Mediated Rejection by Inhibition of B Cell Activation in Presensitized Recipients
Daqiang Zhao, Siwen Li, Tao Liao, Yuan Wei, Xuefeng Hua, Fei Han, Zhiuan Luo, Xiaonan Liu, Qiquan Sun. Guangzhou, Guangdong, China.

C7 Prevention of Donor Specific Antibody Production After Skin Allografting by Mobilization of Endogenous Stem Cells Using a Combination of AMD3100 and Low-Dose FK506 in Rats

C8 Blood Tfh Cells Exhibit Impaired B Cell Help in Operationally Tolerant Patients

C9 Effects of Anti-HLA Antibodies on Endothelial Expression and Serum Levels of Thrombomodulin in Kidney Recipients
Stephanie Beland, Olivier Desy, Patrice Valin, Sacha A. De Serres. Quebec, QC, Canada.

C10 APRIL/BLyS Inhibition Reduces Donor Specific Antibody in Sensitized Mice

C11 Improved Mouse Renal Transplantation Model Simulating Clinical Antibody Mediated Rejection
Daqiang Zhao, Siwen Li, Tao Liao, Xuefeng Hua, Fei Han, Zhiuan Luo, Xiaonan Liu, Qiquan Sun. Guangzhou, Guangdong, China.

C12 Novel Insights into the Synergism of CD40 Autoantibodies and suPAR in Kidney Transplant Patients with FSGS Recurrence
Tara Sigdel, Changli Wei, Flavio Vencentii, Jochen Reiser, Minnie Sarwal. San Francisco.
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
<th>Location/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>C13</td>
<td>Effect of Two Anti-CD20 Abs on B Cell Depletion and Reconstitution in Non-Human Primates</td>
<td>Wenji Sun, Natalie O’Neill, Tianshu Zhang, Gheorghe Braileanu, Keith A. Reimann, Richard N. Pierson, Agnes M. Azimzadeh.</td>
<td>Baltimore, MD; Boston, MA.</td>
</tr>
<tr>
<td>C14</td>
<td>Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status</td>
<td>Adarsh Babu, Nithya Krishnan, David Briggs, Dan Mitchell, Sunil Daga.</td>
<td>Coventry, United Kingdom; Birmingham, United Kingdom; Leeds, United Kingdom.</td>
</tr>
<tr>
<td>C15</td>
<td>Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton’s Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?</td>
<td>Irene Kim, Gordon Wu, Ning-Ning Chai, Andrew Klein, Stanley Jordan.</td>
<td>Los Angeles, CA.</td>
</tr>
<tr>
<td>C16</td>
<td>Anti-HLA I Antibody Enhances Endothelial Cell-Induced Polarization of Human Monocytes to M2a/c-Like Macrophages</td>
<td>Xuedong Wei, Nicole M. Valenzuela, Maura Rossetti, Elaine F. Reed.</td>
<td>Los Angeles, CA.</td>
</tr>
<tr>
<td>C17</td>
<td>Positive Flow Crossmatch After Negative Virtual Crossmatch - A Single Center Experience</td>
<td>Qingyong Xu, Steve Leckie.</td>
<td>London, ON, Canada.</td>
</tr>
<tr>
<td>C18</td>
<td>Inhibition of Memory T Cell Alloresponses by TIM-1+ B Cells</td>
<td>Bruno Gonzalez-Nolasco, Haley E. Tector, James F. Markmann, Gilles Benichou.</td>
<td>Boston, MA.</td>
</tr>
<tr>
<td>C19</td>
<td>Brain-Dead Donors Terminal Inflammation Is Associated to Delayed Graft Function in Kidney Transplant Recipients</td>
<td>David Cucchiari, Diekmann Fritz, Ventura Pedro, Adalia Ramon, Paredes David, Rovira Jordi, Oppenheimer Frederic, Revuelta Ignacio.</td>
<td>Barcelona, Spain.</td>
</tr>
<tr>
<td>C21</td>
<td>A Single Center’s Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney</td>
<td>Nikhil Kapila, Bobby Zervos, Bahaaldeen Ismail, Gabriel Schnickel, John Rivas, Diego Reino, Neerja Agrawal, Andreas Tzakis.</td>
<td>Weston, FL.</td>
</tr>
<tr>
<td>C22</td>
<td>False-Positive Flow Cytometric Crossmatch Results and the Utility of the Virtual Crossmatch</td>
<td>Nicholas K. Brown, John J. Xin, Jerome G. Weidner, Rebecca L. Upchurch, Susana R. Marino.</td>
<td>Chicago, IL.</td>
</tr>
</tbody>
</table>
C25 Controlled Donation After Circulatory Death (cDCD) Donors May Become Similar to Brain Death Donors (DBD)
Corinne Antoine, Michel Videcoq, Bruno Riou, Didier Dorez, Gaëlle Cheisson, Laurent Martin-Lefèvre, Louise Durand, Emilie Savoye, Georges Karam, Benoît Barrou. Saint Denis La Plaine, France; Nantes, France; Paris, France; Annecy, France; Kremlin Bicetre, France; La Roche Sur Yon, France.

C26 Kidney Size Does Not Matter: Should the Decision to Split Pediatric En Bloc Donor Kidneys Be Based on Donor Weight Rather Than Kidney Length?
Andrew Perry, Jakub Woloszyn, John McVicar, Junichiro Sageshima, Richard Perez, Christoph Troppmann, Chandrasekar Santhanakrishnan. Sacramento, CA.

C27 Donor Families’ Perspectives of the Harms of Failed Donation After Circulatory Death: A Qualitative Analysis
Lauren J. Taylor, Anne Buffington, Scalea Joseph, Norman Fost, Margaret L. Schwarze. Madison, WI; Baltimore, MD.

C28 A Nationwide Global Strategy for Kidney Transplantation with Controlled Cardiac Death Donor (cDCD) Has Improved Global Results. Spanish Multicentre SENTRA-GEODAS Group
Jose Portoles, Maria Jose Perez-Saez, Dario Janeiro, Edoardo Melilli, Naroa Maruri Kareaga, Erika de Souza, Francisco Llamas, Jordi Espí, Paloma Martin Moreno, Dolores Navarro, Asuncion Sancho-Calabuig, Maria Luisa Rodriguez-Ferrero, Domingo Hernandez, Julio Pascual. Majadahonda, Spain; Madrid, Spain; Barcelona, Spain.

C29 Donor Age > 50 Years and CIT Longer Than 18 Hour Are Independent Risk Factors for One Year Graft Survival in Renal Transplantation From Uncontrolled Donors After Circulatory Death (uDCD)
Maria Molina, Eduardo Gutierrez, Esther Gonzalez, Enrique Morales, Jimena Cabrera, Amado Andres. Madrid, Spain; Montevideo, Uruguay.

C30 Warm Ischemic Time as an Additive Predictor of Graft Survival in KDPI/KDRI Era of Kidneys from Donors After Cardiac Death: A Single-Center Experience Over Three Decades

C31 Kidney Re-Transplantation (KRTx) from Donation After Cardiocirculatory Death (DCD)-Standard Criteria Donors (SCD)
Muhammad A. Khan, Baha Alradawna, Alan Farney, Jeffrey Rogers, Giuseppe Orlando, Amber Reeves-Daniel, Amudha Palanisamy, Micheal Gautreaux, William Doares, Scott Kaczmarsky, Robert Stratta. Winston Salem, NC.

C32 Kidney Donation After Brain Death Followed by Circulatory Death Confers Comparable Outcomes with Kidney Donation After Brain Death
Qipeng Sun, Qiuan Sun, Honglan Zhou, Ronghua Cao, Minzhuan Lin, Xuelfeng Hua, Liangqing Hong, Zhengyu Huang, Ning Na, Ruiming Cai, Gang Wang, Fanhang Meng. Guangzhou, China; Changchun, China.

C33 Worsening Rather Than Severe Acute Kidney Injury Affects Kidney Transplantation Outcomes
Mi-Yeon Yu, Byung Chul Yu, Yong Chul Kim, Sang Il Mi, Jongwon Ha, Jaeseok Yang, Yon Su Kim, Hajeong Lee. Seoul, Republic of Korea; Bucheon, Republic of Korea.

C34 Kidney Transplantation Outcomes from Donors with Acute Kidney Injury
Sumanth Channapatna Suresh, Michelle Lubetzky, Jay Graham, Attasit Chokechanaisakul, Omar Mohammed, Milan Kinkhabwala, Enver Akalin, Juan Rocca, Puneet Bedi. Bronx, NY.

C35 Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis
Afia Umber, Mary Killackey, Anil Parmesh, Brent Alper, Fred Teran, Adrian Baudy, Yongjun Liu, Joseph Buell, Rubin Zhang. New Orleans, LA.
Use of Pulsatile Perfusion Modifies the Effect of Delayed Graft Function on Graft Failure
Alvin Thomas, Ashton Shaffer, Allan Massie, Dorry Segev. Baltimore.

Evaluation of Outcomes in Renal Transplantation Using Machine Perfusion for the Preservation of Kidneys from Expanded Criteria Donor
Emilie Savoye, Marie Alice Macher, Kidney Working Group, Camille Legeai, Corinne Antoine. Saint Denis La Plaine, France.

Prophylactic Therapy Against Multidrug-Resistant Acinetobacter baumannii Contamination of Preservation Solution in Renal Transplantation: A Single Center Experience
Rending Wang, Jingyi Zhou, Jianyong Wu. Hangzhou, China.

Awareness of Change in the Kidney Allocation System Among Dialysis Providers with Low Waitlisting

Online Patient Resources for Deceased Donor and Live Donor Kidney Recipients: A Comparative Analysis of Readability
Eric P. Zhou, Elizabeth Kiwanuka, William G. Cioffi, Paul E. Morrissey. Providence, RI.

Weekend Discharge and Early Hospital Readmission After Kidney Transplant: A Multi-Center Analysis
Meera N. Harhay, Yaqi Jia, Heather Thiessen Philbrook, Behdad Besharatian, Ramnika Gumber, Francis Weng, Isaac Hall, Mona Doshi, Bernd Schroeppe1, Chirag Parikh, Peter P. Reese. Philadelphia; New Haven; Livingston; Salt Lake City; Detroit; New York.

ABO Incompatible Deceased Donor Renal Transplantation: Exploring the Possibilities
Matthew P. Sypek, Rosemary Masterson, Peter Hughes. Melbourne, Australia.

Characteristics and Performance of Unilateral Deceased Donor Kidney Transplants
S. Ali Husain, Samnang Lee, Sumit Mohan, Stephen Pastan, Rachel Patzer, Mariana Chiles. New York, NY; Atlanta, GA.

Association of Dialysis Facility Neighborhood Socioeconomic Status with Barriers to Kidney Transplant

Barriers to Becoming Active on the Renal Transplant Waiting List: Have They Changed in the Last Five Years?
Emma van Hardeveld, Timothy Furlong, Amanda Robertson, Nancy Suh, Stephen Thwaites, Robert Millar, Rosemary Masterson, Michael Lian, Belinda Jones, Peter Hughes. Melbourne, Australia.

Patient-Reported Barriers to the Pre-Kidney Transplant Evaluation in an At-Risk Population in the United States
Mark B. Lockwood, W. James Chon, Michelle Josephson, Yolanda Becker, Mild Saunder. Chicago, IL.

Ethnocultural Barriers to Pre-Emptive Kidney Transplantation: A Single Centre Retrospective Cohort Study
Aarushi Bansal, Michelle Kwok, Shen Cao, Olusegun Famure, S. Joseph Kim, Istvan Mucsi. Toronto, ON, Canada.

Racial Disparities in Self-Care Among Liver Transplant Candidates
Joel P. Wedd, Jennifer Gander, Kayla Smith, Sobia Mujtaba, Ram Subramanian, Ruth Parker, Carolyn Reilly, Rachel E. Patzer. Atlanta, GA.

Does Gender Affect Renal Transplant Outcomes?
Anita Patel, Rohini Prashar. Detroit, MI.
C50 † Non-Medical Factors Contributing to Racial Disparity in Kidney Transplant Wait-Listing
Yue-Harn Ng, Shane Pankratz, Kellee Bornemann, Emilee Croswell, John Pleis, Ron Shapiro, Mark Unruh, Larissa Myaskovsky. Albuquerque, NM; Pittsburgh, PA; New York, NY.

C51 Access to Living Donor Kidney Transplantation in Nepal
Prakriti Shrestha, Sarah Rasmussen, Alvin Thomas, Susan Ferguson, Allan Massie, Dorry Segev, Pukar Shrestha. Baltimore; Grinnell; Bhaktapur, Nepal.

C52 Ethnicity and Transplant Knowledge Among Canadian ESKD Patients

C53 Transplant without Borders – A New Project for Decentralization of Transplant Centers in Brazil

C54 Implementing a New Specialist Requester Role to the United Kingdom to Address Consent Rates
Susan E. Duncalf, Marian Ryan. Bristol, United Kingdom.

C55 Neighborhood Poverty and Racial/Ethnic Disparities in Access to Live Donor Kidney Transplantation in the US
Tanjala Purnell, Xun Luo, Deidra Crews, Sunjae Bae, Lauren Kucirka, Lisa Cooper, Dorry Segev. Baltimore.

C56 † Disparities in Access to the Liver Transplant Wait List: A Statewide Analysis
Yanik J. Bababekov, David C. Chang, Ya-Ching Hung, Joel T. Adler, Sahael M. Stapleton, James F. Markmann, Heidi Yeh. Boston, MA.

C57 † Non-Directed Kidney Donor Candidate Referral, Care and Attrition in an Online Portal
Rebecca E. Hays, Kathy Schappe, Dixon B. Kaufman, Didier A. Mandelbrot. Madison, WI.

C58 Increasing Living Donation by Implementing the Kidney Coach Program
Dianne LaPointe Rudow, Sara Geatrakas, Jonathan Armenti, Ariella Tomback, Ron Shapiro. New York, NY.

C59 Can We Improve Donation Through Pre-Kidney Transplantation Education Using Internet-Based Resources? An Analysis of Internet Use Patterns Among Hispanics
Helen B. Gomez, Erica Malagon-Blackwell, Juan Carlos Caicedo. Chicago, IL.

C60 Engaging Clinicians and Patients Regarding Frailty Assessment in Kidney Transplant Candidates

C61 Evaluating Online Information on Youtube for Kidney Transplant
Patricia Sheiner, Samantha Silver. Hartford, CT.

C62 Disparity in Transplant Referral Patterns Based on Physician Dependent Variables
Veronica M. Loy, Allison Rzepczynski, Sofia Bello, Colleen Blackburn, Amy Lu. Maywood, IL.

C63 Health Literacy, Functional Status and Transplant Eligibility Among Adult Liver Transplant Candidates
Marina Serper, Kristen Dwinell, Michael S. Wolf, Kim Otthoff. Philadelphia; Chicago.

C64 Medical Mistrust, Perceived Racism and Experiences of Medical Discrimination Among Transplant Patients
Reem Hamoda, Kristie Lipford, Laura McPherson, Jennifer Gander, Rachel E. Patzer. Atlanta, GA.
C65 Substance Use Among Potential Kidney Transplant Candidates and Its Impact on Access to Kidney Transplantation; a Canadian Cohort Study

C66 Are ICD-9 V Codes Representative of the Liver Transplant Wait List?
Yanik J. Bababekov, David C. Chang, Ya-Ching Hung, Joel T. Adler, Sahael M. Stapleton, James F. Markmann, Heidi Yeh. Boston, MA.

C67 Concurrent Psychosocial Variables Confound Perioperative and Postoperative Care in Liver Transplant Recipients with Alcoholic Liver Disease
Samuel T. Sultan, Mary Hodorowicz, Jessica Powell, Mark Connelly, Michelle Tuten, Paul Sacco, William Hutson, Rolf N. Barth, John C. LaMattina. Baltimore.

C68 † HLA Alloimmunization According to the Different Immunization Events and Consequences on Access to Kidney Transplantation
Vincent Pernin, Amandine Cros, Ilan Szwarc, Céline Rene, Jean-François Eliaou, Valérie Garrigue, Georges Mourad, Moglie Le Quintrec-Donnette. Montpellier, France.

C69 Protocol of the KTFT-TALK Study to Reduce Racial Disparities in Kidney Transplant Evaluation and Living Donor Kidney Transplantation

C70 Differences in Racial and Sex Disparities in Liver Transplantation Outcomes Between Older and Younger Adult Recipients
Qiong Huang, Christine Haugen, Xun Luo, Allan Massie, Mara McAdams-DeMarco, Dorry Segev. Baltimore.

C71 Reduced Racial Disparity in Outcomes of Kidney Transplant Recipients
E. Iranpour, A. Tavabi, R. Garakani, R. Gohh, P. Morrisssey, Reza Saidi, Reza Saidi. Providence, RI.

C72 Opioid and Opioid Substitution Therapy in Liver Transplant Candidates: A Survey of Center Policies and Practices
James N. Fleming, Jennifer C. Lai, Helen S. Te, Adnan Said, Erin K. Spengler, Shari S. Rogal. Charleston, SC; San Francisco, CA; Chicago, IL; Madison, WI; Pittsburgh, PA.

C73 Perceived Patient Barriers for Kidney Transplant Evaluation Among Transplant Center Staff
Laura McPherson, Kristie Lipford, Reem Hamoda, Jennifer Gander, Stephen Pastan, Rachel Patzer. Atlanta, GA.

C74 Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin
Jay T. Hazelcorn, Raymond Yau, Noor Sabagha, Mozhgon Moaddab, Melissa J. Manson. Houston, TX.

C75 Telemedicine Utilization After Kidney Transplantation Was Not Associated with Decreased Early Hospital Readmission Rate
Nisreen Elfadawy, Edmund Sanchez, Kenneth Woodside, Joshua Augustine, Donald Hricik, Nagaraju Sarabu. Cleveland, OH.

C76 Burden of Early Hospitalization Among Liver Transplant Recipients
Pratima Sharma, Nathan Goodrich, Douglas Schaubel, Abigail Smith, Robert Merion. Ann Arbor, MI.

C77 Raising Awareness of the Importance of Exercise Training in Solid Organ Transplant: A Description of a Canadian Knowledge Dissemination Project
Tania Janaudis-Ferreira, Sunita Mathur, Tom Blydt-Hansen. Montreal, QC, Canada; Toronto, Canada; Vancouver, Canada.
C78  Association Between Transportation Strategies and Kidney Transplant Center Staff Perceived Racial Disparities  
Kristie J. Lipford, Laura McPherson, Reem Hamoda, Rachel E. Patzer. Atlanta, GA.

C84  Can We Successfully Overcome Obesity as a Barrier for Kidney Transplantation?  

Donor Management: All Organs

C79  The Performance of Four Tools for the Prediction of Potential for Organ Donation After Cardiac Death in Neurocritical Patients: A Prospective, Multicenter, Observational Study  
Zhiyong Guo, Guixing Xu, Paul Schroder, Marti Manyalich, Xiaooshun He, Guodong Chen. Guangzhou, China; Durham; Barcelona, Spain.

C80  Prediction of Evolution Toward Brain Death in Acute Neurocritical Patients Identified as Potential Organ Donors  
Guixing Xu, Ping Xu, Zhiyong Guo, Xiaooshun He. Guangzhou, Guangdong, China; Guangzhou, Guangdong, Ecuador.

C81  Increasing the Kidney Donor Pool by Expanding Limits on Body Mass Index and Age: A Single-Center Evaluation of Safety for Donors and Recipients  
James M. Tonascia, Soo Y. Yi. Baltimore, MD.

C82  Hepatitis C Genotypes Among Deceased Organ Donors in the United States  

C83  A Novel Technique to Increase Donor Utilization: Our Experience Using High-Dose Tissue Plasminogen Activator Flush in Donation-After-Cardiac-Death Donors for Liver Transplantation  
Jay A. Graham, Katherine Lorenzen, Sarah Bellemare, Milan Kinkhabwala, Juan P. Rocca. Bronx, NY.

C85  Accuracy of Computed Tomography for Detecting Hepatic Steatosis in Donors for Liver Transplantation  
Zhiyong Guo, Danping Zheng, Xiaooshun He, Guodong Chen. Guangzhou, China.


C87  Using Buccal Swabs for Deceased Organ Donor HLA Typing  
Chad C. Muse, Sherri Longobardi, Idoia Gimferrer, Jeffrey P. Orlowski. Oklahoma City, OK.

Hearts and VADS: All Topics

C88  Photopheresis for Recalcitrant Rejection After Heart Transplantation: Worthwhile?  
Jignesh Patel, Michelle Kittleson, Xiaohai Zhang, Ellen Klapper, Tamar Aintablian, Kellee Murayama, Lawrence Czer, Dael Geft, David Chang, Jon Kobashigawa. Los Angeles.

C89  Lung Preservation Solution Exposure at Cardiac Procurement Is Associated Increased Incidence of Coronary Arterial Vasculopathy  
Hannah Copeland, Victoria Garcia, Adam Sima, David Baran, Anit Mankind, Gundars Katlaps, Neil Lewis, Benita Dharmaj, Jack G. Copeland. Richmond, VA; Newark, NJ; Tucson, AZ.
C90 Sequential Surgical Strategy for Heart-Kidney Transplantation

C91 Improved Creatinine Immediately Post-LVAD Predicts Lower AKI Risk After Heart Transplant
A. Nanavati, Y. A. He, N. Moazami, S. Demirjian, B. Stephany. Cleveland, OH; Rochester, NY.

C92 Malignancy in Patients Undergoing Simultaneous Heart-Liver and Heart-Kidney Transplant

C93 Implementing a Successful DCD Heart Programme to the United Kingdom
Marian Ryan, Susan E. Duncalf. Bristol, United Kingdom.

C94 Routine Surveillance of Heart Transplant Recipients with Gene Expression Profiling: Lack of an Impact of Race on Outcomes
Jeffrey Teuteberg, Michael A. Shullo, Debbie Rinde-Hoffman, Mark Wigger, Yue Sarah Wang, Theresa Wolf, P. J. Arnold, John Sninsky, Peter Berman. Pittsburgh, PA; Tampa, FL; Nashville, TN; Brisbane, CA.

C95 In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation
Derek Leong, Babak Azarbal, Jignesh Patel, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, David Chang, Dael Geft, Jon Kobashigawa. Los Angeles.

C96 Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients?

C97 Longer Ischemic Time Is Associated with Late Graft Dysfunction in Pediatric Heart Transplant Recipients

C98 Hypogammaglobulinemia in Pediatric Heart Transplant Candidates Is Not Corrected by Transplantation
Rebecca Madan, Rhiannon Penkert, Jasmeen Dara, Jacqueline M. Lamour, Betsy C. Herold, Julia L. Hurwitz. Bronx, NY; Memphis, TN.

C99 A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants
Sandar Min, Tanya Daljevic, Myriam Lafreniere-Roula, Cedric Manlhiot, Nadya Nalli, Hartmut Grasemann, Steven Schwartz, Binita Kamath, Vicky Ng, Rulan Parekh, Seema Mital. Toronto, ON, Canada.

C100 Impact of NODAT on Post-Transplant Survival – An Analysis of UNOS Data
Nagaraju Sarabu, Salil Deo, Soon Park. Cleveland.

C101 Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development?
Jignesh Patel, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Tina Kao, Dael Geft, David Chang, Fardad Esmailian, Jon Kobashigawa. Los Angeles.
C102 Alemtuzumab Use in a Single Center Pediatric Heart Transplant Cohort
Jennifer Case, Jennifer Eshelman, Patricia C. Booker, Shelley D. Miyamoto, Melanie D. Everitt, Scott R. Auerbach. Aurora, CO.

C103 Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation
Michele Gallo, Jaimin R. Trivedi, Dmitry Abramov, Rajakrishnan Vijayakrishnan, Mark S. Slaughter. Louisville.

C104 Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
Olya Witkowsky, Jeffrey Teuteberg, Christopher Sciortino, Michael Shullo. Pittsburgh, PA.

C105 Exploring Differential Antibody Response to Bortezomib in Heart Transplantation

C106 Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience
Phillip McMullen II, John J. Xin, Nicholas K. Brown, Rebecca L. Upchurch, Jerome G. Weidner, Saviri E. Fedson, Aliya N. Husain, Susana R. Marino. Chicago, IL; Houston, TX.

C107 Simultaneous Heart and Kidney Transplant vs Heart Transplant: Single Center Review of Candidate Selection and List Management

C108 Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation

C109 Post-Transplant Sensitization: Does it Make a Difference in the Development of First-Year Intimal Thickening?
Jignesh Patel, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Emily Stimpson, Babak Azarbal, Dael Geft, David Chang, Fardad Esmailian, Jon Kobashigawa. Los Angeles.

C110 Retrospective Review of Early versus Late Initiation of Oral Sildenafil for Right Ventricular Dysfunction in Post-Cardiac Transplant Surgery Patients

C111 Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair?
Jignesh Patel, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Raysha Sharoff, Ryan Levine, Angela Velleca, Danny Ramzy, Fardad Esmailian, Jon Kobashigawa. Los Angeles.

C112 Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence

C113 Timing, Frequency and Precipitating Factors of Early Readmission After Heart Transplant
Jeffrey R. Van Liew, Lisa Potter, Nir Uriel, Laura M. Lourenco. Chicago, IL.

C114 NK Cells Respond to CMV Lysate by Inducing IFNγ and CD107a Surface Expression in an Antibody-Dependent Manner: This Represents a Cytokine Flow Cytometry (CFC) Assay That Could Assess Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) as a Marker of CMV Immunity in Transplant Recipients
Shili Ge, Chu Maggie, Bong-Ha Shin, Artur Karasyov, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

Innate Immunity

C115 Timing, Frequency and Precipitating Factors of Early Readmission After Heart Transplant
Jeffrey R. Van Liew, Lisa Potter, Nir Uriel, Laura M. Lourenco. Chicago, IL.
C115  CD40/CD40 Ligand Signal Controls Cytotoxic Ability of Natural Killer Cells After Invariant Natural Killer T Cell Stimulation
Hironori Fukuda, Toshihito Hiai, Rumi Ishii, Haruki Katsumata, Taichi Kanzawa, Satoshi Miyairi, Masako Ikemiyagi, Yasuyuki Ishii, Masayoshi Okumi, Kazunari Tanabe. Tokyo, Japan.

C116  Patterns of Monocyte Differentiation and Activation in a Non-Human Primate Model of Brain Death
Peter J. Chlebeck, Juan S. Danobeitia, Laura J. Zitur, Tiffany Zens, Xianyao Xu, Scott Odorico, Anthony M. D’Alessandro, Luis A. Fernandez. Madison, WI.

C117  A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens
Hiroshi Sakai, Yuka Tanaka, Hideki Ohdan. Hiroshima, Japan.

C118  Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes Following Lung Transplantation

C119  DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells
Sebastian O. Stead, Svjetlana Kireta, Steven J. McInnes, Peter Rose, Shilpanjali Jesudason, Shane T. Grey, Darling Rojas-Canales, Robert Carroll, Nicolas H. Voelcker, Patrick T. Coates. Adelaide, Australia; Sydney, Australia.

C120  Platelets Stimulate Liver Sinusoidal Endothelial Cells to Secrete Interleukin-6 During the Early Phase of Liver Regeneration in Mice

C121  CD16+ Monocytes and Skewed Macrophage Polarization Towards M2 Type Hallmark Heart Transplant Acute Cellular Rejection

C122  M1 Macrophage-Induced Loss of KLF15 Promotes Chronic Podocyte Injury
Seung Seok Han, Yong Chul Kim, Sunhwa Lee, Hajeong Lee, Ran-Hui Cha, Jung Pyo Lee, Jae Wook Lee, Dong Ki Kim, Yon Su Kim, Seung Hee Yang. Seoul, Korea.

C123  Toll-Like Receptor 4-Dependent CCAAT-Enhancer-Binding Protein Homologous Protein Activation Induces Hepatocellular Cell Death in Liver Ischemia and Reperfusion Injury

C124  A Novel MyD88 Inhibitor Attenuates Allograft Rejection in Heterotopic Tracheal Transplantation in Mice
Min Yang, Xue Zhang, Gen Chen, Zuo-chuan Ding, Yan Miao, Yang Yang, Ping Zhou. Wuhan, Hubei, China.

C125  The Beneficial Effects of mTOR Inhibitors on Liver Resident Natural Killer Cells
Jamilya Saparbay, Yuka Tanaka, Takuya Yano, Hideki Ohdan. Hiroshima, Japan.

C126  CCR5-Mediated Recruitment of NK Cells to the Kidney Is Critical for Resistance to Candida albicans Infections
Jong S. Lee, Vuvi G. Tran, Hye J. Kim, Byungsuk Kwon, Kyung S. Park, Hong R. Cho. Ulsan, Republic of Korea; Ulsan, South Korea, Republic of Korea.

C127  Histone Methyltransferase EZH2 Was Involved in the Mechanism of let-7e Inhibition of TNF-α Expression
Junqi Huang, Yingke Zhang, Qianqian Zhang, Lian Gui, Yan Cai, Xiaohong Deng. Guangzhou, Guangdong, China.
Kidney Complications III

C128 Pregnancy Outcomes in Female Kidney Transplant Recipients Using Assisted Fertility Methods
Lisa A. Coscia, Dawn P. Armenti, Serban Constantinescu, Michael J. Moritz. Philadelphia, PA; Allentown, PA; Tampa, FL.

C129 Discrepancies in Perceived and Measured Cognitive Abilities in Transplant Recipients
Aditi Gupta, Jonathan Mahanken, Jeffrey Klein, David Johnson, Jeffrey Burns. Kansas City, KS; Lawrence, KS; Kansas City.

C130 Decision Tree Analysis of Renal Transplantation Recipients Outcomes: A Single Center Data Mining in the Big Data Era

C131 Subpopulations of Peripheral Blood Monocytes in Kidney Allograft Recipients
Ilja Striz, Veronika Svachova, Alena Sekerkova, Janka Slatinska, Kristyna Kopecka, Martina Fialova, Ondrej Vítkicky. Prague, Czech Republic.

C132 Assessments of Literacy, Cognitive Function and Transplant Medication Knowledge in Renal Transplant Recipients

C133 Polypharmacy and Frailty in Kidney Transplant Recipients
Hao Ying, Mara McAdams-DeMarco, Dorry Segev. Baltimore, MD.

C134 Adjuvant Chemotherapy with Gemcitabine Plus Cisplatin for Kidney Transplant Patients with Transitional Cell Carcinoma
Zhipeng Wang, Jun Lin, Yichen Zhu, Jian Zhang, Jing Xiao, Yuwen Guo, Ye Tian. Beijing, China.

C135 Renal Secretion of Organic Anionic Drugs Is Compromised in Renal Transplant Patients
Hari V. Kalluri, Puneet Sood, Parmjeet Randhawa, Sundaram Hariharan, Amit Tevar, Abhinav Humar, Raman Venkataraman. Pittsburgh, PA.

C136 Primary Urtero-Ureterostomy in Renal Transplant, an Old Forgotten but Promising Technique

C137 Renal Function, Albuminuria and the Risk of Death and Graft Loss After Kidney Transplantation
Ngan N. Lam, Marcello Tonelli, Krista L. Lentine, Brenda Hemmelgarn, Feng Ye, Kevin Wen, Scott Klarenbach. Edmonton, Canada; Calgary, Canada; St. Louis.

C138 Renal Transplant Recipients with Indication for Antiplatelet Therapy: Increased Risk for the Allograft?
Tamas Benko, Marlene Gottmann, Sonia Radunz, Jurgen W. Treckmann, Fuat H. Saner, Andreas Paul, Dieter P. Hoyer. Essen, Germany.

C139 Pregnancy During Kidney Transplantation in a Low Income Population

C140 Impact of Pancreas Transplant Failure in Quality of Life in Simultaneous Kidney Pancreas Transplantation

C141 NAFLD in Kidney Transplant Candidates
Nyingi Kemmer, Jacentha Buggs. Tampa, FL.
C142 Reducing the Early Readmission Rates in Kidney Transplantation
Melissa Gaspar Tavares, Marina Pontello Cristelli, Laila Almeida Viana, Isabelle Malbouisson, Mayara Ivani Paula, Helio Tedesco Silva Junior, Jose Osmar Medina Pestana. São Paulo, Brazil.

C143 Titers of Blood Group B Patients Using Non-A1 Reagent/Donor Cells for the Purpose of ABO Incompatible Kidney Transplantation

C144 Improving Clinical Decisions for Kidney Transplant Recipients Through Online Medical Simulation

C145 Do Perioperative Blood Transfusions Influence Kidney Transplant Outcomes in the Modern Era?
James Lineen, Justin Trac, Yanhong Li, Olusegun Famure, Joseph Kim. Toronto, ON, Canada.

C146 Impact of Type 2 Surgical Injuries in Postmortem Donor Kidneys on the Post-Transplant Outcomes When Compared to Mate Non-Injured Kidney from the Same Donor
Muhammad Mujtaba, Ann Kathleen N. Gamilla-Crudo, Kristene Gugliuzza, Omar Aleté, Sujan Shah, Yvette Chapman, Jeffrey Reese, Somer Masood, Tim Taber. Galveston, TX; Dallas, TX; Indianapolis, IN.

C147 Technical Characteristics, Optimization and Outcomes of Ultrasound-Guided Biopsy Performed on Kidney Transplant Patients
Javier Juega, Monica Perez, Laura Cañas, Maribel Troya, Ioana Bancu, Josep Bonet, Ricardo Lauzurica. Badalona, Spain.

C148 Psychosocial Distress in Chronic Kidney Disease: Benefits of Kidney Transplantation
Candice Richardson, Dmitri Belenko, Eszter C. Mucsi, Nathaniel Edwards, Dorothy Wong, Marta Novak, Madeline Li, Istvan Mucsi. Toronto, ON, Canada.

C149 Very Long Term Graft Survival. Forecasts Factors

C150 Utility of a 10-Minute Functional Test as a Predictor of Kidney Transplant (KTP) Listing
Melissa L. Swee, Jodell L. Hornickel, Roberto S. Kalil. Iowa City, IA.

C151 Clinical Outcomes in Older Kidney Transplant Recipients. A Single Center Experience

C152 Outcomes After Cholecystectomy in Patients with End Stage Renal Disease

C153 Building a Conceptual Framework of Treatment Burden After Kidney Transplant: A Qualitative Study
Elizabeth C. Lorenz, Jason S. Egginton, Mark D. Stegall, Andrea L. Cheville, David T. Eton. Rochester.

C154 Is There a “Weekend Effect” in Kidney Transplantation? – A Single Center Study
Katharina Schütte-Nütgen, Gerold Thölking, Hermann Pavenstädt, Barbara Suwelack, Stefan Reuter. Münster, Germany.

C155 Risk and Prognosis of Developing Procedural Complications in Renal Allograft Biopsy, Including AVF and DVT
Hiroshi Ide, Kazuhiro Iwadoh, Ichiro Nakajima, Shohei Fuchinoue. Shinjuku ku, Tokyo, Japan.

C156 Urinary Concentration Ability in Kidney Transplant Patients as Predictor for CKD
C157 Kidney Transplantation in Octogenarians: The Mayo Clinic Experience
Nadeen Khoury, Thomas Schwab, Mikel Prieto, Hatem Amer. Rochester, MN.

C158 Development and Validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) Criteria to Assess Drug Related Problems in Outpatient Renal Transplant Population

C159 Avascular Necrosis in Kidney Transplant Recipients: Recent Data from a Cohort Study

C160 Outcomes After Hysterectomy in Patients with End Stage Renal Disease

C161 Death After Kidney Transplantation: Assessment of Pre- and Peri-Transplant Risk Factors and of Time-Varying Risk Factors from the Post-Transplant Course
Irina Scheffner, Tanja Abeling, Annika Karch, Michael Mengel, Verena Broeker, Armin Koch, Hermann Haller, Anke Schwarz, Wilfried Gwinner. Hannover, Germany; Edmonton, Canada; Gothenburg, Sweden.

C162 Early Outcomes of Kidney Transplantation When Comparing Waist-to-Hip Ratio vs. Body Mass Index
Rohan Patankar, Ann Kathleen N. Gamilla-Crudo, Kristene Gugliuzza, Omar Salim, Sujan Shah, Farukh Ikram, Muhammad Mujtaba. Galveston, TX.

C163 Utility of Electron Microscopy in Kidney Transplant Biopsies
Jacob Grodsky, Randall Craver, Isa Ashoor. New Orleans, LA.

C164 Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race
Karim Soliman, Aurora Posadas Salas, David Taber. Charleston, SC.

C165 TNFα-1 After Kidney Transplantation
Brenda L. Muth, Brad C. Astor, Didier A. Mandelbrot. Madison, WI.

C166 The Treatment of the Graft and the Recipient with α-Lipoic Acid Improves the Delay Graft Function Severity in the Human Kidney Transplant

C167 Early and Late High Intrapatient Variability of Tacrolimus Levels Can Predict Late Renal Allograft Rejection
Dawn Goodall, Michelle Willcombe, Daniel Swerdlow, Adam McLean, David Taube. London, United Kingdom.

C168 Benefits of Multimodal Enhanced Recovery Pathway in Patients Undergoing Kidney Transplantation

C169 Scoring of Distinct Tubular Injury Features and Assessment of Cellular Proliferation and of Non-Apoptotic Cell Death by the Novel Marker FACL4 Allow to Determine the Long-Term Prognosis of Renal Grafts

C170 Endovascular Management of Transplant Renal Artery Stenosis: A Safe and Effective Treatment
C171 † Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
Syed A. Hussain, Tim Taber, Muhammad S. Yaqub, Oluwafisayo Adebiyi, Dennis Mishler, Asif Sharfuddin. Indianapolis.

C172 † A Comparative Study of Patient and Graft Qualities Between ABO-Compatible and -Incompatible Recipients More Than Ten Years After Kidney Transplantation
Hideki Ishida, Tomokazu Shimizu, Masayoshi Okumi, Kouhei Unagami, Kazuya Omoto, Kazunari Tanabe. Tokyo, Japan.

C174 NFAT-Regulated Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Recipients – A Randomized Controlled Trial

Organ Allocation, Meld Score, Organ Utilization and Transplant Outcomes

C175 † Sequential Liver-Kidney Transplantation Is Equivalent to Simultaneous Liver–Kidney Transplantation in Candidates Requiring Dialysis Pre-Transplant

C176 † Waitlist Outcomes of Patients Re-Listed Following Failed Donation After Cardiac Death (DCD) Liver Transplant
Kristopher P. Croome, David D. Lee, Andrew Keaveny, C. Burcin Taner. Jacksonville, FL.

C177 † National Trends in Utilization of Donation After Cardiac Death Donor Livers for Transplantation
Shekhar Kubal, Richard Mangus, Burcin Ekser, Rich Amos, Jonathan Fridell. Indianapolis, IN.

C178 Survival Benefit of Liver Transplantation for Patients with MELD Spike
Xun Luo, Allan Massie, Dorry Segev. Baltimore, MD.

C179 Proposal for HCC Exception Points to Match Drop Out Risk
Heidi Yeh, Mustafa Akan, Ngai-Hang Leung, James Markmann, Sridhar Tayur. Pittsburgh; Hong Kong, Hong Kong; Boston.

C180 Variables Associated with Liver Graft Utilization and 30-Day Failure: A Liver Graft Quality Index
Jiurui Tang, Mahtash Esfandiari, Ali Zarrinpar. Los Angeles, CA.

C181 Trends in Liver Transplantation Among Older Adults with ESLD
Christine Haugen, Qiong Huang, Marcos Pozo, Mara McAdams-DeMarco, Dorry Segev. Baltimore.

C182 Liver Transplantation Using Pediatric versus Adult Donor Grafts in Adult Recipients
Zhiyong Guo, Yunhua Tang, Xiaoshun He, Guodong Chen. Guangzhou, China.

C183 Development and Validation of an FLF-Transplant Score to Predict Mortality of Patients with Fulminant Liver Failure
Zhiyong Guo, Binfeng Chen, Xiaoshun He, Guodong Chen. Guangzhou, China.

C184 Liver Transplantation Beyond MELD 40

C185 In Mid Wait Regions Shorter Height and Female Sex Confer Lower Probability of Liver Transplant (LT) Among Patients with Hepatocellular Carcinoma (HCC)

C186 Regional Variation in Liver Donor Utilization Across the U.S.
Amy L. Friedman, Pradeep Bagavan, Sander S. Florman, Helen Irving, Benjamin Samstein, Benjamin R. Schleich. New York, NY; Binghamton, NY.

C187 Status 1 Liver Transplantation: Changes in Characteristics and Outcome Over Time
Hung Truong, Lea Lacar, Linda Wong. Honolulu, HI.
C188 Polycystic Liver Disease Patients May Not Be Appropriately Represented by MELD Exception Policy
Sajiv Chandradas, Jill Waalen, Catherine Frenette. La Jolla, CA.

C189 Donation After Cardiac Death (DCD) Liver Transplantation (LT) Is Not Associated with Post-LT Renal Dysfunction
Hani Wadei, Martin Mai, David Lee, Kristopher Croome, Barry Rosser, Andrew Keaveny, Burcin Taner. Jacksonville, FL.

C190 Racial Differences in Liver Cirrhosis-Related Mortality Among Patients with Model for End-Stage Liver Disease Sodium Score (MELDNa) ≤ 15

C191 Anastomosis Time During Liver Transplantation Impairs Transplant Survival

C192 Graft and Patient Survival in Liver Transplantation for Primary Sclerosing Cholangitis with Organs from DCD versus DBD Donors: Analysis of the UNOS Database
Omar Y. Mousa, Juan E. Corral, Mao Yin Pang, David D. Lee, Justin H. Nguyen, Kristopher Croome, Denise Harnois. Jacksonville, FL.

C193 Exceptions Points and Size Drive Gender Disparities in Liver Transplantation

C194 Geographic Differences in Secular Trends of Liver Supply and Demand
Eric Chow, Rashikh Choudhury, Allan Massie, Sommer Gentry, Dorry Segev. Baltimore; Annapolis.

C195 Extraction Time During Liver Retrieval Impairs Survival After Transplantation

C196 WHO Group II Pulmonary Hypertension Is Associated with Decreased Survival in Patients Awaiting Liver Transplantation

C197 Donor Body Mass Index and Utilization of Liver Biopsy: An Evaluation of National Practices and Organ Utilization
Justin A. Steggerda, Daniel R. Marguiles, Darren Malinoski, Matthew B. Bloom. Los Angeles, CA; Portland, OR.

C198 A Surge in Liver Donors After Years of Decline, Is This the Tip of the Iceberg?
Abbas Rana, Matthew Goss, Jeffrey Rees, Michael Kueht, John Vierling, Ayse Mindikoglu, Karim Halazun, Norman Sussman, Bruce Kaplan, Patrick Wood, N. Thao N. Galvan, Ronald Cotton, Christine O'Mahony, John Goss. Houston; Dallas; New York; Phoenix.

C199 Exception Scores for Patients on the Liver Waiting List

C200 Greater Emphasis on Non-Eligible Donors as a Strategy to Decrease the Organ Shortage
Kristopher P. Croome, David D. Lee, Andrew Keaveny, C. Burcin Taner. Jacksonville, FL.

C201 Multidisciplinary Psychosocial Liver Transplant Evaluation in Patients with Alcoholic Liver Disease – Moving Beyond the Six-Month Rule
Kevin E. Wenzke, Sean G. Kelly, Jens C. Eickhoff, Michael R. Lucey, John P. Rice. Madison, WI; Columbus, OH.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>C203</td>
<td>Is It Safe to Use Older Donor Liver Grafts for Older Recipients?</td>
<td>Mohamed Safwan, Kelly Collins, Kazuhiro Takahashi, Michael Rizzari, Atsushi Yoshida, Marwan Abouljoud, Shunji Nagai. Detroit, MI.</td>
</tr>
<tr>
<td>C204</td>
<td>ECMO in Liver Transplant</td>
<td>Naeem Goussous, Steven Hanish, John LaMattina, Zachary Kon, Darryn Potosky, Joseph Scalea, William Hutson, Rolf Barth, David Bruno. Baltimore, MD.</td>
</tr>
<tr>
<td>C207</td>
<td>A Multicenter, Prospective and Randomized Trial Comparing Pancreas versus Islet Transplantation: Should We Do It Now?</td>
<td>Diego Cantarovich, Pierre-Yves Benhamou. Nantes, France; Grenoble, France.</td>
</tr>
<tr>
<td>C209†</td>
<td>Survival Benefit of Kidney and/or Pancreas Transplantation for Patients with Type 1 Diabetes in the United States</td>
<td>Rainer W. G. Gruessner, Mark R. Laftavi, Oleh Pankowycz, Vaughn Whittaker, Zeki Acun, Vikram Aggarwal, Nuri Ozden, Angelika C. Gruessner. Syracuse, NY.</td>
</tr>
<tr>
<td>C210†</td>
<td>Simultaneous Pancreas and Kidney Transplant (SPK) – The New Standard of Care for Uremic Patients with Type 2 Diabetes Mellitus (T2DM)</td>
<td>Angelika C. Gruessner, Mark Laftavi, Vaughn Whittaker, Zeki Acun, Oleh Pankowycz, Rainer Gruessner. Syracuse, NY.</td>
</tr>
<tr>
<td>C213</td>
<td>Beta Cell-Specific Free Circulating DNA May Predict the Outcome After Clinical Islet Transplantation</td>
<td>Boris L. Gala-Lopez, Daniel Neiman, Tatsuya Kin, Doug O’Gorman, Andrew R. Pepper, Andrew J. Malcolm, Benjamin Glaser, Ruth Shemer, Yuval Dor, James Shapiro. Edmonton, AB, Canada; Jerusalem, Israel.</td>
</tr>
<tr>
<td>C214</td>
<td>Post-Transplant Lymphoproliferative Disorder: Risk Analysis for Pancreas Transplant Patients</td>
<td>Emmanuel Minja, Ty Dunn, Arthur Matas, Timothy Pruett, Raja Kandaswamy, Erik Finger. Minneapolis, MN.</td>
</tr>
</tbody>
</table>
C215 Impact of Intensive Dosing of Mycophenolate on Pancreas Allograft Survival  
Jillian Fose, Kate Rolling, Nate Menninga, Glen Le3erson, Margaret Jorgenson, Jon Odorico, Redfield Robert. Madison, WI.  

C216 Neurogenic Orthostatic Hypotension: An Iatrogenic Complication of Successful Pancreas Transplantation?  

C217 Patterns and Associated Risk Factors for Early Readmissions Post Total Pancreatectomy and Islet Auto-Transplantation (TP-IAT)  
Varvara Kirchner, Anantha Bagdiwala, David Vock, Melena Bellin, Gregory Beilman, Louise Berry, Srinath Chinnakotla, Ty Dunn, Martin Freeman, David Sutherland, Timothy Pruett. Minneapolis.  

C218 Impact of Early Pancreas Graft Failure on Patient and Kidney Graft Survival After Simultaneous Pancreas and Kidney Transplantation (SPK)  
Angelika C. Gruessner, Mark R. Laftavi, Vaughn Whittaker, Zeki Acun, Oleh Pankowycz, Rainer Gruessner. Syracuse, NY.  

C219 Association of BK and CMV Viremia with Pancreas Allograft Survival Among Adults receiving Simultaneous Pancreas and Kidney Transplant: The Wisconsin Allograft Recipient Database (WisARD)  
Fahad Aziz, Brad Astor, Sandesh Parajuli, Neetika Garg, Brenda Muth, Didier Mandelbrot, Arjang Djamali, Dixon Kaufman, Jon Odorico, Hans Sollinger, Maha Mohamed. Madison, WI.  

C220 Posttransplant Employment Patterns Are More Favorable in Patients with Solitary Pancreas vs. Simultaneous Pancreas/Kidney (SPK) Transplants – The Impact of Native Kidney Function  

C221 Safety of Percutaneous Pancreas Allograft Biopsy in Enteric Drained Pancreas Transplants  
Yvonne Kassis, Emilio Poggio, Ziad Zaky. Cleveland, OH.  

C222 Does Pancreas Transplantation for the Patients with Diabetes Showed Significant Survival Benefit?  

C223 Outcomes Following Solitary Pancreas Transplantation – Do Steroids Matter?  
Carol C. Chan, Ignatius Y. S. Tang, Jose Oberholzer, Maya Campara. Chicago.  

C224 Clinical Outcome of Pancreas Transplantation in Elderly Patients with Diabetes Mellitus  

C225 Intraomental Non-Purified Islet Transplantation Isolated from DCD Donor Pancreas  
Shusen Wang, Guanghui Pei, Yaojuan Liu, Zhiping Wang, Boya Zhang, Yan Xie, Jinshan Wang, Zhongyang Shen. Tianjin, China.  

C226 Improved Method to Obtain High Islet Mass from Severely Fibrotic Pancreatitis Pancreases Intended for Clinical Islet Auto-Transplantation  

C227 Insulin Therapy in Pancreas Donors as a Predictor of Subsequent Transplant Outcome  
Iestyn M. Shapey, Hussein Khambalia, Angela Summers, Titus Augustine, Martin K. Rutter, David van Dellen. Manchester, United Kingdom.  

C228 Impact of Early Pancreas Graft Failure on Patient and Kidney Graft Survival After Simultaneous Pancreas and Kidney Transplantation (SPK)  
Angelika C. Gruessner, Mark R. Laftavi, Vaughn Whittaker, Zeki Acun, Oleh Pankowycz, Rainer Gruessner. Syracuse, NY.  

C229 Association of BK and CMV Viremia with Pancreas Allograft Survival Among Adults receiving Simultaneous Pancreas and Kidney Transplant: The Wisconsin Allograft Recipient Database (WisARD)  
Fahad Aziz, Brad Astor, Sandesh Parajuli, Neetika Garg, Brenda Muth, Didier Mandelbrot, Arjang Djamali, Dixon Kaufman, Jon Odorico, Hans Sollinger, Maha Mohamed. Madison, WI.  

C230 Posttransplant Employment Patterns Are More Favorable in Patients with Solitary Pancreas vs. Simultaneous Pancreas/Kidney (SPK) Transplants – The Impact of Native Kidney Function  

C231 Safety of Percutaneous Pancreas Allograft Biopsy in Enteric Drained Pancreas Transplants  
Yvonne Kassis, Emilio Poggio, Ziad Zaky. Cleveland, OH.  

C232 Does Pancreas Transplantation for the Patients with Diabetes Showed Significant Survival Benefit?  

C233 Outcomes Following Solitary Pancreas Transplantation – Do Steroids Matter?  
Carol C. Chan, Ignatius Y. S. Tang, Jose Oberholzer, Maya Campara. Chicago.  

C234 Clinical Outcome of Pancreas Transplantation in Elderly Patients with Diabetes Mellitus  

C235 Intraomental Non-Purified Islet Transplantation Isolated from DCD Donor Pancreas  
Shusen Wang, Guanghui Pei, Yaojuan Liu, Zhiping Wang, Boya Zhang, Yan Xie, Jinshan Wang, Zhongyang Shen. Tianjin, China.  

C236 Improved Method to Obtain High Islet Mass from Severely Fibrotic Pancreatitis Pancreases Intended for Clinical Islet Auto-Transplantation  

C237 Insulin Therapy in Pancreas Donors as a Predictor of Subsequent Transplant Outcome  
Iestyn M. Shapey, Hussein Khambalia, Angela Summers, Titus Augustine, Martin K. Rutter, David van Dellen. Manchester, United Kingdom.
Elevated Serum Lipase Levels in Simultaneous Pancreas and Kidney Transplantation May Indicate Anti-HLA Donor Specific Antibody Response
Basit Javaid, Tahir Raza, Peter Abrams, Seyed Ghasemian, Jack Moore, Alexander Gilbert, Monica Grafals, Jennifer Verbeseay, Matthew Cooper. Washington, DC.

Kidney Re-Transplant Rate in Simultaneous Kidney Pancreas Transplant Recipients
Melanie McCormick, Jiangtao Luo, Arika Hoffman. Omaha, NE.

Send Diabetes on a Long Trip: The Pancreas Travels Well
Jay A. Graham, Michelle L. Lubetzky, Attasit Chokechanachaisakul, Milan Kinkhabwala, Juan P. Rocca. Bronx, NY.

HLA Mismatching Does Not Have an Impact on Graft or Patient Survival in Simultaneous Kidney-Pancreas Transplantation. A Single Institution Experience
Irfan Moinuddin, Muhammad S. Yaqub, Tim Taber, Dennis Mishler, Muhammad A. Mujtaba, John Powelson, Oluwafisayo Adebiiyi, Jonathan Fridell, Asif Sharfuddin. Indianapolis.

The Association of Donor Vasoactive Drugs with Pancreas Transplant Graft Survival
Iestyn M. Shapey, Petros Yianoullou, Angela Summers, Titus Augustine, Martin K. Rutter, David van Dellen. Manchester, United Kingdom.

Pancreas Transplant with Duodeno-Duodenostomy and Caval Drainage Using a Diamond Patch Graft: A Single-Center Experience
Byung Hyun Choi, Tae Beom Lee, Young Mok Park, Kwang Ho Yang, Chong Woo Chu, Je Ho Ryu, Byung Hyun Choi. Yangsan, Korea.

Simultaneous Pancreas/Kidney Transplant Recipients Are Predisposed to Symptomatic CMV-Infection and Concomitant Infectious Complications
Thomas Schachtner, Marina Zaks, Andreas Kahl, Petra Reinke. Berlin, Germany.

BK Virus in Simultaneous Pancreas Kidney Transplantation

Impact of Pancreatic Texture Assessment on Islet Isolation and Metabolic Outcome After TPIAT
Gumpei Yoshimatsu, Monila Khadka, Michael C. Lawrence, Balamurugan N. Appakalai, Bashoo Naziruddin. Dallas, TX; Louisville, KY.

Contributing Factors and Impact of Microbial Contamination in Human Islet Isolation and Transplantation

Total Pancreatectomy with Islet Autotransplantation Improves Quality of Life Allowing for the Resolution of the Intractable Pain with Good Glucose Control in Properly Selected Patients with Chronic Pancreatitis
Alexander Kotukhov, Julia Solomina, Evelyn Konur, Kamil Cieply, Lindsay Basto, Ling-jia Wang, Karolina Golab, Martin Tibudan, Andres Gelrud, Celeste Thomas, Jeffrey B. Matthews, Piotr Witkowski. Chicago, IL.

Initial Experience with Total Pancreatectomy-Islet Auto-Transplantation (TP-IAT) for Chronic Pancreatitis at the University of Louisville
Michael Hughes, Eric Davis, Sriprakash Mokshagundam, William Tucker, Gopalakrishnan Loganathan, Stuart Williams, Balamurugan Appakalai. Louisville, KY.
C240 Pancreatectomy and Islet Autotransplantation After Combined Split Liver Transplantation and Pancreaticoduodenectomy: A Case Report
Rune Horneland, Steinar Guvåg, Olle Korsgren, Einar Aandahl. Oslo, Norway; Uppsala, Sweden.

C241 Evaluation of Graft Functional Recovery After Simultaneously Pancreas and Kidney Transplantation with Donation After Cardiac Death in China (16 Cases of Report)

C242 Simultaneous Pancreas-Kidney Transplantation Can Be Safely Done on Dabigatran Therapy
Wojciech Lisik, Agnieszka Jozwik, Jaroslaw Czerwinski, Lukasz Gorski, Maciej Kosieradzki. Warsaw, Poland.

C243 Serva NB1 versus Vitacyte Collagenase: Comparable Human Islet Isolation Outcomes Using DCD Donor Pancreas in China

C244 Total Pancreatectomy and Islet Autotransplantation into the Liver of a Patient with Previous Hepatitis C Infection
Amer Rajab, Jill Buss, Phil A. Hart, Darwin Conwell, Sylvester M. Black, Ken Washburn. Columbus, OH.

C245 Surgical Techniques for Pancreas Transplantation Graft without Vascular Reconstruction (Report of 8 Cases)

C246 Comparative Analysis of Four Surgical Techniques in More Than 700 Pancreas Transplantes in a Single Center
Marcelo Perosa, Juan Branez, Leonardo T. Mota, Beimar Zeballos, Huda Noujaim, Luiz E. Ianhez, David Machado, Leon Alvim, Marcio Paredes, Tercio Genzini. Sao Paulo, Brazil.

C247 Safety and Decreased Inflammation of Early Double Cytokine Blockade (IL-1β and TNF-α) Facilitates Engraftment in Islet Allotransplantation
Nicholas Onaca, Morihito Takita, Marlon F. Levy, Bashoo Naziruddin. Dallas; Richmond.

C248 eHealth Literacy and Patient Portal Utilization Among Transplant Recipients
Kayla D. Smith, Aldrick Ruiz, Joel Wedd, Stephen Pastan, Ruth Parker, Rachel E. Patzer. Atlanta, GA.

C249 Electronic Patient Portal Functionality Among Kidney and Liver Transplant Recipients
Aldrick P. Ruiz, Kayla D. Smith, Joel Wedd, Kendra Little, Stephen Pastan, Rachel E. Patzer. Atlanta, GA.

C250 Transplant Professionals’ Attitudes and Approaches to the Living Kidney Donor-Recipient Relationship: Interview Study
Angeline F. Ralph, Phyllis Butow, Jonathan C. Craig, Jeremy R. Chapman, John Gill, John Kanellis, Allison Tong. Sydney, Australia; Vancouver, Canada; Melbourne, Australia.

C251 Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies
Angeline F. Ralph, Phyllis Butow, Camilla S. Hanson, Steve J. Chadban, Jeremy R. Chapman, Jonathan C. Craig, John Kanellis, Grant Luxton, Allison Tong. Sydney, Australia; Melbourne, Australia.

C252 Pilot Study on Acupuncture in Living Liver and Kidney Donors
Michelle Jesse, Mathew Kulas, Josephine Unitis, Nemie Beltran, Marwan Abouljoud. Detroit.

C253 Impact of Caregiver on 30 Day Readmission After Lung Transplant
Is There a Role for Electronic Health Service in of Therapeutic Drug Monitoring of Immunosuppression? Markus J. Barten, Iris Hausladen, Friedrich W. Mohr, Jens Garbade. Hamburg, Germany; Leipzig, Germany.

Potential Barriers Hindering Non-Directed (Altruistic) Living Kidney Donors from Donating Their Kidneys Ariella Maghen, Lorna Kwan, Grecia B. Vargas, Sarah E. Connor, Sima Nassiri, Elisabeth M. Hicks, Sally L. Maliski, Jeffrey Veale. Los Angeles, CA; Portland, OR; Kansas City, KS.

Spiritual and Religious Faith of Actual and Potential Non-Directed (Altruistic) Living Kidney Donors Ariella Maghen, Grecia B. Vargas, Sarah E. Connor, Sima Nassiri, Elisabeth M. Hicks, Lorna Kwan, Sally L. Maliski, Jeffrey Veale. Los Angeles, CA; Portland, OR; Kansas City, KS.

Commonly Expressed Living Donation Fears and Concerns by Non-Directed (Altruistic) Living Kidney Donors in the United States Ariella Maghen, Grecia B. Vargas, Sarah E. Connor, Sima Nassiri, Elisabeth M. Hicks, Lorna Kwan, Sally L. Maliski, Jeffrey Veale. Los Angeles, CA; Portland, OR; Kansas City, KS.

Medication Adherence and Medicare B Coverage Among Transplant Recipients Safia Boghani, Heather Kirkham, Zina Berry, Meen Kang. Deerfield, IL.


The Efficiency and Safety of Chemotherapy for Urothelial Carcinoma in Post-Kidney Transplanted Patients Yichen Zhu, Jun Lin. Beijing, China.

Long-Term Malignancy Risk in Kidney Transplant Recipients Treated with Cyclophosphamide Pre-Transplant for Native Glomerular Disease Jared Mills, Margaret Jorgenson, Jillian Fose, Brad Astor, Sarah Panzer. Madison, WI.

Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study Antonio Franco, Domingo Hernandez, Naroa Maruri, Angel Alonso, Marta Crespo, Auxiliadora Mazuecos, Carmen Diaz-Corte, Miguel Angel Gentil. Alicante, Spain; Málaga, Spain; Bilbao, Spain; Coruña, Spain; Barcelona, Spain; Cadiz, Spain; Oviedo, Spain; Sevilla, Spain.


C268  Operational Tolerance in Intestinal Transplantation: A Proven Possibility
Brenna Houlihan, Priscilla Cha, Chris Cosentino, Jason Kaiser, Anshi Shukla, Jason Hawksworth, Cal Matsumoto, Thomas Fishbein, Alexander Kroemer. Washington, DC; Bethesda, MD.

C269  A-Antigen (Ag)-Specific Tolerance Following A-Ag Administration to Infant Mice
Bruce Motyka, Yi Quinn Wang, Brendon Lamarche, Ibrahim Adam, Jean Pearcey, Kesheng Tao, Christopher W. Cairo, Peter J. Cowan, Lori J. West. Edmonton, Canada; Melbourne, Australia.

C270  Combination Therapy of iNKT Cell Ligand and CD40-CD154 Signal Blockade Establishes Islet Allograft Tolerance in Non-Myeloablative Bone Marrow Transplant Recipients
Taichi Kanzawa, Toshihito Hirai, Rumi Ishii, Masayoshi Okumi, Hideki Ishida, Yasuyuki Ishii, Kazunari Tanabe. Tokyo, Japan.

C271  The Transcription Factor Batf and IRF1 Controls IL-10/IL-27 Expression in Dendritic Cells and Transplant Tolerance Induction
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

C272  Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates
Kyu Ha Huh, Wiebke Sommer, Kortney Anne Robinson, Ximing Wu, Joshua Thomas Paster, Isabel M. Hanekamp, Abbas Dehnadi, Tatsuo Kawai, Rex Neal Smith, Robert B. Colvin, Gilles Benichou, Joren C. Madsen. Boston, MA.

C273  Human Regulatory T Cells Undergo Self-Inflicted Damage via Granzyme Pathways Upon Activation

C274  Increased Expression of Fibrillin-1 and Presence of Fibroblastic Reticular Cells in Treg-Rich Organized Lymphoid Structures (TOLS) of Accepted Kidney Allografts

C275  IL-33 Enhances the Ability of Dendritic Cells to Expand Human Regulatory T Cells
Yifei Zhao, Hong Zhang, Lisa M. Mathews, Heth R. Turnquist, Angus W. Thomson. Pittsburgh, PA.

C276  Expansion, Function and Clonotypic Analysis of Human Alloreactive Treg Stimulated with Different Dendritic Cell Populations or CD40L-Stimulated B Cells
Hong Zhang, Yifei Zhao, Qizhi Tang, Angus W. Thomson. Pittsburgh, PA; San Francisco, CA.

C277  Tolerogenic Potential, Migratory Pathways, Engraftment and Long-Term Survival of Human Hematopoietic Chimeric Cells – A Novel Strategy to Induce Tolerance in Transplantation
Maria Siemionow, Ewa Bryndza Tfaily, Erzsebet Szilagyi, Joanna Cwykiel, Safak Uygur, Michal Czerwinsi. Chicago, IL.

C278  Aryl Hydrocarbon Receptor Regulates Myeloid Derived Suppressor Cells by Activating the ERK Signaling in a Murine Cardiac Transplantation Model
Tsukasa Nakamura, Koji Yoshimura. Kyoto, Japan.

C279  Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Non-Human Primates
Paula Alonso-Guallart, Raimon Duran-Struuck, Jeffrey Stern, Sigal Kofman, Makenzie Danton, Jonah Zitsman, Yojiro Kato, Erik Berglund, Hugo Sondermeijer, Alicia McMurphy, Megan Levings, Megan Sykes, Adam Griesemer. New York, NY; Vancouver, Canada.
A Composite Score Associated with Spontaneous Operational Tolerance in Kidney Transplant Recipients

Loss of Bat3 Could Promote Transplant Tolerance by Regulating CD4+ T Cells Function
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

CD4*IFN-γ*IL-10* Regulatory Type 1 Cells Facilitate Prolongation of Graft Survival in Old Recipient Mice Treated with Rapamycin
Timm Heinbokel, Markus Quante, Koichiro Minami, Abdallah Elkhal, Stefan G. Tullius. Boston, MA.

CD4 Excision of Bat3 Expression Promotes Transplant Tolerance by Inducing IL-10 Expression in Dendritic Cells
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

Preventing Alloimmune Rejection in Heart Transplantation by Tolerogenic Dendritic Cells Induced by GDF15 Through Up-Regulation of IDO and Inhibition of the NFκB Signalling Pathway
Yixin Zhang, Guangfeng Zhang, Lisa A. Moszczyński, Duo Zhao, Païda Abulizi, Douglas Quan, Tina Mele, Kexiang Liu, Xiufen Zhong. London, ON, Canada; Cahngchun, China.

Which Tr1 Is Better for Transplant Tolerance Induction: Comparing the Tr1 Generated by IL-27 or TGF-bplus IL-27
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity
Cheng Yang, Bo Peng, Ming Xu, Tongyu Zhu. Shanghai, China.

The Intragraft Vascularized Bone Marrow Component and Recipient T Regulatory Cells Facilitate Tolerance Induction After Post Transplant High Dose Cyclophosphamide Treatment in VCA

CD4*CD8null T Cells Require IL-15 & IL-21 to Become Alloresponsive

Liver Targeted Expression of a Single Allogeneic MHC I Molecule Promotes Tolerance to Pancreatic Islet Allograft by Inducing Specific CD8+ Regulatory T Cells in Mice
Valentin Le Guen, Jean-Paul Judor, Vanessa Gauttier, Nicolas Ferry, Jean-Paul Souliliou, Sophie Brouard, Sophie Conchon. Nantes, France; Paris, France.

Induction of Tolerance to Renal Allografts in Non Human Primates by Concomitant Donor-Matched Vascularized Osteomyocutaneous Allotransplantation
Fushun Zhong, Guangyin Zhao, Yong Wang, Jianxing Jiang, Yanfeng Wang, Shaojun Ye, Shengxian Tao, Lin Cai, Xinghuan Wang, Qifa Ye, Gang Chen, Xin Xiao Zheng. Wuhan, Hubei, China; Shanghai, China.

CD4 and CD8 T Cells: Respectively Reprogrammed and Recapitulated in the Neonate to Induce Transplant Tolerance
Roger A. Bascom, KeSheng Tao, Lori J. West. Edmonton, Canada.

Functional Mystacial Pad Allograft Tolerance Induced and Maintained by Vascularized Bone Marrow Transplant
Cheng-Hung Lin, Madonna Rica Anggelia, Chih-Jen Wen, Wen-Yu Chuang, Hui-Yun Cheng, Chih-Hung Lin, Gerald Brandacher. Taoyuan, Taiwan; Baltimore, MD.
C293 Ethylene Carbodiimide Fixed Donor Splenocytes Combined with α-1 Antitrypsin Induce Indefinite Donor Specific Protection to Mice Cardiac Allografts
Guodong Chen, Xingqiang Lai, Longhui Qiu, Yi Zhao, Shuangjin Yu, Jin Zhang, Lizhong Chen. Guangzhou, China.

C294 CTLA4-Ig in Combination with FTY720 Reduces the Frequency of Memory Alloreactive T Cells and Promotes Heart Allograft Survival in Sensitized Recipients
Stella Hsu Wei Khiew, Jinghui Yang, James S. Young, Jianjun Chen, Qiang Wang, Dengping Ying, Vinh Vu, Michelle L. Miller, Roger Sciammas, Maria-Luisa Alegre, Anita Chong. Chicago, IL; Davis, CA.

C295 Liver Transplantation Tolerance Using Outbred Mice
Miwa Morita, Charles Miller, John J. Fung, Lina Lu, Shiguang Qian. Cleveland, OH; Chicago, MI.

C296 Dendritic Cells That Highly Express SOCS1 Induce T-Cell Hyporesponsiveness and Prolong Islet Allograft Survival
Ronghui Deng, Xinjun Lu, Maogen Chen, Zhicheng Xue, Xuzhi Zhang, Jiejie Xu, Linwei Wu, Yi Ma. Guangzhou, China.

C297 Heat Shock Protein 90 Inhibitor, 17DMAG Suppresses Acute Allograft Rejection and Prolongs Allograft Survival in Solid Organ Transplantation
Takeshi Maehana, Toshiaki Tanaka, Naoya Masumori. Sapporo, Japan.

C298 Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?

C299 † MERTK Mediates Transplantation Tolerance via Inhibition of TBK1 Phosphorylation and IFN-α Production
Lei Zhang, Mathew DeBerge, Xiaomin Zhang, Jiaojin Wang, Zheng Zhang, Edward Thorp, Xunrong Luo. Chicago, IL.

C300 † CD8+ TAb-supp Cells Are Key Inhibitors of Humoral Alloimmunity by Inhibiting CD4+ TFH Cells and Killing Germinal Center B Cells
Jason M. Zimmerer, Christina L. Avila, Steven M. Elzein, Bryce A. Ringwald, Robert Warren, Ginny L. Bumgardner. Columbus, OH.

C301 † Exosomes Containing IL35 Are Secreted by Donor-Specific Regulatory T Cells and Cause Linked-Suppression

C302 † A Novel Method for iNKT Cell-Mediated Ex Vivo Treg Expansion Applied to Induce Human Transplant Tolerance
Haruki Katsumata, Masako Ikemiyagi, Satoshi Miyairi, Rumi Ishii, Taichi Kanzawa, Hironori Fukuda, Toshihito Hirai, Masayoshi Okumi, Yasuyuki Ishii, Kazunari Tanabe. Tokyo, Japan; Yokohama, Japan.

Tolerance: Clinical Studies

C303 In Depth Characterization of Ex Vivo Expanded Polyclonal Regulatory T Cells Used in a Phase I Clinical Trial Following Kidney Transplantation
Jessica Heinrichs, James Mathew, Iwona Konieczna, Jie He, Xuemei Haung, Ann LeFever, Joseph Leventhal. Chicago, IL.

C304 † CD19+CD38hiCD24hi Immature Transitional B Cells in PBMCs of Tolerant Kidney Recipients of Facilitating Cell-Enriched Hematopoietic Stem Cells and Renal Allografts
Yujie Wen, Andrea R. Merchak, Yiming Huang, Hong Xu, Larry E. Kahn, Joseph R. Leventhal, Suzanne T. Ildstad. Louisville, KY; Chicago, IL.

C305 Identification of Promising Targets for Tolerance Induction Following Heart Transplantation
Kristin Klaeske, Maja-Theresa Dieterlen, Julia Fischer, Jochen Hahn, Khalil Jawad, Jens Garbade, Friedrich W. Mohr, Sven Lehmann. Leipzig, Germany.
Poster Session D
Poster Viewing: 9:30 am – 12:00 pm
2:30 pm – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm
Hall D1

D# indicates the board location where the poster will be displayed.
† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

Cellular & Bone Marrow Transplantation Session II

D1 In Vitro Optimisation of the Immunotherapeutic Effects of Umbilical Cord Derived MSC
Rotterdam, Netherlands; Galway, Ireland; Birmingham, United Kingdom; Mayfield Village.

D2 The Impact of Tracheal Epithelial Cells Apoptosis on the Biological Behavior of Bone Marrow Mesenchymal Stem Cells (BMSCs) in OB
Xiayi Zhang, Tian Xia, Chuanxiao Wang, Ke Jiang, Jianjun Wang, Jun Nie. Wuhan, Hubei, China.

D3 Experimental Study of Hepatocyte Proliferation Regulated by miR26a

D4 Immunoregulatory Roles of CD137 Signaling in Graft-versus-Host Disease
Hong R. Cho, Juyang Kim, Byungsu Kwon, Jong S. Lee, Kyung S. Park. Ulsan, Republic of Korea.

D5 Induced Pluripotent Stem Cell (iPS) Derived Schwann Cells to Enhance Functional Recovery Following Nerve Injury and Limb Allotransplantation
Barbara Kern, Karim Sarhane, Zuhaib Ibrahim, Bipasha Mukherjee-Clavin, Joshua Budihardjo, Chris Cashman, Kellin Krick, Stefan Schneeeberger, W. P. Andrew Lee, Hai-Quan Mao, Gabsang Lee, Gerald Brandacher. Innsbruck, Austria; Baltimore, MD.

D6 Generation of Potent Monocytic Myeloid-Derived Suppressor Cells from Rhesus Macaque Bone Marrow

D7 Impact of Culture Expansion and Inflammatory Cytokine Challenge on DNA Methylation Profiles in MSC
Rotterdam, Netherlands; Galway, Ireland; Birmingham, United Kingdom.

D8 IP-10 Monoclonal Antibody Treatment Suppresses Inflammatory Components of IBMIR and Improves Pancreatic Islet Graft Function
Gumpei Yoshimatsu, Charles A. Chang, Carly M. Darden, Prathab B. Saravanan, Bashoo Naziruddin, Michael C. Lawrence. Dallas, TX.

D9 Decellularized Rat Liver Scaffolds Support Survival and Metabolic Function of Multilineage Allogenic Cells

D10 Immunosuppressive Role of Pancreas Derived Mesenchymal Stem Cells
Mazhar A. Kanak, Faisal Kunnathodi, Marlon Levy, Michael C. Lawrence, Bashoo Naziruddin. Richmond, VA; Dallas, TX.
D11 Depletion of T-Cells from G-CSF Mobilized Human PBMC Prevents Acute GVHD in NSG Mice
Yiming Huang, Hong Xu, Andrea Merchak, Anita Chhabra, Yujie Wen, Larry Kahn, Suzanne Ildstad. Louisville, KY.

D12 Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model
Joanna Cwykiel, Natalia Filipek, Erzsebet Szilagyi, Ewa Tfaily, Maria Siemionow. Chicago, IL.

D13 Cell-Subset Diversity in Adipose Derived Regenerative Cells Used in Renal Ischemic Reperfusion Injury Treatment
Rashida Lathan, Ryan S. Ghita, Dianne Z. Hillyard, Patrick B. Mark, Marc Clancy. Glasgow, United Kingdom.

D14 Enhanced Hepatic Engraftment of Stem Cell Derivatives Using Magnetic Targeting into Structurally Normal Liver
Naiyou Liu, Sam Fagg, Jeffrey Fair. Galveston, TX.

D15 The Novel Establishment of Neuroma in Continuity Animal Model Based on Buccal Nerve in Rats
Yun-Huan Hsieh, Chih-Jen Wen, Cheng-Hung Lin, Fu-Chan Wei, Yu-Cheng Pei. Taoyuan, Taiwan.

D16 Beneficial Effects of Human Mesenchymal Stromal Cells on Porcine Hepatocytes Viability and Albumin Secretion

D17 Senescence and Uremia Effects in Circulating T Cells Diverge in TREG Population and Cause T Cell Shift to a Memory Profile

D18 Technically Successful Miniaturization of Blood Hemofilters for an Artificial Kidney via Bioengineering Techniques

D19 Biodistribution of Adipose Derived Regenerative Cells Administered via the Renal Artery in Novel Rat Transplant Model
Ryan S. Ghita, Rashida Lathan, Dianne Z. Hillyard, Patrick B. Mark, Marc J. Clancy. Glasgow, United Kingdom.

D20 The Effect of Semimature Dendritic Cell on Transplantation Tolerance of Hepatocytes Differentiated from Mouse Embryonic Stem Cells

Diagnostics/Biomarkers Session II

D21 Noninvasive Renal Transplant Graft Monitoring in Single Institution Using Cell-Free DNA in Recipient Plasma via Insertion-Deletion Allele Polymorphism
Yen Seow Goh, Sze Yee Ho, Lata Raman, Vathsala Anantharaman, Ting Hui Goh, Siew Chuan Koay, Ho Yee Tiong. Singapore, Singapore.

D22 High Eomesodermin Expression Correlates with Potent Human Allo-Reactive CD8+ Effector T Cells
Angelica Perez-Gutierrez, Diana M. Metes, Yoshihiro Ono, Angus W. Thomson, Mohamed B. Ezzelarab. Pittsburgh, PA.
D23 Transcriptome Analysis of CD4-Lymphocyte Specifically Deleted of IKKbeta or NEMO in an Experimental Model of Rapid Progressive glomerulonephritis (RPGN)

D24 Novel Biomarkers for Segregating Lung Transplant Rejection Phenotypes

D25 Pre-Transplant Recipient Transcriptomic Profile May Predict Delayed Graft Function (DGF) in Kidney Transplantation
P. Pontrelli, F. Rascio, F. Pesce, M. Accetturo, G. Castellano, G. Zaza, A. Lupo, M. Fiorentino, L. Gesualdo, G. Stallone, G. Grandaliano. Bari, Italy; Foggia, Italy; Verona, Italy.

D26 Identification of Plasma Protein Biomarkers of Acute Renal Allograft Rejection
Maura Rossetti, Connor Fitzpatrick, Nicholas Harre, Ying Zheng, Neil Mercer, Gemalene Sunga, David Gjertson, Elaine Reed. Los Angeles, CA.

D27 Donor-Derived Cell-Free DNA Parallels Increases in Donor Specific Antibodies in Pediatric Kidney Transplant Recipients
Dan J. Stoltz, Aleah Brubaker, Marica Grskovic, Robert Woodward, Amy E. Gallo. Palo Alto, CA; Brisbane, CA.

D28 Activation of Inflammation Amplifier in Kidney Graft and Urinary Biomarker for Chronic Rejection
Haruka Higuchi, Daiki Iwami, Kiyohiko Hotta, Nobu Shinohara, Masaaki Murakami. Sapporo, Hokkaido, Japan.

D29 Immune Tolerance Monitoring in Renal Allograft Tolerance Induced by Transient Mixed Chimerism in Nonhuman Primates
Kiyohiko Hotta, Tetsu Oura, Abbas Dehnadi, Kyu Ha Huh, Masatoshi Matsunami, Gilles Benichou, Joren C. Madsen, A. Benedect Cosimi, Tatsuo Kawai. Boston, MA.

D30 Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome Appearance After Lung Transplantation
R. Danger, P. J. Royer, D. Rebouleau, J. Loy, A. Tissot, P. Lacoste, A. Roux, M. Reynaud-Gaubert, R. Kessler, S. Musso, C. Dromer, O. Brugiére, J. F. Mornex, R. Guillemain, M. Dahan, C. Knoop, K. Botturi, C. Pison, L. Nicod, S. Brouard, A. Magnan, COLT and SysCLAD Consortia. Nantes, France; Marseille, France; Strasbourg, France; Le Plessis Robinson, France; Bordeaux, France; Paris, France; Lyon, France; Toulouse, France; Bruxelles, Belgium; Grenoble, FranceLausanne, Switzerland.

D31 Life Confocal Imaging of Murine Liver Biopsies as Novel Tool to Assess Graft Viability Prior to Transplantation
Rupert Oberhuber, Margot Fodor, Benno Cardini, Manuel Maglione, Martin Hermann, Jakob Troppmaier. Innsbruck, Austria.

D32 Assessment of C4d Positive Biopsies with No Histological Evidence of Inflammation Using Nanostring nCounter Technology
Katherine M. Dominy, Michelle Willcombe, Tariq Al Johani, Jack Galliford, Adam McLean, Terence Cook, Candice Roufosse. London, United Kingdom; Riyadh, Saudi Arabia.

D33 Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study)
Anne Halpin, Morgan Sosniuk, Simon Urschel, Patricia Campbell, Ingrid Larsen, Lori West. Edmonton, Canada.
D34 Rejection of Human Kidney Allografts According to BANFF Classification Is Associated with a Chemokine-Enriched Protein Microenvironment in Biopsy Tissue
Christine S. Falk, Kerstin Daemen, Jana Keil, Frank Lehner, Hermann Haller, Jessica Schmitz, Jan-Hinrich Bräsen, Cornelia Blume. Hannover, Germany.

D35 Analysis of ApoL1 and MYH9 Genetic Polymorphisms Among the Hispanic Kidney Allograft Recipients
Youngil Chang, Tariq Shah, David Min. Pomona, CA; Los Angeles, CA.

D36 The Immunophenotype of Peritubular Capillaritis in Renal Transplant Biopsies

D37 Next-Generation Sequencing-Based Exosome MicroRNA Profiling for Specific Identification of Islet Damage
Prathab Balaji Saravanan, Jinghua Gu, Xuan Wang, Phuong Nguyen, Gumpei Yoshimatsu, Michael C. Lawrence, Bashoo Naziruddin. Dallas, TX.

D38 CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection
Lena Schiffer, Flavia Diebler, Maximilian Daemmrich, Katja Hueper, Michael Mengel, Anja Thorenz, Sibylle von Vietinghoff, Rong Song, Mario Schiffer, Faikah Gueler. Hannover, Germany; Edmonton, Canada.

D39 Imaging Cell Biology in Transplantation
Takuya Ueno, Martina McGrath, Melissa Yeung, Keehoon Jung, Yu Kihara, Osamu Konno, Yuki Nakamura, Hitoshi Iwamoto, Seok Hyun Yun, Anil Chandraker. Boston, MA; Hachioji, Tokyo, Japan.

D40 Urine Biomarkers (UBio) Correlate Poorly with Pre-Liver Transplant (LT) Kidney Biopsy Findings and Post-LT Kidney Function
Hani Wadei, Justin Belcher, Chirag Parikh, Thomas Gonwa, Martin Mai, John Lieske. Jacksonville, FL; New Haven, CT; Rochester, MN.

D41 Performance Comparison of Barcoded Oligos and Standard qPCR on Matched FFPE and RNAlater-Submerged Human Kidney Allograft Samples
Tara Sigdel, Mark Nguyen, Dejan Dobi, Juliane Liberto, Szu-Chuan Hsieh, Flavio Vincenti, Minnie Sarwal, Zoltan Laszik. San Francisco.

D42 Mechanistic Insights by RNA Profiling on Rejecting Vascularized Composite Allotransplants
Hui-Yun (Helen) Cheng, Shiau-Chin Liu, Chi-Fan Lin, Ling-Yi Shih, Fu-Chan Wei. Taoyuan, Taiwan.

Ischemic Injury and Organ Preservation Session III

D43 Omega 3 Attenuates Ischemia Reperfusion Renal Injury via Enhancement of Autophagy Flux
Jwa-Jin Kim, Jing Young Jeong, Dae Eun Choi, Ki Ryang Na, Kang Wook Lee. Daejeon, Korea.

D44 Protective Effect of New Delivery System of Nitric Oxide Releasing Nanofiber in Rat Model of Renal Ischemia-Reperfusion Injury

D45 Lipid Catabolism Provides Alternative Energy Source and Compensates for Mitochondrial Dysfunction in Reperfused Rat Kidneys After Ischaemia
D46 Beneficial Effects of Hydrogen Sulfide (H2S) on Renal Ischemia-Reperfusion Injury (IRI) in CLAWN Miniature Swine

D47 Preservation Solution Affects the Immunological Milieu in Lung Transplantation and Alters the Inflammatory Balance
Ramon Bellmás Sanz, Midas Seyda, Bettina Wiegmann, Christine Neudoerfl, Axel Haverich, Christine Falk, Gregor Warnecke. Hannover, Germany.

D48 Neuropeptide PACAP Prevents Hepatocyte Damage by Promoting Yes-Associated Protein (YAP) in Mouse Liver Ischemia/Reperfusion Injury
Yuan Liu, Cheng Zhang, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, Qiang Xia, Hao Feng Ji. Los Angeles, CA; Shanghai, China; Hangzhou, China.

D49 The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model
Koichiro Minami, Hirofumi Uehara, Abdallah Elkhal, Soochan Bae, Jake Reder, Brandy Houser, Peter Kang, Stefan G. Tullius. Boston, MA; Lebanon, NH.

D50 PPAR-γ Agonist Attenuates Hepatic Ischemia-Reperfusion Injury in a Mouse Model by Regulating Kupffer Cell Polarization
Ivan Linares, Kaveh Farrokhi, Juan Echeverri, Moritz Kaths, Dagmar Kollman, Matyas Hamar, Peter Urbanellis, Sujani Ganesh, Oyedele Adeyi, Paul Yip, Nazia Selzner, Markus Selzner. Toronto, ON, Canada.

D51 Mitochondrial Dysfunction Is a Common Feature of Injury in Donor Kidneys After Brain and Circulatory Death
M. Letizia Lo Faro, Mohammed Z. Akhtar, Honglei Huang, Maria Kaisar, Rolando Rebolledo, Karl Morten, Lisa Heather, Anthony Dona, Henri Leuvenink, Susan Fuggle, Benedikt Kessler, Christopher Pugh, Rutger Ploeg. Oxford, United Kingdom; Groningen, Netherlands; Sydney, Australia.

D52 Proteins in Preservation Fluid Predict Delayed Graft Function of Kidneys from Donors After Circulatory Death
Bas W. M. van Balkom, Hendrik Gremmels, Liselotte S. S. Ooms, Raechel J. Toorop, Frank J. M. F. Dor, Olivier G. de Jong, Laura A. Michielsen, Gert J. de Borst, Wilco de Jager, Arjan D. van Zuilen, Marianne C. Verhaa. Utrecht, Netherlands; Rotterdam, Netherlands; London, United Kingdom.

D53 ERK and HIF1 Play a Major Role in Hypothermic Protection Against Renal Ischemia-Reperfusion Injury
Kang Wook Lee, Jing Young Jeong, Dae Eun Choi, Ki Ryang Na, Hong Jin Bae, Young Rok Ham. Daejeon, Korea.

D54 Autotransplantation of the Left Lung for the Treatment of Recurrent Life Threatening Pulmonary Hemorrhage Related to Pulmonary Vascular Malformation: A Unique Chance to Study Ischemia/Reperfusion Injury
Christine S. Falk, Igor Tudorache, Carsten Müller, Wiebke Sommer, Kerstin Daemen, Jana Keil, Gesine Hansen, Axel Haverich, Gregor Warnecke, Nicolaus Schwerk. Hannover, Germany; Hannover, Deutschland, Germany.

D55 Direct Comparison of Hypothermic and Normothermic Organ Preservation in a Porcine Ex-Vivo Kidney Model
Natalie Vallant, Bynvant Sandhu, Nienke Wolhagen, Charles Pusey, Vassilios Papalois. London, United Kingdom; Innsbruck, Austria.
D56 Human IL-10 Transfection of Porcine Lungs Significantly Increases IL-10 Levels in Vascular Perfusate During Human Blood Perfusion
Christopher T. Laird, Lars Burdorf, Xiangfei Cheng, Natalie A. O’Neill, Selin Sendil, Dawn Parsell, Marcelo Cypel, Carol Phelps, David Ayares, Agnes M. Azimzadeh, Richard N. Pierson. Baltimore, MD; Toronto, Canada; Blacksburg, VA.

D57 Low Level Light Laser Treatment Reduces Macrophage Retention and ROS Levels Following Tissue Injury

D58 Renoprotective Effects of Carbon Monoxide–Releasing Molecule 3 in Ischemia Reperfusion Injury and Cisplatin-Induced Toxicity

D59 Objective Assessment of Graft Metabolism and Function During Ex Vivo Liver Perfusion
Juan Echeverri, Stuart Cleland, Moritz Kath, Ivan Linares, Roizar Roizales, Nicolas Goldaracena, Dagmar Kollmann, Matyas Hamar, Peter Urbanellis, Sujani Ganesh, Oyedele Adeyi, David Robert Grant, Nazia Selzner, Marcin Wasowicz, Markus Selzner. Toronto, ON, Canada.

D60 Split Liver Ex-situ Oxygenated Machine Perfusion: A Novel Approach to Organ Preservation and Treatment
Negin Karimian, Viola Huang, Sharon Geerts, Safak Mert, Irene Beijert, Fermin Fontan, Mohamed M. Aburawi, Robert J. Porte, Korkut Uygun, James F. Markmann, Heidi Yeh. Boston; Groningen, Netherlands.

D61 Cytotopic Thrombin Inhibition Prior to Cold Ischaemia Attenuates Microvascular Endothelial Ischaemia-Reperfusion Injury

D62 Improved Preservation During Normothermic Ex-Vivo Liver Perfusion with Delta Opioid Agonist (D-Ala2, D-Leu5) Enkephalin (DADLE)
Eliza W. Beal, Jung Lye Kim, Don Hayes Jr., Kenneth Washburn, Bryan A. Whitson, Sylvester M. Black. Columbus, OH.

D63 Deciphering the Mechanism of Remote Ischemic Preconditioning and Its Potential Benefits in Ischemia/Reperfusion Injury by Metabolomics

Kidney Immunosuppression: Novel Regimens and Drug Minimization

D64† Everolimus Does Not Increase Risk of Delayed Graft Function or Prolong Duration of Dialysis in Renal Transplantation
Fuad Shihab, Yasir Qazi, S. P. Mulgaonkar, Kevin McCague, Dharmesh Patel, V. Ram Peddi, David Shaffer. Salt Lake City; Los Angeles; West Orange; East Hanover; San Francisco; Nashville.

D65† Tacrolimus Dose Variability, CYP3A5 Genotype and Acute Rejection in African American and European American Kidney Transplant Recipients

D66† Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial

D68  † Early Steroid Withdrawal and Infection in Kidney Transplant Recipients Sunjae Bae, Christine Durand, Lauren Kucirka, Sandra DiBrito, Robin Avery, Jacqueline Garonzik Wang, Dorry Segev. Baltimore, MD.

D69  † High Risk Renal Transplant Recipients on Steroid Free Immunosuppression Regimen. Indiana University Experience Oluwafisayo Adebiyi, Syed Hussain, Dennis Mishler, William Goggins, Muhammad Yaqub, Tim Taber, Asif Shafuddin. Indianapolis, IN.

D70  † Clinical Impact of Strength and Class of Pre transplant Donor Specific Antibody on Kidney Transplant Recipient Receiving Steroid Free Maintenance Immunosuppression Regimen Oluwafisayo Adebiyi, Olivia Simo, Syed Hussain, Dennis Mishler, William Goggins, Tim Taber, Asif Shafuddin, Muhammad Yaqub. Indianapolis, IN.

D71  † Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts Kathleen E. Brown, William M. Baldwin, Emilio Poggio, William Braun, Robert L. Fairchild. Cleveland, OH.

D72  † Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated with Belatacept William H. Kitchens, Alton B. Farris, Stephen O. Pastan, Thomas C. Pearson, Christian P. Larsen, Andrew B. Adams. Atlanta, GA.

D73  † Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients Max A. Levine, Kevin Wen. Edmonton, AB, Canada.

D74  Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant Diane Cibrik, William Irish, Kevin McCague, Dharmesh Patel, Helio Tedesco. Ann Arbor, MI; Raleigh, NC; East Hanover, NJ; Sao Paulo, Brazil.


D78  Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis J. Howell, R. F. Pollock, J. Schwartz. Markham, ON, Canada; Basel, Switzerland; Northbrook, IL.
D79 Pre Transplant Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipient on Steroid Free Maintenance Immunosupression Regimen
Oluwafisayo Adebiyi, Ayesha Sharfuddin, Muhammad Yaqub, Syed Hussain, Dennis Mishler, Asif Sharfuddin, William Goggins, Tim Taber. Indianapolis, IN; Karachi, Pakistan.

D80 Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts

D81 Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study
Kazunari Yoshida, Yoshihiko Watarai, Ken Nakagawa, Osamu Kamisawa, Sagamihara, Japan; Nagoya, Japan; Ichikawa, Japan; Tokyo, Japan.

D82 Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE study

D83 Benefits of Mycophenolate Sodium Over Mycophenolate Mofetil in Renal Transplant Patients Carrying UGT1A9 Polymorphism

D84 An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients
Natalia Jasiak, James Thielke, Kristin Progar, Jinsong Chen, Christopher Adams, Enrico Benedetti, Patricia West-Thielke. Chicago.

D85 Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem
Paul Raymond Trevillian, Munish Kumar Heer, Sharon Ainsworth, Adrian Donald Hibberd. Newcastle, NSW, Australia.

D86 Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome

D87 One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial
Yuji Hidaka, Shigeyoshi Yamanaga, Mariko Toyoda, Shunji Narumi, Yoshihiko Watarai, Takaaki Kobayashi. Kumamoto, Japan; Nagoya, Aichi, Japan.

D88 Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx)
H. Tedesco, W. Irish, K. Dharmesh, D. Patel, D. Cibrik. Sao Paulo, Brazil; Raleigh; East Hanover; Ann Arbor.

D89 The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes
Allyson Hart, Sally Gustafson, Andrew Wey, Noelle Hadley, Ajay Israni. Minneapolis.
D90  Determinants of Successful Use of Sirolimus in Renal Transplantation
Marcel G. Naik, Wilfried Gwinner, Wolfgang Arns, Edin Basic, Klemens Budde, Fritz Diekmann, Michael Fischereder, Jan Goßmann, Katharina Heller, Nils Heyne, Jan-Steffen Jürgensen, Christian Morath, Udo Riester. Berlin, Germany; Hannover, Germany; Köln, Germany; Barcelona, Spain; München, Germany; Frankfurt, Germany; Erlangen, Germany; Tübingen, Germany; Heidelberg, Germany.

D91  A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation
J. Kim, S. Wilson, N. Undre, S. Fei, R. Kristy, J. Schwartz. Northbrook, IL; Chertsey, United Kingdom.

D92  Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial
Kohei Unagami, Masayoshi Okumi, Toshihito Hirai, Daisuke Toki, Hiroki Shirakawa, Tomokazu Shimizu, Kazuya Omoto, Masashi Inui, Hideki Ishida, Kosaku Nitta, Kazunari Tanabe. Tokyo, Japan; Yachiyo, Japan; Toda, Japan.

D93  Impact of Polymorphisms of UGT 1 A9 on the Prognosis of Renal Transplant Patients. Association with Digestive Tumors

D94  Steroid Withdrawal Using Everolimus in Maintenance Kidney Transplant Recipients with Post-Transplant Diabetes Mellitus

D95  A Novel Endpoint for Evaluating the Effect of Everolimus with Reduced Calcineurin Inhibitor on Long-Term Kidney Graft Outcome: The TRANSFORM Study Protocol

D96  Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
Kumar Jayant, Isabella Reccia, Julie Walton, Ajay Sharma, Ahmed Halawa. Liverpool, United Kingdom; London, United Kingdom; Sheffield, United Kingdom.

D97  Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience
Hiroshi Harada, Yoshiki Wada, Nobuyuki Fukuzawa. Sapporo, Japan.

D98  Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability and Coefficient Variation

D99  Steroid Free Maintenance Immunosuppression in Kidney Transplantation: Indiana University Experience
Syed Hussain, Tim Taber, Asif Sharfuddin, Muhammad Yaqub, William Goggins, Dennis Mishler, Oluwafisayo Adebiyi. Indianapolis, IN.

D100  More Than Renal Function: Use of Belatacept to Improve Drug Toxicities
Elizabeth A. Cohen, Brian Knight, William Asch. New Haven, CT; Storrs, CT.
D101 Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy

D102 Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Dosing

D103 Single-Center, Prospective, Open Label Pilot Study to Investigate the Effectiveness of Everolimus Associated with Mycophenolic Acid and Prednisone in Adult Patients Submitted to an Allograft Renal Transplant with Calcineurin Inhibitor Withdrawal on Week 16th
Luiz Flávio C. Giordano, Marcus F. Lasmar, Heloisra R. Vianna, Euler P. Lasmar. Belo Horizonte, Minas Gerais, Brazil.

D104 A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus
Elias David-Neto, Ana H. Triboni, Fernanda Ramos, Fabiana Agena, Pachoalina Romano, Gerald F Freitas. Sao Paulo, Brazil.

D105 Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients
Chang-Kwon Oh, Sung-Joo Kim, Kyu Ha Huh, Soo Jin Kim, Jin Seok Jeon, Sang Youb Han, Hong Rae Cho, Young Joo Kwon, Su Hyung Lee, Yu Seun Kim. Suwon, Republic of Korea; Seoul, Republic of Korea; Kumi, Republic of Korea; Goyang, Republic of Korea; Ulsan, Republic of Korea.

D106 Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients
Kazuma Tsujimura, Morihito Ota, Hideki Ishida, Kazunari Tanabe. Tomishiro-shi, Okinawa, Japan; Shinjuku-ku, Tokyo, Japan.

D107 The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus
Salwa Rhazouani, Siddiq Anwar, Daniel Brennan, Krista Lentine, Karthikeyan Venkatachalam, Andrew Malone, Tarek Alhamad. Saint Louis; New Castle, United Kingdom; Weston.

D108 Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients

D109 Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation
Gerold Thölking, Julia Steinke, Katharina Schuette-Nuetgen, Hermann Pavenstädt, Barbara Suwelack, Stefan Reuter. Münster, Germany.

D110 Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients
Lihui Qu, Zhoutao Xie, Hongfeng Huang, Hong Jiang, Jianghua Chen, Hong Jiang, Hong Jiang, Jianghua Chen. Hangzhou, Zhejiang Province, China.

D111 Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients
Lindsey DeZotell, Kedra Blunck, Jennifer Guy, Mark Woods, Mary Reffett, Jeannie Terrell, Alisha Palermo, Kensey Gosch, Lee S. Cummings. Kansas City, MO.

D112 Risks Associated with Recombinant IL2 Therapy in Renal Transplantation
Martina M. McGrath, Sudipta Tripathi, Anil Chandraker. Boston.

D113 Early Exposure of Everolimus with and without Calcineurin Inhibitors
Claudia Felipe, Alexandra Ferreira, Tamiris Abait, Adrieli Bessa, Priscilla Ruppel, Liliane Hiramoto, Mayara Ivani, Helio Tedesco, Jose Medina- Pestana. São Paulo, SP, Brazil.
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

CMV and BK Virus Infections in Kidney Transplant Recipients Receiving an mTORi-Based Regimen versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis

Evolution of CCR4highCD4+ Subpopulations in Renal Graft Blood After Steroid Withdrawal: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results

Kidney: Acute Cellular Rejection

Pro Inflammatory Transitional B (TrB) Cells Characterize Renal Allograft Recipients with DSA and T Cell Mediated Rejection (TCMR)
A. Sharma, A. Cherukuri, David Rothstein. Pittsburgh.

Integrated Magnetic-Electrochemical Exosome (iMEX) Technology to Detect Rejection in Kidney Transplant Recipients

A Prospective Observational Study to Evaluate Use of a Panel of Reactive T Cell (PRT) Assay as a Pre-Transplant Marker of Rejection in Kidney Transplant Recipients
Daniel Brennan, Liise Kayler, David Wojciechowski, Ajit Limaye, A. Osama Gaber, Ian Durrant. St. Louis, MO; Buffalo, NY; Boston, MA; Seattle, WA; Houston, TX; Oxfordshire, United Kingdom.

Long-Term Outcomes in HIV(+) Kidney Re-Transplant (ReTx) Recipients vs. Primary Transplant (PrimTx) Recipients

Practice Patterns in the Treatment and Monitoring of Acute Cell-Mediated Kidney Graft Rejection in Canada
Julie Leblanc, Peter Subrt, Michèle Paré, David Hartell, Lynne Sénécal, Tom Blydt-Hansen, Heloïse Cardinal. Montreal, Canada; Vancouver, Canada; Edmonton, Canada.

Soluble Human Leukocyte Antigen-G Levels and Prolonged Allograft Survival: A Demographic Analysis
Christine Callaway, Ashwin Ajjith, Vera Portik-Dobos, Peggy Best, Carlos Zayas, Rajan Kapoor, Anatolij Horuzsko, Laura Mulloy. Augusta, GA.

Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts
Karen S. Keslar, Anna A. Zmijewska, Jianguo Chen, Kenneth A. Newell, Peter S. Heeger, Roslyn B. Mannan, Robert L. Fairchild. Cleveland, OH; Birmingham, AL; Atlanta, GA; New York, NY.

Tacrolimus and Mycophenolate Exposure and Subclinical Tubulo-Interstitial Inflammation in Low Immunological Risk Renal Transplants

The IL6/Th17 Pathway May Play Different Roles in Cell-Mediated and Antibody-Mediated Alloimmune Injury in Renal Allografts
Dejan Dobi, Qizhi Tang, Sindhu Chandran, Flavio Vincenti, Zoltan Laszik. San Francisco, CA.
D126  Pre-Transplant Panel Reactive T Cells (PRT) with IL-15 as a Risk-Stratifier of Acute Rejection in Kidney Transplant Patients on Belatacept Therapy
P. Cravedi, I. Gandolfini, C. Donadei, R. Fairchild, K. A. Newell, R. B. Mannon, P. Heeger, CTOT16 Consortium. New York; Cleveland; Atlanta; Birmingham.

D127  Prediction of Renal Allograft Acute Rejection Using a Novel Non-Invasive Model Based on Acoustic Radiation Force Impulse
Cheng Yang, Yunjie Jin, Shengdi Wu, Tongyu Zhu, Wanyuan He. Shanghai, China.

D128  The Effect of Histological Isolated Endarteritis and Solid Endoarteritis Combined with CD20 Positive B Cell Infiltration Appeared in Acute Cellular Rejection on Kidney Allograft Survival

D129  Persistence/Progression of Early Banff Borderline Changes (BBC) Is Associated with Chronic Renal Allograft Damage and Can Be Predicted by B Cell Cytokine Profile

D130  The Impact of Early Clinical and Subclinical T Cell Rejection After Kidney Transplantation

D131  Clinic-Based Medication Education Pilot Program
Nimisha Sulejmani, Hasenia Albanna, TrisAnn Rendulic, Bryant B. Summers, Arin S. Jantz. Detroit, MI; Lexington, KY.

Kidney: Cardiovascular and Metabolic

D132  Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study

D133  Post-Transplant Graft Function Is Associated with Major Cardiovascular Events in Kidney Transplant Recipients: A Multicenter Cohort Study
Jae Yoon Park, Yong Chul Kim, Seung Hee Yang, Sehoon Park, Su-Kil Park, Duck Jong Han, Yon Su Kim, Young Hoon Kim, Jung Pyo Lee. Gyeonggi-do, Korea; Seoul, Korea.

D134  Myocardial Improvement Six Months After Kidney Transplantation: Non-Contrast Cardiac Resonance Study
Mariana Moraes Contti, Luis Gustavo Modelli Morales-Buenrostro, Hong Si Nga, Paula Dalsoglio Garcia, Mauricio Fregonesi Barbosa, Henrique Mochida Takase, Maryanne Machado da Silva, Ariane Marques Moyses. Botucatu, Sao Paulo, Brazil.

D135  Cyclosporine Effects on Blood Pressure Are Exaggerated in Pubertal Girls After Renal Transplantation
Anette Melk, Rizky Indrameikha Sugianto, Bernhard M. W. Schmidt, Kai Krupka, Britta Höcker, Burkhard Tönshoff, Elke Wühl. Hanover, Germany; Heidelberg, Germany.

D136  Association Between Matrix-gla Protein Levels and Aortic Stiffness in Kidney Transplantation
Miriana Dinic, Nicolas Maillard, Pierre Delanaye, Jean-Marie Krzesinski, Anne-Marie Saint-Remy, Etienne Cavalier, Christophe Mariat. Saint Etienne, France; Liège, Belgium.
D137 Renal Function, Albuminuria and the Risk of Cardiovascular Events After Kidney Transplantation
Ngan N. Lam, Marcello Tonelli, Krista L. Lentine, Brenda Hemmelgarn, Feng Ye, Aminu Bello, Scott Klarenbach. Edmonton, Canada; Calgary, Canada; St. Louis.

D138 Everolimus Reduces Carotid Intima-Media Thickness in Renal Transplant Recipients After One Year: Randomized Controlled Trial
Paula Dalsoglio Garcia, Henrique Moshida Takase, Hong Si Nga, Mariana Moraes Contti, João Carlos Hueb, Luis Gustavo Modelli Morales-Buenrostro. Botucatu, São Paulo, Brazil.

D139 Cardiovascular Disease in Japanese Kidney Transplant Recipients
Masayoshi Okumi, Kohei Unagami, Daiji Fujimori, Keisuke Hata, Toshihito Hirai, Hideki Ishida, Kazunari Tanabe, Japan Academic Consortium of Kidney Transplantation (JACK). Tokyo, Japan.

D140 Change in QTC Interval After Kidney Transplant

D141 Detection of Right Ventricular Dilation and Dysfunction by Transthoracic Echocardiography Predicts Renal Transplant Outcomes
Francis J. Tinney Jr, Stephanie Lazar, Abhijit Naik, Milagros Samaniego-Picota, Nicole Bhave. Detroit, MI; Ann Arbor, MI.

D142 No Impact of One Year of Everolimus, as Compared to MPA, in the Reversal of Left Ventricular Hypertrophy in Elderly Renal Transplant Recipients – Preliminary Data from Then Everold Study

D143 Pulse Pressure After Renal Transplantation – Influence on Outcome: Results from the Collaborative Transplant Study

D144 Impact of Body Mass Index and Waist Circumference in Kidney Transplant Recipients
Jean-Emmanuel Serre, Mathilde Huet, Ilan Scwarc, Vincent Pernin, Moglie Le Quintrec, Georges Mourad. Montpellier, France, Metropolitan.

D145 Muscle Mass Is Predictive of Mortality in Obese Renal Transplant Patients
Jean Sébastien Souweine, Moglie Le Quintrec, Ilan Scwarc, Vincent Pernin, Georges Mourad, Jean Paul Cristol, Jean Emmanuel Serre. Montpellier, France.

D146 Obesity Is an Important Factor in Deceased but Not Living Donor Kidney Transplants
Argiris Asderakis, Adel Ilham, Usman Khalid, Rafael Chavez. Cardiff, United Kingdom.

D147 Glucose Tolerance After Kidney Transplant Is Affected by Systemic Insulin Sensitivity Rather Than Usage of Tacrolimus

D148 Propensity-Matched Comparison of Diabetic Patients and Non-Diabetic Patients in Living Donor Kidney Transplantation
Chung Hee Baek, Hyosang Kim, Won Seok Yang, Duck Jong Han, Su-Kil Park. Seoul, Republic of Korea.
D149  Early Introduction of Oral Paricalcitol in Renal Transplant Recipients. An Open-Label Randomized Study


D150  Serum Phosphorus and Cardiovascular Disease Outcomes, Graft Failure, or Total Mortality in Chronic Kidney Transplant Recipients

Basma Merhi, Theresa Shireman, Myra Carpenter, John Kusek, Paul Jacques, Marc Pfeffer, Andrew Levey, Madhumathi Rao, Joseph Kim, Joachim Ix, Andrew Bostom. Chepachet, RI; Chapel Hill, NC; Bethesda, MD; Boston, MA; Toronto, ON, Canada; San Diego, CA.

D151  Persistent Hypophosphatemia Among Deceased-Donor Kidney Transplant Recipients Is Donor-Dependent and Associated with Superior Long-Term Allograft Outcomes

Natalie Maureen Otto, Thomas Schachtner, Petra Reinke. Berlin, Germany.

D152  Albuminuria in Kidney Transplant Patients Is Associated with Increased Urine Serine Proteases with the Ability to Activate ENaC

Gitte Hinrichs, Claus Bistrup, Henrik Birn, Boye Jensen. Odense, Denmark; Aarhus, Denmark.

D153  Primary Hyperoxaluria Type-1 in Chinese Population: A Case Series and Review of Literature


D154  The Clinical Significance of Red Cell Distribution Width (RDW) in Kidney Transplant Recipients

Sehoon Park, Jonwon Ha, Yong Chul Kim, Hajeong Lee, Yon Su Kim, Chun Soo Lim, In Mok Jung, Duck-Jong Han, Su-Kil Park, Young Hoon Kim, Jung Pyo Lee. Seoul, Korea.

D155  The Effects of Aspirin on Major Adverse Cardiac Events and Kidney Allograft Outcomes: A Meta-Analysis

Wisit Cheungpasitporn, Charat Thongprayoon, Donald G. Mitema, Michael A. Mao, Wonngarm Kittanamgkolchom, Maria L. Gonzalez-Suarez, Stephen B. Erickson. Rochester, MN.

Kidney: Pediatric

D156  Impact of Six-Month Surveillance Biopsies and Monitoring in Pediatric Renal Transplant Recipients

John M. Lyons, Daniel Ranch, Reed Hall, Pamela R. Maxwell, Kelley M. Hitchman, Yoko Hirase, Barrett R. Crowther. San Antonio, TX; Austin, TX.

D157  A Single Center Retrospective Review of Pediatric Kidney Transplant Outcomes According to Banff Grade and Cellular Rejection Treatment

Justin Chen, Rochelle Liverman, Roubas Garro, Stephanie Jernigan, Pamela Winterberg. New York, NY; Atlanta, GA.

D158  Superior Long-Term Hypertension Management in Pediatric Kidney Transplant Recipients with Bilateral Native Nephrectomies


D159  Ambulatory Blood Pressure Monitoring Detects High Prevalence of Hypertension in Recipients of Non-Renal Transplants


D160  Carotid Intima-Media Thickness and Myocardial Strain in Pediatric Kidney Transplant Recipients

D161  A Decade of Paediatric Kidney Transplantation in Children Weighing <20kg

D162  Strategies to Promote Pediatric Kidney Transplant Program in China – A Coming Opportunity with Development of Pediatric Deceased Donation
Longshan Liu, Haibo Wang, Jie Ding, Bingyi Shi, Xuhui Zhong, Wenshi Jiang, Liping Chen, Huaxi Zhang, Changxi Wang. Guangzhou, China; Shenzhen, China; Beijing, China.

D163  mTOR Inhibitor and Low-Dose Tacrolimus in Pediatric Kidney Transplant (PKT): 9-Years Data of a Bi-Therapy Treatment

D164  Long Term Outcomes of Adult Kidney Transplants from Small Single Pediatric Donors Are Equivalent to Standard Criteria Donors

D165  Renal Transplantation to the Extraperitoneal Cavity in Children Weighing Less Than 15 kg Can Be Performed Safely

D166  Donor Creatinine and Graft Outcomes in Pediatric Kidney Transplant Recipients
Nicole Hayde, Marcela Del Rio. Bronx, NY.

D167  Racial and Ethnic Disparities in Renal Replacement Therapy in Pediatric and Young Adult Population with End Stage Renal Disease (2005-2015)
Roshan P. George, Mohua Basu, Larry A. Greenbaum, Allan D. Kirk, Nancy Kutner, Rachel E. Patzer. Atlanta, GA; Durham, NC.

D168  Pediatric Recipients of Deceased Adult Donor Kidneys Have Equivalent Outcomes Compared with Pediatric Donors
David Mikhail, Hemant Sharma, Jingwen Chen, Matthew Cooper, Alp Sener, Patrick Luke. London, ON, Canada; Washington, DC.

D169  Intraoperative Fluid Management During Pediatric Kidney Transplantation with Less Than 15kg Body Weight Using Transesophageal Echocardiography as Hemodynamic Parameter

D170  Single Kidney Transplantation from Pediatric Donors Younger Than 3 Years to Adult Recipients

D171  Age-Related Differences in Gene Expression Among Kidney Allografts with Normal Histology and Calcineurin Inhibitor Nephrotoxicity
Erika Rhone, Sai Vineela Bontha, Patrick D. Walker, Catherine Dumur, Daniel Maluf, Jorge Almenara, Valeria Mas. Charlottesville; Little Rock; Richmond.

D172  Importance of HLA-DR Expression in Pediatric Renal Transplant Biopsies
Omar Moussa, Sally E. Self, Katherine E. Twombley. Charleston.
D173 The Outcome of 0 Mismatch Kidney in Pediatric Population with High Immunologic. The Impact of Induction Therapy. An Analysis of UNOS Database
Vaughn E. Whittaker, Mark Laftavi, Zeki Acun, Rainer W. Gruessner, Angelika Gruessner. Syracuse, NY.

D174 Outcomes and Risk Factors for Graft Loss: Lessons Learned from More Than 1,056 Pediatric Kidney tx at a Single Center
Srinath Chinnakotla, P. Verghese, B. Chavers, V. Kirchner, J. Najarian. M.

D175 Rabbit Anti-Human Thymocyte Immunoglobulin (rATG) for Rescue Treatment of Chronic Antibody-Mediated Rejection (cAMR) After Pediatric Kidney Transplantation

D176 Outcomes for Plasma Cell Rich Rejection in Pediatric Kidney Transplant Patients
Omar Moussa, Sally E. Self, Katherine E. Twombly. Charleston.

D177 Isolated Angiotensin II Receptor Type I Antibodies (AT1R) Are Not Associated with Active Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients
Jua Choi, Mark Haas, Xiaohai Zhang, Olivier Aubert, Helen Pizzo, Elaine Kamil, Kim Irene, Stanley Jordan, Dechu Puliyanda. Los Angeles, CA.

D178 Impairment of Glucose Tolerance After Pediatric Kidney Transplant Is Associated with Worse Systemic Insulin Sensitivity Rather Than Fall in Insulin Secretion

D179 Rates of Lost to Follow-Up Among Pediatric Heart, Kidney and Liver Transplant Recipients
Wida Cherikh, Sharon Bartosh, Read Urban, William Mahle, George Mazariegos, Eileen Brewer. Richmond, VA; Madison, WI; Atlanta, GA; Pittsburgh, PA; Houston, TX.

D180 Successful Implementation of a Pneumococcal Vaccination Program for Pediatric Kidney Transplant Recipients

D181 Impact of a Pharmacist-Led Vaccine Recommendation Program for Pediatric Kidney Transplant Candidates
Clarice Carthon, Reed Hall, Pamela Maxwell, Barrett Crowther. St. Louis, MO; San Antonio, TX.

D182 Urinary Proteomics to Diagnose Chronic-Antibody-Mediated Rejection in Pediatric Kidney Transplantation
Nele K. Kanzelmeyer, Petra Züribig, Harald Mischack, Krisztina Heindl Ruszai, Tomas Seemann, Matthias Hansen, Michael Henn, Alexander Fichtner, Burkhard Toenshoff, Anette Melk, Lars Pape. Hannover, Germany; Vienna, Austria; Prague, Czech Republic; Leipzig, Germany; Heidleberg, Germany.

D183 Small Pediatric Donor Kidney Transplantation in Pediatric Recipients
Hillary C. Yaffe, Patricia Friedmann, Liise K. Kayler. Bronx, NY; Buffalo, NY.

Liver – Kidney Issues in Liver Transplantation

D184 Immediate vs. Delayed Kidney Implantation Is Associated with Improved Kidney Graft Survival in Combined Liver-Kidney Transplantation
Jeffrey Halldorson, Stephen Rayhill. San Diego, CA; Seattle, WA.


D188 A UNOS Database Analysis of Patient Outcomes from Kidney Alone versus Simultaneous Kidney Liver Transplants Utilizing Matched Donor Pairs Tiffany Zens, Juan S. Danobeitia, Paul Stahler, Glen Leerson, Robert Redfield III, Anthony M. D’Alessandro, Luis A. Fernandez. Madison, WI.


D190 Simultaneous Liver-Kidney Transplants Using Donation After Cardiac Death Donors Long Term Outcomes Not Inferior to Brain Dead Donors Josue Alvarez-Casas, Samuel T. Sultan, Joseph R. Scalea, Katrina R. McClure, John C. LaMattina, David A. Bruno, Steven I. Hanish, Rolf N. Barth. Baltimore, MD.


D193 Incidence and Outcomes of Immediate Post-Operative Dialysis in Liver Transplantation Shunji Nagai, Mohamed Safwan, Kelly Collins, Michael Rizzari, Atsushi Yoshida, Marwan Abouljuod. Detroit, MI.


D196 Long-Term Preservation of Renal Function in Liver Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Delayed Initiation of Calcineurin Inhibitors Iman Bajjoka, Alexander S. Yaldo, Catherine Crombez, Kimberly Brown, Marwan S. Abouljuod. Detroit, MI.
D197  Pre-OLT CKD-3 Increases Post-OLT ESRD and AKI Impacts Early Post-OLT Survival
Geovani Faddoul, Luz Liriano-Ward, Paul Chang, Yorg Azzi, Kinsuk Chauhan, Girish Nadkarni, Vinay Nair, Rebecca Kent, Susan Lerner, Steven Coca, Peter Heeger, Sanders Florman, Schiano Thomas, Madhav C. Menon. Irvington, NY.

D198  Restrictive Approach to Simultaneous Liver Kidney Transplantation

D199  Rapid Deterioration of Pre-Transplant Kidney Function Requiring Dialysis Is a Prognostic Factor in Liver Transplant Alone
Shunji Nagai, Mohamed Safwan, Kelly Collins, Michael Pizzari, Dilip Moonka, Anita Patel, Kimberly Brown, Atsushi Yoshida, Marwan Abouljoud. Detroit, MI.

Liver: Immunosuppression and Rejection

D200†  Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients

D201  Prospective DSA Monitoring and Significance of De Novo DSA in Adult Liver Transplantation

D202†  Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction
Nicholas Lange, David Salerno, Chelsea Sammons. New York, NY.

D203  National Variation in Liver Transplant Immunosuppression in the U.S.

D204  Subclinical Histologic Findings Are Observed in 25% of Stable Adult Liver Transplant Recipients (ALTRs) Screened for Immunosuppression Withdrawal (ISW): OPTIMAL (NCT02533180)

D205  Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters

D206  Everolimus Is Associated with Less Weight Gain Than Tacrolimus Two Years Following Liver Transplantation: Results of a Randomized Multicenter Study
Michael Charlton, Mary Rinella, Dharmesh Patel, Kevin McCague, Julie Heimbach, Kimberly Watt. Salt Lake City; Chicago; East Hanover; Rochester.

D207  This is Why We Can’t Have Nice Things- Real World Experience with Everolimus in Livers
D208 Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant - Busting the Myth of Wound Infection Due to mTOR Inhibitors
Shih-Chao Hsu, Ashok Thorat, Long-Bin Jeng, Horng-Ren Yang, Ping-Chun Li, Chun-Chieh Yeh, Te-Hung Chen, Kin-Shing Poon. Taichung, Taiwan.

D209 An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients
Rohini R. Sigireddi, Jennifer M. Moffett, Michael L. Kueht, Ruth L. Ackah, Abbas Rana, Christine A. O'Mahony, John A. Goss, Sadhna Dhingra, Saira A. Khaderi. Houston, TX.

D210 Limited Impact of Pre-Existing Donor Specific HLA Antibodies on Long Term Survival After First Adult Liver Transplantation
Martina Koch, Matthias Marget, Martina Sterneck, Hansjörg Thude, Bjorn Nashan. Hamburg, Germany.

D211 Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients
Chase Skillin, Mba Uzoma Mba, Bahr Madani, Catherine Frenette. La Jolla, CA.

D212 Rapamycin Maintenance Therapy in Pediatric Liver Transplant Recipients Associated with Trend Toward Decreasing Th2 Cytokine Levels Compared to Tacrolimus Therapy

D213 Acute Antibody-Mediated Rejection in Pediatric Liver Transplantation

D214 Course of Inflammatory Bowel Disease Activity in Primary Sclerosing Cholangitis Patients Undergoing Liver Transplantation
Ravish Parekh, Maria Cristina Segovia, Nirmal Kaur. Detroit, MI; Durham, NC.

D215 Liver Transplantation Outcomes Using Anti-Thymocyte Globulin Induction in Patients with Autoimmune Hepatitis
Spencer LeCorchick, Amit Sharma, Idris Yakubu, Chandra Bhati, Trevor Reichman, Le Kang, Marion Levy. Richmond, VA.

D216 Type of Surgical Procedures and Clinical Significance of Calcineurin Inhibitor Temporary Discontinuation Regarding LT Recipients Undergoing Major Elective Surgery

D217 Steroid-Free Immunosuppression After Liver Transplant for Autoimmune Disease Does Not Result in Increased Disease Recurrence
Alexander Hooper, Catherine Frenette. San Diego, CA; La Jolla, CA.

D218 Graft-versus-Host Disease Following Deceased Donor Liver Transplant
Krishna G. Putchakayala, Sharon Skorupski, Shatha Farhan, Marsha Chaffins, Safwan Ilias, Hirak Pahari, Kelly Collins, Shunji Nagai, Marwan Abouljoud. Detroit, MI.

D219 Identification of a Stable Gene Signature of Transplant Tolerance to Liver Allograft by Meta-Analysis
Guangxiang Gu, Hualian Hang, Qiang Xia. Shanghai, China.

D220 Plasma Cell Hepatitis in Primary Sclerosing Cholangitis Patients: 15-Year Experience at a Transplant Center

D221 Treating Refractory Liver Allograft Rejection with Photopheresis
Ileana Lopez Plaza, Arthur Eisenbrey, Mohammad Raoufi, Atsushi Yoshida, Dilip Moonka. Detroit, MI.
Liver: Viral Hepatitis

D222 † HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence

D223 Liver Allograft Hepatitis and Graft Loss After Hepatitis C Clearance

D224 Spousal Transmission of Hepatitis B from a Hepatitis B Core Antibody Positive Liver Transplant Recipient – A Case Report
Janet Gripshover, Kristina Hidalgo, Bharath Ravichandran. Baltimore, MD.

Living Donor Kidney Transplant II

D225 Shared Decision Aid to Decipher Long-Term Treatment Risks for End Stage Renal Disease Patients
Jennifer C. Gander, Amita Manatunga, Kim Jacob Arriola, Stephen O. Pastan, Rachel E. Patzer. Atlanta, GA.

D226 Donor and Recipient Factors Important in Determining the Estimated GFR Difference Between Living Donor and Recipient Pairs Six Months After Transplant
Douglas Keith. Pensacola, FL.

D227 The Implication of the Dominant Side Split Renal Function by Diethylenetriamine Penta-Acetic Acid (DTPA) in Live Kidney Donor

D228 Strategies to Economize Dialysis and Transplantation in Low Resource Settings

D229 Risk Prediction Models for Living Donor Kidney Transplantation to Predict Donor and Recipient Mortality and Graft Loss
Maria C. Haller, Geir Mjøen, Hallvard Holdaas, Georg Heinze, Rainer Oberbauer. Vienna, Austria; Oslo, Norway.

D230 Sexual Dysfunction Among Living Kidney Donors
Samantha Halpern, Alvin Thomas, Courtenay Holscher, Allan Massie, Macey Henderson, Saad Anjum, Jayme Locke, Dorry Segev. Baltimore, MD; Birmingham, AL.

D231 Long-Term Clinical Outcomes of Kidney Transplant Recipients with Body-Size Mismatch Between Recipient and Donor

D232 Retroperitoneoscopic Living Donor Nephrectomy Safely Secures Excellent Graft Function

D233 Sensitized KPD Pairs Take Longer to Find Matches

D234 Enhanced Recovery After Surgery Pathway for Living Donor Nephrectomy Patients Decreases Length of Stay and Narcotic Utilization
D235 Optimizing Support for Living Kidney Donors: Insights from a Prospective Study

D236 Semi-Automated Pre-Donation Computed Topography (CT) Cortical Renal Volume to Predict Kidney Function in Live Kidney Donors 2 Years Following Donation
Ling-Xin Chen, Ghaneh Fananapazir, Robert C. Benzl, Michael T. Corwin, Susan Stewart, Christoph Troppmann. Sacramento, CA; Davis, CA.

D237 Comparison of the Estimated and Measured Glomerular Filtration Rate in Kidney Donor Candidates
Collette O. Akhimiona, Wadi N. Suki, Duc T. Nguyen, Edward Graviss. Houston, TX.

D238 Timing of HLA Testing as a Means of Reducing Cost and Increasing Efficiency of Living Kidney Donation

D239 Lower Rates of Living Donation Among Transplant Centers Located in the Stroke Belt
Rhiannon D. Reed, Brittany A. Shelton, Paul A. MacLennan, Michael Hanaway, Vineeta Kumar, Robert Gaston, Jayme E. Locke. Birmingham.

D240 Predictors of Renal Function Compensation in Live Donor Nephrectomy
J. Hui Choong Choong, Hatem Ali, Aimun Ahmed. Preston, United Kingdom; Prston, United Kingdom.

D241 The Impact of Tacrolimus and MPA Derivative Immunosuppression on Achieved GFR in Recipients without Rejection: A Comparison of GFR of Living Donor Recipient Pairs at Six Months Post-Transplant
Douglas Keith. Pensacola, FL.

D242 How Potential Living Kidney Donors (LKDs) View ESRD Risk: A Multi-Center Study

D243 Impact of Visceral and Subcutaneous Adipose Tissue on Post Donation Renal Function in Living Kidney Donors

D244 The Outcome of Kidney Grafts from Living Donors with Pyelo-Ureteric Junction Dysfunction

D245 Challenges for the Travelling Donor: Variability Between Donor Work-Up and Donor Surgery in the Canadian Kidney Paired Donation Program
Brian A. Reikie, Tadeusz Kroczzak, Thomas B. McGregor. Winnipeg, MB, Canada; Toronto, ON, Canada; Kingston, ON, Canada.

D246 A Retrospective Study on the Impact of Abdominal Surgical Histories on Hand-Assisted Laparoscopic Donor Nephrectomy for Living Donor Adult Kidney Transplant

D247 Tangible Benefits in Caregiving Burden Among Spouses/Partners of Transplant Patients: Adding “Donor Benefit” to Live Donor Risk Assessment
Sarah Rasmussen, Lauren Duquette, Macey Henderson, Dorry Segev. Baltimore.
D248 Expectations and Experiences of Follow-Up and Self-Care After Living Kidney Donation: A Focus Group Study
Karine E. Manera, Camilla S. Hanson, Jeremy R. Chapman, John Kanelis, John Gill, Jonathan C. Craig, Steve J. Chadban, Germaine Wong, Angelique F. Ralph, Allison Tong. Sydney, NSW, Australia; Westmead, NSW, Australia; Clayton, VIC, Australia; Vancouver, BC, Canada; Camperdown, NSW, Australia.

D249 African American Living Kidney Donors’ Attitudes About APOL1 Genetic Testing: Implications for Evaluation and Informed Consent
Elisa J. Gordon, Crystal Johnson, Catherine Wicklund, Richard R. Sharp, John Friedewald. Chicago, IL; Rochester.

D250 Interruption of RAAS in Hypertensive Proteinuric Kidney Donors
Otto A. Sanchez, Laine Ferrara, Danielle Berglund, Arthur J. Matas, Robert Foley, Hassan N. Ibrahim. Mpls, MN; Minneapolis, MN.

D251 Live Donor (LDTx) HIV(+) Kidney Transplantation Improves Allograft Survival vs. Deceased Donor (CRD) Transplantation

D252 Usefulness of Multi-Detector Computed Tomography (MDCT) Scanning as a Replacement for Diethylenetriamine Pentaacetic Acid (DTPA)
Hyung Ho Lee, Woong Kyu Han, Kyu Ha Huh, Myoung Soo Kim, Soon Il Kim, Yu Sean Kim, Young Eun Yoon. Seoul, Republic of Korea.

D253 Recurrence of IgA Nephropathy After Kidney Transplantation in Maintenance Steroids versus Steroid Avoidance Regimens: A UNOS/OPTN Analysis
Napat Leeaphorn, Neetika Garg, Eliyahu Khankin, Francesca Cardarelli, Martha Pavlakis. Boston, MA.

D254 Trends in Long-Term Outcomes of Kidney Transplantation in Australia and New Zealand
Wai Lim, Wing-Chi Yeung, Scott Campbell, Steven Chadban, Phil Clayton, Carmel Hawley, David Johnson, Stephen McDonald, Elaine Pascoe, Germaine Wong, Sunil Badve. Perth, Australia; Sydney, Australia; Brisbane, Australia; Adelaide, Australia.

D255 Renal Function Variability Is a Significant and Independent Risk Factor for Graft Loss and Death in Kidney Transplantation

D256 Predictive Value of Renal Poly (ADP-Ribose) Polymerase (PARP) Expression Both in Inflammation and Interstitial Fibrosis Processes in Recipients with Antibody-Mediated Rejection

D257 Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents
Siva Kanangat, Ricky Miller, Saba Rezaeian, Howie E. Hild, David Cimbaluk, Cristina Fhied, Ina Kurbegovic-Skaljic, Michele Prod, Jeffrey Borgia, Maribeth Flaws, Demetra Castillo, Robert DeCresce. Chicago, IL.

D258 Impact of Type of Kidney (Living vs. Deceased) on Urinary Podocyte Excretion Rate in Renal Allografts

D259 The Effect of BMI on Renal Transplant Outcomes
Emmanouil Giorgakis, Kunam Reddy, Andrew Singer, Hasan Khamash, Raymond Heilman. Phoenix, AZ.

Long Term Kidney Outcomes

D261  Urinary Type III Procollagen (PlllnP) Is Associated with Chronic Allograft Dysfunction and Predicts Graft Survival  Rahmi Yilmaz, Tolga Yildirim, Dilek Baydar, Bu lent Altun, Yunus Erdem. Ankara, Turkey.


D265  Effect of AKI Donor Admit Creatinine on Renal Transplant Outcomes  Emmanouil Giorgakis, Raymond Heilman, Hasan Khamash, Bruce Kaplan, Adyr Moss, Maxwell Smith, Kunam Reddy. Phoenix, AZ.


D268  Seasonality of Mortality and Graft Failure Among Kidney Transplant Recipients in the US  Brad C. Astor, Michal L. Melamed, Didier A. Mandelbrot, Arjang Djamali. Madison, WI; Bronx, NY.


D271  25-Hydroxyvitamin D [25(OH)D], but Not 1,25-Dihydroxyvitamin D [1,25(OH)_2D], Independently Predicts Kidney Graft Failure: The Wisconsin Allograft Recipient Database (WisARD)  Brad C. Astor, Michal L. Melamed, Didier A. Mandelbrot, Arjang Djamali. Madison, WI; Bronx, NY.
D272  Inferior 10-Year Graft and Patient Survival After End-to-Side Reconstruction for Two Renal Arteries in Living Donor Renal Transplantation

D273  Even Non-Donor-Specific HLA-Antibodies Are Associated with a Progressive Decline in Kidney Transplant Function

D274  A Thirteen-Year Mayo Clinic Retrospective Study of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013
Macaulay A. Onuigbo, Nneoma C. Agbasi. Rochester, MN; Eau Claire, WI; Ilford, Essex, United Kingdom.

D275  Serum Alkaline Phosphatase Predicts Graft Failure and Mortality in Kidney Transplant Recipients
Yong Chul Kim, Seokwoo Park, Seung Hee Yang, Hajeong Lee, Young Hoon Kim, Su-Kil Park, Duck Jong Han, In Mok Jung, Jongwon Ha, Chun Soo Lim, Yon Su Kim, Jung Pyo Lee. Seoul, Republic of Korea.

D276  Impact of Non-Adherence in a Cohort of Kidney Transplant Recipients
Maribel Merino-López, Cesar Flores-Gama. Mexico, Mexico.

D277  Allograft Crescent Predicts Graft Failure in Recurrent IgA Nephropathy Patients

D278  Risk Factors of Recurrence of Diabetic Nephropathy in Renal Transplant
Beatriz B. Rodriguez Cubillo, Marta M. Calvo, Virginia V. Lopez De La Manzanara, Jose J. Bautista-Cañas, Isabel I. Perez-Flores, Maria Angeles M. A. Moreno De La Higuera, Natividad N. Calvo Romero, Ana Isabel A. I. Sanchez-Fructuoso. Madrid, Spain.

Non-Organ Specific: Economics, Public Policy, Allocation, Ethics

D279  Deceased Donor-Initiated Non-Simultaneous Extended Altruistic Donor Chains Through the Military Share Program
Michael Rees, Obi Ekwenna, Eric Elster, Ankita Patel, Dan Murtagh, Jr, Alvin Roth, Kim Krawiec, Jeff Arrington, Itai Ashlagi, Jason Hawksworth. Toledo, OH; Perrysburg, OH; Bethesda, MD; Palo Alto, CA; Durham, NC; Findlay, OH.

D280  Perceived Legitimacy of Using Social Support for Transplant Eligibility: Results from a National Survey of Transplant Clinicians
Keren Ladin, Elisa Gordon, Zeeshan Butt, Tara Lavelle, Norman Daniels, Douglas Hanto. Medford, MA; Chicago; Boston; Nashville.

D281  Screening and Referral of High Risk Liver Transplant Recipients to a Transitional Care Coordination (TCC) Program to Reduce Hospital Readmissions
Anahita Masoumi, Jill Krzyzewski, Tina Stern, Nicholas Schluterman, David A. Bruno, Jonathan Bromberg, Rolf Barth, Steven Hanish. Baltimore, MD.

D282  The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis
David A. Axelrod, Krista Lentine, Mark Schnitzler, Huiling Xiao, Xun Lou, Babak Orandi, Jacqueline Garonzik Wang, Allan Massie, Dorry Segev. Greenville, NC; St. Louis, MO; Baltimore, MD.

D283  A Markov Model for Transplant & Renal Outcomes After Liver & Simultaneous Liver-Kidney Transplants
D284  State Law Restrictions on HIV Positive-to-Positive Transplantation
Sarah Rasmussen, Alexandra Glazier, Ayla Cash, Macey Henderson, Brian Boyarsky, Kimberly Miller, Scott Schoettes, Dorry Segev, Christine Durand. Baltimore; Waltham; Arlington; Chicago.

D285  Transplant Center Knowledge and Planned Practice of HIV Positive-to-Positive Transplants
Sarah Rasmussen, Mary Grace Bowring, Ashton Shaffer, Christine Durand, Dorry Segev. Baltimore.

D286  Use of Hepatitis C Infected Organs for Kidney Transplantation: A Cost-Effective Analysis
Bryce Kiberd, Karen Doucette, Karthik K. Tennankore. Halifax, NS, Canada; Edmonton, AB, Canada.

D287  Transplantation of Hepatitis C Kidneys to Hepatitis C Recipients Confers Significantly Shorter Waiting Times in the Era of the New Kidney Allocation System

D288  Potential Living Kidney Donors (LKD) Concerns About Opting Out and Preferences for an ‘Alibi’

D289  Kidney Waitlist Management: The Readiness Model of Predicting Transplants Under the Kidney Allocation System

D290  Hurdles to Broader Implementation of the A₂A₂B→B Deceased Donor Kidney Allocation Provision
Irene Kim, Amber R. Wilk, Amanda Robinson, Paulo Martins, Vaughn Whitaker, Emily Ward, Clifford Miles. Los Angeles, CA; Richmond, VA; Worcester, MA; Syracuse, NY; Omaha, NE.

D291  Race, Admissions and Renal Transplant Waitlisting
Raymond Lynch, Rebecca Zhang, Rachel Patzer, Christian Larsen, Andrew Adams. Atlanta, GA.

D292  The Impact of the New Kidney Allocation System on Living Donor Kidney Transplantation (LDTX) Among Patients in the Lowest Quintile of Expected Post-Transplant Survival (EPTS)
Caren Rose, Jagbir Gill, Julie Lesage, Yayuk Joffres, John Gill. Vancouver, Canada.

D293  The New Kidney Allocation System: The Effect on Elderly Transplantation in the US. Review of UNOS Database
Vaughn E. Whittaker, Mark Laftavi, Zeki Acun, Rainer W. Gruessner, Angelika Gruessner. Syracuse, NY.

D294  18 Month Analysis of the Impact of the New Kidney Allocation System on Deceased Donor Kidney Utilization at the Donor Service Area Level
Winston Ally, Kenneth Brayman, Avinash Agarwal. Charlottesville, VA.

D295†  A Brief Frailty Assessment and Outcomes Among Candidates for Liver Transplantation
Marina Serper, Kristen Dwinnells, Therese Bittermann, Kim Olthoff. Philadelphia, PA.

D296  Use of Modified Geriatric Assessment in Evaluation of Older Adults for Kidney Transplant Suitability
Kellie H. Campbell, Frances Enger, Erin Patrick, Milda Saunders, Michelle Josephson, Yolanda Becker. Chicago, IL.

D297  Pre-Kidney Transplant Lower Extremity Impairment and Post-Transplant Mortality
D298 Multi-Stakeholder Perspectives on the Importance of Outcomes for Trials in Kidney Transplantation: An International Best Worse Scaling Survey
Martin Howell, Nicole Evangelidis, Benoicte Sautenet, Germaine Wong, Jonathan C. Craig, Kirsten Howard, Allison Tong. Sydney, Australia; Sydney, NSW, Australia.

D299 The Forgotten Element of KAS: A2 to B Transplantation Reduces Waiting Time for Blood Group B Patients by 20%
Alexander Gilbert, Shannon Radomski, Albert Langeberg, Bridgette Diedrich, Sandra Rosen-Bronson, Dong Li, Mariam Awwad, Monica Grafals, Jack Moore, Jennifer Verbessy, Peter Abrams, Seyed Ghasemian, Matthew Cooper. Washington, DC.

D300 Willingness of Canadian ESRD Patients to Consider Transplant Tourism

D301 Global Kidney Exchange
Michael Rees, Ty Dunn, Susan Rees, Jeffrey Rogers, Alvin Roth, Christian Kuh, Obi Ekwenna, Kim Krawiec, Samay Jain, Christopher Marsh, Puneet Sindhwani, Michael Zimmerman, Rachel Forbes, Miguel Tan, Itai Ashlagi, Ricardo Correa-Rotter, Siegfredo Paloyo. Toledo, OH; Minneapolis, MN; Perrysburg, OH; Winston Salem, NC; Palo Alto, CA; Seattle, WA; Durham, NC; La Jolla, CA; Milwaukee, WI; Nashville, TN; Atlanta, GA; Mexico City, Mexico; Manila, Philippines.

D302 Use of Forensic DNA Testing to Trace Unethical Organ Procurement and Organ Trafficking Practices
Mai He, Ann Corson, Zhiyuan Wang, Jessica Russo, Torsten Trey. St Louis, MO; Washington DC; New York, NY.

D303 Cost-Effectiveness of Renal Machine Perfusion Use After Long Cold Ischemia Time

D304 Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care
Jiang Tao, Cecelia M. Horstman, Wade Bannister, Mark A. Schnitzler, Frank D. Irwin, Anthony F. Bonagura, Bart Laihinen. Eden Prairie, MN; St Louis, MO.

D305 It’s Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary
Shannon Radomski, Sandra Rosen-Bronson, Bridgette Diedrich, Albert Langeberg, Dong Li, Mariam Awwad, Monica Grafals, Matthew Cooper, Alexander Gilbert. Washington, DC.

D306 Manning the Gap: Using Technology to Reduce Barriers in Access to Renal Transplantation Waiting List Across Dialysis Facilities
Gustavo F. Ferreira, Kamille V. Bastos, Elaine Barbeta, Beatriz S. Pereira, Glauco S. Souza, Marcio de Souza, Vinicius S. Colares. Juiz de Fora, Minas Gerais, Brazil.

D307 Landscape of Multiple Donations from a Living Donor in the US
Alvin Thomas, Allan Massie, Jacqueline Garonzik-Wang, Krista Lentine, Macey Henderson, Dorry Segev. Baltimore; St. Louis.

D308 Barriers and Experiences When Patients Decide on a Kidney Transplant Center
Cory R. Schaffhausen, Marylyn J. Bruin, Jon J. Synder, Bertram L. Kasiske, Ajay K. Israni. Minneapolis, MN.

D309 A Novel KPD Mechanism to Increase Transplants When Some Candidates Have Multiple Willing Donors
Tuomas Sandholm, Gabriele Farina, John Dickerson, Ruthanne Leishman, Darren Stewart, Richard Formica, Carrie Thiessen, Sanjay Kulkarni. Pittsburgh; College Park; Richmond; New Haven.
Prioritization for Kidney Transplant Due to Medical Urgency: Clinical Characteristics and Outcomes After Transplantation